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Background: Synovitis (inflamed joint synovial lining) in rheumatoid arthritis (RA) can be assessed by
clinical examination (CE) or ultrasound (US).
Objective: To investigate the added value of US, compared with CE alone, in RA synovitis in terms of
clinical effectiveness and cost-effectiveness.
Data sources: Electronic databases including MEDLINE, EMBASE and the Cochrane databases were
searched from inception to October 2015.
Review methods: A systematic review sought RA studies that compared additional US with CE. Heterogeneity
of the studies with regard to interventions, comparators and outcomes precluded meta-analyses. Systematic
searches for studies of cost-effectiveness and US and treatment-tapering studies (not necessarily including US)
were undertaken.
Mathematical model: A model was constructed that estimated, for patients in whom drug tapering was
considered, the reduction in costs of disease-modifying anti-rheumatic drugs (DMARDs) and serious
infections at which the addition of US had a cost per quality-adjusted life-year (QALY) gained of £20,000
and £30,000. Furthermore, the reduction in the costs of DMARDs at which US becomes cost neutral was
also estimated. For patients in whom dose escalation was being considered, the reduction in number of
patients escalating treatment and in serious infections at which the addition of US had a cost per QALY
gained of £20,000 and £30,000 was estimated. The reduction in number of patients escalating treatment
for US to become cost neutral was also estimated.
Results: Fifty-eight studies were included. Two randomised controlled trials compared adding US to a
Disease Activity Score (DAS)-based treat-to-target strategy for early RA patients. The addition of power
Doppler ultrasound (PDUS) to a Disease Activity Score 28 joints-based treat-to-target strategy in the
Targeting Synovitis in Early Rheumatoid Arthritis (TaSER) trial resulted in no significant between-group
difference for change in Disease Activity Score 44 joints (DAS44). This study found that significantly more
patients in the PDUS group attained DAS44 remission (p = 0.03). The Aiming for Remission in Rheumatoid
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Arthritis (ARCTIC) trial found that the addition of PDUS and grey-scale ultrasound (GSUS) to a DAS-based
strategy did not produce a significant between-group difference in the primary end point: composite DAS
of < 1.6, no swollen joints and no progression in van der Heijde-modified total Sharp score (vdHSS). The
ARCTIC trial did find that the erosion score of the vdHS had a significant advantage for the US group
(p = 0.04). In the TaSER trial there was no significant group difference for erosion. Other studies suggested
that PDUS was significantly associated with radiographic progression and that US had added value for
wrist and hand joints rather than foot and ankle joints. Heterogeneity between trials made conclusions
uncertain. No studies were identified that reported the cost-effectiveness of US in monitoring synovitis.
The model estimated that an average reduction of 2.5% in the costs of biological DMARDs would be
sufficient to offset the costs of 3-monthly US. The money could not be recouped if oral methotrexate was
the only drug used.
Limitations: Heterogeneity of the trials precluded meta-analysis. Therefore, no summary estimates of
effect were available. Additional costs and health-related quality of life decrements, relating to a flare
following tapering or disease progression, have not been included. The feasibility of increased US
monitoring has not been assessed.
Conclusion: Limited evidence suggests that US monitoring of synovitis could provide a cost-effective
approach to selecting RA patients for treatment tapering or escalation avoidance. Considerable uncertainty
exists for all conclusions. Future research priorities include evaluating US monitoring of RA synovitis in
longitudinal clinical studies.
Study registration: This study is registered as PROSPERO CRD42015017216.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Grey-scale, or B-mode, ultrasound Mode of ultrasound that produces a black and white image of a
tissue. It demonstrates qualitative differences between tissues and is primarily used to identify synovial
hypertrophy and fluid within joints.
Power Doppler ultrasound Mode of ultrasound that detects blood flow. Flow is designated by a colour
(often orange or red), which is overlaid onto the corresponding grey-scale image below. There are different
types of Doppler but power Doppler is thought to be most sensitive to the relatively low blood flow seen
in joints.
Sensitivity Proportion of true-positive results, a measure of the accuracy of a diagnostic test.
Spearman’s rho (ρ) Spearman’s rank correlation coefficient, a measure of the association between
two variables.
Specificity Proportion of true-negative results, a measure of the accuracy of a diagnostic test.
Standardised response mean The ratio of the mean changes to the standard deviation of the changes,
a measure of responsiveness to change.
Synovitis Swelling of the synovial lining of the joints.
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CDAI Clinical Disease Activity Index
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Plain English summary
The aims of this study were to investigate the value of ultrasound (US) in addition to clinical examination(CE) for monitoring synovitis (swelling of joint synovial lining) in rheumatoid arthritis (RA) and whether
or not US could be used to make treatment decisions. A systematic literature review identified 58 studies
providing relevant evidence. Studies indicated that US-detected synovitis was associated with later development
of structural progression assessed by radiography, a sign that RA is causing permanent joint damage. Studies
suggested that US was better than CE at predicting response to treatment and tapering (dose reduction) or
discontinuation of a particular treatment. US was used to make treatment decisions and could increase clinician
and patient confidence in those decisions. However, studies varied in the types of US and CE that were used
and how outcomes were measured, making it difficult to draw firm conclusions about the overall usefulness of
adding US to CE.
No studies on the cost-effectiveness of US for monitoring synovitis were identified, but studies assessing
the impact of reducing treatment doses were identified. These reported that some patients who had
achieved good control of their disease could have their treatment reduced without harmful effects. It may
also be possible to withdraw treatment for some patients although this is rare in established RA. Reduced
dosages can save large sums of money in terms of drug costs. It was estimated that a 2.5% reduction in
dose of biological treatment would more than pay for the use of US every 3 months. The reduction in dose
needed to cover the costs of US rose when less expensive treatments were used but did not become larger
than 6%, assuming that multiple cheaper treatments were used. It appears likely that using US to monitor
synovitis could potentially represent value for money. However, more evidence is needed to reduce the
uncertainty in the current findings.
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Scientific summary
Background
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by progressive, irreversible joint
damage, impaired joint function, pain and tenderness caused by swelling of the synovial lining of joints
(synovitis) and is manifested by increasing disability and reduced quality of life. RA is associated with
substantial costs both directly (associated with drug acquisition and hospitalisation) and indirectly, because of
reduced productivity. Synovitis is assessed by clinical examination (CE) of the joints. Synovitis can also be
assessed using imaging technologies including magnetic resonance imaging (MRI) and ultrasound (US); this
may detect synovitis that is not detected by CE (subclinical synovitis) and may also distinguish between
synovitis and other pathologies more readily than CE alone. US can therefore aid key decision-making with
regard to therapy changes, leading to escalation or tapering of therapy. This is important for a disease area in
which modern therapies are expensive and all therapies are associated with side effects, especially infections.
Objective
This report aimed to address the question: ‘What is the added value of US joint examination for
monitoring synovitis in RA and can it be used to guide treatment decisions?’
Data sources
The following electronic databases were searched: MEDLINE and MEDLINE In-Process & Other Non-Indexed
Citations (via Ovid) (1946 to October 2015), EMBASE (via Ovid) (1974 to October 2015), Cochrane
Database of Systematic Reviews (CDSR) (1996 to October 2015), Cochrane Central Register of Controlled
Trials (CENTRAL) (1898 to October 2015), Health Technology Assessment (HTA) database (1989 to
October 2015), Database of Abstracts of Reviews of Effects (DARE) (1946–2014), NHS Economic Evaluation
Database (NHS EED) (1968–2014), Science Citation Index Expanded (1900 to October 2015), Science
Citation Index and Conference Proceedings Index (1900 to October 2015), ClinicalTrials.gov (October
2015), European League Against Rheumatism Abstract Archive (via Web of Science) (October 2015),
American College of Rheumatology and Association of Rheumatology Health Professionals (via Web of
Science) (October 2015) and Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT)
conference proceedings (via Web of Science) (October 2015).
Review methods
A systematic review of US was conducted. Studies were sought that compared grey-scale US (GSUS) or
power Doppler US (PDUS) with CE, the use of inflammatory biomarkers or disease activity scoring tools.
The patient group considered was adults with RA. Outcomes included diagnostic (detection of synovitis,
responsiveness to change), prognostic (association with progression or other disease outcomes) or
treatment-related (response to treatment, treatment tapering, influence on decisions) measures. Diagnostic
studies, prognostic studies and studies investigating the prediction of response to treatment, or treatment
tapering, or the influence of US on treatment decisions were included. Although there are other methods
for detecting synovitis, the decision was taken to limit the intervention in the review to US. Study selection
was carried out by two reviewers, with disagreements resolved by discussion. Included studies were quality
assessed and data extracted by one reviewer and checked by another reviewer. Data were tabulated and
discussed. Study heterogeneity precluded meta-analyses.
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A review of the cost-effectiveness of the use of US to monitor synovitis and a systematic search for the
outcomes associated with tapering of RA treatment, irrespective of whether or not US was used, were
undertaken. Study selection was carried out by two reviewers: any study deemed relevant by at least one
reviewer was retrieved. Included studies were summarised by one reviewer. The tapering search was
supplemented by checking the reference lists of included studies, searching for subsequent publications
related to any abstracts identified and retrieving papers known to our clinical advisors. Relevant studies
were summarised separately for cost-effectiveness and tapering. A survey publicised to UK rheumatology
units was undertaken to investigate whether or not US is being used to monitor synovitis and guide
treatment decisions in RA.
Mathematical model
The modelling undertaken was purposefully simplistic so that the key interactions between monitoring
synovitis with US and decisions influencing treatment could be examined explicitly. The simple model
estimated for patients in whom the clinician was contemplating reducing the treatment dose included
(1) the reduction in treatment costs and therapy modification leading to serious infection avoidance that
would be required for the addition of US for monitoring synovitis to have a cost per quality-adjusted
life-year (QALY) gained of £20,000 and £30,000 and (2) the reduction in treatment costs required for the
addition of US for monitoring synovitis to become cost saving. For patients in whom the clinician was
thinking of increasing the treatment dose, two analyses were undertaken: (1) the reduction in the number
of patients not progressing to more intensive treatment therapy or avoiding a serious infection through the
use of US needed to achieve cost per QALY gained values of £20,000 and £30,000 and (2) the reduction
in the number of patients escalating treatment needed for US to become cost saving.
Results
In the systematic review, 2724 records were identified from the electronic databases and an additional
26 records were identified from bibliography searching. Following title and abstract sifting, 154 articles
were assessed for eligibility, of which 63 full-text papers were excluded. In total, 75 articles describing
58 studies were included; additionally, one study identified by the search as ongoing was published prior
to publication of this report. A further 16 articles were retained for bibliography checking. Twenty-six
studies provided prognostic and/or treatment data and 32 studies provided diagnostic data only.
Two randomised controlled trials (RCTs) of the treatment strategy did not find significant benefits in terms of
the primary outcome of adding US to a Disease Activity Score (DAS)-based treat-to-target strategy for early
RA patients. The addition of PDUS to a Disease Activity Score 28 joints-based treat-to-target strategy in the
Targeting Synovitis in Early Rheumatoid Arthritis (TaSER) RCT resulted in no significant between-group
difference in change from baseline in Disease Activity Score 44 joints (DAS44) (mean change: intervention
–2.69, control –2.58). This study found that the addition of PDUS to the treatment strategy led to significantly
more patients attaining DAS44 remission (66%) than for the DAS-alone strategy (43%) (p = 0.03). The
Aiming for Remission in Rheumatoid Arthritis (ARCTIC) RCT found that the addition of PDUS and GSUS to a
DAS-based strategy did not produce a significant between-group difference in the primary end point [which
consisted of a composite of DAS of < 1.6, no swollen joints at 16, 20 and 24 months and no progression in
van der Heijde-modified total Sharp score (vdHSS) between 16 and 24 months], with values of 22.0% and
18.8%, respectively. The ARCTIC trial did find that the change in erosion score of the vdHS had a significant
advantage for the US group over the DAS group (changes of 0.5 and 1.0 for the US and control groups,
respectively; p = 0.04). Erosion in the TaSER trial, as measured by change in the erosion score of the
rheumatoid arthritis magnetic resonance imaging scoring system (RAMRIS), was not significantly different
between the groups (changes of 0.5 and 1.0 for the US and control groups, respectively). These studies did
not however explore the value of US when added only in cases of clinical uncertainty, for example, when
there was discrepancy between DAS and clinical evaluation.
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The majority of prospective cohort studies investigating radiographic progression reported that US at
baseline, either GSUS or PDUS, was significantly correlated with progression at follow-up (p = 0.05 to
p < 0.001). Radiographic progression in most, but not all, cases was measured with a modification of the
total Sharp score/vdHSS. PDUS was significantly associated with radiographic progression in 10 studies in
which it was measured. Associations were reported as odds ratios (ORs) in two studies and were 12.21
[95% confidence interval (CI) 3.34 to 44.73; p < 0.001] and 1.80 (95% CI 1.20 to 2.71; p = 0.005).
Associations reported as correlation coefficients ranged from r = 0.099 to r = 0.77 (p = 0.05 to p < 0.001).
Significance levels from Mann–Whitney U-test results reported were p < 0.001 and p = 0.0011. GSUS was
significantly associated with radiographic progression in six studies but not in three studies. Significant
associations reported were Mann–Whitney U-test p = 0.027; r = 0.140 to r = 0.61 (p < 0.001); and ORs of
2.08 (95% CI 1.39 to 3.11) and 2.15 (95% CI 1.23 to 3.75) (p = 0.01). The difference between studies
reporting significant associations and studies reporting non-significant associations could not be explained
by study quality, joints assessed or how the end point was measured.
Other outcomes reported were heterogeneous, making it difficult to draw conclusions. PDUS was
significantly correlated with the proportion of patients experiencing disease flare at follow-up (p = 0.014),
whereas this was not significant for GSUS. US could significantly predict treatment persistence (p = 0.02)
and US predicted treatment tapering or discontinuation failure significantly in two out of three studies
(p = 0.005, p < 0.0005, p = 0.06) whereas clinical measures alone did not. The additional use of US
modified treatment decisions (in 23–88% of cases in UK studies) and significantly increased (p < 0.001 to
p < 0.0005) clinician confidence in treatment decisions.
The review of cost-effectiveness studies identified five articles, although none was directly relevant to the
decision problem. Nineteen papers were identified from the tapering search, which, when supplemented
by checking references of identified articles, by searching for subsequent articles related to identified
abstracts and by articles known to our clinical advisors, resulted in 39 relevant papers being included.
Given that evidence showed that some patients who had achieved a low level of disease activity could
have their treatment tapered, with no or little short-term harm to them, it was deemed appropriate to
model strategies in which a clinician was contemplating a dose reduction. The survey conducted yielded
only 31 responses, 27 of which stated that US was used for treatment decisions. The small sample size
means that the results can not be generalised across the UK.
For patients who have been stable on biological disease-modifying anti-rheumatic drugs (bDMARDs) and in
whom the clinician is contemplating reducing the dose of bDMARDs, the model estimated that an average
reduction of 2.5% in the costs of bDMARDs was sufficient to cover the costs of performing US every
3 months. Similarly, if 2.5% of patients do not have their treatment escalated to bDMARDs, it was estimated
that the use of US to monitor synovitis would be cost neutral. If only conventional disease-modifying
anti-rheumatic drugs (DMARDs) were considered in the current or planned treatment regimen, the money
spent on US monitoring could not be recouped.
Limitations
Few RCTs were available and so lower-quality study designs were included in the review. The heterogeneity of
the studies identified precluded meta-analysis. Therefore, no summary estimates of effect were available,
which is a limitation of the review. There is no gold standard/reference standard for the detection of synovitis,
although it has been suggested that MRI may be used as a gold standard/reference standard; it detects similar
levels of inflammation to US. The systematic search for DMARD tapering was not overly sensitive as many
articles were identified by bibliography and citation searching and contact with clinical advisors (rather than by
database searching). However, the summarised articles provide a broad overview of the literature base and it is
likely that any papers omitted would not have an adverse impact on the findings of this report.
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Limitations in the modelling include the exclusion of biosimilar bDMARDs, which are likely to reduce the
cost associated with bDMARD treatment compared with the base case. However, a sensitivity analyses was
conducted to explore the impact of price reductions on the threshold levels.
A key limitation within the modelling was the lack of robust data relating to key parameters within the
decision problem. As such, threshold analyses have been undertaken to provide indicative levels of drug
dose reduction and avoidance of serious infections required to make the use of US cost neutral.
Conclusion
Limited evidence was available and therefore cost-effectiveness analysis was limited to threshold analysis.
Given the proportions of patients who could potentially taper treatment, or remain on stable therapy
without escalation, the use of US to monitor synovitis could potentially be a cost-effective approach if it
provides clinicians with more confidence in reducing the drug burden. However, there is considerable
uncertainty in this conclusion.
The most important future research studies would be longitudinal studies evaluating the role of US in the
management of synovitis in RA.
Study registration
This study is registered as PROSPERO CRD42015017216.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the health problem
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by progressive, irreversible joint
damage, impaired joint function, pain and tenderness caused by swelling of the synovial lining of the joints
(synovitis) and is manifested with increasing disability and reduced quality of life.1 The primary symptoms
are pain, morning stiffness, swelling, tenderness, loss of movement, fatigue and redness of the peripheral
joints.2,3 RA is associated with substantial costs both directly (associated with drug acquisition and
hospitalisation) and indirectly, because of reduced productivity.4 RA has long been reported as being
associated with increased mortality,5,6 particularly as a result of cardiovascular events.7
Diagnosis of rheumatoid arthritis
The initial classification criteria for RA were produced in 1987 by the American College of Rheumatology
(ACR).8 National Institute for Health and Care Excellence (NICE) clinical guideline 799 provides a summary
of the ACR criteria, with patients needing to have at least four of the seven criteria to be given a diagnosis
of RA: morning stiffness lasting at least 1 hour, swelling in three or more joints, swelling in the hand joints,
symmetric joint swelling, erosions or decalcification on radiography of the hand, rheumatoid nodules and
abnormal serum rheumatoid factor. For the first four criteria these must have been present for at least a
period of 6 weeks. However, in the clinical guideline9 the guideline development group preferred a clinical
diagnosis of RA rather than the ACR criteria to permit early treatment, as consistent with European League
Against Rheumatism (EULAR) recommendations.10
In 2010, the ACR and EULAR jointly published RA classification criteria, which focused on features present at
earlier stages of the disease that are associated with persistent and/or erosive disease rather than defining the
disease by its late-stage features.11 The classification criteria allocate scores to the characteristics of joint
involvement, serology, acute-phase reactants and duration of symptoms to produce a total score between
0 and 10, with those scoring ≥ 6 and with obvious clinical synovitis being defined as having ‘definite RA’ in
the absence of an alternative diagnosis that better explains the synovitis.11 The growing recognition of the
accuracy of modern imaging [such as magnetic resonance imaging (MRI) and ultrasound (US)] over clinical
examination (CE) in detecting synovitis was highlighted in these new classification criteria, which allow the
extent of joint involvement to be determined by imaging.11
Epidemiology
There are an estimated 400,000 people in England and Wales with RA,12 with approximately 10,000
incident cases per year.13 The disease is more prevalent in females (1.16%) than in males (0.44%),13
with the majority of cases being diagnosed when patients are aged between 40 and 80 years14 and a
peak incidence in those in their 70s.13
Measurement of disease activity and damage progression
Synovitis can be detected by CE. Monitoring may involve taking swollen joint counts (SJCs) or tender joint
counts (TJCs). Biomarkers may be used to detect evidence of systemic inflammation, for example anaemia in
chronic disease or elevated levels of C-reactive protein (CRP) or an elevated erythrocyte sedimentation rate
(ESR).9,15 Common measures of disease activity, disability and response to treatment are presented in Table 1.
ACR response19 and EULAR response20 measures have dominated the measurement of improvement in RA
symptoms. The ACR response has been widely adopted in randomised controlled trials (RCTs) although
studies have shown that the value can vary between trials because of the timing of the response.21 The EULAR
response criteria and the ACR20 improvement criteria (see Table 1) were found to have reasonable agreement
in the same set of clinical trials, although van Gestel et al.22 stated that the EULAR response criteria showed
better construct and discriminant validity than the ACR20 criteria. The Disease Activity Score 28 joints
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(DAS28; see Table 1) can be used to classify both the disease activity of the patient and the level of
improvement estimated. The EULAR response has been reported less frequently in RCTs than the ACR
response, although the EULAR criteria are much more closely aligned to the treatment continuation rules
stipulated by NICE,9 which require a DAS28 improvement of > 1.2 to continue treatment.22
The relationship between change in DAS28 and DAS28 reached and EULAR response is shown in Table 2.
Depending on the initial DAS28 of the patient, this change in DAS28 would equate to either a good or
moderate EULAR response, as shown in the second column of Table 2.
Both the ACR criteria and the DAS28-based EULAR criteria rely on subjective measurements and can be
influenced by patients’ pain threshold and comorbidities.24 The DAS28 has been criticised as patients
achieving DAS remission can still have synovitis as evidenced by imaging.25,26 Alternatively, chronic pain
experienced by patients or deformity and residual fibrous tissue leading to the detection of swelling by
manual examination of joints can raise the DAS, thus overestimating disease activity.24 If DAS measurement
is based on CRP levels, it can be influenced by therapies; for example, tocilizumab (TCZ; RoActemra®,
Roche Products Ltd, Welwyn Garden City, UK) has a direct effect on CRP through interleukin-6 and can
therefore artificially lower the DAS28.27 Unlike these subjective measurements, imaging could provide an
objective measurement of synovitis.
TABLE 1 Measurement of disease activity and damage progression
Measure Description
Health Assessment
Questionnaire (HAQ)16
A patient-completed disability assessment with established reliability and validity. Scores
range from 0 to 3, with higher scores indicating greater disability. The HAQ scale is a
discrete scale with step values of 0.125, resulting in 25 points on the scale
Visual analogue scale (VAS) A global assessment of the extent of disease, which may be assessed by the patient or
the physician. This method may also be used for patient-reported pain. The VAS usually
consists of a 100-mm line that represents the total range of the disease extent/pain levels
experienced. Patients/physicians mark a point on the line
DAS28-ESR17 This assesses 28 joints (shoulder, knee, elbow, wrist, MCP joints one to five, PIP joints one
to five, bilaterally) in terms of swelling (SW28) and of tenderness to the touch (TEN28).
It also incorporates measures of the ESR and a subjective assessment (SA) on a scale of
0–100 made by the patient regarding disease activity in the previous week. The DAS28-ESR
score is calculated using the following equation: 0.56 × TEN280.5+ 28 × SW280.5+ 0.70 ×
ln(ESR)+ 0.014 × SA. A DAS28-ESR of ≤ 3.2 indicates inactive disease; a DAS28-ESR of > 3.2
and ≤ 5.1 indicates moderate disease; a DAS28-ESR of > 5.1 indicates very active disease
DAS28-CRP17 Similar to the DAS28-ESR but uses the CRP value instead of the ESR. The DAS28-CRP
is calculated using the following equation: [0.56 × sqrt(TEN28) + 0.28 × sqrt(SW28)
+ 0.36 × ln(CRP + 1)] × 1.10+ 1.15
Clinical Disease Activity Index
(CDAI)18
A composite index based on SJCs (0–28), TJCs (0–28), CRP, patient global assessment
of disease activity VAS (0–10 cm) and physician global assessment of disease activity
VAS (0–10 cm)
Simplified Disease Activity
Index (SDAI)18
A simplified version of the CDAI based on SJCs (0–28), TJCs (0–28), patient global
assessment of disease activity VAS (0–10 cm) and physician global assessment of disease
activity VAS (0–10 cm)
ACR response19 An ACR20 response requires a 20% improvement in TJCs; a 20% improvement in SJCs;
and a 20% improvement in at least three of the following five ‘core set items’: physician
global assessment, patient global assessment, patient pain, self-reported disability (using a
validated instrument) and ESR or CRP. ACR50 and ACR70 responses require 50% and
70% improvements, respectively
EULAR response20 Participants are classified as good, moderate or non-responders based on the individual
change in DAS28 and the DAS28 reached.20 The relationship between change in DAS28
and DAS28 reached and EULAR response is shown in Table 2
DAS28-CRP, Disease Activity Score 28 joints using C-reactive protein; DAS28-ESR, Disease Activity Score 28 joints using
erythrocyte sedimentation rate; MCP, metacarpophalangeal; PIP, proximal interphalangeal; sqrt, square root.
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The role of imaging
Imaging techniques used in the diagnosis and monitoring of RA include US, conventional radiography,
MRI and computerised axial tomography (CT). Initial diagnosis of RA, or differential diagnosis of forms of
arthritis, may be aided by imaging. There is a EULAR recommendation that US, MRI and conventional
radiography can improve the certainty of a RA diagnosis if there is diagnostic doubt.28
In terms of detecting inflammation, there is evidence to demonstrate that both US and MRI detect more
cases of synovitis than CE.9,28 The benefit of US as an addition to CE will be influenced by the ability of this
subclinical synovitis to predict disease progression. Prognostic studies of US-detected synovitis were sought
in this report (see Chapter 3). Because of their three-dimensional acquisition, both US and MRI are also
more sensitive than conventional radiography at detecting erosion damage and early signs of erosion.9
MRI can detect bone oedema, which may be a predictor of radiographic progression.28
Although MRI may be more sensitive than US for detecting erosions,29 US and MRI have comparable
abilities to detect synovitis.28–30 Arthritis Research UK30 suggests that US has an advantage over other
imaging techniques as it can be used immediately after CE to assess symptomatic areas or clinical
abnormalities and this has the added advantage of improving clinical skills.30
There is no conclusive gold standard (sometimes referred to as a reference standard) for assessing synovitis.
When compiling their 2009 guidelines, NICE9 recognised that many clinicians had limited access to US and
so it considered clinician examination as the gold standard for the detection of synovitis in practice. It is
possible that US has become more widespread since then. To address this issue, a survey was conducted
to determine the usage of US in UK clinical practice (see Appendix 1).
Conventional radiography is commonly used to measure disease progression.9 In clinical trials this may be
carried out using the total Sharp score (TSS), the van der Heijde-modified total Sharp score (vdHSS)31 or the
modified Genant et al.32 scoring method, which measure erosions and joint space narrowing, although
systematic scoring of radiographs in routine clinical care is very uncommon.
Treatment strategies based on a therapeutic outcome target (known as ‘treat to target’; TTT) are becoming
more widely used within rheumatology.33–35 Typically, targets are either remission or low disease activity (when
remission is not attainable). These are usually clinically defined [e.g. DAS of < 2.6, Simplified Disease Activity
Index (SDAI) score of ≤ 3.3].34,36 However, as a previous review has reported that US has been shown to be
superior to CE for detecting synovitis, providing that this is linked to later outcomes,28 US-defined remission
may be a more appropriate target for TTT strategies. This previous review thoroughly examined the use of US
to detect synovitis;28 however, it was published prior to the publication of the treatment studies, including
RCTs, in this report. Research is starting to examine the effectiveness of US compared with clinical treatment
targets within TTT strategies in RA.36,37
TABLE 2 Determining the EULAR response based on DAS2823
DAS28 at end point
Improvement in DAS2823
> 1.2 > 0.6 and ≤ 1.2 ≤ 0.6
≤ 3.2 Good Moderate None
> 3.2 and ≤ 5.1 Moderate Moderate None
> 5.1 Moderate None None
Notes
The shaded cells indicate where patients continue treatment based on current NICE technology appraisal guidance.9
This table contains information from Stevenson et al.,23 licensed under the Non-Commercial Government Licence v2.0.
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Significance for the NHS
Because previous NICE technology appraisals have recommended a number of biological disease-modifying
anti-rheumatic drugs (bDMARDs) (see Current service provision), with a potential sequence of three
bDMARDs, there has been a considerable increase in expenditure on RA interventions as bDMARDs are
markedly more expensive than conventional disease-modifying anti-rheumatic drugs (cDMARDs). Any
imaging technology that could inform decisions on when to start, or to taper or discontinue, treatments
has the potential to benefit the NHS. The frequency of monitoring would influence cost-effectiveness.
Further detailed information on RA can be found in NICE clinical guideline 79.9 Additional information can
also be located in the British Society for Rheumatology (BSR) guidelines.38
Current service provision
Traditionally, patients have been treated with cDMARDs, which include methotrexate (MTX), sulfasalazine
(SSZ), hydroxychloroquine (HCQ), leflunomide, ciclosporin and gold injections as well as corticosteroids,
analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). However, more recently, a group of drugs
has been developed consisting of monoclonal antibodies and soluble receptors that specifically modify
the disease process by blocking key protein messenger molecules (such as cytokines) or cells (such as
B-lymphocytes).9 Such drugs have been labelled as bDMARDs.
A simplified model of the RA clinical pathway has been provided by NICE,39 with the use of US falling into
the monitoring and review box. For the purposes of this report, modelling assumes that US would be used
only at points in the pathway where a change of treatment is being considered, specifically for those
patients for whom a clinician is considering tapering treatment to assess the current level of synovitis and
for those patients for whom a clinician is contemplating escalating treatment to rule out non-synovitis-
related reasons.
Clinical guidelines
For people with newly diagnosed RA, NICE clinical guideline 799 recommends a combination of cDMARDs
[including MTX and at least one other disease-modifying anti-rheumatic drug (DMARD) plus short-term
glucocorticoids] as first-line treatment, ideally beginning within 3 months of the onset of persistent symptoms.
When combination therapies are not appropriate (e.g. when there are comorbidities or the patient is
pregnant), DMARD monotherapy is recommended. When DMARD monotherapy is used, emphasis should be
on increasing the dose quickly to obtain the best disease control. For the purposes of this report, the term
‘intensive DMARDs’ has been used to denote treatment with multiple cDMARDs simultaneously.
Current National Institute for Health and Care Excellence technology appraisal guidance
National Institute for Health and Care Excellence guidance [technology appraisal (TA) 375]40 recommends
the use of the tumour necrosis factor inhibitors (TNFis) etanercept (ETN; Enbrel®, Pfizer Ltd, Sandwich, UK),
infliximab (IFX; Remicade®, Merck Sharp & Dohme Ltd, Hoddesdon, UK), adalimumab (ADA; Humira®,
AbbVie Ltd, maidenhead, UK), certolizumab pegol (CTZ; Cimzia®, UCB Pharma, Slough, UK) and
golimumab (GOL; Simponi®, Merck Sharp & Dohme Ltd), in combination with MTX, in people with RA
after the failure of two cDMARDs, including MTX, and who have a DAS28 of > 5.1 and when bDMARDs
have not been tried previously. TA375 also recommends the use of TCZ and abatacept (ABT; Orencia®,
Bristol-Myers Squibb, Uxbridge, UK) as alternatives to TNFis in the same circumstances.
Technology appraisal 375 did not recommend the use of bDMARDs in patients with a DAS of ≤ 5.1 nor in
patients in whom cDMARDs have failed.40
The National Institute for Health and Care Excellence has also issued guidance on the treatment of RA
after the failure of a TNFi (TA195,41 TA22542 and TA24743).
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National Institute for Health and Care Excellence clinical guideline 799 recommends the use of intensive
cDMARDs – two cDMARDs used in combination, rather than two cDMARDs used sequentially – although
this latter option is acceptable.
A simplified summary of the typical pathway recommended by NICE would be the use of intensive
cDMARDs followed by a bDMARD, followed by rituximab (RTX; MabTheraR, Roche Products Ltd, Welwyn
Garden City, UK) plus MTX and then TCZ before returning to cDMARDs. If RTX or MTX is contraindicated
then ADA, ETN, IFX or ABT in combination with MTX or ADA or ETN monotherapy can be used instead
(TA19541), as can TCZ in combination with MTX (TA24743) and GOL in combination with MTX (TA22542).
A NICE single technology appraisal recommended the use of CTZ after an inadequate response to a TNFi
for patients with a DAS28 of > 5.1 for whom RTX is contraindicated or not tolerated.44
National Institute for Health and Care Excellence criteria for continuing treatment
Each of the NICE TAs state that for patients to continue treatment with a bDMARD there must have been
an improvement in DAS28 of at least 1.2 points at 6 months. If this criterion has not been met, treatment
should be stopped and the next intervention in the sequence initiated.
Current service cost
The decision problem compares the use of US for the monitoring of synovitis in addition to CE compared
with CE alone, assuming that there are US facilities within the hospital. As such, no attempt has been made
to estimate the costs of providing a rheumatology service without US monitoring, as it is presumed that
these costs, such as maintenance costs, consumable costs and receptionist costs, will be the same regardless
of whether or not US monitoring is undertaken for RA patients. No analyses have been undertaken assuming
that the machinery required to perform US would be bought primarily for the use of RA patients, although it
is expected that in such circumstances the costs per US scan would be markedly higher.
Description of the technology under assessment
In US, reflected pulses of high-frequency sound are used to assess soft tissue, cartilage and bone surfaces.30
Grey-scale ultrasound (GSUS) (also known as B-mode ultrasound) displays different intensities of echoes,
denoting different densities of tissue, in black, white and shades of grey.30 GSUS can measure synovial
hypertrophy and effusion.45 Doppler US is based on the principle that sound waves increase or decrease in
frequency when objects (such as blood cells) move towards or away from the transducer, respectively.30
Thus, power Doppler ultrasound (PDUS) can be used to detect the volume of blood flow.30
Musculoskeletal US can be used for evaluating joint and soft tissue pathology.30 Within the field of
rheumatology, US can be used for the initial diagnosis of arthritis and for US-guided injections or aspirations
(which fall outside the scope of this report).30 It can also be used to assess the extent of inflammatory disease
and determine the response to therapy.30 A significant advantage of US over other imaging technologies
such as MRI and CT is the ability to focus on the area of symptoms or clinical abnormality with the US probe
immediately after CE.30
The ACR has published guidelines on the use of US in rheumatology.46 This included several recommendations
across a range of disorders and various stages of the clinical pathway, including that it is reasonable to use US
to evaluate inflammatory disease activity.46
The EULAR recommendations on imaging for RA, published in 2013, covered several imaging technologies
and pathologies across stages of the clinical pathway.28 Recommendations included that US be used to
detect and monitor inflammation and that imaging be used to predict the response to therapy.
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Ultrasound is useful for distinguishing inflammatory from non-inflammatory joint disease. Effusion may
indicate synovial inflammation; however, abnormally thickened hypoechoic intra-articular tissue may
indicate synovitis in the absence of effusion.30 PDUS can be used to assess synovitis as it can detect
minimal increases in perfusion in the synovium.30 US can detect subclinical synovitis.28,30 Subclinical synovitis
may predict structural deterioration in RA patients; thus, prognostic studies were sought (see Chapter 3)
as progression can occur in RA patients in remission.47,48 The benefit of US as an addition to CE will be
influenced by the ability of this subclinical synovitis to predict disease progression.
Interpreting US scans is a skill. In the past, there have been concerns about inter-rater reliability; however,
a review published in 201049 found that both intra-rater and inter-rater reliability for still-image interpretation
was high for both GSUS and PDUS. Limited evidence is available for assessing image acquisition reliability.50
The Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) US task force has addressed
many issues involved in measuring RA and has looked specifically at the variability of US.30,51 In the past,
GSUS was used to assess the presence or absence of synovitis, but this was followed by the creation of
semiquantitative scoring systems (Table 3).45 PDUS used to detect vascularity may be quantified30 (see Table 3).
Concerns had also been voiced regarding intermachine variability, but with current high-end systems this
is now less of a concern.30,45 D’Agostino et al.,60 as reported by Arthritis Research UK,30 showed that there
is good reliability between experts using different types of US machine. There may be some variability in
synovitis throughout the day; response to cDMARDs may be detected within 6–8 weeks and response to
bDMARDS may be seen as early as 1 week.61,62 The optimal frequency of testing will depend on the frequency
of treatment decisions. It is envisaged that the number of US tests conducted per year would be aligned to
the frequency at which clinical decisions regarding changing the treatment for a patient would be undertaken.
At the OMERACT 7 meeting in 2004 an international panel of experts agreed on the first definitions of
sonographic pathology.51 This meeting achieved consensus in US definitions of joint effusion, bursal
effusion and synovitis. Studies following on from that meeting, undertaken within the EULAR/OMERACT
network, were reported at the OMERACT 8 meeting in 2006.63 The international panel of experts
TABLE 3 Ultrasound semiquantitative scoring systems
Reference Scoring system
Szkudlarek et al. 200352 Joint effusion (compressible anechoic intracapsular area):
l 0= no effusion
l 1=minimal amount of joint effusion
l 2=moderate amount of joint effusion (without distension of the
joint capsule)
l 3= extensive amount of joint effusion (with distension of the joint capsule)
Synovitis (non-compressible hypoechoic intracapsular area):
l 0= no synovial thickening
l 1=minimal synovial thickening (filling the angle between the periarticular
bones, without bulging over the line linking the tops of the bones)
l 2= synovial thickening bulging over the line linking the tops of the
periarticular bones but without extension along the bone diaphysis
l 3= synovial thickening bulging over the line linking the tops of the
periarticular bones and with extension to at least one of the bone diaphyses
Power Doppler (flow signal in the synovium):
l 0= no flow in the synovium
l 1= single vessel signals
l 2= confluent vessel signals in less than half of the area of the synovium
l 3= vessel signals in more than half of the area of the synovium
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concluded that the standardised definitions produced by OMERACT had improved inter-rater and intra-rater
reliability for detecting and grading synovitis of the hand joints.63 The OMERACT US special interest group
defined a Global Synovitis Score, which combines synovial hypertrophy and the PDUS signal in a composite
score and has acceptable reliability.64,65
Although the 28-joint count is well established for CE, the optimal joint count for US is currently unclear.
Joint counts featuring smaller numbers of joints are more feasible for a clinical encounter.45 Several studies
have compared various different joint counts;45,66–70 however, there is no clear consensus on the optimal
joint count at present and joint counts vary between studies, rendering comparison across studies difficult.
Research is ongoing.
TABLE 3 Ultrasound semiquantitative scoring systems (continued )
Reference Scoring system
Scheel et al. 200553 Synovitis and effusion included in a combined scoring method (the larger the
anechoic structure or extent of synovial hypertrophy seen on US images, the
higher the assigned score):
l 0= no effusion/hypertrophy (no anechoic, hypoechoic or hyperechoic
structure visible)
l 1=minimal effusion/hypertrophy
l 2=moderate effusion/hypertrophy
l 3= extensive effusion/hypertrophy
Naredo et al. 2005,54 Naredo et al.
2007,55 Naredo et al. 200856
Subjective grading of joint effusion and synovitis from 0 to 3:
l 0= absence
l 1=mild
l 2=moderate
l 3=marked
Subjective grading of the intra-articular PDUS signal from 0 to 3:
l 0= absence, no synovial flow
l 1=mild, three or fewer isolated signals
l 2=moderate, more than three isolated signals or confluent signal in less
than half of the synovial area
l 3=marked, signals in more than half of the synovial area
Karim et al. 200457 Semiquantitative assessment for degree of synovitis:
l normal= no synovitis
l mild = flat, thickened synovium
l moderate = thickened synovium with few villi-like protrusions
l severe =marked thickening with multiple villi-like protrusions
Schmidt et al. 200058 Subjective grading of echogenity of effusion on a 0–3 scale:
l 0= no echoes in the effusion
l 1–3 = increasing degrees of echogenity in the effusion
PDUS perfusion intensity as analysed subjectively on a 0–3 scale:
l 0= no perfusion
l 1–3 = increasing degrees of perfusion
Klauser et al. 200459 Criteria for grading intra-articular vascularisation with colour Doppler US/PDUS:
l 0= no intra-articular colour-flow signals
l 1= one to five intra-articular colour-flow signals
l 2= six to 10 intra-articular colour-flow signals
l 3=≥ 11 intra-articular colour-flow signals
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Patient experience of ultrasound
Ultrasound is relatively inexpensive and safe, avoiding the exposure to radiation that is necessary for
conventional radiography and CT. US is a painless and harmless procedure, being non-invasive and not
radioactive. As confirmed by this study’s patient advisor (see Appendix 2), US is comfortable for the
patient, unlike MRI, which can be noisy, can make the patient feel claustrophobic and requires lying still
for a prolonged period of time. It should be noted that only one patient advisor contributed to this report.
The advent of portable US machines means that scans can be carried out at the bedside or in the
outpatient clinic without the need for a second appointment in the radiology department. Most scans for
RA involve the hand or wrist joints or focus on the most affected joint and take < 20 minutes.
Current usage in the NHS
Few published data were identified on the current usage of US for RA in the NHS. Therefore, a survey was
conducted to address this issue (see Appendix 1).
A published survey conducted in 200571 analysed data from 126 UK rheumatologists. It found that 93%
(117/126) of the surveyed rheumatologists used US results in patient management, with 33% (41/126)
conducting the US examination themselves. Of the 60% (76/126) who referred patients to other departments
for US, the majority referred patients to the radiology department (56%, 71/126). Synovitis was the second
most common indication (estimate from graph: 87%, 110/126) for investigation by US, after tenosynovitis.
The authors acknowledge the possibility that US use was overestimated because of the sample of
rheumatologists being targeted at imaging events and because of response bias (126 questionnaires
returned out of 250 circulated).
Another survey of 100 rheumatologists, conducted in 2009 (Richard Wakefield, University of Leeds,
22 March 2016, personal communication), found that most used US results to detect inflammatory arthritis
(84%), but fewer used US for prognostic assessment (44%) or disease monitoring (32%). In total, 28% had
conducted the US examination themselves and 81% had referred patients to the radiology department. Of
those surveyed, 40% reported that US frequently influenced patient management (Richard Wakefield,
personal communication).
The Targeted Ultrasound Initiative,72 founded in 2012, provides training and resources regarding US. A
survey of its international users suggests that > 90% use US for diagnosis and the assessment of remission
and approximately 80% use US for routine monitoring (Richard Wakefield, personal communication).
Anticipated costs associated with the intervention
The cost of monitoring synovitis using US was estimated using data provided by our clinical experts
(Professor Philip Conaghan, University of Leeds; Dr Cristina Estrach, Aintree University Hospitals NHS
Foundation Trust; Professor Christopher Edwards, University of Southampton; and Dr Richard Wakefield,
University of Leeds) and a survey (see Appendix 1) sent to members of the BSR. Our clinical advisors stated
that US used for monitoring synovitis would be undertaken as an outpatient appointment and that
contrast would not be required. A broad consensus was reached that two-thirds of scans would take
< 20 minutes with one-third taking ≥ 20 minutes. Based on this advice, it was assumed that two-thirds
of scans would be costed as NHS reference cost RD40Z (£55.03) and the remainder would be costed as
NHS reference cost RD42Z (£59.90), resulting in a weighted cost per scan of £56.66.73 Therefore, if it is
assumed that, on average, four USs are performed on a patient every year, this would equate to a yearly
cost of US monitoring of £226.62. No distinction has been made between different types of US for two
reasons. First, detailed data on the differential costs have not been identified. Second, there was no clear
evidence of a distinction between different US modes regarding the association with synovitis levels
detected and in the successful tapering of treatment. Four US scans were chosen as the base case as it
was assumed that clinicians may actively monitor patients in whom they had tapered treatment. This
assumption was tested in sensitivity analyses.
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Chapter 2 Definition of the decision problem
Decision problem
Purpose of the decision to be made
The aim of this assessment was to systematically review the evidence on the use of US examination in
addition to clinical assessment, compared with CE only, in relation to how synovitis in patients with RA can
be used to predict prognosis or response to treatment and to investigate the cost-effectiveness of US joint
examination for monitoring synovitis in terms of guiding decisions about when treatment can be tapered
or which patients should be progressed to more intensive treatment.
Intervention
The included intervention was US examination of joints in patients with RA used in addition to CE to
detect synovitis. US technologies included were GSUS and PDUS.
Population/setting
The population was adult patients with a confirmed diagnosis of RA at any point in the disease pathway.
The setting was secondary care.
Relevant comparators
The comparator was assessment of synovitis by CE, without the use of US technology. This included
assessment of inflammatory biomarkers68 such as ESR or CRP15 and the use of disease activity scoring
tools68 such as the DAS28,17 Health Assessment Questionnaire (HAQ),16 SDAI18 and Clinical Disease Activity
Index (CDAI)18 (see Table 1).
Outside the scope of the decision problem
Ultrasound used in the initial diagnosis of arthritis or to determine the type of arthritis or US to
guide injections.
Key factors to be addressed
The review aimed to address the clinical value of US in addition to CE for detecting synovitis at different
joints and at different points in the disease pathway, compared with CE alone. The review aimed to
investigate the economic costs and benefits associated with the use of US to monitor synovitis in RA.
Overall aims and objectives of the assessment
The review aimed to:
l investigate reported data on the detection of synovitis in RA patients by US and CE and the ability of
US and clinically detected synovitis to predict clinical outcome or response to RA treatment
l investigate the economic costs and benefits associated with the use of US to monitor synovitis in RA
l suggest key areas for primary research.
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Chapter 3 Assessment of ultrasound studies
Methods for reviewing ultrasound studies
The search for evidence on US for monitoring synovitis in RA was undertaken systematically following the
general principles recommended in the PRISMA statement.74 The search strategies used are provided in
Appendix 3.
Identification of studies
The following electronic databases were searched:
l MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (via Ovid) (1946 to October 2015)
l EMBASE (via Ovid) (1974 to October 2015)
l Cochrane Database of Systematic Reviews (CDSR) (via Wiley Online Library) (1996–2015)
l Cochrane Central Register of Controlled Trials (CENTRAL) (via Wiley Online Library) (1898–2015)
l Health Technology Assessment (HTA) database (via Wiley Online Library) (1989–2015)
l Database of Abstracts of Reviews of Effects (DARE) (via Wiley Online Library) (1946–2014)
l NHS Economic Evaluation Database (NHS EED) (via Wiley Online Library) (1968–2014)
l Science Citation Index Expanded (via Web of Science) (1900 to October 2015)
l Science Citation Index and Conference Proceedings Index (via Web of Science) (1900 to October 2015)
l ClinicalTrials.gov (US National Institutes of Health) (October 2015)
l European League Against Rheumatism Abstract Archive (via Web of Science) (October 2015)
l American College of Rheumatology and Association of Rheumatology Health Professionals (via Web of
Science) (October 2015)
l OMERACT conference proceedings (via Web of Science) (October 2015).
In addition to electronic database searching, bibliographies of systematic reviews and included studies
were checked for studies meeting the review inclusion criteria.
Initial scoping searches identified eight relevant guidelines.9,24,28,30,46,75–77 Bibliographies of these guidelines
were also checked.
Following the submission of the report for peer review, the full results of one of the included studies [Targeting
Synovitis in Early Rheumatoid Arthritis (TaSER)] were published.78 On the request of a peer reviewer, the results
from this publication have been included. The searches were not updated. However, as this was a publication
of an already included study, with data relevant to the treatment strategies, it was decided that the publication
would be included. Additionally, the Aiming for Remission in Rheumatoid Arthritis (ARCTIC) trial, although not
published in full at the time of peer review, was published in a preliminary conference abstract in November
2015.79 It was decided that this publication would also be discussed.
Inclusion and exclusion criteria
Population
Adult patients diagnosed with RA.11
Intervention
The intervention was US of joints in patients with RA, as used to assess synovitis. Studies were not
excluded on the basis of type of US technology used. US technologies included were GSUS and PDUS.
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Comparators
The comparator was assessment of synovitis by CE without the use of US technology (in the same patients).
This included assessment of inflammatory biomarkers such as ESR or CRP15 and the use of disease activity
scoring tools such as the DAS2817 and HAQ.16
Outcomes
Outcomes were diagnostic accuracy measured by sensitivity and specificity (CE with reference US, or reported
US with reference CE, or sufficient data reported to calculate sensitivity or specificity); responsiveness to
change in inflammation as measured by standardised response mean (SRM);80 synovitis detection rate;
prognostic sensitivity or prognosis associated with baseline measures; prediction of response to treatment;
or the use of US in clinical decision-making.
For diagnostic accuracy data, studies were accepted if they reported sensitivity or specificity or if they
provided sufficient data to calculate sensitivity or specificity.
Study design
Diagnostic studies, prognostic studies and studies investigating prediction of response to treatment, or the
influence of US on treatment decisions, whether as a one-off US test or as serial US testing, were included.
Studies were not excluded based on quality alone; however, for prognostic studies, the method and
setting of outcome measurement had to be the same for all study participants.81
Additionally, systematic reviews were sought and were used to identify studies meeting the inclusion
criteria for the review.
Exclusion criteria
The exclusion criteria were as follows:
l US used for RA diagnosis only (for initial diagnosis of arthritis or for differentiating between types
of arthritis)
l US used to guide injections
l US used for inflammatory conditions other than RA
l studies with healthy control subjects unless outcome data were reported separately for the
RA subgroup
l studies of US compared with another imaging technology (or other diagnostic method) for which
clinical comparator data were not available or for which data did not allow comparison of US with CE
l studies with a low proportion (< 80%) of patients diagnosed with RA, unless outcome data were
reported separately for the RA subgroup
l studies of US reporting inter-rater or intra-rater reliability only
l studies of tenosynovitis not reporting data about synovitis
l animal models
l preclinical and biological studies
l narrative reviews, editorials and opinions
l non-English-language papers
l abstracts reporting insufficient details to allow inclusion.
This review concentrated on US as the intervention. There is no conclusive gold standard/reference standard
for assessing synovitis related to disease progression. This review investigated the association of US-detected
synovitis with later outcomes in prognostic studies (see Assessment of prognostic studies). This can be
considered as validating the test results.28 For detection of synovitis, it may be considered that surgery is the
gold standard/reference standard, allowing direct visualisation of the synovial membrane.57 In clinical practice,
this would not be used for monitoring synovitis, and limiting studies to those including surgery would limit
the amount of studies eligible for the review. In terms of other imaging techniques that have a potential
role in monitoring, it has been suggested that MRI may be used as a gold standard/reference standard.
ASSESSMENT OF ULTRASOUND STUDIES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
However, it has been reported that US and MRI detect similar rates of inflammation.28 Scintigraphy and
positron emission tomography (PET) have been reported to detect similar rates of inflammation to CE.28 Other
imaging techniques with a potential for use in RA patients are conventional radiography and CT scans. US is
more likely to be practical than other imaging techniques in assessing synovitis. US is more comfortable for
the patient than MRI, is less expensive and has an advantage over other imaging techniques as it can be used
immediately after CE to assess symptomatic areas.30 Limiting studies to those including an additional imaging
technique would have limited the number of studies eligible for the review. As this review concentrated on US
as the intervention, the decision was taken not to compare US-detected synovitis with synovitis detected by
other imaging techniques.
Study selection
Titles and abstracts were examined by one reviewer. Study selection based on full texts was carried out by
two reviewers, with discrepancies resolved by discussion.
Data extraction strategy
Data relevant to the decision problem were extracted from all studies by one reviewer using a standardised
data extraction form. All data extracted were checked thoroughly by a second reviewer. Data were
extracted without blinding to authors or journal. Discrepancies were resolved by discussion.
Quality assessment strategy
The methodological quality of each included study was assessed by one reviewer and checked by a second
reviewer. Discrepancies were resolved by discussion. Diagnostic studies were assessed using criteria based
on the QUADAS (Quality Assessment of Diagnostic Accuracy Studies) tool.82 The QUADAS tool was selected
as it is a validated, evidence-based tool that has been widely used in diagnostic review. Prognostic studies
were assessed using criteria taken from the Generic Appraisal Tool for Epidemiology (GATE)83 and the
Quality in Prognosis Studies (QUIPS)81 tool. These are both validated tools that have been used for reviewing
prognostic studies. Two items of particular relevance to RA studies were adapted from recommendations on
inclusion criteria and study design for RA studies by Karsh et al.84
Methods of analysis/synthesis
For calculations of diagnostic accuracy, US was counted as the reference standard and the accuracy of
the clinical comparator was assessed using sensitivity, that is, the proportion of true positives (TPs), and
specificity, that is, the proportion of true negatives (TNs), calculated as follows: sensitivity is the number of
TPs divided by the sum of the TPs and the false negatives (FNs); specificity is the number of TNs divided by
the sum of the TNs and the false positives (FPs).
Data were tabulated and discussed. Evidence synthesis would be attempted unless precluded by
heterogeneity (of population, intervention, comparator or outcomes).
Survey
In addition to the systematic review, a survey was conducted to investigate current usage of US in
treatment decisions for RA patients. The survey was publicised by the BSR through newsletters. The
questions used in the survey are provided in Appendix 1. The survey was available to clinicians from
December 2015 to February 2016.
Results
Quantity and quality of research available
A total of 2724 records were identified from the electronic databases following deletion of
duplicate records.
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Eight guidelines were identified through grey literature searching.9,24,28,30,46,75–77 Eight systematic reviews of
relevance to the decision problem were also identified.25,29,45,50,85–88 Guidelines were published on US in
rheumatology by the ACR,46 Arthritis Research UK30 and EULAR,75 which also published guidelines on imaging
in RA.28 Guidelines on the management of RA were published by NICE9,77 and the Scottish Intercollegiate
Guidelines Network.76 Reviews were published on the use of US in inflammatory arthritis29,85–87 or US for use in
RA including the detection of synovitis and defining remission.24,25,45,50,88 The bibliographies of these guidelines
and reviews were searched to identify studies meeting the review inclusion criteria, identifying an additional
26 records. This led to a total of 2750 records being screened.
The study selection process is provided in Figure 1. At title and abstract sift, 2596 records were excluded.
The 63 records excluded at full paper sift are presented with reasons for exclusion in Appendix 4.
A total of 75 articles53,55,68,69,89–158 describing 58 studies were included in the review; following the searches
but prior to publication of this report, one of the studies identified as ongoing by the searches (ARCTIC) was
published as an abstract.79 Data extraction forms for these included studies are provided in Appendix 5.
Study quality assessment forms for the included studies are provided in Appendix 6.
Ten89–98 of the 58 included studies were reported as abstracts only and so limited details were available.
Of the 58 studies included, diagnosis of RA was reported as being confirmed using the ACR or
EULAR classification criteria for RA, either the 2010 criteria11 or an earlier version,8 in all except nine
studies.89,90,92–96,98,99
Included articles
(n = 75)
58 studies were addressed
Records screened
(n = 2750)
Records excluded at title and
abstract level
(n = 2596)
Full-text articles assessed for
eligibility
(n = 154)
Articles excluded at full text
(n = 63)
(see Appendix 6)
Records identified through database searching with
duplicates removed (including update search)
(n = 2724)
Additional records identified
(n = 26)
Relevant reviews or guidelines,
bibliographies checked
(n = 16)
• 26 studies: prognositic and/or treatment data
• 32 studies: diagnostic data only (see Appendix 7 )
FIGURE 1 Flow diagram of study inclusion.
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An established US scoring system was referenced in all but nine89,91,94,95,100–104 of the 58 included studies.
According to the hierarchy of evidence published by Merlin et al.,159 diagnostic accuracy studies are of
higher quality if they are blinded and recruit consecutive patients and prospective cohort studies are of
higher quality than other forms of prognostic studies. Of 33 studies53,92,96,102–116,118–132 reporting diagnostic
accuracy or detection rates of synovitis, 13102–104,107,109–111,113–115,118,119,124 were blinded comparisons of
consecutive patients. Of 15 studies of prognosis,55,69,97,98,113,134,135,137–144 all but one,138 an ancillary study to a
RCT, were prospective cohort studies.
Studies reporting the detection of synovitis are described in Appendix 7 (see Tables 138–140). Diagnostic
data were extracted from 37 publications53,68,92,96,99,102–132,146 reporting on 33 studies. One of these
studies113,146 also provided prognostic data.
For most of the studies providing diagnostic data (see Appendix 7, Table 138), CE had a high specificity
and low sensitivity when using PDUS or GSUS as the reference standard. This indicates some agreement
between CE and US, with US detecting synovitis in some joints that CE did not detect and only a few
cases in which CE detected synovitis and US did not. This agrees with the higher detected rates of synovitis
for US over CE (see Appendix 7, Table 139) reported in the majority of studies.
However, five studies found lower rates of detection of synovitis with US than with CE.106,115,123,125,130 Also,
there were mixed results in three studies, with higher detection rates for GSUS than for CE but lower
detection rates for PDUS than for CE in two studies108,119 and lower detection rates for PDUS than for CE
for metacarpophalangeal (MCP) joints but higher detection rates for PDUS than for CE for proximal
interphalangeal (PIP) and wrist joints in one study.131
The five studies106,115,123,125,130 that found lower rates of detection with US than with CE were some of the
older trials; however, there were other trials from the early 2000s that did not report this finding and so
this cannot explain the difference between these trials and trials finding a higher rate of detection with US
than with CE. Study quality did not explain the differences between the study results, although one of the
studies reporting a lower rate of detection with US than with CE had a small sample size (n = 6), and the
differences did not appear to be caused by the US scoring system used (0–1 vs. 0–3 or 0–4; see Table 3).
It may be that the types of joint examined could explain the differences between the study results. Of the
studies finding lower rates of detection with US than with CE, three studies106,115,130 investigated ankle and/or
foot joints and one study123 included metatarsophalangeal (MTP) joints; however, this study also assessed PIP
and MCP joints, which have been shown to have higher rates of detection of synovitis using US than using
CE.125 This agrees with one within-study comparison of joints, which reported that CE had a lower sensitivity
for MTP joints than for MCP or PIP joints.160 However, heterogeneity between other studies, suggesting that
US is less useful for foot and ankle joints than for wrist and hand joints, means that there is uncertainty in
the findings.
The detection of subclinical synovitis would be useful only if clinically relevant, as investigated using
prognostic studies.
Prognostic data were extracted from 23 publications55,56,69,97,98,100,113,134–139,141–148,150,151 reporting on 15 studies.
One of these studies was an ancillary study to a RCT.138 The other studies were prospective cohort studies in
which a cohort of patients was assessed at baseline with US and with CE and was then followed up to assess
the association of these baseline measures with a given outcome. Prognostic data are provided in Tables 6–8.
Treatment data were extracted from 16 publications89–91,93–95,100,101,139,152–157 reporting on 13 studies. Following the
searches but prior to publication of this report, one of the studies identified as ongoing (ARCTIC) was published
as an abstract.79 This abstract was included to provide treatment data, meaning that 14 studies in total provided
data relating to treatment. Six of these were prospective cohort studies that measured the association of an
outcome at follow-up with the US and CE variables measured at baseline93,101 or US and CE variables measured
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after 4 months of treatment139 or at the time of treatment discontinuation or tapering.95,155,156 One study
reported data from a prospective cohort in which baseline US and CE variables were tested for association
with an outcome taken from a RCT of RA treatment.95,132 Two studies were RCTs comparing treatment
strategies with or without US.79,154 One of these RCTs154 also provided data on treatment decisions. Treatment
decisions were also investigated using observational data.89–91,94,152 Treatment data are provided in Tables 9–14.
Meta-analyses were not performed because of heterogeneity in the type of US used, US scoring systems
used (see Table 3), joints assessed, clinical comparators (type of examination; use of composite clinical
scoring), outcome measures and follow-up times.
Assessment of prognostic studies
Heterogeneity of trials precluded meta-analysis. Therefore, no summary estimates of effect were available,
which is a limitation of the review. Significance values refer to the association of baseline US and CE
measures with later outcome measures. Radiographic progression measures are of importance to patients
as they reflect structural damage, which is associated with loss of function over time. Other outcomes
assessed are of importance to patients as they reflect disease activity and function. Studies investigated
whether or not baseline measures could be predictive of later outcomes, rather than directly comparing
different baseline measures. As well as heterogeneity of outcome measures, studies differed in the statistics
reported to assess the association of baseline US and CE measures with clinical outcome at follow-up,
including Spearman correlations (R) and odds ratios (ORs) (univariate analysis unless otherwise stated).
Two studies113,134 reported the sensitivity of US and CE measures to predict progression (Table 4). These were
prospective cohort studies in which patients were tested with US and underwent CE at baseline and were then
followed up and evaluated for the outcome measures of progression. Boyesen and Haavardsholm134 used
a measure of GSUS inflammation based on synovitis and tenosynovitis and found that this US measure had a
similar sensitivity for predicting erosive progression as MRI at 12 months, indicating that the majority of patients
with a high US score, or high DAS, relapsed. This measure of GSUS inflammation134 had a higher specificity
than DAS28 (although neither US nor DAS28 had high specificity) for predicting erosive progression as
measured by MRI at 12 months, indicating that more patients with a low GSUS score than a low DAS did not
progress. Ikeda et al.113 found that GSUS, PDUS and Disease Activity Score 28 joints using C-reactive protein
(DAS28-CRP; see Table 1) had similar sensitivities for predicting radiographic progression at 24 weeks (see
Table 4). GSUS had a lower specificity than PDUS and DAS28 for predicting radiographic progression.113 This
study subgrouped patients by recently retrieved treatment and found that in MTX-treated patients (n= 16) and
TCZ-treated patients (n= 17) PDUS had higher specificity than DAS28-CRP, but that specificities were similar in
TNFi-treated patients (n= 24) (see Appendix 5). Both of these studies were prospective cohort studies, at level II
in the study quality hierarchy, although the study by Ikeda et al.113 was a better-quality and more rigorous study
given that blinding was unclear in the study by Boyesen and Haavardsholm134 (see Appendix 8).
Eleven studies (with 14 publications55,69,97,113,134–136,138–141,144,148,150) reported an association of US and CE
prognostic factors with radiographic progression/erosion (Table 5). These were prospective cohort studies
in which patients were tested with US and underwent CE at baseline and were then followed up and
evaluated for the outcome measures of progression.
Of the 11 studies, seven55,69,113,138–140,144 found that US and at least one of the clinical measures investigated
could significantly predict radiographic progression, most of which were of high quality (with the exception
of two studies69,138 in which blinding was unclear). Three studies found that US could significantly predict
radiographic progression whereas the clinical comparator could not (DAS28-ESR/ESR/CRP;134 joint counts;135
SJC97), two97,134 of which were less rigorous in terms of study quality, with blinding being unclear. One
study141 found that neither US nor the clinical comparator (ESR) was significantly associated with later
progression; this study was more rigorous in terms of study quality. All of the studies were prospective
cohort studies, at level II in the study quality hierarchy, with the exception of one study,138 which was an
ancillary study to a RCT (see Appendix 8).
ASSESSMENT OF ULTRASOUND STUDIES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
TABLE 4 Sensitivity and clinical prognosis
Study Population Outcome
Patients with
outcome, n (%) US measure
Sensitivity
(95% CI), %
Specificity
(95% CI), % Clinical measure Sensitivity, % Specificity, %
Boyesen 2011134 79 patients,
dominant wrist
MRI erosive progression
at 12 months (≥ 1-unit
increase in RAMRIS)
53 (67.1) GSUS inflammation
score cut-off values
< 0.5 vs. ≥ 0.5a
79 (NR) 55 (NR) DAS28 remission/low
vs. moderate/highb
74 (NR) 21 (NR)
Ikeda 2013113 57 patients,
28 joints of
DAS28
Radiographic progression
(mTSS) at 24 weeksc
21 (36.8) Total GSUS score
cut-off values
of < 62
56 (NR) 57 (NR) DAS28-CRP cut-off
of < 9.0
64 (NR) 81 (NR)
Total PDUS score
cut-off values
of < 21
69 (NR) 76 (NR)
CI, confidence interval; mTSS, modified total Sharp score; NR, not reported; RAMRIS, rheumatoid arthritis magnetic resonance imaging scoring system.
a Composite score of synovitis and tenosynovitis.
b Cut-off values not reported.
c vdHSS.
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TABLE 5 Correlation of US and CE with prognosis: radiographic progression
Study Population Joints Follow-up Outcome Type of US
Correlation of US
synovitis with
outcome Type of CE
Correlation of CE
with outcome
Backhaus 201369 453 patients US7 score 12 months Bone erosion
(US7 erosion
sum score)
US7 synovitis sum
score in GSUS
R± SD: 0.140± 0.038
(95% CI 0.066 to
0.215; p < 0.001)
DAS28, ESR, CRP R± SD: DAS28 of 0.621±
0.141 (95% CI 0.345 to
0.898; p< 0.001); ESR
0.008± 0.010 (95% CI
−0.011 to 0.027;
p= 0.399); CRP 0.001±
0.009 (95% CI −0.017 to
0.018; p= 0.945)
US7 synovitis score
in PDUS
R± SD: 0.099± 0.051
(95% CI −0.001 to
0.200; p = 0.053)
Boyesen 2011134 84 patients Dominant wrist 1 year MRI erosive
progressiona
GSUS (univariate
analysis)b
OR 2.15 (95% CI
1.23 to 3.75; p= 0.01)
DAS28 (univariate
analysis)
OR 1.15 [95% CI 0.80 to
1.64; p= 0.46 (NS)]
GSUS (multivariate
analysis)b,c
OR 2.01 (95% CI
1.14 to 3.53; p= 0.02)
ESR (univariate
analysis)
OR 1.02 [95% CI 0.98 to
1.06; p= 0.29 (NS)]
GSUS synovitis
(radiocarpal joint
assessed in the
dorsal midline)
OR 7.2 (95% CI
0.9 to 61.0; p= NS)
CRP (univariate
analysis)
OR 1.04 [95% CI 0.98 to
1.10; p= 0.16 (NS)]
Brown 2008135
(same study as
Ikeda 2007136)
90 patients in
clinical remission
Dominant hand
MCP joint and
wrist
12 months Progressive
radiographic
damage (both
hands and feet)d
PDUS signal OR 12.21 (95% CI
3.34 to 44.73;
p< 0.001)
Painful
joint count
OR 3.32 (95% CI 0.39 to
28.30; p= 0.273)
GSUS synovial
hypertrophy
OR 1.92 (95% CI
0.49 to 7.54;
p= 0.350)
TJC OR 2.17 (95% CI 0.26 to
18.10; p= 0.473)
SJC OR 1.69 (95% CI 0.43 to
6.67; p= 0.457)
Ikeda 2007136
(same study as
Brown 2008135)
107 patients in
remission (clinician
assessed) on
DMARDs
Dominant hand
MCP and wrist
12 months Radiographic
progression (direct
assessment of
individual joints)
GSUS synovial
hypertrophy score
Mann–Whitney U-test
p= 0.027
Painful joints Chi-squared test
p = 0.284
PDUS score p< 0.001 (in
asymptomatic joints
only p= 0.002)
Tender joints p = 0.389
Increased
PDUS signal
Likelihood ratio 7.02,
chi-squared test
p= 0.037
Swollen joints p = 0.417
A
S
S
E
S
S
M
E
N
T
O
F
U
L
T
R
A
S
O
U
N
D
S
T
U
D
IE
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
1
8
Study Population Joints Follow-up Outcome Type of US
Correlation of US
synovitis with
outcome Type of CE
Correlation of CE
with outcome
Cavet 2009138 24 patients 10 MCP joints100 110 weeks Radiographic
progressione
GSUS synovial
thickening
R= 0.59 (p-value NR) Biomarkers (93
serum proteins)
at 6 weeks
(multivariate
model)
Significant correlation
R = 0.79 (p-value NR)
Power Doppler
area)
R= 0.77 (p-value NR)
Dougados 2013139,149 59 patients MCP (×10), PIP
(×10), wrist (×2)
and MTP (×10)
joints
2 years Radiological
progressionf
GSUS (0 vs. 1–3) OR 1.64 (95% CI
1.08 to 2.47)
Clinical synovitis
g
0 vs. 1–3: OR 2.08
(95% CI 1.39 to 3.11;
p < 0.001); 0–1 vs. 2–3:
OR 1.64 (95% CI 1.14 to
2.36; p= 0.008)
GSUS (0–1 vs. 2–3) OR 1.91 (95% CI
1.18 to 3.10)
Tender joints OR 1.53 (95% CI 1.02 to
2.29; p= 0.04)
PDUS 0 vs. 1–3 OR 1.80 (95% CI 1.20
to 2.71; p= 0.005)
Tender joints with
clinical synovitis
OR 1.89 (95% CI 1.25 to
2.85; p= 0.002)
PDUS 0–1 vs. 2–3 OR 1.36 (95% CI 0.78
to 2.38; p= 0.278)
Ikeda 2013113 57 patients
(MTX, n= 16;
TNFi, n = 24;
TCZ, n= 17)
Finger, wrist,
elbow, shoulder
and knee
24 weeks Radiographic
damagee
GSUS (cumulative
total GSUS score)
R= 0.062; p= 0.649
(MTX, r = 0.210,
p= 0.436; TNFi,
r = 0.027, p = 0.900;
TCZ, r = 0.492,
p= 0.179)
Cumulative
DAS28-CRP
R = 0.342, p= 0.009
(MTX, r = 0.487,
p = 0.056; TNFi,
r = 0.308, p= 0.144;
TCZ, r = 0.369,
p = 0.145)
PDUS (cumulative
total PDUS score)
R= 0.357; p= 0.006
(MTX, r = 0.679,
p= 0.004; TNFi,
r = 0.153, p = 0.476;
TCZ, r = 0.353,
p= 0.165)
Naredo 200755 42 RA patients
starting DMARDs
(38 patients
followed up to
1 year)
28 joints 1 year Total radiographic
score progression
(radiographic
erosion score and
JSN score)e
Joint count for
GSUSh
GSUS r = 0.61;
p< 0.001
SJC, TJC, DAS28,
HAQ, ESR, CRP
SJC, r = 0.46, p< 0.01;
TJC, r = 0.36, p< 0.05;
DAS28, r = 0.40,
p < 0.05; HAQ, r = 0.36,
p < 0.05; ESR/CRP, NS
Joint count for
PDUS signali
PDUS r = 0.59;
p< 0.001
continued
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TABLE 5 Correlation of US and CE with prognosis: radiographic progression (continued )
Study Population Joints Follow-up Outcome Type of US
Correlation of US
synovitis with
outcome Type of CE
Correlation of CE
with outcome
Naredo 2008140 278 patients with
complete data (of
367 RA patients
starting TNFis)
86 intra-articular
and periarticular
sites in 28 joints
1 year Total radiographic
score progression
(radiographic
erosion score and
JSN score);e
multivariate
analysis
j
Time integrated
values of US joint
count for PDUS
signal
Total radiographic
score (R = 0.59)
significant; erosion
score (R = 0.64)
significant; JSN
score NS
ESR, CRP Total radiographic score:
ESR (R= 0.59) significant;
ESR for erosion or JSN
score NS; baseline CRP
level weak predictive
value for JSN score
progression (R= 0.2);
CRP NS for erosion and
total scores
Osipyants 201397,150 35 patients Wrists 1 year Radiographic
progression
(mTSS)e
PDUS signals
of residual
inflammation of
the wrists at
6 months
Significantly correlated
(r= 0.696; p= 0.011);
mTSS at 1 year
significantly higher
[93 (range 56–131) vs.
32.5 (range 19.5–83)
units; p< 0.04] in
patients with middle-
or high-active PDUS
signals (n= 27)
(SJC> 1, PDUS> 1)
than in cases with
lower imaging activity
or the absence of the
PD signals (n= 8) at
6 months
SJC Non-significantly
lower radiographic
progression over 1 year
in those with SJC≤ 1
[55 (range 31–116) vs.
88.5 (range 55–130);
p< 0.205] than in those
with SJC > 1 (n= 25)
Reynolds 2009141 25 patients
(providing data
at the 2-year
follow-up of
40 patients
recruited)
MCP and
PIP joints
2 years Erosion
progressionk
GSUS and PDUS Mann–Whitney U-test
synovial score (0–3) NS;
mean synovial thickness
(cm) NS; pre-contrast
PDUS score (0–3) NS;
post-contrast PDUS
score (0–3) NS
ESR NS
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Study Population Joints Follow-up Outcome Type of US
Correlation of US
synovitis with
outcome Type of CE
Correlation of CE
with outcome
Yoshimi 2013144 22 RA patients in
clinical remission
(of 31 recruited)
Bilateral wrists
and all of the
MCP and
PIP joints
2 years Radiographic
progressione
Total PDUS score Total PDUS score
significantly higher
in patients with
radiographic
progression than in
patients without
(6.00 ± 6.44 vs.
0.87 ± 1.15;
p= 0.0011)
SJC, DAS28,
gVAS and the
serum levels of
ESR, CRP and
MMP-3
Significant differences in
SJC (0.33 ± 0.79 vs.
1.29± 0.70; p= 0.0040)
and DAS28-ESR
(p= 0.0010) and DAS28-
CRP (p= 0.041) between
the radiographic
progression group and the
non-progression group.
Borderline significance for
TJC (p= 0.054). No
significant difference in
other clinical parameters
(gVAS and the serum
levels of ESR, CRP and
MMP-3) between the
radiographic progression
group and the non-
progression group
Total GSUS score No significant
difference in the total
GSUS score, (12.6 ±
12.4 vs. 8.80± 5.78;
p= 0.57), between
the radiographic
progression group and
the non-progression
group
CI, confidence interval; gVAS, general visual analogue scale; JSN, joint space narrowing; MMP-3, matrix metalloproteinase 3; mTSS, modified total Sharp score; NR, not reported;
NS, non-significant radiographic progression; PD, power doppler; RAMRIS, rheumatoid arthritis magnetic resonance imaging scoring system; SD, standard deviation; US7, ultrasound 7 score.
a ≥ 1-unit increase in 1-year RAMRIS erosive change.
b Composite score of synovitis and tenosynovitis.
c CE measures were not included in the stepwise regression analysis as they did not reach statistical significance. Multivariate analysis included GSUS, bone marrow oedema, gender
and age.
d Genant-mTSS.
e vdHSS.
f Occurrence or worsening of erosion or JSN.
g 0= no synovitis; 1= doubtful synovitis; 2= obvious and moderate synovitis; 3= obvious and important synovitis.
h Grey-scale USJCAS (ultrasonographic joint count for active synovitis).
i Power Doppler USJIPD (ultrasonographic joint index for power Doppler signal).
j Multivariate analysis included time-integrated PDUS, rheumatoid factor, CRP and ESR.
k Measured by US, graded from 0 to 3.
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1
The majority of the studies reported a significant correlation between US and radiographic progression,
using GSUS55,69,134–136,138,139,148 or PDUS;55,69,97,113,134–136,138–140,144,148 most of these studies were rigorous in
terms of study quality, with four less rigorous studies in which blinding was unclear.69,97,134,138
In some cases, GSUS was not significantly correlated with radiographic progression whereas PDUS was
(see Table 5). There was no significant correlation with radiological progression for GSUS in the study by
Ikeda et al.,113 which did not find improved sensitivity or specificity above those for DAS28-CRP at
24 weeks (see Table 4). This study also found that PDUS was significantly correlated with radiological
progression in the MTX-treated subgroup but not in bDMARD-treated patients.
Grey-scale ultrasound was not significantly correlated with radiographic progression in a study of 22
patients in clinical remission whereas there was a significant correlation between PDUS and radiographic
progression.144 One study135,136 found that PDUS was significantly associated with later radiographic
outcomes. Another study of 25 patients found that neither GSUS nor PDUS was significantly correlated
with erosion progression at 2 years’ follow-up.141
Some studies reported a significant association of CE with radiographic progression (see Table 5). DAS28
was significantly correlated with radiographic progression in four studies,55,69,113,144 although not in the
study by Boyesen and Haavardsholm134 nor in the bDMARD subsets in the study by Ikeda et al.113 HAQ
score was significantly correlated with radiographic progression in the only study reporting this outcome.55
ESR and CRP did not significantly correlate with radiographic progression,55,69,134,141,144 with the exception
of the study by Naredo et al.,140 which found that ESR and total radiographic score progression were
significantly associated. Biomarkers (serum proteins) were significantly correlated with modified total Sharp
score (mTSS) in the only study reporting this comparator.138
Swollen joint count and TJC were significantly correlated with radiographic progression in three
studies55,139,144 but not in two studies97,135,136 and painful joint count was not significantly correlated with
radiographic progression in one study.135,136
Power Doppler ultrasound was significantly associated with radiographic progression in 10 studies in which it
was measured. Associations reported as ORs were as follows: OR 12.21 [95% confidence interval (CI) 3.34
to 44.73; p < 0.001]135 and OR 1.80 (95% CI 1.20 to 2.71; p = 0.005).139 Associations reported at correlation
coefficients were as follows: r = 0.099 (p = 0.05);69 r = 0.357 (p = 0.006);113 r = 0.59 (p < 0.001);55 r = 0.696
(p = 0.011);97 r = 0.59 (p-value not reported);140 and r = 0.77 (p-value not reported).138 Mann–Whitney U-test
results reported were p < 0.001136 and p = 0.0011.144
One study141 reported a non-significant association of baseline PDUS with the outcome measure. This
different result could not be explained by study quality or the joints assessed and, although the authors
suggested that the scoring system used was not as sensitive as that used in other studies, other studies
that used semiquantitative scores found significant associations. This study did differ from most in that the
outcome of erosion was measured by US. The other study that used US to measure the end point was
the study reporting borderline significance for association.69
Grey-scale ultrasound was significantly associated with radiographic progression in six studies. Significant
associations reported were as follows: Mann–Whitney U-test p= 0.027,136 r = 0.140 (p< 0.001),69 r = 0.61
(p< 0.001),55 OR 2.15 (95% CI 1.23 to 3.75; p= 0.01)134 and OR 2.08 (95% CI 1.39 to 3.11).139 A moderate
correlation was found between GSUS and radiographic progression in one study.138 GSUS was not significantly
associated with radiographic progression in three studies: OR 1.92 (95% CI 0.49 to 7.54; p = 0.350);135
R = 0.062 (p = 0.649);113 and Mann–Whitney U-test non-significant.141 One of these studies113 had a shorter
follow-up time (24 weeks) than the others, but the other two studies135,141 with non-significant associations
had similar follow-up times to the studies finding significant associations. These two studies135,141 were two of
the older studies included in the review, which may indicate a difference in the US machines used; however,
because of the heterogeneity between studies, it is uncertain why these studies differed from those reporting
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a significant association. The difference between studies reporting significant associations and studies
reporting non-significant associations could not be explained by study quality, joints assessed or how the end
point was measured.
The DAS28 joints was significantly correlated with radiographic progression in one study measuring
progression using the ultrasound 7 score (US7) score (r = 0.621, p < 0.001)69 and three studies measuring
progression using the mTSS [r = 0.342, p = 0.009;113 r = 0.40, p < 0.05;55 and p = 0.0010 (DAS28-ESR) and
p = 0.041 (DAS28-CRP) (only p-values reported)144]. DAS28 was not significantly correlated in one study
measuring MRI erosive progression.134 Given heterogeneity between trials, it is uncertain whether outcome
measure was the factor explaining the difference between trials finding a significant association, or not,
between DAS28 and later radiographic progression.
Other outcomes
Studies reporting outcomes other than radiographic progression (measures of disease activity) are shown in
Table 6. These were prospective cohort studies in which patients were tested with US and underwent CE
at baseline and were then followed up and evaluated for outcome measures of disease activity. All studies
used measures in the baseline CE that were not the same as the outcome measure at follow-up (although
some studies additionally reported assessment of the outcome measure at baseline (DAS28 and HAQ
score;55 components of the composite outcome measure145).
In three cases, US and at least one clinical comparator measure were associated with the later outcome
[ESR,98 Health Assessment Questionnaire Disability Index (HAQ-DI)142 and DAS55]. Three studies found that
US was significantly associated with the later outcome but the clinical comparator was not (DAS28-CRP
or SDAI;97 DAS28-CRP, DAS28-ESR, SJC, TJC, CRP and ESR;145 and SJC and DAS28137). In the study by
Naredo et al.,55 the clinical comparator DAS28 was associated with the later HAQ outcome, but the US
joint count of 28 joints was not. The authors suggested that their results may differ from those of other
studies because early RA patients were used in their study and, at this point of disease, functional status is
related to inflammatory activity more than residual structural damage.
Low disease activity (i.e. a DAS of < 2.4) at 1 year was not significantly correlated with PDUS or the
biomarker chemokine (C-X-C motif) ligand 13 (CXCL13).147
The Disease Activity Score 28 joints at 1 year was significantly correlated with GSUS and PDUS and HAQ,
SJC, TJC and ESR/CRP.55 Relapse from clinical remission (i.e. of DAS28 of < 2.6) was significantly correlated
with PDUS and ESR but not transforming growth factor beta 1 (TGFβ1).98 Relapse (i.e. a DAS of ≥ 1.6) at
6 months was significantly correlated with PDUS, SJC and DAS but not GSUS.137 Time to clinical remission
(DAS28 of < 2.6) was not significantly correlated with GSUS, PDUS or DAS28 at baseline in a study of
10 patients.143
Remission, defined by ACR/EULAR Boolean criteria [score of ≤ 1 for all of the TJC, SJC, CRP and patient
global assessment components], at 2 years was significantly correlated with PDUS and GSUS, but not with
the clinical comparators DAS28, SJC, TJC, CRP or ESR.145
Flare, defined as any increase in disease activity requiring a change in therapy, at 12 months was
significantly correlated with PDUS, HAQ and Rheumatoid Arthritis Quality of Life (RAQoL), but not with
GSUS, SJC, TJC, CRP, DAS28 or SDAI.142
Two studies investigated HAQ, one of which found that HAQ score at 1 year of follow-up was not
significantly correlated with GSUS, PDUS, SJC, or ESR, but was with DAS28 and TJC.55 One study97 found
that HAQ score at 6 months was significantly correlated with PDUS, but not with DAS28 or SDAI (DAS28
and SDAI were significantly correlated in the subgroup with a disease duration of < 2 years but there were
only nine patients in this subgroup).
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TABLE 6 Correlation of US and CE with prognosis outcomes other than radiographic progression
Study Population Joints Follow-up Outcome Type of US
Correlation of US
synovitis with
outcome Type of CE
Correlation of CE with
outcome
Scirè 2009137
(same study as
Bugatti 2012147)
43 patients
achieving clinical
remission
Bilateral shoulder,
elbow, wrist,
MCP, PIP,
sternoclavicular,
acromioclavicular,
knee, ankle and
MTP joints
6 months Clinical relapse US joint count > 2
(multivariable)a
OR 4.6 (95% CI 0.4 to
49.5; NS)
SJC > 1 OR 0.6 (95% CI 0.1 to 5.5)
PDUS > 0 OR 12.8 (95% CI 1.6,
103.5; p< 0.05)
DAS28 of > 1.1 OR 9 (95% CI 0.7 to 110.3)
Bugatti 2012147
(same study as
Scirè 2009137)
161 patients with
early RA
Hands 12 months Low disease
activity
(i.e. a DAS
of < 2.4)
PDUS synovitis
scored (0–3)
OR 0.94 [0.31 to 2.83;
p = 0.91 (NS)]
Serum levels of
the chemokine
CXCL13
NS
Naredo 200755 42 patients with RA
starting DMARDs
(38 followed up for
1 year)
28 joints 1 year DAS28 Joint count
for GSUSb
GSUS r = 0.63;
p < 0.001
SJC, TJC, DAS28,
HAQ, ESR, CRP
DAS28, r= 0.75, p< 0.001;
HAQ; r= 0.66, p< 0.001;
TJC, r= 0.50, p< 0.01;
SJC; r= 0.45, p< 0.01;
ESR/CRP, r= 0.49, p< 0.01
Joint count for
PDUS signalc
PDUS r = 0.63;
p < 0.001
HAQ Joint count
for GSUSb
GSUS NS SJC, TJC, DAS28,
HAQ, ESR, CRP
HAQ, r = 0.82, p< 0.001;
DAS28; r = 0.49, p < 0.01;
TJC, r = 0.50, p < 0.01;
SJC NS; ESR NSJoint count for
PDUS signalc
PDUS NS
Osipyants 201397,150 35 Wrists 6 months HAQ PDUS Significant (r = –0.821;
p = 0.003)
DAS28-CRP, SDAI Association with baseline
DAS28 or SDAI NS.
Subgroup [disease duration
< 2 years (n= 9)]: HAQ
score at 6 months
correlated with baseline
DAS28-CRP (r= 0.705,
p= 0.02) and SDAI
(r= 0.678, p= 0.03)
Ramirez García
201498
28 Knees and hands
(wrists, MCP,
PIP flexor and
extensor tendons
of the hand)
12 months Relapse from
clinical remission
(i.e. a DAS28
of < 2.6)
PDUS p = 0.034; logistic
regression model
OR 6.18d
ESR, TGFβ1 ESR, p = 0.046; TGFβ1,
p= 0.082
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Study Population Joints Follow-up Outcome Type of US
Correlation of US
synovitis with
outcome Type of CE
Correlation of CE with
outcome
Saleem 2012142 93 RA patients in
clinical remission
as determined by
their treating
rheumatologist
Hand and wrist 12 months Flare – defined as
any increase in
disease activity
requiring a change
in therapy [24/93
(26%)]
PDUS and GSUS PDUS (unadjusted OR
4.08, 95% CI 1.26 to
13.19; p= 0.014);
GSUS score was not
significantly associated
(p= 0.658)
HAQ-DI, TJC,
SJC, RAQoL, CRP,
DAS28, SDAI
HAQ-DI per 0.1 unit OR
1.27 (95% CI 1.07 to
1.52; p= 0.006). RAQol
OR 1.10 (95% CI 1.01 to
1.20; p= 0.036). Other
variables were NS: SJC,
p= 0.690; TJC, p = 0.827;
CRP, p = 0.308; DAS28
remission, p= 0.499; SDAI
remission, p= 0.616
Wakefield 2007143 10 Bilateral
glenohumeral,
elbow, wrist,
MCP, PIP, knee,
tibiotalar,
midtarsal and
MTP joints
46 weeks Time to
clinical remission
GSUS score R = –0.221 (NS) Baseline DAS28 r = 0.627; p= 0.071
(NS trend)
PDUS score R = –0.289 (NS)
Yoshimi 2014145 22 patient with RA
in clinical remission
(of 31 recruited)
Bilateral wrists
and all of the
MCP and
PIP joints
2 years Remission, defined
by ACR/EULAR
Boolean criteria;
score of ≤ 1 for
all of TJC, SJC,
CRP and PGA
components
PDUS total score p = 0.020 DAS28-CRP,
DAS28-ESR, SJC,
TJC, CRP, ESR
NS for all: DAS28-CRP,
p= 0.76; DAS28-ESR;
p= 0.38; SJC; p= 0.060;
TJC, p= 1.00; CRP,
p= 0.17; ESR, p= 0.39
GSUS total score p = 0.020
CXCL13, chemokine (C-X-C motif) ligand 13; HAQ-DI, Health Assessment Questionnaire Disability Index; NS, non-significant; PGA, patient global assessment; RAQoL, Rheumatoid Arthritis
Quality of Life; TGFβ1, transforming growth factor beta 1.
a Multivariable analysis included US joint count, PDUS > 0, DAS, SJC and steroid use.
b Grey-scale USJCAS (ultrasonographic joint count for active synovitis).
c Power Doppler USJIPD (ultrasonographic joint index for power Doppler signal).
d Logistic regression included PDUS, ESR and TGFβ1.
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5
Treatment studies
Treatment response or strategies
Nine studies79,93,95,100,101,139,154–156 reported data relating to treatment response or strategies. RA was reported
as being diagnosed by 2010 ACR/EULAR criteria11 in two studies154,155 and by pre-2010 ACR/EULAR criteria8
in four studies;100,101,139,156 the criteria used were not reported in two studies.93,95 Established semiquantitative
scoring systems were used by Dougados et al.,139 Inanc et al.,93 Naredo et al.156 (scoring system published by
Wakefield51), Iwamoto et al.155 (scoring system published by Naredo et al.140) and Dale et al.154 (scoring
system published by Szkudlarek et al.52). The heterogeneity of the trials precluded meta-analysis. Therefore,
no summary estimates of effect are available, which is a limitation of the review. Significance values referred
to the association of baseline US and CE measures with treatment measures (such as treatment persistence
or response to treatment tapering). These measures could be of importance to patients in so far as they can
be used to refine treatment.
Ultrasound was compared with CE as potential predictors of treatment persistence or response (Table 7).
The study by Ellegaard et al.101 investigated patients starting TNFi treatment to determine whether or not
treatment persistence at 1 year of follow-up was associated with US and clinical measures [TJC, SJC, CRP,
visual analogue scale (VAS), HAQ and DAS28]. This was a prospective cohort study in which patients were
tested with US and underwent CE at baseline and were then followed up and evaluated to investigate the
ability of these factors to predict treatment adherence, defined as patients remaining on TNFi therapy at the
1-year follow-up. Among US measures, the square root of the US Doppler colour fraction (USDCF), a
measure of hyperaemia, was the only measure that significantly predicted TNFi continuation (p = 0.008).
None of the clinical measures assessed, including SJC, TJC, DAS28 and CRP, was significantly associated
with treatment persistence.101 In the study by Inanc et al.93, when considering EULAR response compared
with no response after 3 months, baseline PDUS (p = 0.029) and GSUS (p = 0.020) differed significantly
between responders and non-responders. This was a prospective cohort study in which patients were tested
with US and underwent CE at baseline and were then followed up and evaluated to investigate the association
with EULAR response at 3 months’ follow-up. Two of the clinical measures assessed also significantly
differentiated between responders and non-responders [pain VAS (p = 0.009) and SJC (p = 0.05)], whereas
other clinical measures (DAS28, TJC, ESR and CRP) did not.93
Patients with persistent synovitis measured by GSUS or PDUS (Table 8), after 4 months of bDMARD treatment,
were significantly more likely to have radiological progression at 2 years’ follow-up.139 The study by Dougados
et al.139 was a prospective cohort study in which 4 months of biological therapy were prescribed, with further
follow-up up to 2 years. The association of lack of response to treatment at 4 months, measured by US or CE
using a semiquantitative scoring system, with radiological progression at 2 years was assessed. For persistent
synovitis as measured by CE, this did not reach significance.139 Taylor et al.100 reported prognostic data from a
study that was part of a RCT comparing MTX plus IFX with MTX plus placebo in aggressive early RA. Baseline
US and CRP were tested for association with radiological progression at 54 weeks. US could significantly
predict radiological progression in MTX plus placebo-treated patients (p = 0.020), but not in IFX plus
MTX-treated patients (p = 0.479).100 However, there were only 12 patients in each group in this study.
Baseline CRP did not significantly predict progression in either treatment group.100
One prospective cohort study with 6 months’ follow-up155 reported the ability of US and CE to predict
relapse following discontinuation of bDMARD (TNFi or TCZ) treatment (Table 9). GSUS- and PDUS-detected
synovitis at the time of treatment discontinuation (total GSUS score of ≥ 14, total PDUS score of ≥ 3) had
higher positive predictive values (PPVs) than DAS28 (≥ 1.5) for predicting relapse within 6 months. Relapse
was defined as a DAS28 of > 3.2 in conjunction with escalation of anti-rheumatic treatment. Using these
cut-off points patients were more likely to relapse if they had high GSUS (p = 0.007) or PDUS (p = 0.001)
scores, but this was not the case for high DAS28 (p = 0.297). Few patients with high US scores did not
relapse (GSUS, n = 2/10, PDUS, n = 1/9), but several patients with high DAS28 did not relapse (n = 15/28).
However, negative predictive values (NPVs) were similar for GSUS, PDUS and DAS28 as most patients with
scores below the cut-off point for US or DAS did not relapse.
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TABLE 7 Treatment persistence or response
Study Population Joints Follow-up Outcome US type
US association
with outcome CE association with outcome
Ellegaard
2011101
109 patients starting
TNFis (ADA, ETN
or IFX)
Wrist (most
affected)
1 year (n= 69
with US
follow-up)
Treatment persistence
(continued with TNFi)
USDCF square
roota
Treatment persistence
vs. dropouts because
of lack of efficacy,
p= 0.024; treatment
persistence vs. all
dropouts, p= 0.008
Treatment persistence vs. dropouts
because of lack of efficacy (all NS):
TJC, p= 0.86; SJC, p= 0.98;
CRP, p = 0.86; VAS (patient global),
p= 0.08; HAQ, p = 0.416; DAS28,
p= 0.943. Treatment persistence
vs. all dropouts (all NS): TJC,
p= 0.321; SJC, p= 0.486; CRP,
p= 0.453; VAS (patient global),
p= 0.240; HAQ, p= 0.098;
DAS28, p= 0.375
Inanc 201493 43 patients starting
TNFis (drugs NR)
28 joints according
to EULAR guideline
3 months EULAR no response
vs. response
PDUS p= 0.029 Pain VAS, p= 0.009; SJC, p = 0.05;
other clinical measures NS (DAS28,
p= 0.90; TJC, p= 0.12; HAQ,
p= 0.31; ESR, p = 0.61; CRP,
p= 0.98)
GSUS p= 0.020
EULAR good/moderate
response (multivariate
analysis)b
PDUS OR 0.88 (95% CI
0.68 to 0.94;
p= 0.04)
NR
GSUS NS
NR, not reported; NS, not significant.
a Other US measures not significant.
b Multivariate analysis included extra-articular involvement, pain VAS and sum score of baseline PDUS.
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TABLE 8 Progression and treatment response
Study Population
Follow-up
duration Joints Outcome Type of US
US association
with outcome Type of CE
CE association
with outcome
Taylor 2004100 24 (IFX +MTX,
n= 12; MTX +
PBO, n= 12)
54 weeks Hands and feet Radiological
progression
at 54 weeksa
Baseline synovial
thickness
MTX + PBO, r = 0.69,
p= 0.020; IFX +MTX,
r = –0.23, p= 0.479 (NS)
Baseline CRP MTX + PBO, r = 0.58,
p= 0.077; IFX +MTX,
r = 0.19, p = 0.562
Baseline synovial
vascularity
MTX + PBO, r = 0.78,
p= 0.005; IFX +MTX,
r = –0.28, p= 0.372 (NS)
Dougados
2013139
59 (ETN, n= 34;
ADA, n = 23;
IFX, n= 2)
2 years Wrist, MCP,
PIP and MTP
joints
Radiological
progressionb
GSUS (> 0 on scale
from 0 to 3),
persistent synovitis
after 4 months
of treatment
OR 3.14 (95% CI 1.50
to 6.55; p = 0.002)
CE synovitis (> 0 on
scale 0–3) persistent
synovitis after 4 months
of treatment
OR 1.70 (95% CI 0.93
to 3.12; p= 0.086)
PDUS (> 0 on scale
from 0 to 3),
persistent synovitis
after 4 months
of treatment
OR 2.79 (95% CI 1.19
to 6.56; p = 0.019)
PBO, placebo.
a vdHSS.
b Occurrence or worsening of erosion or joint space narrowing.
TABLE 9 Accuracy of US to predict relapse following discontinuation of treatment
Study Population Follow-up Joints
Outcome
measure US type
a
US PPV
(95% CI), %
US NPV
(95% CI), %
US sensitivity
(95% CI), %
US specificity
(95% CI), % CE type
a
DAS28
PPV, %
DAS28
NPV, %
DAS28
sensitivity, %
DAS28
specificity, %
Iwamoto
2014
155
40 patients
in clinical
remission
who had
discontinued
bDMARDs
6 months 134 synovial
sites in
40 joints
Relapse DAS28
of > 3.2 and
anti-rheumatic
treatment
escalated
GSUS cut-off
point ≥ 14
(n= 10)
80 (NR) 73 (NR) 50 (NR) 92 (NR) DAS28 cut-off
point ≥ 1.5
(n= 28)
46 75 81 38
PDUS cut-off
point ≥ 3
(n= 9)
89 (NR) 74 (NR) 50 (NR) 96 (NR) DAS28 cut-off
point < 1.5
(n= 12)
25 NR NR NR
NR, not reported.
a Cut-off points determined by receiver operating characteristic (ROC) curve analysis.
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This study155 also compared the median values of several variables for patients with and without relapse
(Table 10); the total GSUS score differed significantly between the groups (p = 0.005), as did the total
PDUS score (p = 0.002), whereas clinical variables (DAS28, SDAI, CDAI and HAQ) did not. Two other
prospective cohort studies95,156 investigated the association of outcomes with US assessment or CE at the
time of treatment discontinuation or tapering (see Table 10).
A study of patients in clinical remission with a reducing dose of bDMARDS156 found that PDUS could
significantly predict tapering failure (p < 0.0005), defined as an increase in bDMARD dose and/or the
presence of clinical disease activity according to both DAS28 and SDAI criteria (see Table 10), whereas
GSUS was not significantly associated with tapering failure. Some clinical variables could also significantly
predict tapering failure, namely DAS28 (p = 0.011) and SDAI (p = 0.003).156 In a study of patients in clinical
remission discontinuing or tapering DMARDS (bDMARDs or cDMARDs not specified),95 PDUS significantly
predicted disease flare (p = 0.06 by multivariate analysis) (see Table 10), as did the number of DMARDs
taken at baseline, whereas DAS28 did not.
One RCT154 investigated treatment strategies with and without US (Table 11). In this study, patients were
given the same treatment for 3 months and then either step-up DMARD escalation strategies guided by
DAS28 alone (n = 57) (target = DAS28 of < 3.2) or step-up DMARD escalation strategies guided by DAS28
plus PDUS assessment of a limited joint set (n = 53) (target = PDUS signal in one or fewer joints). Dale
et al.154 found that, at 18 months, significantly more patients in the group receiving PDUS had attained
Disease Activity Score 44 joints (DAS44) remission (p = 0.046). Since drafting this report, the full results
of this study have been published.78 At 18 months’ follow-up, significantly more patients in the group
receiving PDUS had attained DAS44 remission (p = 0.03) (see Table 11). However, for the two co-primary
end points, change from baseline in DAS44 and rheumatoid arthritis magnetic resonance imaging scoring
system (RAMRIS) erosion score, there was no significant between-group difference (p = 0.72 and p = 0.33,
respectively). A preliminary publication of the ARCTIC study results,79 identified post search, also
investigated treatment strategies with and without US in a randomised comparison (see Table 11). The
primary end point (a DAS of < 1.6 and no swollen joints at 16, 20 and 24 months and no progression in
vdHSS between 16 and 24 months) was reached by 26 patients in the US strategy group and 21 in the
control group, with no significant difference between the groups.
For both randomised trials (TaSER and ARCTIC), there was no significant difference in primary end point
between the clinical strategy group and the strategy group based on US and clinical measures. Both trials
found a significant advantage of the strategy including US for one of the secondary outcomes (DAS
remission in the TaSER study and erosion score in the ARCTIC study), but not for the other secondary
outcomes (ACR core set variables in the TaSER study; CDAI or SDAI remission or EULAR response in the
ARCTIC study). This suggests that adding US to a DAS-based strategy is not beneficial after 18–24 months.
It is uncertain whether this is because of a genuine lack of improvement caused by the US strategy or
because of other factors. Both trials included early RA patients only and PDUS (the ARCTIC study also used
GSUS) and have some incorporation bias in terms of the clinical strategy and primary outcome being DAS
related (although in the TaSER study the strategy used DAS28 and one of the co-primary outcomes was
DAS44 and in the ARCTIC study the primary outcome was a composite measure of remission that
included DAS).
Treatment decisions
Six studies89–91,94,152,153 reported on the use of US in addition to clinical measures and the impact on
treatment decisions (Table 12). These were fairly small studies, with sample sizes ranging from 1789 to
10994 (see Appendix 8). Four studies89,90,94,153 took place in rheumatology clinics in the UK, one152 was from
the USA and one91 was from France. Four studies89–91,152 did not report the source of funding, although
three89–91 of these stated that the authors had no conflicts of interest. Two studies94,153 were supported by
pharmaceutical companies. Dale et al.153 stated that neither of their funders had any role in the design,
performance, analysis, interpretation or reporting of the study.
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TABLE 10 Tapering and treatment discontinuation
Study Population Follow-up Joints Outcome US type
US association
with outcome
CE association
with outcome
Iwamoto 2014155 42 RA patients in
clinical remission,
discontinued
biological therapya
6 months 134 synovial
sites in
40 joints
Relapse (i.e. a DAS28
of > 3.2) and anti-
rheumatic treatment
escalated
Total GSUS score p= 0.005 All NS: DAS28-ESR, p = 0.609;
DAS28-CRP, p = 0.389; SDAI,
p= 0.180; CDAI, p= 0.275;
HAQ-DI, p= 0.721
Total PDUS score p= 0.002
Luengroongroj
201595
32 RA patients in
clinical remission
on DMARD(s),
about to stop or
reduce doseb
3 months NR Disease flare (arthritis
symptoms and signs
detected)
PDUS (median
total score)
Univariate analysis: OR
2.14 (95% CI 1.13 to
4.05) (significant; p-value
NR). Multivariate analysis:c
NS (trend); OR 3.06, (95%
CI 0.95 to 9.84; p = 0.06)
Number of DMARDs: univariate
analysis – OR 5.88 (95% CI
1.12 to 30.88) (significant);
in multivariate analysis NS.
DAS28-CRP: NS by univariate
or multivariate analysis
Naredo 2015156,157 77 RA patients in
sustained clinical
remissiond
12 months
(n= 35, 45.5%,
tapering failure
at 12 months)
42 (including
hands and feet)
bDMARD tapering
failure (increase in
bDMARD doses
and/or the presence of
clinical disease activity
according to both
DAS28 and SDAI
criteria)
PDUS global
index for Doppler
synovitis (DSI)
calculated
Significant associations:
higher DSI (p< 0.0005);
and DSI > 0 (p< 0.0005)
at baseline. Multivariate
analysis: DSI > 0 (OR
29.92, 95% CI 6.81 to
131.40; p< 0.0005)
Significant associations: longer
duration of RA (p = 0.009),
higher number of previous
synthetic DMARDs (p= 0.003),
higher DAS28 (p= 0.011),
higher SDAI (p= 0.003) at
baseline. Multivariate analysis:
DAS28 of ≥ 2.2 (OR 5.81,
95% CI 1.62 to 20.93;
p= 0.007). Other clinical
variables (duration of
remission) were not significant
predictors in multiple
regression analysis
GSUS GSUS was not a
significant predictor of
tapering failure in the
multiple regression
analysise
NR, not reported, NS, not significant.
a Remission: DAS28 of < 2.6.
b Remission: CDAI of < 2.8.
c Multivariate analysis included number of DMARDs, anti-cyclic citrullinated peptide antibody level, mean DAS28-CRP and median total PDUS score.
d A DAS28 of < 2.6 or a SDAI of < 3.3.
e Multivariate analysis included baseline DAS28 and the global index for Doppler synovitis (DSI) for 42 joints, 12 joints and wrist–MCP–ankle–MTP.
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TABLE 11 Treatment strategies with and without US
Study Population
Follow-up
duration Outcome
US treatment strategy
group
Clinical treatment strategy
group Comparison
Dale 2013154
(TaSER)
110 early RA patients
randomised to 3 months of
the same treatment and
then step-up DMARD
escalation strategies guided
by either DAS28 alone
(n= 57) (target: DAS28 of
< 3.2) or DAS28+ PDUS
assessment of a limited
joint set (n= 53) (target:
PDUS signal in one or
fewer joints)
18 months DAS44 remission
(i.e. a DAS44
of < 1.6)
Strategy PDUS and DAS28:
significant improvement in
DAS44 (mean change −2.76,
95% CI −0.84 to 0.33;
p= 0.39). DAS44 remission:
33% at 3 months, 65% at
18 months
Strategy DAS28: significant
improvement in DAS44
(mean change in DAS44
−2.51, 95% CI NR). DAS44
remission: 43% at 3 months,
44% at 18 months
After 18 months, more patients
in the PDUS group had attained
DAS44 remission (p= 0.046)
(at 3 months, difference was
not significant: p= 0.32)
Dale 201678
(TaSER)
111 RA or undifferentiated
arthritis patientsa
18 months DAS44 remission
(i.e. a DAS44
of < 1.6)
(n= 54)
DAS44 remission: 35 (66%)
(n= 57)
DAS44 remission: 25 (43%)
DAS44 remission (p= 0.03)
Mean change
in DAS44
–2.69 (significant
improvement)
–2.58 (significant
improvement)
Non-significant difference
between groups (p = 0.72)
Median (IQR) change
in RAMRIS erosion
score
0.5 (0.0–1.0) 1.0 (0.0–2.0) Non-significant difference
between groups (p = 0.33)
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TABLE 11 Treatment strategies with and without US (continued )
Study Population
Follow-up
duration Outcome
US treatment strategy
group
Clinical treatment strategy
group Comparison
Haavardsholm
201579 (ARCTIC)
130 early RA patients 24 months Primary end point
was a DAS of < 1.6,
a SJC44 of < 1 and
a ΔvdHSS of < 0.5
between 16 and
24 months
(n= 118)
Strategy PDUS and GSUS and
DAS: 26 (22.0%)
(n= 112)
Strategy DAS: 21 (18.8%)
p= 0.54
DAS remission
(i.e. a DAS of < 1.6)
80 (67.8%) 75 (67.0%) p= 0.89
Median (IQR) change
in vdHSS total score
between 0 and
24 months
1.0 (0–2.5) 1.5 (0.5–3.0) p= 0.09
Median (IQR) change
in vdHSS erosion
score between 0 and
24 months
0.5 (0–1.5) 1.0 (0.5–2.0) p= 0.04
IQR, interquartile range; NR, not reported.
a Only one patient did not meet 2010 ACR/EULAR RA classification criteria.11
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When the percentage of treatment decisions modified by the additional use of US was reported, this
ranged from 13% to 88% of cases89–91,153 (for studies based in the UK the percentages were 23%,90 29%153
and 88%89).
One study89 examined treatment decisions in clinician-evaluated patients by survey and found that 15 out
of 17 (88%) treatment escalations were influenced by the addition of US. Of two observational studies,
one91 found that US (in addition to CE and DAS28) influenced treatment decisions in only 7 out of 52
(13%) patients; however, clinician confidence was significantly improved following US (p < 0.001). The
other observational study94 found a significant difference in time to initiation of DMARDs (p = 0.02) (the
US-monitored group had a shorter time to initiation than the group undergoing clinical evaluation alone)
(see Table 12). Two studies investigated the utility of routine US and reported a change in treatment
following US in 9 out of 39 (23%) patients with clinician-evaluated synovitis90 and a modification of the
bDMARD or cDMARD used in 7 out of 51 patients (compared with clinical evaluation of swollen joints and
CDAI);152 clinician confidence was also significantly improved following US (p < 0.0005) in one of the
studies.152 A study of treatment strategy153 reported that, on 120 occasions (29%), GSUS findings
contradicted the DAS28 and led to modified treatment decisions (see Table 12).
TABLE 12 Use of US in addition to CE alone and impact on treatment decisions
Study
Source of
funding
Population,
number of
patients Setting US and treatment decisions
Bhamra 201489 NR 17 Nuffield Orthopaedic Hospital
Emergency Rheumatology
Clinic, UK
In 15/17 (88%) patients, treatment
escalation was directly influenced by
GSUS findings
Ceponis
2014152
NR 51 San Diego Health System,
CA, USA
US use modified the bDMARD and/or
cDMARD used in seven cases, but
did not affect the overall treatment
plan (p> 0.15) or overall cDMARD
(p< 0.062) or bDMARD use (p> 1.0).
Use of US increased physicians’
confidence (p< 0.0005) and patients
reported that their confidence in
physicians’ medical decisions had
increased (88.4% of cases)
Ciurtin 201390 NR 39 Department of Rheumatology,
University College Hospital,
London, UK
Study identified 9/39 (23%) RA
patients with active synovitis with
a positive Doppler signal that
prompted a change of treatment
Dale 2014153,161
(TaSER)
Chief Scientist’s
Office, Scottish
Executive, and
Pfizer UK
53 Three Glasgow teaching
hospital sites, UK
On 120 occasions (29%), GSUS
findings contradicted the DAS28 and
led to modified treatment decisions
Gandjbakhch
200891
NR 52 University rheumatology
centre, Paris, France
US results caused a change in
treatment in 13% of patients.
Confidence of the clinician,
measured using a VAS (0–100),
increased by 11 points (95% CI
5.9 to 16.9 points) following
US (p< 0.001)
Kelly 201394 AbbVie 109 Four secondary care
rheumatology clinics: two in
London, one in Southampton
and one in Antrim, UK
The US-monitored group (n = 54)
had a significantly shorter time to
initiation of DMARDs (1.45 vs. 2.38
months) than the non-US group
(n= 55) (t-test, p= 0.02)
NR, not reported.
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Survey
A survey of UK rheumatology units (see Appendix 1) with 31 respondents suggested that US is already
being used in some units for modifying treatment decisions in RA. Twenty respondents (65%) said that they
used US for monitoring synovitis. Additionally, one respondent said that their unit planned to use US in the
future. Survey respondents were self-selecting and so the sample may have been biased. Only 31 responses
were received by the end of February 2016 and the small sample size is a limitation of the survey.
Discussion
This systematic review aimed to investigate the value of US in addition to CE for monitoring synovitis
and whether or not US could be used to guide treatment decisions. There were few RCTs available and
thus lower-quality study designs were included.
Thirty-three53,92,96,102–116,118–132 studies provided diagnostic data (see Appendix 7). The majority of these
studies reported that US detected more cases of synovitis than CE alone. The detection of subclinical
synovitis would be useful only if clinically relevant, with prognostic studies suggesting that US-detected
synovitis was associated with radiographic progression.
Power Doppler ultrasound was significantly associated with radiographic progression in all studies in which
it was measured. GSUS was significantly associated with radiographic progression in some, but not all,
studies in which it was measured. Similarly, DAS was significantly associated with radiographic progression
in some, but not all, studies in which it was measured. Studies varied in terms of interventions, comparators
and outcomes, making it difficult to draw firm conclusions from the available evidence. Few studies were
identified that compared US with CE and their effect on treatment; however, these studies suggested that
US was superior to CE alone in predicting response to treatment tapering or discontinuation. Few data were
identified regarding the additional influence of US in current practice, but studies suggested that US was
used in treatment decisions and could increase physician confidence in those decisions. A small survey of
UK rheumatology units (see Appendix 1) suggested that US is already being used in some units for
modifying treatment decisions in RA.
US could also distinguish synovitis from inflammation resulting from other pathologies. Most of these
studies assessed synovitis in hand and wrist joints, reporting that US detected more cases of synovitis in
these joints than CE; this was also the case for elbow and shoulder joints. Foot and ankle joints were less
likely to show an advantage of US over CE. The majority of studies investigating responsiveness found
similar responsiveness for US and clinical comparator measures including DAS28110,111,113,116,132 SDAI111,116,117
CDAI111,113 SJC111 TJC111 and CRP.129
Fifteen studies55,69,97,98,113,134,135,138–144,147 provided prognostic data. Although the design of these studies was
of high quality (prospective cohort), data reported were correlations and sample sizes ranged from 10 to
453 (in total, data were available from 1523 patients but study heterogeneity precluded meta-analysis).
The majority of studies investigating radiographic progression reported that US was a significant predictor,
either GSUS55,69,134,135,138,139 or PDUS.55,69,97,113,135,138–140,144,160 There were mixed results regarding the
association of clinical comparators with outcome measures. Regarding other outcome measures, PDUS was
a significant predictor in the majority of studies for DAS28,55,98,137 ACR/EULAR remission145 and flare.142
There were conflicting results for the association between HAQ score and US.55,97 The data suggested that
there was a stronger association with outcomes for PDUS than for GSUS.
Nine studies79,93,95,100,101,139,154–156 reported data relating to the impact of US on treatment response or
strategies. Two were RCTs79,154 and the others were prospective cohort studies 93,95,100,101,139,155,156 Sample
sizes ranged from 24 to 130, with data available from 627 patients in total (although study heterogeneity
precluded meta-analysis). Six small (sample size 17–109 patients; 321 patients in total) studies89–91,94,152,153
reported observational data on the impact of US on treatment decisions.
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One study101 found that US was the only measure that significantly predicted TNFi continuation. One study93
found that baseline PDUS and GSUS differed significantly between EULAR responders and non-responders.
US-measured treatment response was associated with radiological progression100,139 and PDUS and GSUS
were better predictors of relapse following treatment discontinuation than DAS28.155 PDUS was more highly
associated with tapering failure than clinical variables156 and PDUS significantly predicted disease flare on
treatment whereas DAS28 did not.95
Randomised controlled trial evidence of early RA patients reported that the addition of PDUS to a DAS28-
based treat-to-target strategy led to significantly more patients attaining DAS44 remission, but there was
no significant between-group difference in change from baseline in DAS44 and RAMRIS erosion score.154
In the ARTIC study,162 there was no significant between-group difference (PDUS, GSUS and DAS vs. DAS)
in the primary end point, which consisted of a composite of a DAS of < 1.6 and no swollen joints at 16,
20 and 24 months and no progression in vdHSS between 16 and 24 months. Both RCTs were subject to
incorporation bias, with DAS being used in the treatment strategy groups and forming part of the primary
outcome measure; however, the use of DAS reflects real-world practice. Outcome measures not subject
to incorporation bias were the erosion scores, with RAMRIS not being significantly different between
groups in the TaSER study154 and the vdHSS erosion score having a significant advantage for the strategy
with additional US in the ARCTIC study.162 Only two RCTs154,162 were found comparing US strategies with
clinical strategies alone. In clinical practice, a diagnostic test should only be considered when there is
clinical uncertainty. These two studies did not explore the value of US when added only in cases of clinical
uncertainty, for example, when there was discrepancy between DAS and clinical evaluation. Several small
studies have used US in combination with clinical measures for treatment decisions.26,163,164 Most studies
relied on one-off US measurements at baseline; however, the two RCTs employed US serially as part of
treatment strategies. Heterogeneity of trials precluded meta-analysis. Therefore, no summary estimates of
effect are available, which is a limitation of the review.
Treatment decisions were modified by the additional use of US in 13%–88% of case.89–91,153 Clinician
confidence was significantly improved following US.91,152 A study of treatment strategy153 reported that,
on 120 occasions (29%), GSUS findings contradicted the DAS28 and led to modified treatment decisions.
Guidelines and reviews were identified that were of relevance to this report,9,24,25,28–30,45,46,50,75–77,85–88
although none had a scope that was identical to the systematic review conducted here. The bibliographies
of these guidelines and reviews were searched and studies meeting the systematic review inclusion criteria
were included in the review.
Guidelines and reviews differed in scope from this report by not being restricted to RA29,46,85–87 or by
looking at the initial diagnosis of RA,28,30,46,88 by not being restricted to synovitis9,25,28–30,46,75–77 or not
including synovitis85 or by focusing on management9,76,77 or not covering management decisions.24,25,86,88
Some imaging reviews differed from the review in this report by including US-guided injections,30,46 by not
being restricted to US as an imaging technique28,29,45,87 or by focusing on inter-rater reliability.50
The EULAR guidelines on imaging in RA28 covered all of the questions addressed by the scope of this report,
apart from the percentage of treatment decisions influenced by the addition of US to CE. However, as these
guidelines were published in 2013, they could not include the more recent publications that this report
included. As the studies relating to treatment identified in this report were nearly all from 2013 or later,
only one101 of these studies was included in the published EULAR guidelines.28
The findings of this report were in agreement with these published guidelines and reviews in that US detects
synovitis that is not apparent on CE and that US detects synovitis in patients in clinical remission.24,25,28,30,45,88
The findings of this report were also in agreement with these published guidelines and reviews in that US
can assess the course of disease,30,76,87 with similar responsiveness to that of DAS28.28
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With regard to prognosis, the findings from this report agreed with the published guidelines and reviews
in that PDUS is a predictor of erosive progression and disease flare.25,28,76,88
Other reviews have suggested that there is still a need for more evidence regarding which joints should be
assessed by US for the most effective practice.24,45
Most studies were carried out outside the UK and, as such, treatment pathways may differ from treatment
pathways in UK patients. However, the results from this report are generalisable to UK practice in terms of
studies using international definitions of RA. Additionally, most used standardised semiquantitative scoring
systems for US measures of synovitis and clinical measures that are used internationally, for example
DAS28. Treatments assessed included cDMARDs and bDMARDs, as would be relevant to UK practice.
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Chapter 4 Assessment of cost-effectiveness
Literature reviews undertaken
Reviews were undertaken to identify literature on the:
l cost-effectiveness of the use of US for monitoring synovitis in RA
l economic impact of tapering bDMARDs in the treatment of RA.
For brevity these have been denoted the ‘monitoring’ search and the ‘tapering’ search, respectively.
The search strategies for these searches are provided in Appendix 3.
Following deduplication, 226 hits were obtained in the monitoring search and 54 hits were obtained in the
tapering search. Abstracts were sifted by two reviewers and, because of the relatively small numbers of hits
obtained, a sensitive approach was taken in which any paper felt to be of potential relevance by either reviewer
was retrieved as a full paper. From the sift, five papers were retrieved from the monitoring search165–169 and
19 papers were retrieved from the tapering search.170–187 All papers were reviewed and, when their reference
lists indicated that further papers would potentially be of benefit, these were also reviewed.
Papers potentially relating to the cost-effectiveness of ultrasound for
monitoring synovitis or tapering drug doses
Three cost-effectiveness studies relevant to the decision problem were identified although all of these were
related to tapering of the amount of drugs used.176–178 The first study by Kobelt et al.176 concluded that, in a
situation in which a considerable proportion of patients achieve remission, dose adjustments would increase
the cost-effectiveness of ETN. A similar conclusion was produced in a later publication by Kobelt et al.,177
whereby dose reduction was assumed to be the most cost-effective strategy for patients with moderate
disease rather than full-dose ETN or no ETN use. Krieckaert et al.178 assessed the cost-effectiveness of
personalised treatment for RA based on clinical response and drug levels at 6 months. For patients who had
a EULAR response at 6 months, a decision to stop treatment, continue treatment or prolong the interval
between ADA doses was made based on the drug levels detectable within patients. The authors concluded
that tailoring ADA based on short-term outcome and drug levels was cost-effective compared with
usual care.
No papers were identified on the cost-effectiveness of US use in monitoring levels of synovitis. Thus, any
analysis undertaken within this report is, to the authors’ knowledge, the first such assessment. The consensus
from the three papers regarding the cost-effectiveness of tapering RA treatment indicates that dose reductions
would represent a cost saving that could be used in other areas of the health service; in addition, providing
that response and/or remission was maintained, dose reductions would also be beneficial to patients because
of the avoidance of potential adverse events associated with taking bDMARDs. A review of adverse events
associated with bDMARDs within RCTs is reported by Stevenson et al.23
Papers potentially relating to the efficacy of conventional or biological
disease-modifying anti-rheumatic drugs when the dose has been tapered
Evidence regarding the continued efficacy of cDMARDs or bDMARDs following a reduction in dose or
withdrawal of treatment was identified in papers retrieved in the literature review (both clinical and
cost-effectiveness reviews) and from references within these papers. When abstracts were identified,
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searches for a later publication were undertaken. Only the most recent papers were included when
multiple papers related to the same study unless the older papers contained data that were not included in
the more recent paper. Furthermore, papers known to our clinical experts but not identified by other
means were also included.
A limitation of this approach is that the sensitivity of the search strategies was not high, with a minority of
the final set of papers also identified within the tapering search. As such, potentially relevant papers may
have been omitted, although for the purposes of this report this was deemed acceptable as the intention
was to provide a broad overview rather than to fully detail the evidence.
A brief summary of the methods and conclusions from these papers is provided in Table 13, with papers
listed in reverse chronological order. The evidence suggests that drug tapering, treatment holidays or
treatment withdrawal in patients induced into remission or low disease activity can occur without harm in
a sizeable proportion of patients, although the evidence for withdrawal of treatment in patients receiving
ADA or CTZ is arguably weaker than that for IFX. Tapering drug doses would have many benefits including
reduced drug acquisition costs and potential avoidance of the adverse events associated with DMARDs.
TABLE 13 Results from a review of dose tapering studies within RA
Study Setting Summarised detailsa Summarised authors’ conclusions
Fautrel 2016188 France An 18-month equivalence randomised
trial including (1) patients receiving ETN
and ADA at stable doses for ≥ 1 year,
(2) patients in remission according
to the DAS28 for ≥ 6 months and
(3) patients with stable joint damage. In
total, 137 patients were randomised to
standard maintenance (n= 73) or to a
regime using an algorithm to increase
the period between injections based
on the DAS28, every 3 months, until
completely stopping (n= 64). In the
algorithm arm bDMARDs were stopped
for 39%, tapered for 36% and
maintained at full dose for 20%. The
status of the remaining patients (5%) was
not clear. Relapse was more common in
the algorithm arm (76.6% vs. 46.5%;
p= 0.0004). However, there was no
difference in structural damage
progression (p= 0.8)
The tapering algorithm was not
equivalent to the maintenance strategy,
resulting in more relapses without
impacting structural damage progression
Galloway 2015189 UK A pragmatic 12-month RCT evaluating
if tapering bDMARDs causes loss of
response. In total, 103 patients receiving
ETN or ADA and with a DAS28 of < 3.2
for > 3 months were randomised to one
of three groups for 6 months: (1) constant
bDMARD dose, (2) 33% tapered dose or
(3) 66% tapered dose. Flares, defined as
an increase in DAS28 to ≥ 3.2 and one
or more swollen joint, occurred in 7/50
(14%) control subjects, 6/48 (13%) in the
33% tapering group and 14/38 (37%) in
the 66% tapering group. Post-tapering
flares resolved when TNFi was restarted.
The OR for a flare in the 33% tapering
group compared with the 66% tapered
group was 4.2 (95% CI 1.3 to 14.5).
There were no significant differences at
6 months (p-value not reported)
Good responses are maintained after
bDMARD doses are tapered by one-third.
Tapering by two-thirds results in more
flares, but these respond to restarting
bDMARDs and did not adversely affect
disability progression. The 33% tapering
strategy retains responses at substantially
reduced drug costs
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TABLE 13 Results from a review of dose tapering studies within RA (continued )
Study Setting Summarised detailsa Summarised authors’ conclusions
Ghiti Moghadam
2015190
The Netherlands An open-label RCT assessing whether
RA patients with a DAS28 of < 3.2 in
the previous 6 months can effectively
and safely stop and restart bDMARDs.
Patients were randomised 2 : 1 to stop
or continue their current bDMARD. A
flare was defined as a DAS28 of ≥ 3.2
with an increase of ≥ 0.6 compared
with the previous DAS28. In total,
531 patients were randomised to stop
treatment and 286 were randomised
to continue treatment. At 6 months,
significantly more patients in the stop
group (29.3%) had experienced a
DAS28 flare than in the continuation
group (9.7%) (p < 0.0001). At 12
months, these values were 40.8% and
14.4%, respectively (p< 0.0001). Of the
patients who restarted a TNFi within the
first 26 weeks after stopping, 83% had
regained a DAS28 of < 3.2 6 months
later, with a median time to regained
DAS28 of < 3.2 of 12 weeks (95% Cl
10.9 to 13.1 weeks)
During a 12-month follow-up period,
59% of RA-patients with a DAS28
of < 3.2 were able to stop bDMARDs
without experiencing a flare. The data
suggest that bDMARDs can be
restarted effectively and safely
Luengroongroj
201595
Thailand A prospective study to assess whether
or not US can be used to predict relapse
after tapering of DMARDs. Thirty-two
patients with established RA and
clinical remission defined by a CDAI
of < 2.8 were enrolled. Patients on
a maintenance dose had their dose
reduced to a half-dose, whereas those
on lower doses had their treatment
withdrawn. A relapse was defined as
having arthritis symptoms and clinical
signs. Four patients (12.5%) relapsed
within 3 months
Reducing doses of DMARD for a short
period of time appears to be safe;
however, close monitoring for disease
relapse is needed, especially in patients
with subclinical synovitis
Marks 201526 England Prospective cohort study analysing
the possibility of reducing the dose
of bDMARDs by one-third. Seventy
patients were recruited who were
in disease remission (i.e. a DAS28 of
≤ 2.6), had had an absence of synovitis
on PDUS for > 6 months and who were
not taking corticosteroids. Combined
DAS28 and PDUS remission was
maintained by 96% at 3 months,
63% at 6 months, 37% at 9 months
and 34% at 18 months. Those who
continued on the reduced doses were
more likely to have lower DAS28 scores
on initiation of bDMARD therapy and
to be rheumatoid factor negative
Combined clinical and US assessment
identifies individuals in remission who
may be suitable for bDMARD dose
reduction
Tanaka 2015191 Japan Prospective cohort study analysing the
possibility of discontinuing ADA for
1 year. A flare was defined as a DAS28
of ≥ 3.2. In total, 75 patients who were
steroid free and with a DAS28 of < 2.6
for 6 months participated in the study;
52 patients chose to discontinue ADA
whereas 23 chose to remain on
The possibility of remaining ADA
free for a year was demonstrated,
particularly in those with deep
remission
continued
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TABLE 13 Results from a review of dose tapering studies within RA (continued )
Study Setting Summarised detailsa Summarised authors’ conclusions
treatment. The proportion of patients
maintaining remission was significantly
higher in the continuation group. In
patients with deep remission (i.e. a
DAS28 of ≤ 1.98) there was no
significant difference between the
groups. ADA readministration to those
with a flare was effective
van Herwaarden
2015187
The Netherlands A randomised, controlled, open-label,
non-inferiority study (n= 180) evaluating
disease activity-guided dose reductions
of ADA or ETN (n= 121) vs. usual care
(n= 59) over an 18-month period.
Patients in the dose reduction arm
increased the injection interval every
3 months until flare, defined as a DAS28
score increase of > 1.2 or an increase of
> 0.6 and a DAS score of ≥ 3.2, or
bDMARD discontinuation. Following a
flare the last effective dosing regimen
was reinstated. A major flare was
defined as a flare with a duration of
> 3 months. Dose reduction was
non-inferior to usual care: 12% had a
major flare in the dose reduction arm
compared with 10% in the usual care
arm. bDMARDs could be successfully
stopped in 20% of patients, but dose
reduction was reportedly not possible in
37%. Although functional status, quality
of life, relevant radiographic progression
and adverse events did not differ
between strategies, flares (73% vs. 27%)
and radiographic progression (32% vs.
15%) were more frequent in the dose
reduction arm
A strategy of disease activity-guided
dose reduction is non-inferior to usual
care with regard to major flaring,
resulting in successful dose reduction or
stopping in two-thirds of patients
van
Vollenhoven
2015192
Europe
(16 European sites)
A randomised, double-blind trial
assessing the impact of dose reductions
of ETN in 91 patients with stable low
disease activity (i.e. a DAS28 of ≤ 3.2)
receiving ETN treatment. Following an
8-week screening period, 73 patients
were randomised to the usual dose of
ETN (50 mg) (n= 23), a half-dose
(25 mg) (n= 27) or placebo (n= 23).
Sixty-six patients completed the study.
The proportions of patients who did
not flare at week 48 were 52% for
full-dose ETN, 44% for half-dose ETN
and 13% for placebo. The majority of
patients who flared regained low
disease activity with 50 mg of ETN
In patients who have achieved stable
low disease activity on ETN, continuing
treatment is superior to placebo.
Reduced-dose ETN was also more
effective than placebo in maintaining a
favourable response, suggesting that
a maintenance strategy with reduced-
dose ETN may be possible
Emery 2014193 Global (57 sites in
Europe and Asia)
In total, 306 patients with early active
disease were enrolled and treated with
ETN plus MTX. A total of 193 patients
with a DAS28 of ≤ 3.2 at week 39 of
treatment and a DAS28 of < 2.6 at
week 52 were randomised to receive
one of 25 mg of ETN plus MTX, MTX
alone or placebo for 39 weeks. Patients
with a DAS28 of ≤ 3.2 at week 39 of
the randomised period had all study
Patients with early RA who achieved
remission while receiving 50mg of ETN
plus MTX had better disease control
with 25 mg of ETN plus MTX than
MTX alone or placebo. No significant
difference was observed in radiographic
progression between the three groups
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TABLE 13 Results from a review of dose tapering studies within RA (continued )
Study Setting Summarised detailsa Summarised authors’ conclusions
treatment withdrawn. At the end of the
randomised period, significantly more
patients on combination therapy had
sustained remission than patients
receiving the remaining strategies: 40/63
(63%) of the combination therapy
group, 26/65 (40%) of the MTX group
and 15/65 (23%) of the placebo group.
Following the treatment withdrawal
period, the combination therapy group
was no longer significantly better at
sustaining remission than the MTX
group (p= 0.10): 28/63 (44%) of the
combination therapy group, 19/65
(29%) of the MTX group and 15/65
(23%) of the placebo group. No
significant between-group differences
were observed in radiographic
progression of disease (p≥ 0.34 for all
comparisons). Serious adverse events
were reported in three patients (5%) in
the combination therapy group, two
(3%) in the MTX alone group and two
(3%) in the placebo group (p-value
not reported)
Iwamoto 2014155 Japan A prospective study of patients on
bDMARDs to assess whether or not
US assessment of synovitis predicts
relapse after withdrawal of bDMARDs.
42 patients were enrolled who were
in clinical remission (i.e. a DAS28 of
< 2.6) and who agreed to withdraw
treatment. The mean duration of
remission was 23 months (range
3–73 months)
Comprehensive US assessment
predicted relapse within a short term
after discontinuation of bDMARDs
Naredo 2014156 Spain 77 patients treated with bDMARDs
were recruited if they met the following
criteria: (1) stable dose of treatment in
the previous 12 months, (2) sustained
clinical remission based on DAS28
or SDAI in the previous 12 months,
(3) ≤ 5mg/day of prednisone treatment
in the previous 6 months and (4) not
having needed NSAIDs for > 1 week
nor local corticosteroid injections in the
previous 6 months. bDMARDs were
tapered by increasing the duration
between doses or reducing the dose.
Tapering failure (assessed at 6 and
13 months) was defined as an increase
in the dose and/or disease activity on the
DASA28 or SDAI. In total, 23 (29.9%)
patients were tapering failures at
≤ 6 months and 35 (45.5%) were
tapering failures at 12 months. Significant
predictors of failure at 6 months (p≤ 0.05)
were longer duration of RA, a higher
number of synthetic DMARDs, a higher
DAS28 at baseline, a higher SDAI at
baseline, a higher global index for Doppler
synovitis (DSI) at baseline and a DSI > 0
at baseline
The results suggested that the presence
and grade of Doppler-detected synovitis
may predict biologic therapy tapering
failure in RA patients in sustained
clinical remission
continued
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TABLE 13 Results from a review of dose tapering studies within RA (continued )
Study Setting Summarised detailsa Summarised authors’ conclusions
Smolen 2014182 Global (161 sites
worldwide)
Patients with low disease activity [i.e. a
DAS28 of < 3.2 at weeks 22 and
26 from the Optimal Protocol for
Treatment Initiation with Methotrexate
and Adalimumab (OPTIMA trial)194]
were randomised to either ADA
continuation or withdrawal for a period
of 52 weeks or, if not on ADA, were
maintained on MTX monotherapy.
A total of 207 patients on ADA were
rerandomised (105 continued to take
ADA); 112 patients continued on MTX
monotherapy. In total, 95/103 (92%)
patients continuing ADA treatment
maintained a DAS28 of < 3.2 compared
with 75/90 (83%) whose treatment
was withdrawn (p= 0.0569); 90/103
(87%) continuing ADA had a DAS of
< 2.6 compared with 62/90 (69%)
whose treatment was withdrawn
(p= 0.017)
Outcomes were similar regardless of
whether ADA was continued or
withdrawn in patients who initially
responded to ADA
Aguilar-Lozano
2013195
Mexico A prospective cohort study of patients
(n= 45) in remission (i.e. a DAS28 of
≤ 2.6) with no swollen joints following
cessation of TCZ. In total, 20 patients
maintained remission during the
12-month follow-up period. Of the 25
who relapsed, 14 (56%) did so within
3 months of the last dose of TCZ
Long-term clinical remission is possible
in a number of patients with RA after
the suspension of TCZ
Detert 2013196 Germany Prospective trial comparing the use of
ADA with placebo for 24 weeks after
which both groups received MTX alone
for 24 weeks. The trial recruited 172
people with active early (≤ 12 months)
RA. At week 48, there was no
statistically significant difference in
DAS28 score between the groups
(p= 0.41), although changes in
radiographic progression significantly
favoured the ADA group
A greater, and significant, reduction in
radiographic progression was seen in
the ADA arm, but this was not the case
for DAS28
Holroyd 2013163 England A prospective study of people in clinical
and US remission (i.e. a DAS28 of < 2.6
and PDUS= 0) who had their dose of
bDMARDs reduced by one-third. In
total, 56 of 321 patients met the
eligibility criteria. Of these, 42 (75%)
remained on the tapered dose for a
mean of 8.7 months. Fourteen patients
(25%) flared and returned to the full
dosages at a mean of 5.9 months
Using US alongside clinical assessment
may increase the likelihood of selecting
patients who could successfully reduce
the dose of bDMARDs while maintaining
clinical and US remission
Nishimoto
201327
Japan Tis study examined the possibility of
drug-free remission induced by TCZ
monotherapy. In total, 187 patients
were enrolled who had achieved a
DAS28 of < 3.2. Loss of efficacy was
defined as either a DAS28 of > 3.2
at two consecutive visits or initiation
of additional treatments on patient
request. A DAS28 of < 3.2 was
maintained in 65 patients at 24 weeks
after discontinuation and 24 patients at
TCZ monotherapy may induce
bDMARD-free remission or low disease
activity without concomitant use of
synthetic DMARDs
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TABLE 13 Results from a review of dose tapering studies within RA (continued )
Study Setting Summarised detailsa Summarised authors’ conclusions
week 52; 19 patients (10%) were drug
free for 52 weeks, with 17 patients
meeting the criteria for remission (i.e. a
DAS28 of < 2.6). Low serum interleukin
6 (IL-6) and normalisation of matrix
metalloproteinase 3 (MMP-3) levels at
cessation of TCZ monotherapy were
identified as independent predictive
markers for longer duration of low
disease activity
Smolen 2013183 Global (80 sites in
Europe, Latin
America, Asia
and Australia)
RCT (PRESERVE) of adult patients with
an initial DAS28 of > 3.2 and ≤ 5.1
that had been reduced to low disease
activity (mean DAS28 of ≤ 3.2 between
weeks 12 and 36 and a DAS28 of ≤ 3.2
at week 36). Patients were assigned to
50mg of ETN (n= 202), 25 mg of ETN
(n= 202) or placebo (n = 200). In total,
166/201 (83%) of those receiving
50mg of ETN had low disease activity
compared with 84/197 (43%) of those
receiving placebo and 159/201 (79%)
of those receiving 25mg of ETN.
Significantly more patients receiving
either dose of ETN had low disease
activity than patients receiving placebo
(p< 0.0001). The authors reported that
there was no significant difference
between the two ETN doses (p< 0.379)
Conventional or reduced doses of ETN
maintain low disease activity more
effectively than placebo
Smolen 2014197 Global
(31 European sites)
52-week double-blind RCT (CERTAIN)
including a 24-week treatment period
and 28-week follow-up period in
patients with low to moderate disease
activity and stopping therapy in patients
in sustained remission. Patients had a
CDAI of > 6 and ≤ 16, two or more
tender joints, two or more swollen joints
and either a ESR of ≥ 28mm/hour or
CRP level of > 10mg/l at screening and
baseline. In total, 194 patients were
randomised to placebo (n = 98) or CTZ
(n= 96). A total of 20 patients receiving
CTZ and 7 patients receiving placebo
achieved remission, defined as a CDAI
of ≤ 2.8 at both weeks 20 and 24, and
had treatment withdrawn. Only 3/17
CTZ and 2/6 placebo patients
maintained remission until week 52,
although reinstitution of CTZ induced a
renewed improvement. Retreatment
with placebo did not occur
The data suggest that CTZ cannot be
withdrawn in patients achieving
remission
Chatzidionysiou
2012198
Sweden Randomised controlled open-label pilot
study evaluating whether or not remission
can be sustained after cessation of ADA
in patients with a DAS28 of < 2.6 for
≥ 3 months (n= 31). Remission was rarely
maintained in patients who discontinued
ADA. The proportion with sustained
remission was significantly lower than
among those continuing on ADA
ADA discontinuation may be feasible
only in a minority of patients with RA
in stable clinical remission
continued
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TABLE 13 Results from a review of dose tapering studies within RA (continued )
Study Setting Summarised detailsa Summarised authors’ conclusions
Haragai 2012199 Japan A retrospective study to assess the
cessation of ADA monotherapy in
patients with low disease activity (i.e. a
DAS28 of < 2.7). In total, 24 patients
continued ADA treatment, with 22
patients ceasing treatment. Of these,
14/22 patients did not restart
bDMARDs, with 4/22 maintaining low
disease activity for 52 weeks
Some RA patients who have achieved
low disease activity can discontinue
ADA without increasing disease activity.
This should be confirmed in a
prospective, randomised study
Kaine 2012200 USA A prospective study (n= 167) to
assess the temporary interruption of
ABT treatment. After a 12-week
introduction period, 120 patients
were randomised to either placebo
or continuation of ABT treatment.
Following this, 79 patients on placebo
were reintroduced to ABT. A non-
significant increase in immunogenicity
(p= 0.119) was observed following ABT
withdrawal. Safety was comparable
across treatment schedules
A stop–start schedule of ABT was well
tolerated with little impact on safety
or efficacy
van der Maas
2012201
The Netherlands An observational cohort study assessing
the feasibility of down-titrating or
discontinuing IFX. IFX was down-titrated
by 3 mg/kg (25% of the original dose)
every 8–12 weeks until discontinuation
or a flare in patients with a DAS28 of
< 3.2 for ≥ 6 months. Flares (i.e. a
DAS28 of > 3.2) were treated with the
last effective dose of IFX. IFX could be
discontinued in 16% of the cohort and
down-titrated in 45%. There was no
statistically significant difference in
patients’ quality of life (p < 0.152) after
down-titrating and mean costs per
patient were reduced by €3474
In the majority of patients with a stable
DAS28 of < 3.2 and stable IFX
treatment, IFX can be down-titrated or
discontinued without influencing
patients’ quality of life, generating a
considerable cost saving
Klarenbeek
2011202
The Netherlands To determine the relapse rate and
predictors of relapse in patients in
sustained clinical remission following
the withdrawal of treatment. In total,
115 patients in the BeSt study203 achieved
a DAS28 of < 1.6 for > 6 months and
all treatment (including conventional
DMARDs) was discontinued. A total of
59/115 patients maintained drug-free
remission for a median duration of
23 months; 53/115 restarted treatment
as the DAS28 reached > 1.6 (median
duration to restarting treatment
23 months); and 3 patients were lost
to follow-up. In total, 39/53 people who
restarted treatment attained remission
within 3–6 months of restarting
treatment
Approximately 25% of patients with RA
achieved drug-free remission; 46%
restarted DMARD monotherapy
because of a relapse, the majority of
whom again achieved clinical remission
without showing radiological
progression during the relapse
van den Broek
2011204
The Netherlands Post hoc analyses (n = 104) of the BeSt
study203 to identify predictive factors for
maintaining low disease activity (i.e. a
DAS28 of ≤ 2.4) for 6 months without
IFX treatment. Low disease activity was
maintained in 52% of patients, with a
higher success rate in those initially
Maintaining IFX-free low disease activity
was successful in the majority of
patients and, of those who did flare,
the large majority regained low disease
activity following treatment with IFX
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TABLE 13 Results from a review of dose tapering studies within RA (continued )
Study Setting Summarised detailsa Summarised authors’ conclusions
treated with IFX. Of those who flared
(48%), 84% regained low disease
activity with IFX treatment. Predictive
factors for requiring IFX treatment were
smoking, long IFX treatment duration
(≥ 18 months) and shared epitope
Bejarano 2010205 England Prospective cohort study (n = 20) of
patients with poor prognosis of RA with
< 1 year of symptoms. Patients were
randomised to receive IFX or placebo
for 1 year; these were then removed
and patients were treated with MTX
monotherapy alone in accordance with
standard clinical care. At 8 years,
disease activity data were collected. At
follow-up, four patients in the IFX group
were in remission compared with none
in the placebo group. One patient in the
IFX group achieved drug-free remission.
Median DAS28 was significantly lower
in the IFX group than in the placebo
group (2.7 vs. 4.3; p= 0.02)
A remission induction regime with IFX
for 1 year in early RA can improve
long-term clinical outcomes
Saleem 2010206 England Prospective cohort study (n= 47) of
patients in remission attempting to
define markers that are predictive of
sustained remission following cessation
of bDMARD treatment. Of the 47
patients, 27 had received initial
treatment and 20 delayed treatment.
Two years after treatment withdrawal,
59% in the initial treatment group and
15% in the delayed treatment group
had sustained remission. In the initial
treatment group, secondary analyses
showed that shorter symptom duration
was the only clinical predictor of
successful treatment withdrawal.
Several immunological parameters were
significantly (p < 0.05) associated with
sustained remission
In patients in remission, short duration
of untreated symptoms and
immunological parameters are
associated with successful withdrawal
of bDMARDs
Tanaka 2010184 Japan Prospective cohort study (n= 114)
analysing the possibility of
discontinuing IFX after achieving low
disease activity (i.e. a DAS28 of < 3.2).
When low disease activity was
maintained for > 24 weeks, IFX was
withdrawn (n= 102). A total of 56
patients (55%) maintained low disease
activity at 1 year post IFX treatment; 46
patients were not classed as successful,
with IFX being restarted or having a
DAS28 of > 3.2 at 1 year
After achieving low disease activity
through IFX treatment, the majority of
patients remained in this state without
IFX treatment
Brocq 2009207 France A prospective cohort study of 304
patients taking a bDMARD for RA.
Those who achieved remission (i.e. a
DAS28 of < 2.6 for at least 6 months
without NSAIDs or prednisolone)
(n= 21) had their bDMARD removed;
this was reinstated following a relapse
(i.e. a DAS28 of > 3.2)
A relapse occurred within 12 months
in 75% of patients who had ceased
bDMARD treatment. Relapsing patients
responded well to the resumption of
the same bDMARD
continued
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TABLE 13 Results from a review of dose tapering studies within RA (continued )
Study Setting Summarised detailsa Summarised authors’ conclusions
van der Kooij
2009208
The Netherlands An analysis of patients from the BeSt
study203 with a sustained DAS28 of
< 1.6 for at least 6 consecutive months
who discontinued treatment at year 3.
Of the entire cohort, based on the four
treatment strategies in the BeSt study,
the percentage of patients in drug-free
remission at the end of year 4 ranged
from 8% to 18%, with a non-
significant (p= 0.14) difference
across strategies
In patients with recent-onset RA,
drug-free remission was achieved in up
to 18% given DAS-driven treatment
Nawata 2008209 Japan A prospective cohort of 172 patients
with active RA were provided with
IFX treatment. After induction and
maintenance of clinical remission
(i.e. a DAS28 of > 2.6), tapering of
corticosteroids and/or NSAIDs was
attempted. If clinical remission
was maintained for > 24 weeks,
discontinuation of IFX was considered.
In total, 52 patients met the remission
criteria and nine patients discontinued
IFX and maintained remission for a
mean of 14 months without recurrence.
The duration of disease was shorter
and the points from Steinbrocker’s
stage classification were significantly
lower in the IFX-discontinued group
than in the IFX-continued group
The study indicates that DAS28 could
be a good indicator of whether or not to
perform a strategic reduction of IFX. The
findings imply that early intervention
with IFX appears to be advantageous
for achieving clinical remission and for
discontinuing IFX after clinical remission
van den Bilj
2007210
The Netherlands Analysis from the BeSt study203 of
120 patients with early RA receiving
IFX treatment. Sixty-seven patients had
persistent (> 6 months) low disease
activity (i.e. a DAS28 of ≤ 2.4) and had
IFX tapered and finally withdrawn
at a median time of 10 months. Ten
patients had IFX withdrawn but
experienced a disease flare and
resumed IFX treatment after a median
of 4 months. This represents a
bDMARD-free maintenance success rate
of 67/120 (56%) during a 2-year
follow-up period
56% of patients with early RA, initially
treated with IFX, could discontinue IFX
after achieving a DAS28 of < 2.4
Quinn 2005211 England A 12-month double-blind study (n = 20)
attempting to induce remission with or
without IFX treatment in those with
symptoms for < 12 months. Of those
on IFX (n = 10) who responded to
treatment (n = 9), seven maintained
their DAS28, whereas two had
increases in DAS28 in the following
52 weeks after withdrawal of
treatment. No patient had a functional
deterioration as measured by the HAQ
after withdrawal of IFX treatment
Functional and quality of life benefits
were sustained a year following the
withdrawal of IFX treatment
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The potential advantages of using ultrasound for monitoring synovitis
The possibility of a reduced bDMARD burden was not considered by the manufacturers, the Assessment
Group or the NICE Appraisal Committee in the recent evaluation of bDMARDs,40 indicating that tapering
of treatment in patients who have responded well may not reflect routine clinical practice. A relevant
question is, ‘Why is this the case?’. If it is because clinicians are unwilling to risk treatment reductions in
patients whose disease may worsen if dosing is amended, then monitoring synovitis in patients such that
treatment could be reinstated, or the dosage amended, when disease activity reoccurred could have the
potential to be a cost-saving strategy and also one that could be beneficial to patients. In a survey sent to
members of the BSR (see Appendix 1), 27 out of the 31 (87%) respondents replied that US is used to
make decisions regarding RA therapy, with the majority stating that US was used to make decisions
whether to start or stop medication or to taper or increase dosages. There was no consensus among the
respondents about how often US was used in RA patients, although it appeared that this would likely be
dependent on patients’ symptoms and the uncertainty around disease activity; a minority of respondents
indicated that US would be routinely undertaken on patients at visits to the clinic. Although the data
provided by those BSR members responding to the survey are helpful, it is not clear to what extent
selection bias could have influenced the results. It cannot be ruled out that the majority of those who
chose to respond were advocates of the use of US for monitoring synovitis.
Cost-effectiveness analyses undertaken
The economic evaluation compared the use of US as an adjunct to CE and the use of CE only in
determining the most appropriate treatment in RA. This analysis was performed using four scenarios:
(1) patients who have been perceived to be clinically stable on a bDMARD and for whom the clinician may
consider dose reductions; (2) patients who have been perceived to be clinically stable on a cDMARD and
for whom the clinician may consider dose reductions; (3) patients who appear to have disease progression
despite bDMARD treatment and for whom the clinician is contemplating amending treatment; and
(4) patients who appear to have disease progression despite cDMARD treatment and for whom the clinician
is contemplating amending treatment. It should be noted that the groups of patients within these four
scenarios do not equate to the entire RA population. If a clinician did not believe that escalation or tapering
of treatment was warranted, it was assumed that patients would not have synovitis measured with US.
TABLE 13 Results from a review of dose tapering studies within RA (continued )
Study Setting Summarised detailsa Summarised authors’ conclusions
Buch 2004212 England Prospective 2-year extension of the
Anti-TNF Therapy in RA with
Concomitant Therapy (ATTRACT)
study213 (n= 17). All patients had a
flare, with 15 choosing retreatment
with IFX, although one stopped
treatment because of attempted
pregnancy. After retreatment the ACR
response was comparable in 12 out
of 14 patients and worse in 2 out of
14 patients. No adverse reactions
were observed
IFX treatment can be restarted after an
interval of several months without any
observable problems
BeSt, Behandelstrategieen voor Reumatoide Artritis.
a All studies are assumed to have allowed concurrent cDMARD use unless explicitly stated otherwise.
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All analyses were undertaken using a 1-year time horizon assuming that the decisions faced by clinicians
would be recurrent, that is, that patients would continue to be monitored to ensure that the initial treatment
decision remained appropriate. Given the short time horizon of the analysis, the results have not been
discounted. It was assumed that if a strategy of monitoring synovitis using US was employed then this would
be consistently undertaken in all patients who met the criteria of the four scenarios in all future years. In all
analyses, incidental benefits and incidental costs, for example those related to detecting a condition that
could have been mistaken for a worsening of RA, have been excluded from the simple model.
In the base-case analysis it was assumed that, on average, four US scans would be undertaken per year, at
a cost of £226.62 per year; this was adjusted in sensitivity analyses. This frequency of monitoring in those
patients for whom a clinician was considering a change of treatment or in patients following a change of
treatment was considered prudent to ensure that any increase in synovitis was detected relatively early.
Were four US scans per year adopted in clinical practice this could impact on sonographer capacity; if
additional resources were required then the cost savings required for monitoring of synovitis with US to be
cost neutral would increase.
The analyses presented detail the reductions in average drug use and the number of serious infections that
would need to be avoided for US plus CE to have an incremental cost-effectiveness ratio (ICER) of £20,000
per quality-adjusted life-year (QALY) gained and £30,000 per QALY gained214 relative to CE alone. These
two willingness-to-pay thresholds have been selected as they are reported in NICE’s Guide to the Methods
of Technology Appraisal 2013214 and were current at the time of report writing (2016).
Serious infections were considered as potential adverse events of treatment. It was estimated that a serious
infection would be associated with a cost of £1479 and a QALY loss of 0.012.23 Although serious infections
are more typically associated with bDMARDs, the possibility of this adverse event has also been included for
patients on cDMARDs. The net monetary benefit of an avoided serious infection was calculated assuming
both a £20,000 per QALY gained threshold and a £30,000 per QALY gained threshold. The formula for
this is:
Assumed cost of a serious infection + (QALY loss associated with a serious infection
× cost per QALY gained threshold). (1)
Thus, the net monetary benefit of an avoided serious infection using a £20,000 threshold is £1718
[£1479 + (0.012 × £20,000)] and using a £30,000 threshold is £1838 [£1479 + (0.012 × £30,000)].
The threshold levels for reductions in average drug use and the number of serious infections that need to
be avoided are not intended to imply that monitoring synovitis with US is or is not cost-effective, rather
that these are the levels at which the use of US becomes cost neutral. These threshold values may or may
not be achieved in reality and it is conceivable that there would not be a saving if the use of US led to
overtreatment.
It is acknowledged that the decision to amend treatment is likely to be multifactorial. However, there is
not sufficient certainty in these factors, and potential heterogeneity of their implementation to allow a
meaningful analysis to be conducted. We have therefore chosen to subsume all factors into threshold
metrics (either in reduction of drug use or in reduction in serious infection) that would need to be achieved
through the extra information supplied by the use of US as an adjunct to CE.
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Analyses undertaken when dose tapering is being considered
For the modelling of strategies in which a clinician is contemplating a dose reduction, a simplistic approach
has been taken using threshold analyses. This is in contrast to the protocol,215 in which it was anticipated
that the model constructed for the recent NICE appraisal of bDMARDs and documented in Stevenson et al.23
would be used. Given the uncertainty in the evidence base, it was deemed more useful to provide indicative
results that focus on the key parameters related to US use, rather than to provide results of potentially
spurious accuracy from a model with a much larger number of parameters, which could obscure the impact
on the decision problem that we have been tasked to address.
Analyses undertaken when a change in treatment is being considered
The potential consequences associated with changing treatment are more complicated than those associated
with tapering treatments as patients may have a decrease in HAQ score if they respond to the new
intervention. More aggressive treatment could also potentially stop disease progression. However, as with
the analyses relating to dose tapering, a simplistic approach has been undertaken to provide an indicative
level of the proportion of patients not escalating treatment, because of the added information provided by a
US scan, that would be result in an ICER of £20,000 or £30,000 per QALY gained. The costs of DMARDs and
the impacts of a serious infection have been assumed to be the same as in the tapering analyses. Incidental
benefits, for example detecting a condition that could have been mistaken for a worsening of RA, have been
excluded from the model.
Costs assumed within the model
As detailed in Chapter 3 (see Anticipated costs associated with the intervention), we calculated that the use
of US to monitor synovitis would be associated with a cost of £56.66. We assumed that all US appointments
were outpatient appointments, that contrast was not used and that two-thirds of appointments took
< 20 minutes and the remainder took ≥ 20 minutes.
For simplicity, it was assumed that clinical assessment was associated with no cost; as clinical assessment is
included in both treatment strategies, and there is unlikely to be a mortality difference between strategies,
this was believed not to influence the results.
The assumed cost of a bDMARD was sourced from a recent Health Technology Assessment report.23 Several
bDMARDs are subject to a commercial-in-confidence patient access scheme; however, for the interventions
for which an estimated cost per year can be reported, the prices were commonly around £9200 per year.
This price was assumed in our analyses. It should be noted, however, that biosimilar drugs have entered the
market for IFX, ADA, RTX and ETN and thus, potentially, drug acquisition costs may decrease in future years.
An additional £1608 per year was assumed for monitoring and administration for all regimens.
The assumed cost of cDMARD treatment was dependent on the actual regimen used. The most intensive
course of treatment that would be used was assumed to replicate that in the study by Stevenson et al.:23
oral MTX (20 mg weekly), HCQ (6.5 mg/kg daily), SSZ (3 g daily) and oral prednisolone (7.5 mg daily).
This had an estimated cost of £1826 per year when monitoring and administration costs were included
and £218 per year when these costs were excluded.
In a sensitivity analysis the impact of MTX being given subcutaneously rather than orally was explored, as
this is the formulation recommended for people with severe active RA, with oral MTX recommended for
people with moderate to severe RA.216 The annual cost of two 10-mg tablets of MTX per week is £39.28
whereas the annual cost of a weekly 20-mg solution for injection is £837.99.216 The costs of intensive
cDMARDs and MTX were both increased by £798.71 (£837.99 – £39.28) in the sensitivity analysis.
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The costs of serious adverse advents are included; these were estimated to be £1479.23
Utilities assumed within the model
The only utility implication considered within the model was that associated with serious adverse events.
These were assumed to be associated with a QALY loss of 0.012.23
Summarised model inputs
Table 14 provides the model parameters used in the base-case analysis.
An illustrative example of how thresholds were calculated
An example of the calculation of a threshold is provided, assuming a cost per QALY gained threshold
of £20,000 and a reduction in the costs of bDMARDs of 1%. A saving of £92 (£9200 × 1%) would be
made on bDMARD acquisition costs, which would reduce the net costs of a US strategy to £134.62
(£226.62 – £92). Given a net monetary benefit of £1718 per serious infection avoided, 0.078 (£134.62/
£1718) serious infections would need to be avoided to achieve a cost per QALY gained of £20,000.
TABLE 14 Model parameters used in the base-case analysis
Parameter Value Reference
Cost of a US scan £56.66 Assumption based on
NHS Reference Costs
2014 to 201573
Number of US scans per year per patient 4 Assumption
Cost of US scans per year per patient £226.62 Calculated
Annual cost of bDMARD treatmenta £9200 Stevenson et al.23
Annual cost of intensive cDMARD treatmenta,b £218.17 BNF216
Annual cost of oral MTX treatmenta £39.28 BNF216
Annual cost of subcutaneous MTX treatmenta £837.99 BNF216
Cost of a serious infection £1479 Stevenson et al.23
QALY loss associated with a serious infection 0.012 Stevenson et al.23
Net monetary benefit of a serious infection avoided at a threshold of £20,000
per QALY gained
£1718 Calculated
Net monetary benefit of a serious infection avoided at a threshold of £20,000
per QALY gained
£1838 Calculated
BNF, British National Formulary.
a Excluding monitoring and administration costs, which were estimated to be £1608 per annum.
b Assumed to consist of MTX (20mg weekly), HCQ (6.5mg/kg daily), SSZ (3 g daily) and oral prednisolone (7.5 mg daily).
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Results
The cost-effectiveness of ultrasound monitoring in patients who have been stable on
biological disease-modifying anti-rheumatic drugs and for whom the clinician is
contemplating reducing the dose of biological disease-modifying anti-rheumatic drug
The average reduction in bDMARD use that would be required for a strategy of US monitoring to be
cost neutral was calculated. This was 2.46% (£226.62/£9200). The levels of drug reduction and serious
infections avoided at which US is at the threshold of cost-effectiveness are shown in Figure 2.
The cost-effectiveness of ultrasound monitoring in patients who have been stable on
conventional disease-modifying anti-rheumatic drugs and for whom the clinician is
contemplating reducing the dose of conventional disease-modifying anti-rheumatic drug
The average reduction in cDMARD use that would be required for a strategy of US monitoring to be cost
neutral was calculated. It was not possible to recoup the assumed costs of US (£227) with reduced use
of either intensive cDMARDs (£218 per annum) or MTX (£39 per annum). However, the levels of drug
reduction and serious infections avoided at which US is at the threshold of cost-effectiveness are shown
in Figure 3.
The cost-effectiveness of ultrasound monitoring in patients who appear to have disease
progression despite biological disease-modifying anti-rheumatic drug treatment and for
whom the clinician is contemplating amending treatment
This analysis was not formally conducted as there was insufficient evidence to provide any robust
assessment. The likely impact of a change in treatment for a patient on bDMARDs will vary depending
on the current treatment and on whether or not the disease was progressing.
At the time of writing, NICE guidance41 recommended that patients progressing from first-line bDMARDs
should receive RTX in combination with MTX as it is cheaper than other bDMARDs and has a similar
efficacy.23 As such, the immediate impact of a patient moving to RTX would be a cost saving, regardless of
whether or not the disease was progressing and regardless of any US result. However, a potential treatment
option has been exhausted, which may have longer-term impacts if the disease had not progressed at the
time of the switch to RTX, but began progressing on subsequent treatments. It is unclear to what extent the
decision to move to RTX would be influenced by the use of US to monitor synovitis.
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FIGURE 2 The average levels of bDMARD drug reduction and serious infections avoided that result in a cost per
QALY gained of £20,000 and £30,000 for the use of US in monitoring synovitis.
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In contrast, if a patient was on full-dose TCZ following RTX treatment, at the point that the clinician was
contemplating amending treatment, current NICE guidance would allow no further bDMARDs. It is unclear
to what extent the knowledge of underlying synovitis would influence a clinician’s decision to amend
treatment. The threshold proportion of patients who could be moved onto RTX from their initial bDMARD,
at which point the savings in bDMARD acquisition cost would offset the costs of US monitoring, has
been calculated. This threshold value, assuming a cost per year of £4900 for RTX, would be £226.62/
(£9200 – £4900), which is 5.3%. The components of this formula are the annual costs of US monitoring
and the annual costs associated with bDMARDs and RTX.
If a patient was on a reduced-dose bDMARD because of previous tapering then the use of US to decide
whether or not to increase the dose is easier to model, although the answer would be dependent on the
assumed increase in dose. It has earlier been shown that the assumed costs of US per year equate to 2.46%
of the annual costs of bDMARDs. The proportion of patients who would not need an increase in dose
because of the information provided by US for a strategy of monitoring with US to be cost neutral can be
calculated as £226.62/[assumed increase in bDMARD dose (as a percentage of the full dose) × £9200].
Thus, if a dose increase of 33% of the full dose was contemplated, the threshold proportion of patients
who do not need to be treated would be £226.62/(33% × £9200), which is equal to 7.4%.
The cost-effectiveness of ultrasound monitoring in patients who appear to have disease
progression despite conventional disease-modifying anti-rheumatic drug treatment and
for whom the clinician is contemplating amending treatment
This analysis has again been divided into those patients on intensive cDMARDs and those on MTX alone.
It has been assumed that those on MTX alone would progress to an intensive cDMARD strategy, whereas
those on intensive cDMARDs would move to a bDMARD. The thresholds for patients on intensive
cDMARDs are shown in Figure 4 and the thresholds for those on MTX alone are shown in Figure 5.
Assuming no changes in serious infections the threshold value was 2.52% for those not progressing to
bDMARDs; the threshold value could not be attained for those not progressing to intensive cDMARDs.
When a patient is on a reduced dose of intensive cDMARDs or MTX because of previous tapering,
the threshold for the proportion of patients at which monitoring with US becomes cost neutral can be
calculated in a similar manner to that illustrated for patients on bDMARDs who have received tapered
medication and the clinician is contemplating increasing the dose.
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FIGURE 3 The average levels of intensive cDMARD drug reduction and serious infections avoided that result in a
cost per QALY gained of £20,000 and £30,000 for the use of US in monitoring synovitis.
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Sensitivity analysis
Sensitivity analysis was undertaken assuming that the number of US scans required per patient to monitor
synovitis ranged from one per year to 12 per year. The cost of a scan was assumed constant at £56.66.
Figure 6 provides data relating to the analyses in which the treatment dose was being tapered. It was
calculated that, even if a scan was provided on a monthly basis, this approach would be cost neutral if the
average decrease in bDMARD costs was 7.39%. This value was 15.99% for intensive cDMARDs. In contrast,
for patients on intensive cDMARDs, even when only one scan was performed per year a reduction in drug
costs of 26% would be needed to make US cost neutral.
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FIGURE 4 The average levels of reduction in patients moving to bDMARDs and serious infections avoided that
result in a cost per QALY gained of £20,000 and £30,000 for the use of US in monitoring synovitis.
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FIGURE 5 The average levels of reduction in patients moving to intensive cDMARDs and serious infections avoided
that result in a cost per QALY gained of £20,000 and £30,000 for the use of US in monitoring synovitis.
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Further sensitivity analysis was undertaken looking at the percentage reduction in the cost of bDMARDs,
assuming lower prices than the £9200 assumed in the base case. The motivation for this sensitivity analysis
was the fact that biosimilars have entered the market. This sensitivity analysis is shown in Figure 7.
It is seen that, as the price of bDMARDs approaches 50% of the price assumed in the base case, a 5%
reduction in bDMARD use would still be sufficient to make monitoring with US cost saving.
Additional sensitivity analysis was conducted to assess the impact of the increased costs associated with
use of subcutaneous MTX, which was assumed to cost £798.71 per annum more than oral MTX.
The results for the tapering analyses when assuming costs associated with subcutaneous MTX are provided
in Figures 8–11. The reduction in drug costs at which the use of US became cost neutral were 2.27% for
patients on bDMARDs, 22.9% for those on intensive cDMARDs and 27.04% for patients on subcutaneous
MTX alone.
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FIGURE 8 The average levels of bDMARD drug reduction and serious infections avoided that result in a cost per QALY
gained of £20,000 and £30,000 for the use of US in monitoring synovitis assuming the use of subcutaneous MTX.
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FIGURE 10 The average levels of MTX drug reduction and serious infections avoided that result in a cost per QALY
gained of £20,000 and £30,000 for the use of US in monitoring synovitis assuming the use of subcutaneous MTX.
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FIGURE 9 The average levels of intensive cDMARD drug reduction and serious infections avoided that result in a cost per
QALY gained of £20,000 and £30,000 for the use of US in monitoring synovitis assuming the use of subcutaneous MTX.
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Interpretation of the results
For patients for whom a clinician is contemplating a reduction in bDMARD use because of stable disease,
our analyses indicate that only a small average reduction in bDMARD use (2.46%) would be sufficient to
offset the costs associated with monitoring patients with US. This value is likely to be higher than in reality
should the drug burden be reduced for multiple years and the frequency of monitoring be reduced. Data
collated from a review of the evidence for bDMARD tapering (see Table 13) indicate that dose reduction
can occur in a sizeable proportion of patients. As such, a 2.46% reduction in bDMARD dose, which is
sufficient to offset the costs associated with monitoring patients with US, could be seen to be plausible if
the use of US made a clinician more confident to taper bDMARDs. An analysis was undertaken exploring
how these results would change if the average price of bDMARDs falls following the introduction of
biosimilars. This indicated that, if the cost was to fall by 50% of that assumed in the base case, the
reduction in bDMARD costs required for the use of adjunct US to be cost neutral would remain below 5%.
Reducing intensive cDMARD drug costs or MTX costs alone would not be sufficient to offset the costs
of US.
For both the bDMARD and cDMARD tapering scenarios there is the potential for fewer serious adverse
events if drug intake is reduced. This has been explicitly shown in Figures 2–4. The calculations suggest
that 0.13 serious infections saved per person (or approximately one per eight patients) would be sufficient
to make US for monitoring synovitis cost-effective. However, this threshold may be academic only: it is not
known whether or not such reductions in adverse events would be attainable only with dose reductions
that would already have made monitoring with US cost saving.
For patients who appear to undergo disease progression despite bDMARD treatment and for whom the
clinician is contemplating amending treatment, the decision problem is more complex. No analyses were
undertaken for patients changing treatment because of the uncertain impacts of downstream treatment.
However, an example calculation of the threshold value for the number of patients in whom increased
treatment was not necessary was provided for patients increasing their dosage subsequent to previous
tapering. The threshold value is dependent on the proposed increased dose of the bDMARD and it is
uncertain whether or not US is likely to be cost-effective in this group.
The use of US in monitoring synovitis in patients on cDMARDs was modelled as there were clear next-
treatment options dependent on the current regimen, namely bDMARDs for those on intensive cDMARDs
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or intensive cDMARDs for those on MTX alone. The results in this group were not dissimilar from those
when tapering was being considered, with a relatively small (approximately 2.5%) reduction in the number
of patients progressing to bDMARDs being required to make the use of US cost-effective.
Ultimately, the cost-effectiveness of US for monitoring synovitis will be dependent on how clinicians
change their decisions about care given the additional knowledge provided by US. If the results do not
feed into treatment strategies, then the use of US would not be cost-effective. However, evidence
presented in Table 12 suggests that the use of US to monitor synovitis was fairly prevalent, with a range
of 23–88% for studies based in the UK.89,90,153 Furthermore, it was reported that clinician confidence was
significantly improved (p < 0.0005) by the use of US.152 As such, it is anticipated that the use of US in
monitoring synovitis is plausibly cost-effective, particularly when activity identified on US has been shown
to be predictive of flares.142,155,156,163,164
However, the authors note that there remains considerable uncertainty around all decisions because of the
lack of robust evidence and that any conclusion should be interpreted with caution.
Analysis was undertaken to assess the impact of the increased acquisition price if subcutaneous MTX were
used rather than oral MTX. This reduced the thresholds required for the use of adjunct US to be cost
neutral, but there remained considerable uncertainty in the result.
Discussion
The modelling undertaken was purposefully simplistic so that the key interactions between monitoring
synovitis with US and decisions influencing treatment could be examined explicitly. The results presented
appear to indicate that monitoring synovitis with US could be cost-effective given the evidence on the
potential tapering of DMARDs presented in Table 13.
It has been assumed that monitoring with US would allow a clinician to better identify disease worsening
when drugs have been tapered. If that is not the case, and irreversible damage has been caused to
patients, then the thresholds presented will be favourable to US monitoring, with patients potentially
costing more in direct medical costs and having a reduced health-related quality of life. Although evidence
on long-term patient outcomes is limited, the majority of comparative studies have reported that there
were no differences in outcomes between tapered groups and non-tapered groups and comparative and
observational data have shown that patients who flared regained a favourable disease activity state when
treatment was reintroduced. Evidence for successful ADA or CTZ tapering is arguably less strong than
evidence for successful IFX tapering, although longer-term data are needed to form any conclusions.
If it is possible to reduce the frequency of US monitoring post DMARD tapering, or having established that
treatment escalation is not required, then the threshold values presented in this report will be unfavourable
to US monitoring.
Data from randomised clinical trials assessing the monitoring of synovitis with US as an adjunct to CE
compared with CE alone are needed. The TaSER study78 (see Table 11) was one such RCT and the full
results of this study were included in the review described in Chapter 3. Incorporating long-term radiographic
data into such a study would allow an insight into whether or not irreversible damage is caused by tapered
treatment. Wakefield et al.24 state that ‘there is now a compelling argument to suggest that the addition of
ultrasound assessment . . . is likely to improve the prediction on clinical outcomes’. At the time of writing,
ARCTIC trial interim data had been presented in an abstract79 (November 2015) and these data were
included in Chapter 3. At the time of the last search, the Targeted Ultrasound in Rheumatoid Arthritis (TURA)
study217 was ongoing and had a reported 32% global recruitment rate. As an identified ongoing study, the
authors checked (in February 2016) for any publications from the TURA study; however, it was still ongoing.
There is no information available on when these studies will report results. The objective of the ARCTIC study
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was to assess whether or not the information provided by ultrasonography assessment produces better
outcomes than when treatment decisions are made solely on clinical and laboratory assessments. The results
from these trials are expected to reduce the decision uncertainty regarding whether or not monitoring of
synovitis in RA patients with US is clinically effective and cost-effective. Furthermore, two ongoing studies
(NCT02064400 and NCT01602302) were identified from a search of ClinicalTrials.gov, although neither
is a RCT.
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Chapter 5 Assessment of factors relevant to the
NHS and other parties
Evidence identified for this report appears to indicate that monitoring synovitis with US could potentiallybe cost-effective given the possibility of tapering of DMARDs or inappropriate escalation of treatment.
There are a number of potential implications for NHS resources. If monitoring of synovitis becomes more
widespread (and there are a number of unknowns, for example US use may vary according to the
apparent clinical level of disease activity), depending on the number of US scans undertaken per year,
there may be a need for more sonographers. Such increased resources would also depend on drivers
outside the scope of this report. US has clinical advantages beyond the monitoring of inflammatory
arthritis, both for diagnosis (e.g. for a proportion of patients with suspected inflammatory arthritis,
enabling earlier intervention) and for guiding the accurate placement of needles for therapeutic injection.
All of this has implications for US access in both rheumatology and radiology departments. This also raises
issues regarding timely and equal access to US.
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Chapter 6 Discussion
Principal findings
Studies included in the systematic review varied in interventions, comparators and outcomes, making
it difficult to draw firm conclusions from the available evidence. Fifteen studies provided prognostic
data.55,69,97,98,113,134,135,137–144 Although the study designs were of high quality (prospective cohort), the data
reported were correlations and sample sizes ranged from 10 to 453 (in total, data were available from
1523 patients but study heterogeneity precluded meta-analysis). PDUS was significantly associated with
radiographic progression at follow-up in all studies in which it was investigated.55,69,97,113,135,138–140,144 The
majority of studies investigating radiographic progression reported that GSUS was a significant predictor;
however, this was not the case in all studies of GSUS. Some studies found a significant association
between DAS and later radiographic progression. PDUS was significantly associated in the majority of
studies with follow-up DAS28,55,98,137 ACR/EULAR remission145 and flare.142
Nine studies reported data regarding the use of US for monitoring treatment response or
strategies.79,93,95,100,101,139,154–156
Two were RCTs79,154 and the others were prospective cohort studies.93,95,100,101,139,155,156 Most studies relied
on one-off US measurements at baseline; however, the two RCTs employed US serially as part of the
treatment strategies. Sample sizes ranged from 24 to 130, with data available from 627 patients in total
(although study heterogeneity precluded meta-analysis). These studies found that US predicted treatment
continuation and response to treatment. When treatment was discontinued or tapered, PDUS significantly
predicted relapse or disease flare and was a better predictor than DAS28. In the RCTs, the addition of
PDUS to a DAS28-based treatment strategy did not lead to significant between-group differences in
change from baseline in DAS44 and RAMRIS erosion score154 or a significant between-group difference in
the primary end point, which consisted of a DAS of < 1.6 and no swollen joints at 16, 20 and 24 months
and no progression in vdHSS between 16 and 24 months.162 However, in the TaSER study, the US plus
DAS group had significantly more patients attaining DAS44 remission. Six small studies (sample size
17–109 patients; 321 patients in total) reported observational data on the impact of US on treatment
decisions.89–91,94,152,153 Adding US to CE led to modified treatment decisions and significantly improved
clinician confidence in these decisions.
A simple model was constructed. Monitoring with US was not assumed for all patients but rather for those
for whom the clinician was contemplating a change (escalation or tapering) of treatment. Screening of all
patients could have wider implications for cost-effectiveness and was not considered here. The modelling
undertaken indicated that only small proportions of patients tapering treatment, or not escalating
treatment, were necessary for the savings associated with reduced treatment to offset the costs associated
with monitoring synovitis with US. A systematic review of the literature on tapering of DMARDs indicated
that some patients achieving low disease activity could have treatment tapered with no, or little, resultant
harm, with the majority of those who flared regaining their previous condition on retreatment. As such,
there is clearly potential for the monitoring of synovitis with US to be cost-effective.
Strengths, limitations and uncertainties
Strengths
Relevant literature on prognosis, treatment and cost-effectiveness was reviewed systematically according to
a prespecified protocol. The research team was independent and experienced in the methodology and
clinical advisors were experienced in the field. A patient advisor provided information on patient experience
and contributed to the plain English summary.
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The review findings agreed with the findings of previous reviews with regard to diagnosis and prognosis.
We also compared US with CE in relation to treatment strategies/decisions, which had not previously been
systematically reviewed.
Results from this study are generalisable to UK practice. The studies included in the review used
international definitions of RA; most used standardised semiquantitative scoring systems for US measures
of synovitis; and clinical measures were also used internationally, for example the DAS28. Treatments
assessed included cDMARDs and bDMARDs, as would be relevant to UK practice.
To our knowledge, this is the first study to model the cost-effectiveness of the use of US to monitor
synovitis. In addition, we also carried out a systematic review of the literature on the tapering of DMARDs.
Limitations/uncertainties
There is no conclusive gold standard/reference standard for assessing synovitis and so diagnostic accuracy
comparisons may be flawed. The heterogeneity of the trials precluded meta-analysis; therefore, no
summary estimates of effect were available, which is a limitation of the review. Few studies were identified
that compared US with CE with regard to their effect on treatment. Few data were identified regarding
the additional influence of US in current practice. The review excluded studies not published in English.
The inclusion of conference proceedings may have resulted in the effectiveness of the interventions being
underestimated.218
There is a lack of long-term follow-up of studies of tapering medication. The survey conducted had few
responses and was subject to selection bias.
The mathematical model was simplistic, although this was by design to enable us to focus on aspects clearly
related to the impact of monitoring synovitis with US in patients with RA. There remains considerable
uncertainty around the cost-effectiveness of the use of US for monitoring synovitis.
The systematic review of the literature on DMARD tapering had relatively poor sensitivity, with the majority
of papers being identified from reference searching or being known to our clinical advisors. As such,
relevant papers may not have been identified, although it is unlikely that these would change the broad
conclusions of the review.
DISCUSSION
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Chapter 7 Conclusions
L ittle evidence matched the decision problem. However, this systematic review found correlationalevidence that US-detected synovitis was significantly associated with later radiographic progression.
PDUS-detected synovitis also significantly predicted DAS28, ACR/EULAR remission and flare. Studies
suggested that US was superior to CE alone in predicting response to treatment tapering or discontinuation.
Studies varied with regard to interventions, comparators and outcomes, precluding meta-analysis and
meaning that there is uncertainty in the available evidence. With regard to treatment strategies, studies
were not all consistent with regard to the statistical significance of the benefit of US. Only two RCTs were
identified and the addition of US to DAS-based strategies did not significantly influence the primary end
points, although one of these RCTs significantly favoured the addition of US for the outcome of attaining
DAS remission. It is uncertain whether the lack of significant influence on the primary end point is due to a
genuine lack of improvement caused by the US strategy or other factors such as joint counts and types of
US used within studies. Small studies suggested that US was used in treatment decisions and could increase
physician confidence in those decisions. A small survey of UK rheumatology units suggested that US is
already being used in some units for modifying treatment decisions in RA. Most studies relied on one-off US
measurements at baseline; however, the two RCTs employed US serially as part of treatment strategies.
The purposefully simplistic modelling undertaken shows that there is potential for the monitoring of
synovitis with US to be cost-effective, although there remains considerable uncertainty around
this conclusion.
Implications for service provision
Limited evidence identified for this report appears to indicate that monitoring synovitis with US in those
patients for whom clinicians are contemplating a change in treatment has the potential to be cost-effective,
given the possibility of tapering of DMARDs or inappropriate escalation of treatment. There are a number of
potential implications for NHS resources. If monitoring of synovitis becomes more widespread (and there are
a number of unknowns, e.g. US use may vary depending on the apparent clinical level of disease activity),
there may be a need for more sonographers, depending on the number of US scans undertaken per year.
Such increased resources would also depend on drivers outside the scope of this report. US has clinical
advantages beyond the monitoring of inflammatory arthritis, both in diagnosis (e.g. for a proportion of
patients with suspected inflammatory arthritis, enabling earlier intervention) and in guiding the accurate
placement of needles for therapeutic injection. All of this has implications for US access in both
rheumatology and radiology departments. This also raises issues regarding timely and equal access to US.
Suggested research priorities
An important future research recommendation is to evaluate the role of US using methodologically robust
studies that prospectively evaluate test accuracy and evaluate the role of US. For any future study thought
should be given to validity and efficient design, as discussed by Bossuyt et al.,219 who emphasise the
benefits of retaining solely those patients who have discordant results (in this case, between US and CE)
and randomising these patients to amended treatment or usual treatment. A feature of the decision
problem in this study, however, is the temporal aspect: it could be that clinicians were inclined to taper
treatment but would wait to be further convinced and would have amended treatment earlier if their view
was supported by evidence from US.
The heterogeneity of trials precluded meta-analysis; therefore, no summary estimates of effect were
available, which is a limitation of the review. Heterogeneity could be limited in future studies by employing
protocols that use comparable US joint counts (data would have to be presented for all joints scanned so
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that comparisons could be made with the currently used joint sets, which vary substantially in the included
joint count); comparable scoring systems for GSUS, PDUS and GSUS and PDUS combined, including similar
severity scales; comparable US definitions of what constitutes ‘positive’ involvement at both the joint and
the patient level (important for trials in which positive/negative findings dictate therapeutic decision-
making); and the same clinical outcomes (which has been less of a problem in more recent studies that
have reported a range of clinical outcomes).
Further important research questions include:
l What are the long-term effects on function and joint damage in patients who have had treatment
tapered as a result of imaging findings?
l Which joints should be assessed with US?
l Can a pre-selected set of joints be used for imaging or does imaging need to be guided by symptoms?
l How often should US assessment occur and could it be restricted to situations in which a treatment
decision is to be made, which should be assessed in serial testing studies?
l Would the cost-effectiveness of US change if all patients were screened rather than only those patients
for whom a change in management was being considered?
Studies including an assessment of costs and health-related quality of life would be useful to inform future
health policy decisions.
Given the range of questions that still need answering, it is unlikely that one study could provide all of the
answers. Different frequencies of monitoring could be compared within a randomised trial; however,
feasibility or trial practice would limit how many different frequencies of monitoring could be assessed
within one trial. Similarly, there are many variations of joint counts. The more joints assessed, the more
time is needed for assessment. Different joint counts need to be assessed to determine the most efficient
way to use US; enough joints need to be measured to warrant treatment decisions being influenced, while
ensuring that the time required by sonographers and patients remains manageable. It is uncertain whether
or not particular joint counts could serve all patients or whether or not the most affected joints of
individual patients would need to be taken into account. Similarly, there are different systems for assessing
the severity of US pathology. The OMERACT initiative has developed and validated standardised scoring
systems; however, trials would need to assess, for example, whether GSUS or PDUS alone could be used to
inform treatment strategies or whether or not a combination of GSUS and PDUS would be more effective.
CONCLUSIONS
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Appendix 1 Survey
There were few publications regarding US and its use in treatment decisions (see Chapter 1). A surveywas conducted of UK rheumatology units to investigate how US was being used in practice to influence
therapy. The BSR publicised the survey to UK rheumatology units. Additionally, the BSR requested that
respondents be questioned about the use of US in the diagnosis of RA.
The survey was available to clinicians from December 2015 to February 2016.
Only 31 responses were received by the end of February 2016. Survey respondents were self-selecting and
so the sample may have been biased.
Survey form
Do you use US for diagnosis of RA, yes/no?
Do you use US for monitoring synovitis in RA, yes/no?
If you answered yes to the previous question, how frequently are patients monitored?
and what information is routinely collected (e.g. number of joints, is a particular joint count used)?
Do you use US to make decisions regarding RA therapy, yes/no?
If so, is this for decisions to start/stop medication?
Is it used for dose adjustments (e.g. tapering medication)?
Is it used for decisions regarding cDMARDs, biologics, and/or steroids?
Who conducts US, rheumatologists or radiologists or other allied health professionals
(e.g. physiotherapists, nurses, podiatrists)?
Have the people conducting US received formal training in US to detect synovitis?
In which Rheumatology Unit are you based?
This survey is to provide background information for a project funded by the NIHR Health Technology
Assessment programme. Survey results will be aggregated for publication and no identifying information of
participants will be published. The project will be published in the Health Technology Assessment journal
series. Visit the HTA programme website for more details www.nets.nihr.ac.uk/programmes/hta
Any views and opinions expressed in Health Technology Assessment journal articles are those of the
authors and do not necessarily reflect those of the Department of Health.
Survey answers
Ultrasound was used in the diagnosis of RA by 27 out of 31 (87%) respondents.
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Twenty respondents said they used US for monitoring synovitis (Table 15). Additionally, one respondent
said that their unit planned to use US in the future. Of the 20 respondents using US for monitoring
synovitis, five said that monitoring was routine, with two stating that monitoring was routine only in early
arthritis. When monitoring was routine, this was every 3 or 6 months or annually. US assessment was
stated explicitly to be used for cases of uncertainty regarding synovitis (12/20) or symptoms change (1/20),
for distinguishing synovitis from other pathology (1/20) or for making a treatment decision or monitoring
treatment (7/20). Information collected was stated by four respondents to be specific to the clinical or
treatment question for which the patient was referred for US. Three respondents stated that information
was collected on the presence or absence of synovitis and four stated that the number of active joints was
recorded. Most respondents did not use a particular joint count, but there was one mention each of a
seven-joint score, the DAS28 and 34 joints and three respondents assessed wrist and hand joints. Four
respondents mentioned that grading of GSUS and PDUS was used. US was reported as being conducted
by rheumatologists (23/31), radiologists (16/31) and allied professionals (6/31).
Twenty-seven respondents stated that US was used for making treatment decisions, with 20 out of
27 respondents using US for making decisions about starting or stopping medication and 4 out of
27 respondents using US for making decisions about starting medication (not stopping). US was used
in making decisions around dose adjustment by 19 of the 27 respondents, with an additional two
respondents stating that US was used to make decisions around escalating (but not tapering) medication.
A further respondent stated that US may be used in the future for making treatment decisions.
Ultrasound was used for making treatment decisions around cDMARDs, bDMARDs and steroids by
17 respondents, for bDMARDs by three respondents and for cDMARDs and steroids by three respondents.
Two respondents reported the use of US when treatment decisions were difficult for selected patients.
Two respondents commented that there were plans to use US in the future for making decisions about
treatment with bDMARDs.
From the responses, it can be concluded that some units do use US for making treatment decisions, but
the small sample size and potential for bias mean that the results cannot be generalised across all UK
rheumatology units.
TABLE 15 Survey results
Question Yes, n/N (%) No, n/N (%)
Don’t know,
n/N (%)
Do you use US for monitoring synovitis in RA? 20/31 (65) 11/31 (35)
Do you use US to make decisions regarding RA therapy? 27/31 (87) 4/31(13)
Have the people conducting US received formal training in US to
detect synovitis?
25/31 (81) 1/31 (3) 5/31 (16)
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Appendix 2 Patient involvement
The National Rheumatoid Arthritis Society were contacted about patient involvement in the study. Itprovided the names of two patients with RA who were willing to be contacted about being involved.
Both patients were sent a draft of the plain English summary and were asked to provide feedback. The full
report was available to provide further information. The two patients were also invited to provide comments
regarding the patient experience of US and suggestions for future research priorities.
One patient did not respond. The other patient provided feedback on the plain English summary and
contributed text on the patient experience of US. This feedback was helpful and was deemed to improve
the accessibility of the plain English summary to a lay audience. The text of the plain English summary
was amended in accordance with the patient’s suggestions. The background section of the report was
amended based on information provided by the patient advisor on the patient experience of US.
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Appendix 3 Literature search strategies
There were three phases of searches: (1) initial searches to identify key words, (2) the phase 1 scopingsearches and (3) the phase 2 comprehensive searches. The scoping searches were conducted to
determine whether or not evidence was available on US for monitoring synovitis in RA and, therefore,
whether or not phase 2 of the project could be justified and whether or not any cost-effectiveness analyses
could be conducted.
The phase 1 searches identified diagnostic accuracy and prognostic studies relevant to the monitoring of
synovitis by US and so comprehensive searches for the diagnostic, prognostic and treatment effectiveness
section of the project were conducted as planned. However, the phase 1 scoping searches revealed a lack
of data to populate the planned cost-effectiveness model. Following advice from the clinical advisors and
consultation with the NIHR HTA programme, it was decided that an analysis of the costs and benefits
associated with US would be of value to the clinical community. However, attempting to achieve this using
the model that informed the recent NICE multiple technology appraisal40 was not deemed sensible as this
contained many elements that would be unnecessary when focusing on current decision problem and
would add uncertainty to the results. Therefore, a simpler model was constructed, which was subject to
sensitivity analyses and threshold analyses.
Initial searches to identify key words
Following the peer reviewer comments on the protocol,215 initial scoping searches for reviews and
diagnostic accuracy studies were carried out on 12 March 2015 to predict the size of the evidence base.
Searches for existing guidelines (national and international) were considered in the scoping searches.
Existing systematic reviews were searched for in a selected number of databases by applying a specific
reviews search filter. Focused diagnostic accuracy studies were searched for by applying a specific
diagnostic filter. This identified 114 records, indicating that a broader search would be useful.
Phase 1 searches
Based on the initial scoping searches, design filters were not combined with the search strategies.
Date and English-language limits were not applied.
The following databases were searched on 12 March 2015:
l MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
l EMBASE (via Ovid)
l The Cochrane Library (via Wiley Online Library)
l Science Citation Index Expanded (via Web of Science)
l Science Citation Index and Conference Proceedings Index (via Web of Science).
The number of records from each database (without date limits or application of a study design filter) is
shown in Table 16.
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MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (via Ovid) (1946–2015)
Date searched: 12 March 2015.
Search strategy
1. exp Arthritis, Rheumatoid/
2. rheumatoid arthritis.tw.
3. or/1-2
4. exp Synovitis/
5. synovitis.tw.
6. ((synovial or synovium) adj5 inflam$).tw.
7. or/4-6
8. exp Ultrasonography/
9. ultrasound.tw.
10. ultrason$.tw.
11. sonography.tw.
12. echography.tw.
13. or/8-12
14. 3 and 7 and 13
TABLE 16 Results of the database searches, 12 March 2015
Approach Source Number of records
Electronic database MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations 459
EMBASE 1313
HTA database 0
DARE 3
CDSR 0
CENTRAL 35
NHS EED 0
Science Citation Index Expanded and Science Citation Index and
Conference Proceedings Index
734
Electronic database and
trials registry
ClinicalTrials.gov 123
Total Retrieved 2677
Unique 1742
Conference abstracts via
Web of Science
European League Against Rheumatism Abstract Archive 18
American College of Rheumatology and Association of
Rheumatology Health Professionals
52
OMERACT conference proceedings 6
Total Retrieved 76
Unique 25
Overall total Unique records 1767
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EMBASE (via Ovid) (1974 to 11 March 2015)
Date searched: 12 March 2015.
Search strategy
1. exp rheumatoid arthritis/
2. rheumatoid arthritis.tw.
3. or/1-2
4. exp synovitis/
5. synovitis.tw.
6. ((synovial or synovium) adj5 inflam$).tw.
7. or/4-6
8. exp echography/
9. ultrasound.tw.
10. ultrason$.tw.
11. sonography.tw.
12. echography.tw.
13. or/8-12
14. 3 and 7 and 13
The Cochrane Library: Cochrane Database of Systematic Reviews (1996–2015), Cochrane
Central Register of Controlled Trials (1898–2015), Health Technology Assessment
database (1989–2015), Database of Abstracts of Reviews of Effects (1946–2014) and NHS
Economic Evaluation Database (1968–2014) (via Wiley Online Library)
Date searched: 12 March 2015.
Search strategy
#1 MeSH descriptor: [Arthritis, Rheumatoid] explode all trees
#2 rheumatoid arthritis:ti,ab,kw
#3 #1 or #2
#4 MeSH descriptor: [Synovitis] explode all trees
#5 synovitis:ti,ab,kw
#6 ((synovial or synovium) next/5 inflam*):ti,ab,kw
#7 #4 or #5 or #6
#8 ultrasound:ti,ab,kw
#9 ultrason*:ti,ab,kw
#10 sonography:ti,ab,kw
#11 or #8-#10
#12 #3 and #7 and #11
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Science Citation Index Expanded and Science Citation Index and Conference Proceedings
Index (1990–2015) (via Web of Science)
Date searched: 12 March 2015.
Search strategy
#10 #9 AND #4 AND #1
#9 #8 OR #7 OR #6 OR #5
#8 TOPIC: (echography)
#7 TOPIC: (sonography)
#6 TOPIC: (ultrason*)
#5 TOPIC: (ultrasound)
#4 #3 OR #2
#3 TOPIC: (((synovial or synovium) NEAR/5 inflam*))
#2 TOPIC: (synovitis)
#1 TOPIC: (rheumatoid arthritis)
ClinicalTrials.gov (US National Institutes of Health)
Date searched: 12 March 2015.
123 studies found for ultrasound | arthritis.
122 studies found for ultrasonography | arthritis.
122 studies found for sonography | arthritis.
122 studies found for echography | arthritis.
European League Against Rheumatism Abstract Archive (via Web of Science)
URL: http://scientific.sparx-ip.net/archiveeular/ (accessed 20 March 2015); published in Annals of the
Rheumatic Diseases.
Date searched: 20 March 2015.
Number of results: 18.
Search strategy
#4 #3 AND #2 AND #1
#3 TOPIC: (ultrasound) OR TOPIC: (ultrason*) OR TOPIC: (sonography) OR TOPIC: (echography)
#2 TOPIC: (((synovial or synovium) NEAR/5 inflam*)) OR TOPIC: (synovitis)
#1 PUBLICATION NAME: (ann rheum dis)
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American College of Rheumatology and Association of Rheumatology Health
Professionals (Web of Science)
URL: http://acrabstracts.org/ (accessed 8 February 2018); published in Arthritis & Rheumatology.
Date searched: 20 March 2015.
Number of results: 52.
Search strategy
#4 #3 AND #2 AND #1
#3 TOPIC: (ultrasound) OR TOPIC: (ultrason*) OR TOPIC: (sonography) OR TOPIC: (echography)
#2 TOPIC: ((((synovial or synovium) NEAR/5 inflam*))) OR TOPIC: ((synovitis))
#1 SO=(ARTHRITIS “AND” RHEUMATISM)
An update search was carried out in May 2015, with 32 unique records retrieved (Table 17). Added to the
1767 records identified from the searches conducted in March 2015, this gave a total of 1799 records
from the phase 1 electronic database searches.
The study selection criteria were refined based on the phase 1 search results. The protocol215 had stated that
‘For studies of diagnostic accuracy, study designs will be accepted into the review according to the hierarchy
of evidence published by Merlin et al.159’ As few studies were identified with diagnostic accuracy data, it
was decided that diagnostic studies providing sensitivity or specificity data would be included, even if this
was not the highest level of evidence according to the hierarchy,159 that is, diagnostic test accuracy studies
with an independent, blinded comparator of a valid reference standard, tested on consecutive patients.
TABLE 17 Results of the update database searches, 13 May 2015
Approach Source Number of records
Electronic database MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations 11
EMBASE 20
HTA database 0
DARE 0
CDSR 0
CENTRAL 0
NHS EED 0
Science Citation Index Expanded and Science Citation Index and
Conference Proceedings Index
21
PubMed 24
Conference abstracts via
Web of Science
European League Against Rheumatism Abstract Archive 1
American College of Rheumatology and Association of
Rheumatology Health Professionals
0
OMERACT conference abstracts proceedings 3
Total Retrieved 80
Final total Records from all databases with duplicates removed 32 unique to add
to database
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The phase 1 searches did not identify many prognostic studies or studies about response to treatment.
Studies of any level according to the hierarchy of prognostic studies159 were included as well as studies
with any outcome relating the use of US to treatment decisions or incorporating US to predict treatment
adherence, response, failure, relapse on, or following, discontinuation of treatment and surveys looking at
how US is used in treatment decisions in practice.
Phase 2 searches
The phase 1 scoping searches had identified that relevant diagnostic and prognostic studies were available
and therefore the phase 2 searches were carried out. However, the phase 1 searches also revealed a lack
of data to populate the planned cost-effectiveness model. As such, it was proposed that a simpler model
would be constructed.
As the phase 1 searches had been successful in identifying relevant studies and had not incorporated
design filters or date and English-language limits, it was decided that the same search strategies would be
used, slightly broadened, for the clinical effectiveness searches in phase 2. Additionally, a cost-effectiveness
filter was applied for the cost-effectiveness searches.
The following databases were searched for clinical effectiveness, cost-effectiveness and dose modification
studies between 22 October and 6 November 2015:
l BIOSIS Previews
l MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
l EMBASE (via Ovid)
l The Cochrane Library (via Wiley Online Library)
l Cumulative Index to Nursing and Allied Health Literature (CINAHL) (via EBSCOhost)
l PsycINFO (via Ovid)
l Science Citation Index Expanded (via Web of Science)
l Science Citation Index and Conference Proceedings Index (Web of Science)
l TOXLINE (via ProQuest)
l ProQuest Dissertations & Theses A&I (formerly Dissertation Abstracts International)
l ProQuest Dissertations & Theses – UK & Ireland
l EconLit.
The following trial registries, conference proceedings and websites were searched between 26 and
27 October 2015:
l American College of Rheumatology and Association of Rheumatology Health Professionals
l European League Against Rheumatism Abstract Archive
l ClinicalTrials.gov
l Current Controlled Trials
l NICE Evidence Search
l BSR
l Arthritis Research UK
l British Pain Society
l Arthritis and Musculoskeletal Alliance
l National Guideline Clearinghouse
l Royal College of Physicians
l Royal College of Radiologists
l Royal College of Pathologists
l Royal College of Surgeons
l NRAS.
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The phase 2 clinical effectiveness searches identified an additional 925 records. Added to the results of the
phase 1 searches this gave a total of 2724 unique records from the electronic database and supplementary
searches (study selection for the clinical effectiveness records is shown in Figure 1). In addition, the
cost-effectiveness searches identified 226 records and a parameter search for dose modification, which
was not restricted to imaging studies, identified 54 records (study selection for the cost-effectiveness
review is shown in Chapter 4).
TABLE 18 Results of the database searches, October–November 2015
Approach Source Number of records
Electronic database MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations 596
EMBASE 1574
CINAHL 132
DARE 2
CDSR 0
CENTRAL 1
NHS EED 0
EconLit 0
PsycINFO 1
TOXLINE 2
BIOSIS Previews 508
Science Citation Index Expanded and Science Citation Index and
Conference Proceedings Index
975
ProQuest Dissertations & Theses A&I 434
ProQuest Dissertations & Theses – UK & Ireland 23
Conference abstracts via
Web of Science
European League Against Rheumatism Abstract Archive 0
American College of Rheumatology and Association of
Rheumatology Health Professionals
3
OMERACT conference abstracts 0
Grey literature Current Controlled Trials 1
ClinicalTrials.gov 23
BSR 0
Royal College of Physicians 0
Royal College of Radiologists 3
Royal College of Surgeons 0
NRAS 41
Royal College of Pathologists 0
Arthritis Research UK 16
British Pain Society 0
Arthritis and Musculoskeletal Alliance 1
National Guideline Clearinghouse 19
NICE Evidence Search 33
Total Retrieved total 4388
Unique total 1205
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Search strategies
BIOSIS Previews (via Web of Science) (1969–2015)
Date searched: 6 November 2015.
Search strategy
#1 TOPIC: (rheumat* NEAR/5 (nodule or arthritis))
#2 TOPIC: =(felty* NEAR/2 syndrome)
#3 TOPIC: =(Caplan* NEAR/2 syndrome)
#4 TOPIC: (Sjogren* NEAR/2 syndrome)
#5 TOPIC: (Sicca NEAR/2 syndrome)
#6 TOPIC: Still* disease
#7 TOPIC: Bechterew* disease
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
#9 TOPIC: Synovitis
#10 TOPIC: ((Synovial or synovium) NEAR/5 (inflam* or hypertrophy))
#11 #9 OR #10
#12 TOPIC: Ultrasound
#13 TOPIC: Ultrason*
#14 TOPIC: Sonography
#15 TOPIC: Echography
#16 TOPIC: Ultrasonic
#17 #12 OR #13 OR #14 OR #15 OR #16
#18 #8 AND #11 #17
Cumulative Index to Nursing and Allied Health Literature (via EBSCOhost) (1969–2015)
Date searched: 22 October 2015.
Search strategy
S1 (MH “Arthritis, Rheumatoid+”)
S2 TX (Rheumat* N5 (nodule or arthritis))
S3 (Felty* N2 syndrome)
S4 TX (Sjogren* N2 syndrome)
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S5 TX (Sicca N2 syndrome)
S6 TX Still* disease
S7 TX Bechterew*
S8 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7
S9 (MH “Synovitis”)
S10 TS=((Synovial or synovium) NEAR/5 (inflam* or hypertrophy))
S11 #9 OR #10
S12 TX Ultrasound
S13 TX Ultrason*
S14 TX Sonography
S15 TX Echography
S16 TX Ultrasonic
S17 S12 OR S13 OR S14 OR S15 OR S16
S18 S8 AND S11 AND S17
The Cochrane Library: Cochrane Database of Systematic Reviews (1996–2015), Cochrane
Central Register of Controlled Trials (1898–2015), Health Technology Assessment
database (1989–2015), Database of Abstracts of Reviews of Effects (1946–2014) and NHS
Economic Evaluation Database (1968–2014) (via Wiley Online Library)
Date searched: 22 October 2015.
Search strategy
#1 MeSH descriptor: [Arthritis, Rheumatoid] explode all trees
#2 (Rheumat* next/5 (nodule or arthritis)):ti,ab,kw
#3 (felty* next/2 syndrome):ti,ab,kw
#4 (caplan* next/2 syndrome):ti,ab,kw
#5 (Sjogren* next/2 syndrome):ti,ab,kw
#6 (Sicca next/2 syndrome):ti,ab,kw
#7 Still* disease:ti,ab,kw
#8 Bechterew* disease:ti,ab,kw
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
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#10 MeSH descriptor: [Synovitis] explode all trees
#11 synovitis:ti,ab,kw
#12 synovitis:ti,ab,kw
#13 #10 OR #11 OR #12
#14 MeSH descriptor: [Ultrasonography] explode all trees
#15 Ultrasound:ti,ab,kw
#16 Ultrason*:ti,ab,kw
#17 Sonography:ti,ab,kw
#18 Echography:ti,ab,kw
#19 Ultrasonic:ti,ab,kw
#20 #14 or #15 or #16 or #17 or #18 or #19
#21 #9 and #13 and #20
ClinicalTrials.gov (US National Institutes of Health)
Date searched: 26 October 2015.
91 studies found for ultrasound | rheumatoid arthritis.
Checked for duplicates: 23 imported.
Current Controlled Trials
Date searched: 27 October 2015.
Search strategy
1. text search: Synovitis condition: Rheumatoid Arthritis AND Interventions: ultrasonography 0
results found
2. Condition: Rheumatoid Arthritis AND Interventions: ultrasonography 1 result found
3. Condition: Rheumatoid Arthritis AND Interventions: ultrasonound 0 results found
4. Condition: Rheumatoid Arthritis AND Interventions: sonography 0 results found
5. Condition: Rheumatoid Arthritis AND Interventions: Echography 0 results found
EMBASE (via Ovid) (1974 to 20 October 2015)
Date searched: 20 October 2015.
Search strategy
1. exp rheumatoid arthritis/
2. (rheumat$ adj5 (nodule or arthritis)).tw.
3. felty$ adj2 syndrome).tw
4. (caplan$ adj2 syndrome).tw
5. (rheumat$ adj2 (nodule or arthritis)).tw
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6. (sjogren$ adj2 syndrome).tw
7. (sicca adj2 syndrome).tw
8. still$ disease.tw
9. bechterew$ disease.tw
10. or/1-9
11. exp synovitis/
12. synovitis.tw.
13. ((Synovial or synovium) adj5 (inflam$ or hypertrophy)).tw
14. or/11-13
15. exp echography/
16. ultrasound.tw.
17. ultrason$.tw.
18. sonography.tw.
19. echography.tw.
20. Ultrasonic.tw
21. or/15-20
22. 11 and 14 and 21
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (via Ovid) (1946–2015)
Date searched: 21 October 2015.
Search strategy
1. exp Arthritis, Rheumatoid/
2. (Rheumat$ adj5 (nodule or arthritis)).tw
3. (Felty$ adj2 syndrome).tw
4. (Caplan$ adj2 syndrome).tw
5. (Sjogren$ adj2 syndrome).tw
6. (Sicca adj2 syndrome).tw
7. Still$ disease.tw
8. Bechterew$ disease.tw
9. or/1-8
10. Synovitis/
11. Synovitis.tw.
12. ((Synovial or synovium) adj5 (inflam$ or hypertrophy)).tw.
13. or/10-12
14. exp Ultrasonography/
15. Ultrasound.tw
16. Ultrason$.tw.
17. Sonography.tw
18. Echography.tw.
19. Ultrasonic.tw
20. or/14-19
21. 9 and 13 and 20
NICE Evidence Search
URL: www.evidence.nhs.uk/ (accessed 8 February 2018).
Date searched: 26 October 2015.
52 studies found for “rheumatoid arthritis” | “Synovitis” | “ultrasonography”
Checked for duplicates: 33 imported
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Science Citation Index Expanded and Science Citation Index and Conference Proceedings
Index (via Web of Science) (1900–2015)
Date searched: 22 October 2015.
Search strategy
#18 #8 AND #11 AND #17
#17 #12 OR #13 OR #14 OR #15 OR #16
#16 TOPIC: Ultrasonic
#15 TOPIC: Echography
#14 TOPIC: Sonography
#13 TOPIC: Ultrason*
#12 TOPIC: Ultrasound
#11 #9 OR #10
#10 TOPIC: ((Synovial or synovium) NEAR/5 (inflam* or hypertrophy))
#9 TOPIC: Synovitis
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
#7 TOPIC: Bechterew* disease
#6 TOPIC: Still* disease
#5 TOPIC: (Sicca NEAR/2 syndrome)
#4 TOPIC: (Sjogren* NEAR/2 syndrome)
#3 TOPIC: (Caplan* NEAR/2 syndrome)
#2 TOPIC: (Felty* NEAR/2 syndrome)
#1 TOPIC: (rheumat* NEAR/5 (nodule or arthritis))
TOXLINE (via ProQuest) (1999–2015)
Date searched: 6 November 2015.
Search strategy
S17 S7 AND S10 AND S16
S16 S11 OR S12 OR S13 OR S14 OR S15
S15 Ultrasonic
S14 Echography
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S13 Sonography
S12 Ultrason*
S11 Ultrasound
S10 S8 OR S9
S9 ((Synovial or synovium) NEAR/5 (inflam* or hypertrophy))
S8 Synovitis
S7 S1 OR S2 OR S3 OR S4 OR S5 OR S6
S6 Still* disease
S5 (Sicca NEAR/2 syndrome)
S4 (Caplan NEAR/2 syndrome)
S3 (Felty* NEAR/2 syndrome)
S2 (Rheumat* NEAR/5 (nodule or arthritis))
S1 Arthritis, Rheumatoid
PsycINFO (via Ovid) (1806 to October week 3 2015)
Date searched: 21 October 2015.
Search strategy
1. exp Rheumatoid Arthritis/
2. (Rheumat$ adj5 (nodule or arthritis)).tw.
3. (Felty$ adj2 syndrome).tw.
4. (Caplan$ adj2 syndrome).tw.
5. (Sjogren$ adj2 syndrome).tw.
6. (Sicca adj2 syndrome).tw.
7. Still$ disease.tw.
8. Bechterew$ disease.tw.
9. or/1-8
10. Synovitis.tw
11. ((Synovial or synovium) adj5 (inflam$ or hypertrophy)).tw
12. or/10-11
13. exp Ultrasound/
14. Ultrasound.tw
15. Ultrason$.tw
16. Sonography.tw
17. Echography.tw
18. Ultrasonic.tw
19. or/13-18
20. 9 and 12 and 19
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ProQuest Dissertations & Theses A&I (via ProQuest) (1743–2015)
Date searched: 26 October 2015.
Search strategy
S1 (Rheumat* NEAR/5 (nodule or arthritis))
S2 (Felty* NEAR/2 syndrome)
S3 (Caplan* NEAR/2 syndrome)
S4 (Sjogren* NEAR/2 syndrome)
S5”Still* disease”
S6 “Bechterew* disease”
S7 S1 OR S2 OR S3 OR S4 OR S5 OR S6
S8 Synovitis
S9 ((Synovial or synovium) NEAR/5 (inflam* or hypertrophy))
S10 s8 or s9
S11 Ultrasound
S12 Ultrason*
S13 Sonography
S14 Echography
S15 Ultrasonic
S16 S11 OR S12 OR S13 OR S14 OR S15
S17 S7 AND S10 AND S16
ProQuest Dissertations & Theses – UK & Ireland (via ProQuest) (1986–2015)
Date searched: 26 October 2015.
Search strategy
S1 (Rheumat* NEAR/5 (nodule or arthritis))
S2 (Felty* NEAR/2 syndrome)
S3 (Caplan* NEAR/2 syndrome)
S4 (Sjogren* NEAR/2 syndrome)
S5 “Still* disease”
S6 “Bechterew* disease”
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S7 S1 OR S2 OR S3 OR S4 OR S5 OR S6
S8 Synovitis
S9 ((Synovial or synovium) NEAR/5 (inflam* or hypertrophy))
S10 S8 or S9
S11 Ultrasound
S12 Ultrason*
S13 Sonography
S14 Echography
S15 Ultrasonic
S16 S11 OR S12 OR S13 OR S14 OR S15
S17 S7 AND S10 AND S16
European League Against Rheumatism Abstract Archive (via Web of Science)
URL: http://scientific.sparx-ip.net/archiveeular/ (accessed 9 November 2015); published in Annals of the
Rheumatic Diseases.
Date searched: 9 November 2015.
Search strategy
#4 #3 AND #2 AND #1
#3 TOPIC: (ultrasound) OR TOPIC: (ultrason*) OR TOPIC: (sonography) OR TOPIC: (echography)
#2 TOPIC: (((synovial or synovium) NEAR/5 inflam*)) OR TOPIC: (synovitis)
#1 PUBLICATION NAME: (ann rheum dis)
American College of Rheumatology and Association of Rheumatology Health
Professionals (via Web of Science)
URL: http://acrabstracts.org/ (accessed 8 February 2018); published in Arthritis & Rheumatology.
Date searched: 9 November 2015.
Search strategy
#4 #3 AND #2 AND #1
#3 TOPIC: (ultrasound) OR TOPIC: (ultrason*) OR TOPIC: (sonography) OR TOPIC: (echography)
#2 TOPIC: ((((synovial or synovium) NEAR/5 inflam*))) OR TOPIC: ((synovitis))
#1 SO=(ARTHRITIS “AND” RHEUMATISM)
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British Society for Rheumatology
URL: www.rheumatology.org.uk/
Date searched: 27 October 2015.
0 studies found for Ultrasound.
0 studies found for Ultrasonography.
0 studies found for Sonography.
0 studies found for Echography.
0 studies found for Synovitis.
Royal College of Physicians
URL: www.rcplondon.ac.uk/
Date searched: 27 October 2015.
0 studies found for Ultrasound synovitis.
0 studies found for Ultrasonography.
0 studies found for Sonography.
0 studies found for Echography.
0 studies found for Synovitis.
Royal College of Radiologists
URL: www.rcr.ac.uk/
Date searched: 27 October 2015.
0 studies found for Rheumatoid arthritis ultrasound.
0 studies found for Rheumatoid arthritis ultrasonography.
0 studies found for Rheumatoid arthritis sonography.
0 studies found for Rheumatoid arthritis echography.
0 studies found for Rheumatoid arthritis synovitis.
Royal College of Surgeons
URL: www.rcseng.ac.uk
Date searched: 27 October 2015.
0 results found for Synovitis.
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Royal College of Pathologists
URL: www.rcpath.org/
Date searched: 27 October 2015.
0 studies found for Ultrasound synovitis
0 studies found for Ultrasonography synovitis
0 studies found for Sonography synovitis
0 studies found for Echography synovitis
National Rheumatoid Arthritis Society
URL: www.nras.org.uk (accessed 18 March 2015).
Date searched: 27 October 2015.
25 results found for Ultrasound synovitis.
6 studies found for Ultrasonography synovitis.
5 studies found for Sonography synovitis.
5 studies found for Echography synovitis.
Arthritis Research UK
URL: www.arthritisresearchuk.org/
Date searched: 27 October 2015.
13 studies found for Ultrasound synovitis (filter by research).
1 study found for Ultrasonography synovitis.
1 study found for Sonography synovitis.
1 study found for Echography synovitis.
British Pain Society
URL: www.britishpainsociety.org/
Date searched: 27 October 2015.
0 studies found for Rheumatoid arthritis
National Guideline Clearinghouse
URL: www.guideline.gov/
Date searched: 27 October 2015.
19 studies found for “Rheumatoid arthritis ultrasonography”.
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Cost-effectiveness searches
Cumulative Index to Nursing and Allied Health Literature (via EBSCOhost) (1969–2015)
Date searched: 22 October 2015.
Search strategy
S1 (MH “Economics+”)
S2 (MH “Financial Management+”)
S3 (MH “Financial Support+”)
S4 (MH “Financing, Organized+”)
S5 (MH “Business+”)
S6 S2 OR S3 OR S4 OR S5
S7 S1 NOT S6
S8 MH Health resource allocation
S9 MH Health resource utilization
S10 S8 OR S9
S11 S7 OR S10
S12 TX (Cost or costs or economic* or pharmacoeconomic* or price* or pricing*)
S13 S11 OR S12
S14 PT Editorial
S15 PT Letter
S16 PT News
S17 S14 OR S15 OR S16
S18 S13 NOT S17
S19 (MH “Animal Studies”)
S20 S18 NOT S19
S21 (MH “Arthritis, Rheumatoid+”)
S22 TX (Rheumat* N5 (nodule or arthritis))
S23 (Felty* N2 syndrome)
S24 TX (Caplan* N2 syndrome)
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S25 TX (Sjogren* N2 syndrome)
S26 TX (Sicca N2 syndrome)
S27 TX Still* disease
S28 TX Bechterew* disease
S29 S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28
S30 (MH “Ultrasonography+”)
S31 TX Ultrasound
S32 TX Ultrason*
S33 TX Sonography
S34 TX Echography
S35 TX Ultrasonic
S36 S30 OR S31 OR S32 OR S33 OR S34 OR S35
S37 S18 AND S29 AND S36
EMBASE (via Ovid) (1974 to 20 October 2015)
Date searched: 21 October 2015.
Search strategy
1. Socioeconomics/
2. Cost benefit analysis/
3. Cost-effectiveness analysis/
4. Cost of illness/
5. Cost control/
6. Economic aspect/
7. Financial management/
8. Health care cost/
9. Health care financing/
10. Health economics/
11. Hospital cost/
12. (fiscal or financial or finance or funding).tw
13. Cost minimisation analysis/
14. (cost adj estimate$).mp
15. (cost adj variable$).mp
16. (unit adj cost$).mp
17. or/1–16
18. exp rheumatoid arthritis/
19. (rheumat$adj5 (nodule or arthritis)).tw synovitis.tw.
20. (felty$adj2 syndrome).tw
21. (Caplan$adj2 syndrome).tw
22. (Rheumat$adj2 (nodule or arthritis)).tw
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23. (Sjogren$adj2 syndrome).tw
24. (Sicca adj2 syndrome).tw
25. Still$disease.tw
26. Bechterew$disease.tW
27. or/18–26
28. exp echography/
29. ultrasound.tw.
30. ultrason$.tw.
31. sonography.tw.
32. echography.tw.
33. Ultrasonic.tw
34. or/28–33
35. 17 and 28 and 34
MEDLINE, MEDLINE Daily and MEDLINE In-Process & Other Non-Indexed Citations
(via Ovid) (1946–2015)
Date searched: 21 October 2015.
Search strategy
1. Economics/
2. “costs and cost analysis”/
3. Cost-effectiveness analysis/
4. Cost–benefit analysis/
5. Cost control/
6. Cost savings/
7. Cost of illness/
8. Cost sharing/
9. “deductibles and coinsurance”/
10. Medical savings accounts/
11. Health care costs/
12. Direct service costs/
13. Drug costs/
14. Employer health costs/
15. Hospital costs/
16. Health expenditures/
17. Capital expenditures/
18. Value of life/
19. exp economics, hospital/
20. exp economics, medical/
21. Economics, nursing/
22. Economics, pharmaceutical/
23. exp “fees and charges”/
24. exp budgets/
25. (Low adj cost).mp.
26. (High adj cost).mp.
27. (Health?care adj cost$).mp.
28. (Fiscal or funding or financial or finance).tw.
29. (Cost adj estimate$).mp.
30. (Cost adj variable).mp.
31. (Unit adj cost$).mp.
32. (Economic$or pharmacoeconomic$or price$or pricing).tw.
33. or/1–32
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34. exp Arthritis, Rheumatoid/
35. (Rheumat$adj5 (nodule or arthritis)).tw
36. (Felty$adj2 syndrome).tw.
37. (Caplan$adj2 syndrome).tw.
38. (Sjogren$adj2 syndrome).tw.
39. (Sicca adj2 syndrome).tw.
40. Still$disease.tw.
41. Bechterew$disease.tw.
42. or/34–41
43. exp Ultrasonography/
44. Ultrasound.tw.
45. Ultrason$.tw.
46. Sonography.tw.
47. Echography.tw.
48. Ultrasonic.tw.
49. or/43–48
50. 33 and 42 and 49
Science Citation Index Expanded and Science Citation Index and Conference Proceedings
Index (via Web of Science) (1900–2015)
Date searched: 23 October 2015.
Search strategy
#22 #21 AND #15 AND #7
#21 #16 OR #17 OR #18 OR #19 OR #20
#20 TOPIC: Ultrasonic
#19 TOPIC: Echography
#18 TOPIC: Sonography
#17 TS = Ultrason*
#16 TOPIC: Ultrasound
#15 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14
#14 TOPIC: Bechterew* disease
#13 TOPIC: Still* disease
#12 TOPIC: (Sicca NEAR/2 syndrome)
#11 TOPIC: (Sjogren* NEAR/2 syndrome)
#10 TOPIC: (Caplan* NEAR/2 syndrome)
#9 TOPIC: (Felty* NEAR/2 syndrome)
#8 TOPIC: (Rheumat* NEAR/5 (nodule or arthritis))
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#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
#6 TOPIC: (Pharmacoeconomic* or price* or pricing)
#5 TOPIC: (Cost NEAR (estimate* OR variable OR unit))
#4 TOPIC: (Fiscal or funding or financial or finance)
#3 TOPIC: ((Low OR high) near cost*)
#2 TOPIC: (Cost* near/3 (analy* or benefit* or control or saving or illness* or sharing))
#1 TOPIC: Economic*
EconLit (via Ovid) (1961–2015)
Date searched: 22 October 2015.
As this database is dedicated to economic studies, no filters were used in the search.
Search strategy
1. (rheumat$adj5 (nodule or arthritis)).tw.
2. (felty$adj2 syndrome).tw.
3. (caplan$adj2 syndrome).tw.
4. (sjogren$adj2 syndrome).tw.
5. (sicca adj2 syndrome).tw.
6. still$disease.tw.
7. bechterew$disease.tw.
8. or/1–7
9. synovitis.tw.
10. ((Synovial or synovium) adj5 (inflam$or hypertrophy)).tw.
11. or/9–10
12. Ultrasound.tw.
13. Ultrason$.tw.
14. Sonography.tw.
15. Echography.tw.
16. Ultrasonic.tw.
17. or/12–16
18. 8 AND 11 AND 17
NHS Economic Evaluation Database (1968–2014) (via Wiley Online Library)
Searched as part of The Cochrane Library search [see The Cochrane Library: Cochrane Database of
Systematic Reviews (1996–2015), Cochrane Central Register of Controlled Trials (1898–2015), Health
Technology Assessment database (1989–2015), Database of Abstracts of Reviews of Effects (1946–2014)
and NHS Economic Evaluation Database (1968–2014) (via Wiley Online Library) on page 101].
Parameter search
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (via Ovid) (1946–2015)
Date searched: 20 October 2015.
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Search strategy
1. Economics/
2. “costs and cost analysis”/
3. Cost-effectiveness analysis/
4. Cost–benefit analysis/
5. Cost control/
6. Cost savings/
7. Cost of illness/
8. Cost sharing/
9. “deductibles and coinsurance”/
10. Medical savings accounts/
11. Health care costs/
12. Direct service costs/
13. Drug costs/
14. Employer health costs/
15. Hospital costs/
16. Health expenditures/
17. Capital expenditures/
18. Value of life/
19. exp economics, hospital/
20. exp economics, medical/
21. Economics, nursing/
22. Economics, pharmaceutical/
23. exp “fees and charges”/
24. exp budgets/
25. (Low adj cost).mp.
26. (High adj cost).mp.
27. (Health?care adj cost$).mp.
28. (Fiscal or funding or financial or finance).tw.
29. (Cost adj estimate$).mp.
30. (Cost adj variable).mp.
31. (Unit adj cost$).mp.
32. (Economic$or pharmacoeconomic$or price$or pricing).tw.
33. or/1–32
34. exp Arthritis, Rheumatoid/
35. Rheumatoid arthritis.tw.
36. (Felty$adj2 syndrome).tw.
37. (Caplan$adj2 syndrome).tw.
38. (Rheumat$adj2 (nodule or arthritis)).tw.
39. (Sjogren$adj2 syndrome).tw.
40. (Sicca adj2 syndrome).tw.
41. Still$disease.tw.
42. Bechterew$disease.tw.
43. or/34–42
44. Biologic$.tw.
45. Anti-TNF.tw.
46. TNF-antagonist.tw.
47. TNF-inhibitor.tw.
48. (Abatacept or orencia).tw
49. (Adalimumab or humira or exemptia).tw.
50. (Certolizumab or CDP870 or cimzia).tw.
51. (Etanercept or enbrel).tw.
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52. (Golimumab or CNTO 148 or simponi).tw.
53. (Infliximab or remicade or remsima or inflectra).tw.
54. (Rituximab or rituxan or mabthera or zytux).tw.
55. (Tocilizumab or atlizumab or actemra or RoActemra).tw.
56. or/44–55
57. Taper$.tw.
58. Withdraw$.tw.
59. Discontinu$.tw.
60. Stop$.tw.
61. or/57–60
62. 33 and 43 and 56 and 61
Ongoing studies
The search of ClinicalTrials.gov identified some relevant studies that were ongoing or for which the results
were not reported at the time of writing (March 2016) (Table 19).
TABLE 19 Ongoing studies identified from search of ClinicalTrials.gov (31 March 2016)
NCT number Trial title
NCT01205854 Aiming for Remission in Rheumatoid Arthritis (RA) – the ARCTIC Trial (ARCTIC)
NCT02219347 Biomarkers of Remission in Rheumatoid Arthritis (BioRRA)
NCT01526434 Health-related Quality of Life and Patient-reported Outcomes in Rheumatoid Arthritis Patients Treated
with Certolizumab Pegol (SONAR-12)
NCT02140229 Is Ultrasound Remission a Real Remission? Does Ultrasound Permit to Achieve and Maintain the
Remission in Rheumatoid Arthritis Patients More Efficiently Than Clinical Scores? (REVECHO)
NCT02321930 Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid
Arthritis Patients
NCT01717859 Musculoskeletal Ultrasound in Predicting Early Dose Titration with Tocilizumab (RASTS)
NCT01443364 Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients with
Rheumatoid Arthritis (SPEED)
NCT02064400 Pilot Study of Ultrasound in Rheumatoid Arthritis
NCT00854243 Role of Greyscale and Power Doppler Sonography in Therapy Monitoring in Early Rheumatoid
Arthritis (RA)
NCT02202837 Study with Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice
(REACH RA)
NCT02056184 Targeted Ultrasound in Rheumatoid Arthritis (TURA)
NCT01752309 The Predictive Value of Ultrasound in Early Rheumatoid Arthritis (EVA)
NCT01282528 Ultrasonographic Monitoring of Response to Infliximab in Patients with Rheumatoid Arthritis (ULTRA)
NCT00781989 Ultrasonography as a Biomarker in Early Rheumatoid Arthritis
NCT01602302 Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (RA-BioStop)
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Appendix 4 Excluded studies
T able 20 shows the studies excluded at full-text sift, with reasons for exclusion.
TABLE 20 Excluded studies
First author Year of publication Reason for exclusion
Alfredo Chávez-López220 2007 Non-English language
Andersen221 2014 No outcome data meeting review inclusion criteria
Andonopoulos222 1995 Study not about synovitis
Baan223 2011 No outcome data meeting review inclusion criteria
Bajaj224 2007 No clinical comparator
Boesen225 2008 No relevant outcomes
Brown226 2006 No outcome data meeting review inclusion criteria
Bruyn227 2009 No clinical comparator
Carotti228 2002 No outcome data meeting review inclusion criteria
Cheung50 2010 No outcome data meeting review inclusion criteria
D’agostino62 2016 No clinical comparator
Damjanov229 2012 No outcome data meeting review inclusion criteria
da Silva Chakr230 2015 No outcome data meeting review inclusion criteria
Dejaco231 2012 No outcome data meeting review inclusion criteria
DiFranco232 2015 No outcome data meeting review inclusion criteria
Dohn233 2011 No outcome data meeting review inclusion criteria
Epis234 2014 No outcome data meeting review inclusion criteria
Foltz235 2012 No clinical comparator
Freeston236 2008 No clinical comparator
Fukae237 2013 No clinical comparator
Fukae238 2014 No clinical comparator
Funck-Brentano239 2009 Not all patients have RA
Funck-Brentano240 2013 No clinical comparator
Geng241 2014 No outcome data meeting review inclusion criteria
Haavardsholm110 2009 No clinical comparator
Hameed242 2008 No outcome data meeting review inclusion criteria
Harman243 2015 No clinical comparator
Harman244 2015 No outcome data meeting review inclusion criteria
Hermann245 2003 No outcome data meeting review inclusion criteria
Hmamouchi246 2011 Study not about synovitis
Janta247 2013 No outcome data meeting review inclusion criteria
Kawashiri248 2014 No clinical comparator
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TABLE 20 Excluded studies (continued )
First author Year of publication Reason for exclusion
Kawashiri249 2015 No clinical comparator
Kelly250 2015 No outcome data meeting review inclusion criteria
Klauser251 2005 No clinical comparator
Klauser252 2010 Study not about synovitis
Krejza253 1998 Study about initial diagnosis of arthritis
Lillegraven254 2011 Study not about synovitis
Lillegraven255 2012 Not a US study
Makinen256 2007 Not a US study
Marks26 2015 No clinical comparator
Molenaar48 2004 Not a US study
Montoro257 2015 No outcome data meeting review inclusion criteria
Naredo54 2005 No outcome data meeting review inclusion criteria
Naredo258 2013 No outcome data meeting review inclusion criteria
Naredo259 2014 No outcome data meeting review inclusion criteria
Nordal260 2014 No outcome data meeting review inclusion criteria
Peluso261 2011 No clinical comparator
Ramirez262 2014 No outcome data meeting review inclusion criteria
Reiche263 2014 No clinical comparator
Schmidt264 2013 No relevant clinical comparator data
Spinella265 2012 No outcome data meeting review inclusion criteria
Stramare266 2014 No outcome data meeting review inclusion criteria
Strunk267 2013 No outcome data meeting review inclusion criteria
Szkudlarek268 2001 No separate data for RA patients
Taouli269 2004 Not a US study
Terslev270 2012 No outcome data meeting review inclusion criteria
Varsamidis271 2005 No clinical comparator
Wakefield272 2007 Study not about synovitis
Watanabe273 2012 No outcome data meeting review inclusion criteria
Yoshimi274 2015 No clinical comparator
Zheng275 2014 No outcome data meeting review inclusion criteria
Ziswiler276 2009 No outcome data meeting review inclusion criteria
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Appendix 5 Data extraction tables
For calculations of diagnostic accuracy, US was counted as the reference standard and the accuracy ofthe clinical comparator was assessed using sensitivity (i.e. the proportion of TPs) and specificity (i.e. the
proportion of TNs). Sensitivity is calculated as the number of TPs divided by the sum of the TPs and FNs;
specificity is calculated as the number of TNs divided by the sum of the TNs and FPs.
TABLE 21 Data extraction table: Backhaus et al.69
First author (study name) Backhaus69
Year 2013
Abstract or full paper Full paper
Study design Prognostic
Study objective To determine the sensitivity to change of the US7 score among RA
patients under various therapies and to analyse the effect of each
therapeutic option over 1 year. To estimate predictors for the
development of destructive bone changes
p. 1163
Population sample size 432
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early
RA, remission)
RA
Population baseline characteristics 81% female, 19% male
Mean (SD, range) age 57 (12.8, 17–84) years
Mean (SD, range) disease duration 8.3 (8.7, 0.08–58.3) years
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
73.2% prednisolone equivalent with a mean daily dosage of 8.8mg per day
Divided into four therapy groups at baseline:
l group 1 – first-line DMARD after new initiation (n= 118; 27.3%)
l group 2 – therapy switch from DMARD to a second DMARD
(n= 108; 25.0%)
l group 3 – first-line biologic after DMARD therapy (n = 153; 35.4%)
l group 4 – therapy switch from biologic to a second biologic
(n= 53; 12.3%).
Joints assessed CE: DAS28
US: seven-joint count – wrist, MCP 2 and 3, PIP 2 and 3, MTP 2 and 5
Type(s) of US and US details (including the
machine used, scoring system used and
diagnostic cut-off if applicable)
GSUS and PDUS
Settings for GSUS: frequency 16MHz, length of scanner 40–42mm
Settings for PDUS: frequency 9.1 MHz, pulse repetition frequency
500–750 Hz (depending on machine setting). Machine NR
Joints were evaluated for synovitis and tenosynovitis/paratenonitis and
superficial bone erosions according to EULAR criteria and OMERACT
definition including GSUS and PDUS
GSUS was graded on the Scheel semiquantitative scale and PDUS was
graded from 0 to 3 on the Szkudlarek semiquantitative scale
Who conducted US NR
Comparator CE details DAS28, ESR, CRP
Who conducted comparator CE NR
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TABLE 21 Data extraction table: Backhaus et al.69 (continued )
First author (study name) Backhaus69
Follow-up duration (if relevant) 12 months
Primary outcome of study Sensitivity to change of the US7 score among a large cohort of RA
patients under various therapies (cDMARDs and/or biological therapy) and
analysis of the effect of each therapeutic option over a period of 1 year
Outcome(s) reported in main body of report Prognostic
Study authors’ conclusions The US7 score was comparable to clinical and laboratory data, illustrating
its potential to reflect the therapeutic response and sensitivity to change.
Erosions declined significantly among patients who switched from one
biologic to another, but were stable in the other groups
NR, not reported; SD, standard deviation.
TABLE 22 Data extraction table: Balsa et al.105
First author (study name) Balsa105
Year 2010
Abstract or full paper Full paper
Study design Diagnostic
Study objective To investigate the accuracy of composite scores in classifying RA
patients who are in remission using the absence of inflammatory
activity detected by US as a gold standard
p. 683
Population sample size 97
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early
RA, remission)
Patients were classified as being in clinical remission by their attending
rheumatologist using subjective clinical judgement
Population baseline characteristics 70 female, 27 male
Mean (SD, range) age 56 (12.2, 18–82) years
Mean (SD, range) disease duration 5.9 (9.6, 1–18) years
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
Taking DMARD therapy or biological agents at baseline. Excluded if taking
a high dose of steroids (> 7.5 mg of prednisone daily) or had a history of
intra-articular steroid joint injection during the past 6 months
Joints assessed 42 joints: PIP, MCP, wrist, elbow, bilateral glenohumeral, knee, ankle and
midtarsal and MTP joints
Type(s) of US and US details (including the
machine used, scoring system used and
diagnostic cut-off if applicable)
GSUS and PDUS
Acuson Antares Siemens system with a linear probe (5–13MHz) and a
Doppler frequency of 5–8.9 MHz
GSUS for synovial hypertrophy (SH) and/or joint effusion graded using a
0–3 semiquantitative scoring method (0= no SH, 1=mild SH, 2=moderate
SH and 3= severe SH). PDUS graded using a 0–3 semiquantitative scoring
method (0= no PD signal, 1= one or two vessels in small joints or up to
three single vessels in large joints, 2= less than half of the synovial area and
3=more than half of the synovial area)
Who conducted US Expert US rheumatologist
Comparator CE details DAS28, SDAI
Who conducted comparator CE Attending rheumatologist
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TABLE 22 Data extraction table: Balsa et al.105 (continued )
First author (study name) Balsa105
Primary outcome of study The relationship between clinical remission and imaging remission
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions ‘SDAI classification of remission is closer to the concept of an absence of
inflammatory activity, as defined by the absence of a positive PD signal by
US’ (p. 683), than DAS28 classification of remission
SD, standard deviation.
TABLE 23 Data extraction table: Beckers et al.106
First author (study name) Beckers106
Year 2004
Abstract or full paper Full papera
Study design Diagnostic
Study objective To assess synovitis by 18F-FDG PET in an individual joint analysis and
in a global analysis of RA disease activity and to compare 18F-FDG
PET parameters with clinical, biological and sonographic (US)
rheumatoid parameters
p. 956
Population sample size 21
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early
RA, remission)
Active RA, no DMARDs within 2 months
Population baseline characteristics 17 women, 4 men
Mean (range) age 48 (34–69) years
Mean (range) disease duration 11 (1–24) years
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
Previously treated with 3.4 (range 1–8) DMARDs. Seventeen patients
received low-dose oral corticosteroids (mean 7mg/day, range 4–10mg/day
of prednisolone) and all received NSAIDs. None had taken a DMARD for
2 months before study entry
Joints assessed 356 joints in total: knees in all subjects and either wrists as well as MCP
and PIP joints in 13 patients or ankles and the first MTP joints in the
remaining eight patients
Type(s) of US and US details (including the
machine used, scoring system used and
diagnostic cut-off if applicable)
GSUS and PDUS
GSUS 13.0-MHz transducer and PDUS 5-MHz transducer (Aloka Prosound
5500). Pulse repetition frequency of 651 Hz for PDUS. Cut-off for US positivity
was synovitis of ≥ 1-mm thick. PDUS scored on a 0–3 semiquantitative scale
(0= no signal, 1= intermittent, 2= persistent single spotting within the same
location, 3=multiple persistent spotting within the same location). Joints
assessed at multiple sites (wrists and knees) were considered positive for
GSUS and PDUS if at least one measurement/signal was identified
Who conducted US One radiologist and one rheumatologist experienced in US
Comparator CE details SJCs and TJCs
Who conducted comparator CE Experienced study nurse
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TABLE 24 Data extraction table: Bhamra et al.89
First author (study name) Bhamra89
Year 2014
Abstract or full paper Abstract
Study design Treatment
Study objective To evaluate the impact of clinic-based ultrasonography (MSUS) on
the diagnosis and management of cases seen in [an] emergency
rheumatology clinic
p. 659
Population sample size 17 RA (of 62 in study)
Population diagnosis of RA NR
Population eligibility details (e.g. early
RA, remission)
Patients referred to rheumatology clinic (not all RA)
Population baseline characteristics NR for 17 RA patients. For 62 study patients, 25 men, 38 women;
mean (range) age 57.17 (range 30–88) years
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
NR
Joints assessed 10 MCP and PIP joints, radiocarpal joint and ulnar styloid
Type(s) of US and US details (including the
machine used, scoring system used and
diagnostic cut-off if applicable)
GSUS and PDUS
GE Logiq E9 using a linear transducer. Scoring system NR
Who conducted US Consultant rheumatologist
Comparator CE details NR
Who conducted comparator CE Referring clinician
Follow-up duration (if relevant) NA
Primary outcome of study Treatment decision change following US
Outcome(s) reported in main body of report Treatment decision
Study authors’ conclusions There is a positive impact of US in the rheumatology clinic; specifically
highlighted multiple benefits in daily practice of reduced visits,
discharge at first encounter and immediate management decisions
p. 660
NA, not applicable; NR, not reported.
TABLE 23 Data extraction table: Beckers et al.106 (continued )
First author (study name) Beckers106
Primary outcome of study To compare 18F-FDG PET parameters with clinical, biological and
sonographic (US) rheumatoid parameters
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions 18F-FDG PET is a unique imaging technique that can assess the
metabolic activity of synovitis and measure disease activity in RA
p. 956
18F-FDG PET, 18F-fluorodeoxyglucose positron emission tomography.
a This research was originally published in JNM. Beckers et al. Assessment of disease activity in rheumatoid arthritis with
F-18-FDG PET. J Nucl Med 2004;45(6):956–64. © by the Society of Nuclear Medicine and Molecular Imaging, Inc.106
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TABLE 25 Data extraction table: Boyesen et al.134
First author (study name) Boyesen134
Year 2011
Abstract or full paper Full paper
Study design Prognostic
Study objective To examine the associations between modern imaging modalities and joint
damage measured as 1-year MRI erosive progression in early RA patients
p. 176
Population sample size 84 recruited, 79 with 1-year follow-up data
Population diagnosis of RA ACR 1987 criteria
Population eligibility details
(e.g. early RA, remission)
Early RA (< 1 year), treatment NR
Population
baseline characteristics
65 patients (77%) female, 19 male
Median (IQR) age 58 (47–67) years
Median (IQR) disease duration 107 (70–188) days
Population treatment at
baseline (e.g. bDMARDS
or cDMARDs)
NR
Joints assessed CE: DAS28
US: dominant wrist
Type(s) of US and US details
(including the machine used,
scoring system used and
diagnostic cut-off if applicable)
GSUS
8–16-MHz linear array transducer on a Diasus machine (Dynamic Imaging,
Livingstone, UK). All findings were graded as 0= none, 1 =mild, 2=moderate
or 3 =marked
Who conducted US Trained user
Comparator CE details DAS28-ESR
Who conducted comparator CE NR
Follow-up duration (if relevant) 12 months
Primary outcome of study Prediction of erosions at 1 year as measured by MRI
Outcome(s) reported in main
body of report
Prognostic
Study authors’ conclusions GSUS inflammation and MRI bone marrow oedema were independent
predictors of MRI erosive progression in early RA patients on a group level.
The exact prognosis of the individual patients could not be determined by
imaging alone
p. 176
IQR, interquartile range; NR, not reported.
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TABLE 26 Data extraction table: Brown et al.135 and Ikeda et al.136
First author (study name) Brown135 and Ikeda136
Year 2008 and 2007
Abstract or full paper Full paper
Study design Prognostic
Study objective To evaluate the long-term significance of subclinical synovitis and its
relationship to structural outcome
p. 2958
Setting UK, outpatient clinics
Population sample size 102 (90 with a full set of radiographs at both time points)135
107136
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early
RA, remission)
In remission (while taking cDMARDs – stable therapy for 6 months prior
to baseline)
Population baseline characteristics Mean age 57 (IQR 24–81) years
67% female; 33% male
Duration of RA, median (range) 7 (2–38) years
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
cDMARDs
Joints assessed Hand and wrist – MCP, radiocarpal, ulnar carpal, distal radioulnar,
intercarpal compartments
Type(s) of US and US details (including the
machine used, scoring system used and
diagnostic cut-off if applicable)
GSUS and PDUS
ATL HDI 3000 machine (ATL Ultrasound, Bothell, WA, USA) with a
10–5MHz linear array ‘hockey-stick’ transducer, according to the EULAR
guidelines. Presence and location of synovial hypertrophy (SH) and
erosions were recorded according to OMERACT definitions. SH was
graded using a 0–3 semiquantitative scoring method (0 = no SH, 1=mild
SH, 2=moderate SH and 3= severe SH). PDUS images were scored using
a 0–3 semiquantitative technique (0 = normal/minimal vascularity, 1=mild
hyperaemia, 2=moderate hyperaemia and 3=marked hyperaemia).
Erosions were scored using a similar 0–3 semiquantitative scale, according
to their location and severity/size
Who conducted US A single experienced sonographer
Comparator CE details Duration of morning stiffness; Likert scale and VAS for fatigue, joint pain,
physician’s assessment of disease activity and patient’s global impression
of health and disease activity; number of painful, tender and swollen
joints as assessed by an independent trained metrologist; HAQ; RAQoL;
ACR; DAS28; ESR; CRP
Who conducted comparator CE Consultant rheumatologist and trained metrologist
Follow-up duration (if relevant) 12 months
Primary outcome of study Progression of joint damage – erosions135
Long-term radiological and clinical outcome136
Outcome(s) reported in main body of report Prognostic
Study authors’ conclusions The present study supports the use of sensitive imaging techniques
for the accurate evaluation of disease status and the prediction of
outcome in patients with RA, even when the findings of standard
clinical measures of inflammatory activity have returned to normal
p. 2966
IQR, interquartile range.
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TABLE 27 Data extraction table: Bugatti et al.147 and Scirè et al.137
First author (study name) aBugatti147 and Scirè137
Year 2012 and 2009
Abstract or full paper Full paper
Study design Prognostic
Study objective To investigate whether baseline serum levels of the chemokine CXCL13 might
predict clinical and ultrasonographic outcomes in patients with recent-onset RA
Bugatti et al.,147 p. 1
To evaluate the usefulness of a systematic musculoskeletal ultrasonographic
assessment in the detection of residual disease activity in patients with early RA
who achieved clinical remission
Scirè et al.,137 p. 1092
Population sample size 161 (155 at 12-month follow-up)147
106137
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early
RA, remission)
Early RA; DMARD and glucocorticoid naive
Population baseline characteristics From n= 161:147 median (IQR) age 64 (50–73) years; 112 female (69.6%),
49 male; median (IQR) disease duration 3 (2–6) months
From n= 106:137 mean (SD) age 59.5 (14.4) years; 75 female, 31 male; mean (SD)
disease duration 3.8 (2.8) months
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
n= 72 starting with MTX, n = 31 starting with HCQ, n= 48 starting with
prednisone
Joints assessed Bilateral shoulder, elbow, wrist (radiocarpal and midcarpal joint), MCP joints, PIP
joints of the hands, sternoclavicular and acromioclavicular joints, knee, ankle and
MTP joints
Type(s) of US and US details
(including the machine used, scoring
system used and diagnostic cut-off
if applicable)
GSUS and PDUS
GE Logiq 9 scanner (General Electrics Medical Systems, Milwaukee, WI, USA) with
a multifrequency linear array transducer (10–15MHz), performed according to
EULAR guidelines
GSUS and PDUS signals were scored on 0–3 semiquantitative scales.277 GSUS
scoring: 0 = normal, 1=mild, 2=moderate, 3 =marked. PDUS scoring:
0= absence or minimal flow, 1=mild (single-vessel signal), 2=moderate
(confluent vessels), 3 =marked (vessel signals in > 50% of the joint area)
Who conducted US A single experienced operator
Comparator CE details SJC and TJC on the 44-joint count, Ritchie Articular Index (RAI), global health
assessment on a 0–100mm VAS, evaluator global assessment of disease activity
and patient global assessment of disease activity on a 0–10 cm VAS, ESR and CRP
Who conducted comparator CE NR
Follow-up duration (if relevant) 12 months
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TABLE 27 Data extraction table: Bugatti et al.147 and Scirè et al.137 (continued )
First author (study name) aBugatti147 and Scirè137
Primary outcome of study Ultrasonic outcome (PDUS scores)147
Residual disease activity137
Outcome(s) reported in main body
of report
Prognostic
Study authors’ conclusions CXCL13 is a promising prognostic marker in early RA, accurate in assessing the
severity of synovitis and its persistence over time in response to conventional
treatments
Bugatti et al.,147 p. 8
The data support the specific role of US in detecting residual disease activity in
early RA
Scirè et al.,137 p. 1096
PD-positive synovial hypertrophy identifies ongoing inflammation even during
remission and predicts short-term relapse
Scirè et al.,137 p. 1092
IQR, interquartile range; NR, not reported; SD, standard deviation.
a Both studies included patients from the Early Arthritis Clinic (EAC) of the University Hospital of Pavia cohort.
TABLE 28 Data extraction table: Taylor et al.100 and Cavet et al.138
First author (study name) Taylor100 and Cavet138
Year 2004 and 2009
Abstract or full paper Full paper and abstract
Study design Prognostic
Study objective To investigate the ability of US and biomarkers to predict progressive joint damage
Population sample size 24
Population diagnosis of RA ACR 1987 criteria100
Population eligibility details (e.g. early
RA, remission)
RA patients who were followed in a 2-year blinded study comparing MTX + IFX
with MTX alone in aggressive early RA
RA, symptoms for 6 months to 3 years, a minimum of two swollen MCP joints
despite treatment with oral MTX (minimum 8 weeks) and seropositivity for
immunoglobulin M rheumatoid factor; either erosion of at least one MCP joint as
demonstrated on plain radiography or GSUS or erosions of at least two MCP joints
on GSUS and PDUS; stable dosage of 12.5–17.5 mg/week of folic acid at least
4 weeks prior to screening; if on corticosteroids must have been on a stable dose
for 4 weeks (< 10mg/day); screening laboratory tests100
Population baseline characteristics 18 female, 6 male100
Mean (SD) age: MTX treated 51.4 (14.0) years, IFX+MTX treated 55.2 (11.8) years100
Mean (SD) disease duration: MTX treated 1.64 (0.63) years, IFX+MTX treated 1.33
(0.64) years100
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TABLE 28 Data extraction table: Taylor et al.100 and Cavet et al.138 (continued )
First author (study name) Taylor100 and Cavet138
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
Treatment with MTX at a mean weekly dosage of approximately 15 mg for a
mean duration of 0.91 years
Joints assessed 10 MCP joints
Type(s) of US and US details
(including the machine used, scoring
system used and diagnostic cut-off
if applicable)
GSUS and PDUS
Scored for synovial thickening and for vascularity by PD area
High-frequency (13-MHz) US and PD (14-MHz) imaging were performed using a
15L8 transducer (Acuson Sequoia, Siemens Medical Systems, Ultrasound Group,
Issaquah, WA, USA) with constant settings in both GSUS and PDUS100
GSUS images were evaluated for synovial thickness and assigned a score of 0–5.
PDUS: number of colour Doppler pixels was determined in a defined region of
interest for each joint and a total vascularity score was calculated as the sum of
the individual joint scores100
Who conducted US The same sonographer for all patients100
Comparator CE details 93 serum proteins associated with biological processes underlying joint damage
were measured in serum samples
TJC, SJC, morning stiffness duration (minutes), pain 0–10 VAS, patient and
physician global assessment of disease activity 0–5 VAS, ACR 20/50/70 responses,
DAS28, ESR
Who conducted comparator CE An independent assessor
Follow-up duration (if relevant) 110 weeks
Primary outcome of study Association of US and biomarkers with modified Sharp score at 110 weeks
Outcome(s) reported in main body
of report
Prognostic and treatment
Study authors’ conclusions Both ultrasonographic imaging and quantitative serum protein biomarkers can
be used to estimate rates of progression and predict joint damage in RA.
Serum proteins associated with change in TSS represent multiple biological
pathways. Predictive models using US and biomarkers have the potential to
improve patient outcomes
Cavet et al.138 p. 1464
SD, standard deviation.
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TABLE 29 Data extraction table: Ceponis et al.152
First author (study name) Ceponis152
Year 2014
Abstract or full paper Full paper
Study design Treatment decision and diagnostic
Study objective To investigate the usefulness of point-of-care hand and wrist joint US
examination in patients with established RA
p. 236
Population sample size 51 (also included healthy control subjects, but data reported separately for
RA patients)
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early
RA, remission)
RA, no history or suspicion of fibromyalgia
Population baseline characteristics Female 42 (91%), male 4 (9%)
Mean (range) age 61.8 (28–82) years
Mean (range) disease duration 16.6 (1–38) years
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
Majority of patients were receiving cDMARDs, including MTX (60.9%;
mean dosage 15.2 mg/week, range 5–25mg/week) and leflunomide
(15.2%; mean dosage 17.5 mg/day, range 10–20mg/day) with or without
a biologic agent [34.6%; either TNFi (n = 14), interleukin-6 inhibitor (n= 1)
or RTX (n = 1)]
Joints assessed MCP 1–5, PIP 2–5, wrist
Type(s) of US and US details (including the
machine used, scoring system used and
diagnostic cut-off if applicable)
GSUS and PDUS
A LOGIQ e US machine (GE Healthcare) equipped with a multifrequency
8- to 13-MHz linear transducer was used. Settings were standardised,
with GSUS frequency of 12–13MHz, gain of 58–64%, PD frequency of
6.7 MHz, gain of 9–12% and pulse repetition frequency of 0.6–0.8 Hz
OMERACT definitions were used to assess joints for joint effusion and
synovial hypertrophy, using a semiquantitative scale from 0 to 3 for GSUS
and PDUS (0 = absence, 1=mild, 2=moderate and 3= severe).52,53
PD scoring: grade 0= no intra-articular colour signal, grade 1= single
vessel signal(s), grade 2= confluent colour signal in less than half of the
intra-articular area and grade 3= confluent colour signal in more than half
of the intra-articular area52
Who conducted US Experienced sonographer
Comparator CE details CDAI, SJC, TJC, HAQ, pain VAS, morning stiffness, fatigue VAS, patient
global assessment VAS
Who conducted comparator CE Four board-certified rheumatologists
Follow-up duration (if relevant) NA
Primary outcome of study Agreement between US and clinical findings and its impact on physicians’
confidence and clinical decision were assessed
Outcome(s) reported in main body of report Treatment decision
Study authors’ conclusions PD examination of the wrist and second/third MCP joints might be
feasible and clinically meaningful in evaluation of disease activity in
patients with established RA. US examination of the hand/wrist joints
in RA increases physicians’ confidence in their clinical decisions and can
help to individualise DMARD and biologic agent use
p. 236
NA, not applicable.
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TABLE 30 Data extraction table: Ciurtin et al.90,158
First author (study name) Ciurtin90,158
Year 2013 and 2012
Abstract or full paper Abstract
Study design Treatment
Study objective To evaluate the usefulness of a 22 hand joints scoring
system, adapted from the OMERACT recommendations,
in assessing and differentiating patients with established RA
from those with possible or definite early undifferentiated
inflammatory arthritis. To establish the usefulness of the
musculoskeletal US findings in guiding treatment decisions
p. 295
Population sample size 39 RA patients (of 98 in study)
Population diagnosis of RA NR (established RA)
Population eligibility details (e.g. early RA, remission) Patients referred to US service with inflammatory arthritis or
suspected arthritis
Population baseline characteristics NR for RA subset; for overall study: 69 females [mean (SD)
age 50.03 (11.2) years) and 29 males [mean (SD) age 48.8
(11.7) years)
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
6/39 RA patients on biological therapy
Joints assessed 22 wrist joints and MCP and PIP joints
Type(s) of US and US details (including the machine used,
scoring system used and diagnostic cut-off if applicable)
GSUS and PDUS
Machine NR. Scoring system adapted from the OMERACT
recommendations; no details on scoring system reported
Who conducted US Specialist US service
Comparator CE details NR
Who conducted comparator CE NR
Follow-up duration (if relevant) NA
Primary outcome of study Distinguishing RA from undifferentiated inflammatory arthritis
and treatment decisions
Outcome(s) reported in main body of report Treatment
Study authors’ conclusions In the 22 hand joints US scoring system, the presence of joint
effusion grade 1 affecting < 5 joints and minimal synovial
hypertrophy affecting < 3 joints did not correlate with any
laboratory evidence of inflammatory or autoimmune abnormalities
NA, not applicable; NR, not reported; SD, standard deviation.
TABLE 31 Data extraction table: Dale et al.153,154
First author (study name) Dale153,154 (TaSER)
Year 2014 and 2013
Abstract or full paper Full paper
Study design Treatment
Study objective To determine the level of agreement and potential impact on DMARD
escalation decisions and of adding musculoskeletal ultrasound (MSUS)
assessment of disease activity to the DAS28
Dale et al.,153 p. 19
continued
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TABLE 31 Data extraction table: Dale et al.153,154 (continued )
First author (study name) Dale153,154 (TaSER)
To test whether the efficacy of DAS28-driven treat-to-target DMARD strategies
could be improved by the addition of a regular MSUS
Dale et al.,154 p. S338
Population sample size 53 in the MSUS arm (110 with RA in the whole trial)
Population diagnosis of RA ACR/EULAR 2010 criteria
Population eligibility details (e.g. early
RA, remission)
Early RA/anti-citrullinated protein antibody-positive undifferentiated arthritis, untreated
Population baseline characteristics Of the 53 patients in the MSUS arm: mean (SD) age NR; 30 females (59%);
mean (SD) symptom duration 5.1 (2.8) months
In the whole trial population (n= 110): median disease duration 4 months; DAS28
group contained a higher proportion of females (78%) than the MSUS group
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
Step-up therapy (MTX; triple therapy; triple therapy with subcutaneous MTX;
triple therapy + ETN)
Joints assessed Dorsal recesses of 14 joints (second and third PIP joints, second and third MCP
joints, wrist joints and second and fifth MTP joints bilaterally)
Type(s) of US and US details
(including the machine used, scoring
system used and diagnostic cut-off
if applicable)
GSUS and PDUS
All examinations were conducted using the same portable US machine (Voluson I,
GE Healthcare) and a 10- to 16-MHz linear array probe (SP 10–16RS, GE
Healthcare). PD examination was standardised using frequency high (machine
preset), pulse repetition frequency 0.9 kHz, wall filter low and gain adjusted to
below the level at which Doppler artefact appeared beneath bone. The presence
of GS and PD synovitis positivity was graded on a 0–3 semiquantitative scale.52
Active disease on MSUS was defined as the presence of a grade 1 or higher
intra-articular PD signal in at least two joints. Therefore, the presence of a PD
signal in two or more joints was used as a threshold for DMARD escalation
Who conducted US Trained metrologist
Comparator CE details DAS28, CRP, ESR, SJC, TJC, patient global assessment of disease activity, HAQ
Who conducted comparator CE Trained metrologist
Follow-up duration (if relevant) 18 months
Primary outcome of study Improvements in DAS44
Outcome(s) reported in main body
of report
Treatment
Study authors’ conclusions Compared with the DAS28, global RA disease activity assessment using a
limited MSUS joint set provided additional disease activity information and led
to altered treatment decisions in a significant minority of occasions
Dale et al.,153 p. 19
This may allow further tailoring of DMARD therapy by supporting DMARD
escalation in patients with continuing subclinical synovitis and preventing
escalation in symptomatic patients with minimal clinical and/or ultrasonographic
synovitis
Both groups exhibited similar, very robust improvements in clinical outcomes
MSUS disease activity assessment was not associated with improved clinical
outcomes except for a higher rate of DAS44 remission after 18 months
Dale et al.,154 p. S339
NR, not reported; SD, standard deviation.
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TABLE 32 Data extraction table: Dougados et al.139,149 and Cheung et al.148
First author (study name) Dougados139,149 and Cheung148
Year 2013 and 2014
Abstract or full paper Full paper
Study design Prognostic and management
Study objective To evaluate synovitis (clinical vs. ultrasound (US)) to predict
structural progression in RA
p. 665
Population sample size 59 with data (from 77 recruited)
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) RA, minimum disease activity of at least six swollen joints by
CE, eligible for TNFi (investigator opinion)
Population baseline characteristics Female 81%, male 19%
Mean (SD) age 56 (12) years
Mean (SD) disease duration 10 (8) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
Mean number of previous cDMARDs 3.0. History of TNFis
32%. At baseline assigned to 4 months treatment with
bDMARD (ETN, n= 34; ADA, n= 23, IFX, n= 2)
Joints assessed MCP (×10), PIP (×10), wrist (×2) and MTP (×10) joints for US
and CE
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
Real-time scanners (e.g. Esaote Technos MPX, Esaote MyLab,
Toshiba Aplio, Philips HD11, BK MiniFocus) using
multifrequency linear transducers (7–12MHz)
Synovitis was defined according to the OMERACT definition,
using a semiquantitative scale from 0 to 3 [GS: 0= absence of
synovial thickening, 1=mild synovial thickening, 2 =moderate
synovial thickening, 3=marked synovial thickening; PD:
0= absence of signal, no intra-articular flow, 1=mild, one- or
two-vessel signal (including one confluent vessel) for small
joints and two to three signals for large joints (including two
confluent vessels), 2=moderate confluent vessels (> grade 1)
and < 50% of normal area, 3=marked vessel signals in more
than half of the synovial area]
Who conducted US Either a radiologist or a rheumatologist with experience
Comparator CE details Clinical evaluation of synovitis and tender joints
Who conducted comparator CE Either a rheumatologist or a research nurse with experience
Follow-up duration (if relevant) 2 years
Primary outcome of study Association between structural deterioration and the presence
of baseline synovitis, or its persistence, after 4 months
of therapy
Outcome(s) reported in main body of report Prognostic and treatment
Study authors’ conclusions This study confirms the validity of synovitis for predicting
subsequent structural deterioration, irrespective of the
modality of examination of joints, but also suggests that
both clinical and ultrasonographic examinations may be
relevant to optimally evaluate the risk of subsequent
structural deterioration
p. 665
SD, standard deviation.
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TABLE 33 Data extraction table: Ellegaard et al.101
First author (study name) Ellegaard101
Year 2011
Abstract or full paper Full paper
Study design Treatment
Study objective To investigate the predictive ability of core outcomes
applied in RA trials, including PDUS measurements
differentiating patients who remain on TNFi therapy
following 1 year
p. 506
Population sample size 109
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Active RA, treated with TNFi (ADA, ETN or IFX)
Population baseline characteristics 78 females (71.1%)
Mean (SD, range) age 57.9 (13.9, 25.5–84.3) years
Mean (SD, range) duration of RA 10.4 (9.0, 1.0–34.6) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
TNFi (ADA, ETN or IFX)
Joints assessed Wrists (most affected)
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
PDUS
Scanning was performed with a US machine (Siemens,
Mountainview, CA, USA) using a linear array transducer with
14-MHz centre frequency, with no adjustments of Doppler
parameters performed
No details provided on scoring system used
Who conducted US Head of the US unit, with 20 years’ US experience; other
investigators with several years of US training and 1 month of
specific training on wrist scans
Comparator CE details TJC, SJC, ESR, CRP, HAQ, patient general health VAS global,
DAS28-CRP
Who conducted comparator CE A rheumatologist unaware of the results of the US examination
Follow-up duration (if relevant) 1 year
Primary outcome of study Remaining on TNFi therapy at 1 year
Outcome(s) reported in main body of report Treatment
Study authors’ conclusions There is now evidence to support that baseline PDUS, in
contrast to clinical measures, can predict which patients will
remain on TNFis 1 year after initiating therapy
p. 506
SD, standard deviation.
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TABLE 34 Data extraction table: Filippucci et al.107
First author (study name) Filippucci107
Year 2006
Abstract or full paper Full paper
Study design Diagnostic
Study objective To use PDUS to evaluate changes in synovial perfusion induced by
adalimumab in the wrist joints of patients with RA
p. 1433
Setting Two rheumatology centres in Italy
Population sample size 48 wrists of 24 patients
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early
RA, remission)
Active disease, aged ≥ 18 years, not pregnant, not in another
trial of other biologic agents, no history of intra-articular steroid
injections at the wrist, no changes in DMARD dose in the previous
3 months
Population baseline characteristics 18 female, 6 male
Median (SD) age 61.5 (SD 10.5) years (IQR 48–67 years)
Median (SD) disease duration 10 (SD 7.9) years (IQR 5–17 years)
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
Started on ADA
Joints assessed Wrists
Type(s) of US and US details (including the
machine used, scoring system used and
diagnostic cut-off if applicable)
PDUS
AU5 Harmonic (Esaote Biomedica, Genoa, Italy) with a 10- to
14-MHz linear probe, standardised with a pulse repetition frequency of
1000 Hz and a colour mode frequency of 7MHz
Representative pictures of the highest expression of intra-articular
PDUS signals were obtained. A score from 0 to 3 was assigned
according to the overall expression of PDUS signals at the wrist level
(semiquantitative visual scale: 0 = normal or minimal degree, 1 =mild
degree, 2 =moderate degree and 3=marked degree)
Who conducted US An experienced operator blinded to both clinical and laboratory
findings
Comparator CE details Physician’s global assessment of disease activity, ESR using the
Westergren method, serum levels of CRP (upper reference level 4 mg/l;
not measured at week 2)
Who conducted comparator CE An experienced rheumatologist
Follow-up duration (if relevant) 12 weeks
Primary outcome of study Change from baseline in clinical and US assessments
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions Our study suggests that:
PDUS is a feasible and sensitive imaging tool for assessing the
response to treatment of synovitis at the small-joint level. In particular,
we have shown that the wrist joint is a suitable anatomical site to be
assessed by PDUS for detecting changes in synovial perfusion induced
by systemic drug treatment
p. 1437
Ongoing follow-up will add further insight into the persistence of
considerable reductions in PDUS scores and their correlation with DAS28.
In particular, long-term follow-up will provide information on the
predictive value of rapid PDUS signal reduction for sustained remission
of the disease at the small-joint level
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TABLE 34 Data extraction table: Filippucci et al.107 (continued )
Joint swelling (n= 24, 192 joints) PDUS negative PDUS positive Total
Clinically swollen 13 61 74
Clinical not swollen 32 86 118
Total 45 147 192
Joint tenderness (n= 24, 192 joints) PDUS negative PDUS positive Total
Clinically tender 10 58 68
Clinically not tender 35 89 124
Total 45 147 192
Population
Diagnostic
accuracy
comparison Sensitivity, % Specificity, % PPV, % NPV, %
Joint swelling
(n = 24, 192 joints)
CE with
reference GSUS
41 71 82 27
Joint swelling
(n = 24, 192 joints)
CE with
reference GSUS
82 27 41 71
Joint tenderness
(n = 24, 192 joints)
GSUS with
reference CE
39 78 85 28
Joint tenderness
(n = 24, 192 joints)
GSUS with
reference CE
85 28 39 78
IQR, interquartile range; SD, standard deviation.
TABLE 35 Data extraction table: Gandjbakhch et al.91
First author (study name) Gandjbakhch91
Year 2008
Abstract or full paper Abstract
Study design Treatment decision
Study objective To evaluate therapeutic decisions in daily practice and determine if US examination
may influence therapeutic decisions in the management of RA patients
p. S467
Population sample size 52
Population diagnosis of RA ACR criteria
Population eligibility details (e.g. early
RA, remission)
RA patients referred for therapy adjustment
Population baseline characteristics Sex NR
Mean age 54 years
Mean disease duration 10.3 years
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
cDMARD, n = 43; TNFi, n= 7; no ongoing DMARDs, n= 2
Joints assessed US: bilaterally on wrists, MCP 2–5 joints, PIP 2–5 joints, elbows, shoulders, knees
and MTP 2–5 joints
CE: DAS28
Type(s) of US and US details
(including the machine used, scoring
system used and diagnostic cut-off
if applicable)
GSUS and PDUS
Machine and scoring system NR
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TABLE 35 Data extraction table: Gandjbakhch et al.91 (continued )
First author (study name) Gandjbakhch91
Who conducted US An experienced rheumatologist
Comparator CE details DAS28
Who conducted comparator CE One of nine trained rheumatologists
Follow-up duration (if relevant) NA
Primary outcome of study Change in treatment decision (%) following US
Outcome(s) reported in main body
of report
Treatment
Study authors’ conclusions Rheumatologists’ therapeutic decision was mainly made according to disease
activity assessed by the DAS28. US findings increased clinician confidence and
resulted in a change in therapeutic decision for 13% of the patients. US
examination seems useful to detect residual inflammatory activity
p. S468
NA, not applicable; NR, not reported.
TABLE 36 Data extraction table: Garrigues et al.108
First author (study name) Garrigues108
Year 2013
Abstract or full paper Full paper
Study design Diagnostic
Study objective To evaluate concordance between CE and US of joints in a heterogeneous
group of patients with rheumatoid arthritis
p. 597
Population sample size 40
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early
RA, remission)
Age ≥ 18 years
Population baseline characteristics 29 women and 11 men
Mean (SD) age 55.9 (14) years
Mean (SD) disease duration 11.2 (8.7) years
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
Most patients receiving intravenous treatment for RA
Joints assessed 40 joints, namely the 28 joints included in the DAS28 (shoulders, elbows, wrists,
MCP joints, PIP joints and knees) and tibiotalar and MTP joints
Type(s) of US and US details
(including the machine used, scoring
system used and diagnostic cut-off
if applicable)
GSUS and PDUS
Multiplanar GSUS (B-mode) and PDUS images were obtained using commercially
available real-time scanners (Esaote MyLab60 and Philips IU22) and multifrequency
linear transducers (7–12.5 MHz)
Synovitis defined according to 2005 OMERACT definitions
GSUS: 0–3 semiquantitative scoring: 0= no synovial thickening; 1=mild synovial
thickening (minimal synovial thickening not bulging beyond bone surfaces);
2=moderate synovial thickening (synovial thickening bulging beyond bone
surfaces without extension along the diaphysis); 3=marked synovial thickening
(synovial thickening bulging beyond the bone surfaces with extension along at
least one of the diaphysis)
continued
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TABLE 36 Data extraction table: Garrigues et al.108 (continued )
First author (study name) Garrigues108
PDUS: 0–3 semiquantitative scoring: 0= no signal, no intra-articular flow; 1=mild,
until three isolated points or two confluents points or one confluent point and up
to two isolated points; 2=moderate vessel confluence (> grade 1) occupying
< 50% of the normal synovial surface area; 3=marked vessel confluence
occupying > 50% of the normal synovial surface area
Who conducted US Two sonographers (one radiologist, one rheumatologist)
Comparator CE details SJC and TJC
Who conducted comparator CE Rheumatologist
Primary outcome of study Concordance between CE and US
Outcome(s) reported in main body
of report
Diagnostic
Study authors’ conclusions Ultrasound adds information to clinical examination, most notably at the shoulders,
wrists and MTP joints. Concordance was moderate to strong at other joint sites
p. 597
SD, standard deviation.
TABLE 37 Data extraction table: Gartner et al.109
First author (study name) Gartner109
Year 2013
Abstract or full paper Full paper
Study design Diagnostic
Study objective To compare clinically active joints with sonographically active joints in patients
with RA, applying different sonographic definitions of an active joint
p. 2005
Setting Rheumatology outpatient clinic in Austria
Population sample size 90 patients (60 in clinical remission, 30 not in clinical remission)
Population diagnosis of RA ACR 2010 criteria
Population eligibility details (e.g. early
RA, remission)
Remission and active disease, no restriction on medication
Population baseline characteristics In clinical remission: female 78.3%; mean (SD) age 60.1 (10.8) years; mean (SD)
disease duration 9.4 (8.9) years; mean (SD) DAS28 2.2 (0.5)
Not in clinical remission: female 76.7%; mean (SD) age 60.1 (11.3) years;
mean (SD) disease duration 10.3 (7.7) years; mean DAS28 3.8 (1.1)
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
NR
Joints assessed CE: 28 joints
US: 11 joints of each hand, including PIP, MCP and wrist joints
Type(s) of US and US details
(including the machine used, scoring
system used and diagnostic cut-off
if applicable)
PDUS and GSUS
Logiq E9 (General Electric) with a ML 6–15 transducer, frequency range
9–15MHz; for PD, pulse repetition frequency was set between 500 Hz and 800 Hz
and receiver gain settings were controlled to eliminate the appearance of artefacts
GS and PD signals for signs of synovitis were graded using a 0–3 semiquantitative
scoring system (0 = none, 1 =mild, 2=moderate and 3 = severe)52
Who conducted US An experienced sonographer who had no access to the clinical and laboratory
data and who was unaware of the results of the clinical joint examination
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TABLE 37 Data extraction table: Gartner et al.109 (continued )
First author (study name) Gartner109
Comparator CE details TJCs and SJCs were performed on 28 joints in all patients. Swelling and
tenderness were defined in accordance with the standardised assessment
recommendations from EULAR, whereby, in the presence of any doubt, a joint
was considered ‘not swollen’; 100-mm VAS for pain and global assessment of
disease (patient’s and evaluator’s); duration of morning stiffness (minutes);
HAQ-DI; CRP, ESR; CDAI; SDAI; DAS28
Who conducted comparator CE NR
Primary outcome of study Comparative analysis of sonographic and clinical joint assessment
Outcome(s) reported in main body
of report
Diagnostic
Study authors’ conclusions . . . sonography as a tool to detect synovitis may have sufficient value only
when the signals are high and that low signals may not necessarily represent
inflammation and, in contrast to the clinical findings, are not related to disability
p. 2012
Thus, the present findings reveal that more detailed assessment of sonographic data
is needed to fully appreciate the value of US in the follow-up of patients with RA
NR, not reported; SD, standard deviation.
TABLE 38 Data extraction table: Haavardsholm and Ostergaard110
First author (study name) Haavardsholm110
Year 2009
Abstract or full paper Full paper
Study design Diagnostic
Study objective To evaluate the responsiveness of MRI and US compared with conventional
measures of disease activity and structural damage in patients with RA during
the first year of treatment with TNFis
p. 1572
Population sample size 36
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early
RA, remission)
Active RA (started on TNFi treatment)
Population baseline characteristics 80.6% female
Median (IQR) age 52.8 (24.0) years
Median (IQR) disease duration 7.6 (8.0) years
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
Started on TNFi
Joints assessed One wrist for US, both hands and wrists for CE
Type(s) of US and US details
(including the machine used, scoring
system used and diagnostic cut-off
if applicable)
GSUS
All of the US measurements were performed using an 8- to 16-MHz linear array
transducer (Diasus, Dynamic Imaging, Livingstone, UK)
Synovitis/tenosynovitis and effusions were graded using a 0–4 semiquantitative
scale (0 = none, 1= uncertain, 2=minimal, 3=medium and 4= high amount of
hypoechoic material)
Who conducted US An experienced ultrasonographer
Comparator CE details 28 SJC, 28 TJC, patient- and investigator-perceived pain 100-mm VAS, disability
via modified HAQ, DAS28-ESR, SDAI, CDAI, CRP, ESR
continued
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TABLE 39 Data extraction table: Haarvardsholm et al.79
First author (study name) Haarvardsholm79 (ARCTIC)
Year 2015
Abstract or full paper
Study design
Study objective
Population sample size
Population diagnosis of RA
Population eligibility details (e.g. early
RA, remission)
Population baseline characteristics
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
Joints assessed
Type(s) of US and US details
(including the machine used, scoring
system used and diagnostic cut-off
if applicable)
Who conducted US
Comparator CE details
Who conducted comparator CE
Follow-up duration (if relevant)
Primary outcome of study
Outcome(s) reported in main body
of report
Study authors’ conclusions
Abstract
Treatment
To investigatetightcontrolstrategiestoseewhetherornotatreatmentstrategy
additionally includingUSwould leadtobetterclinicalandradiographicoutcomes
comparedwithaconventionaltreatmentstrategy
118intheUSarm(105hadcompletedthestudyatthetimeofabstractpublication)
112intheconventionalstrategyarm(99hadcompletedthestudyatthetimeof
abstractpublication)
ACR/EULAR2010criteria
EarlyRA(symptomdurationupto2years),DMARDnaive, indicationforDMARDs
NR
DMARDnaive.Treatmentstrategy intrial:MTX,thentriplecDMARDs,
thenbDMARD
44 jointsofDAS44;PDUSandGSUSassessed32 jointsona0–3scale111
PDUSandGSUSassessedona0–3scale.111 MachinedetailsNR
Experiencedsonographers
DAS,SJC
NR
2years
Patientsmeetingallthreeassessmentsat16,20and24monthswithaDASof
<1.6,noswollen jointsat16,20and24months,andnoprogression invdHSS
(<0.5units)from16to24months
Treatment
Nostatisticallysignificantdifferencebetweenthetwostrategiesfortheprimary
outcome
NR, not reported.
TABLE 38 Data extraction table: Haavardsholm and Ostergaard110 (continued )
First author (study name) Haavardsholm110
Who conducted comparator CE A trained research nurse
Follow-up duration (if relevant) 12 months
Primary outcome of study SRM
Outcome(s) reported in main body
of report
Diagnostic
Study authors’ conclusions The most responsive measure of inflammation when evaluating TNFi medication
was a composite measure comprising MRI synovitis, tenosynovitis and bone
marrow oedema, and this may be a promising outcome measure in clinical studies
p. 1572
IQR, interquartile range.
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TABLE 40 Data extraction table: Hammer and Kvien68 and Hammer et al.111
First author (study name) Hammer68,111
Year 2011 and 2010
Abstract or full paper Full paper
Study design Diagnostic
Study objective To examine associations between ultrasonography assessments (GS and PD) of a
large number of joints and traditional assessments of disease
Hammer et al.,111 p. 1349
To explore the associations between a comprehensive ultrasonographic
assessment of joints, tendons and bursae and previously described reduced joint
counts (7-, 12-, 28- and 44- joint score)
Hammer and Kvien68 p. 1
Population sample size 20
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early
RA, remission)
Active RA, commencing ADA
Population baseline characteristics 15 female (75%)
Median (range) age 53 (21–78) years
Median (range) disease duration 7.5 (1–26) years
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
Starting ADA
Joints assessed US: PIP 1–5 (dorsal), MCP 1–5 (dorsal), carpometacarpal 1–5 (dorsal), wrist
(radiocarpal, intercarpal and radioulnar joints) (dorsal), elbow (anterior and
posterior), shoulder (glenohumeral and acromioclavicular joints) (anterior, posterior
and upper), hip (anterior), knee (anterior and lateral), ankle (talocrural joint)
(anterior), four major foot joints (talonavicular, subtalar, calcaneocuboidal and
cuneonavicular) (anterior and lateral), tarsometatarsal 1–5 (dorsal), MTP 1–5
(dorsal) and the interphalangeal (dorsal) joint of the first toe (a total of 78 joints)
CE: PIP 1–5, MCP 1–5, wrist, elbow, shoulder, knee, ankle and MTP 1–5
Type(s) of US and US details
(including the machine used, scoring
system used and diagnostic cut-off
if applicable)
GSUS and PDUS
US examinations were performed with a 5- to 13-MHz probe and fixed settings
optimal for PD signals (Siemens Antares, Sonoline; Siemens Medical Solutions,
CA, USA). The same US machine and the same PD setting optimised for more
superficial structures (most of the joints assessed) were used throughout the study
All joints were scored according to OMERACT criteria for GSUS (presence of
synovitis and joint fluid) and PDUS (presence of vascularisation) (0 = none;
1=minor; 2=moderate; 3 =major presence)
Who conducted US One experienced sonographer
Comparator CE details Tenderness and swelling of 40 joints (for comparisons between clinical and US
examinations, a B-mode score of ≥ 1 was used to define a joint as inflamed), patient
and study nurse global disease activity VAS, ESR, CRP, DAS28-ESR, SDAI, CDAI
Who conducted comparator CE One of two study nurses, both with > 5 years’ experience with joint counts in
clinical studies
Follow-up duration (if relevant) 12 months
Primary outcome of study Association between US and CE
Outcome(s) reported in main body
of report
Diagnostic
continued
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TABLE 41 Data extraction table: Hayashi et al.92
First author (study name) Hayashi92
Year 2014
Abstract or full paper Abstract
Study design Diagnostic
Study objective To compare US findings with joint examination findings sorted
by the presence of tenderness and/or swelling in the hand
(proximal) interphalangeal (IP/PIP), MCP and wrist joints
p. S181
Population sample size 208
Population diagnosis of RA NR
Population eligibility details (e.g. early RA, remission) RA patients
Population baseline characteristics 158/208 female (76%)
Mean age 66 years
Mean disease duration NR
Population treatment (e.g. bDMARDS or cDMARDs) NR
Joints assessed MCP, PIP, wrists
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
US synovitis was defined as a GS imaging score of ≥ 1 (graded
0–3) or a synovial PD signal score of ≥ 2 (graded 0–3). Details of
the machines and scoring systems used were not provided
Who conducted US NR
Comparator CE details Clinical joint assessments determined the presence of tenderness
and/or swelling
Who conducted comparator CE NR
Follow-up duration (if relevant) NA
Primary outcome of study Detection of synovitis by US or CE
TABLE 40 Data extraction table: Hammer and Kvien68 and Hammer et al.111 (continued )
First author (study name) Hammer68,111
Study authors’ conclusions The comprehensive US assessments were associated with clinical and
laboratory variables of disease activity and were highly sensitive to change
during treatment with biological agents
Hammer et al.,111 p. 1349
The reduced joint combinations were highly associated with the 78-joint score
. . . [indicating] that an approach focusing on few joints and tendons gives
equivalent information about the inflammatory activity in RA patients to a
comprehensive US examination
Hammer and Kvien68 p. 1
The optimal combination of joints and tendons for a valid, reliable and feasible US
measurement should be further explored to define a US score for follow-up of RA
patients on biological treatment68
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TABLE 42 Data extraction table: Horikoshi et al.112
First author (study name) Horikoshi112
Year 2010
Abstract or full paper Full paper
Study design Diagnostic
Study objective To compare MRI and US in the detection of joint inflammation
in RA
p. 556
Population sample size 6
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) All patients were assessed clinically within 1 month of the study
for disease activity using the DAS28-CRP
Population baseline characteristics All females
Mean (SD) age 50.2 (13.4) years
Mean (SD) disease duration 13.5 (8.1) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
Treated with one of the following bDMARDs: IFX, ETN, ADA
or TCZ
Joints assessed Intercarpal joints, radioulnar joints, second to fifth PIP joints and
first to fifth MCP joints, first interphalangeal and radiocarpal
joints. A total of 156 joints per patient were assessed by US
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
US was performed using a Aplio SSA-700A system (Toshiba,
Tokyo, Japan) with a 12-MHz linear array and a 12-MHz ‘hockey-
stick’ array transducer. Joint inflammation on GSUS was defined
as a hypoechoic intracapsular area and on PDUS was represented
by the presence of positive findings of flow signal. These findings
on both GSUS and PDUS were scored on a scale from 0 to 352
Who conducted US Two experienced rheumatologists
Comparator CE details DAS28-CRP
Who conducted comparator CE NR
Primary outcome of study Agreement between US and MRI
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions Findings of PDUS correlated with those of MRI. Low-field MRI
and PDUS are useful tools for the assessment of patients
with RA
p. 556
NR, not reported; SD, standard deviation.
TABLE 41 Data extraction table: Hayashi et al.92 (continued )
First author (study name) Hayashi92
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions Clinical joint examination of the IP/PIP joints overestimated, and of
the wrist joints underestimated, synovitis, compared with US. The
importance of US examination in daily clinical practice may differ
among joint sites
NA, not applicable; NR, not reported.
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TABLE 43 Data extraction table: Ikeda et al.113,146
First author (study name) Ikeda113,146
Year 2013 and 2012
Abstract or full paper Full paper
Study design Prognostic
Study objective To demonstrate that structural damage progression is associated with
time-integrated PDUS signals more significantly than with time-integrated
DAS28 in RA patients receiving MTX or biological agents
Ikeda et al.,146 p. 550
Population sample size 57 (n= 57 with data at 24 weeks out of n= 69)
Population diagnosis of RA ACR 1987 criteria
Population eligibility details
(e.g. early RA, remission)
RA, required treatment with MTX or bDMARD
Population
baseline characteristics
40 female (73%), male 29
Mean (SD) age 54.9 (14.0) years
Median (IQR) disease duration 37 (17–111) months
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
MTX 60/69 (87%)
Corticosteroid 41/69 (59%)
TNFi: ETN, n= 10, IFX, n= 9, ADA, n= 9
Joints assessed 28 joints of the DAS28 for US and CE
Type(s) of US and US details
(including the machine used,
scoring system used and
diagnostic cut-off if applicable)
GSUS and PDUS
Either LOGIQ 7 PRO (GE Healthcare), LOGIQ E9 (GE Healthcare), Vlamo (Toshiba
Medica Systems Corporation) or HI VISION Avius (Hitachi Medical Corporation)
GS and PD semiquantitative scores (0–3) (Naredo scoring). GS: 0= absent; 1 =mild;
2 =moderate; 3=marked. PD: 0= absent (no synovial flow); 1=mild (three or fewer
isolated signals); 2=moderate (more than three isolated signals or confluent signal
in less than half of the synovial area); 3=marked (signals in more than half of the
synovial area)
Who conducted US Two rheumatologists trained in US
Comparator CE details 28-joint SJC and TJC, CRP, VAS for patient and physician global assessments
Who conducted comparator CE NR
Follow-up duration (if relevant) 24 weeks
Primary outcome of study Correlation of PD score and joint damage progression
Outcome(s) reported in main
body of report
Prognostic and diagnostic
Study authors’ conclusions Synovial PD activity more accurately reflects active synovial inflammation that
causes joint destruction than conventional measures in RA patients treated
with MTX
Ikeda et al.,113 p. 1967
TNFis can inhibit short-term radiographic progression in the presence of active synovitis
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TABLE 43 Data extraction table: Ikeda et al.113,146 (continued )
Sensitivity to predict non-radiographic progression at 24 weeks (CIs NR)113
Population
Baseline measure
(optimum cut-off
so different by
treatment group) Sensitivity, % Specificity, % PPV, % NPV, %
57 (n= 57 with data at 24 weeks
out of n= 69)
Total GS score cut-off
point of < 62
56 57 69 43
MTX (n = 16) Total GS score cut-off
point of < 60
78 43 64 60
TNFi (n = 24) Total GS score cut-off
point of < 70
65 57 79 40
TCZ (n= 17) Total GS score cut-off
point of < 62
60 71 75 56
57 (n= 57 with data at 24 weeks
out of n= 69)
Total PD score cut-off
point of < 21
69 76 83 59
MTX (n = 16) Total PD score cut-off
point of < 20
89 86 86 89
TNFi (n = 24) Total PD score cut-off
point of < 21
65 71 85 46
TCZ (n= 17) Total PD score cut-off
point of < 18
70 86 88 67
57 (n= 57 with data at 24 weeks
out of n= 69)
DAS28-CRP cut-off point
of < 9.0
64 81 85 57
MTX (n = 16) DAS28-CRP cut-off point
of < 10.8
89 71 80 83
TNFi (n = 24) DAS28-CRP cut-off point
of < 11.9
88 71 88 71
TCZ (n= 17) DAS28-CRP cut-off point
of < 9.0
80 71 80 71
IQR, interquartile range; NR, not reported; SD, standard deviation.
TABLE 44 Data extraction table: Inanc et al.93
First author (study name) Inanc93
Year 2014
Abstract or full paper Abstract
Study design Treatment prediction, prediction of response to bDMARDs by
baseline US and clinical features
Study objective To investigate the ability of ultrasonographic parameters to
predict which patients with RA will benefit from treatment
with TNFi in terms of EULAR response
p. 468
Population sample size 43
Population diagnosis of RA Either rheumatoid factor or anti-cyclic citrullinated peptide (CCP)
antibody positive
continued
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TABLE 44 Data extraction table: Inanc et al.93 (continued )
First author (study name) Inanc93
Population eligibility details (e.g. early RA, remission) RA, bDMARD naive, starting TNFi
Population baseline characteristics 34 female, 9 male
Mean (SD) age: responders (n = 28) 46 (11); non-responders
(n= 15) 47 (11)
Mean disease duration 8.0± 6.7 years
Mean DAS28 of 5.4± 1.1
Population treatment (e.g. bDMARDS or cDMARDs) Starting TNFi
Joints assessed 28 joints from DAS28
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
US synovitis GS and PD signals were semiquantitatively graded
from 0 to 3 (scoring system NR) using MyLab 70 US machine
(Esaote, Italy)
Who conducted US Experienced sonographer
Comparator CE details TJS/SJC, DAS28, HAQ scores, ESR, CRP
Who conducted comparator CE NR
Follow-up duration (if relevant) 12 months (with response data at 3 months)
Primary outcome of study Response to TNFi related to baseline US
Outcome(s) reported in main body of report Treatment
Study authors’ conclusions Despite similar clinical features, baseline PD scores, despite similar
clinical features, can predict which patients will respond to TNFi
therapy. Patients who respond at the third month are more likely
to achieve low disease activity at 1 year. Ultrasonographic
response to TNFi treatment can be achieved substantially in the
first 3 months, beyond which changes in US scores are mostly
non-significant
Outcome data not added to main report Patients who responded at the third month were significantly
more likely to achieve low disease activity (p= 0.019) or remission
(p= 0.008) at 1 year. There was a significant decrease in mean PD
and GS sum scores from baseline to the third month (p < 0.001
for both), but not between the third and sixth months
(PD, p= 0.68; GS, p= 0.77)
NR, not reported; SD, standard deviation.
TABLE 45 Data extraction table: Iwamoto et al.155
First author (study name) Iwamoto155
Year 2014
Abstract or full paper Full paper
Study design Prospective cohort study (treatment prediction, 6-month
follow-up)
Study objective To determine whether the comprehensive US assessment of
synovial inflammation predicts relapse after discontinuation of
treatment with a biologic agent (TNFi or TCZ) in patients with
RA in clinical remission
p. 1576
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TABLE 45 Data extraction table: Iwamoto et al.155 (continued )
First author (study name) Iwamoto155
Population sample size 42 (n= 40 with data at 6 months)
Population diagnosis of RA ACR 1987 and ACR/EULAR 2010 criteria
Population eligibility details (e.g. early RA, remission) RA, clinical remission (i.e. a DAS28 of < 2.6), on bDMARD and
willing to discontinue bDMARD
Population baseline characteristics 33 female, 9 male
Mean (SD) age 59.6 (12.8) years
Mean (SD) disease duration 8.2 (6.7) years
Population treatment (e.g. bDMARDS or cDMARDs) At baseline on bDMARD, discontinued at start of study. Baseline
bDMARDS: IFX, n= 17; ETN, n= 3; ADA, n= 6; GOL, n= 5;
CTZ, n= 1; TCZ, n= 10. Baseline median (IQR) MTX dose 8.0
(6.0–12.0) mg/week (n= 38). Baseline median (IQR) prednisolone
dose 3.0 (2.0–5.0) mg/day (n= 7)
Joints assessed 134 synovial sites in 40 joints: finger, toe: interphalangeal, PIP
(2–5), MCP (1–5), MTP (1–5) joints, flexor digitorum tendons;
wrist: radiocarpal joint, intercarpal joints, distal radioulnar joint,
compartment II/IV/VI of extensor tendons; elbow: humeroradial
joint, humeroulnar joint, olecranon bursa; shoulder: glenohumeral
joint, long head of biceps tendon, subacromion/subdeltoid
bursae; knee: suprapatellar recess, femorotibial joint, popliteal
bursa (Baker’s cyst); ankle: tibiotalar joint, extensor tendons, flexor
tendons, peroneal tendons
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
Systematic multiplanar GSUS and PDUS
Aplio XG, Viamo (Toshiba Medical Systems), HI VISION Avius or HI
VISION Ascendus (Hitachi Medical) systems
Severity of US findings was graded semiquantitatively on a scale
of 0–3. Each patient’s total GS and PD scores were calculated by
summing the corresponding scores of 40 joints
Who conducted US Six rheumatologists trained for musculoskeletal US who were
blinded to clinical information and laboratory data
Comparator CE details DAS28, SJC, TJC, VAS physician and patient global assessment,
HAQ-DI, ESR, CRP
Who conducted comparator CE Nine rheumatologists who were blinded to the baseline
US findings
Follow-up duration (if relevant) 6 months
Primary outcome of study Relapse rates following bDMARD discontinuation and association
with baseline US values. Relapse outcome defined as a DAS28
of > 3.2
Outcome(s) reported in main body of report Treatment
Study authors’ conclusions In RA patients in clinical remission receiving treatment with a
biologic agent, residual synovial inflammation determined by
comprehensive US assessment predicted relapse within a short
time after discontinuation of the treatment
p. 1576
IQR, interquartile range; ROC, receiver operating characteristic; SD, standard deviation.
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TABLE 46 Data extraction table: Kamishima et al.114
First author (study name) Kamishima114
Year 2011
Abstract or full paper Full paper
Study design Diagnostic
Study objective To compare quantitative MRI and PDUS with conventional
measures of disease activity in RA patients treated with
the anti-interleukin 6 receptor antibody TCZ in terms of
responsiveness at a few months to disease activity and ability
to predict structural damage at 1 year
p. 745
Population sample size 29
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Active RA, treated with TCZ
Population baseline characteristics 2 males, 27 females
Mean (range) age 61 (27–74) years
Median (range) duration of symptoms 8 (1–34) months
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
TCZ
Joints assessed Bilateral MCP joints
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
PDUS
A 13-MHz linear array transducer was used (Hitachi EUP-L34P,
Hitachi, Tokyo, Japan). PD settings (75-dB dynamic range, medium
persistence, medium frame rate, low wall filter, 1300-Hz pulse
repetition frequency, medium vein flow optimisation, 1300-Hz
speed velocity) were identical throughout the examinations
Graded on a 0–3 semiquantitative scale (0= absence of signal,
1= single vessel dots, 2= vessel dots over less than half of the
synovial area, 3= vessel dots over more than half of the synovial
area)277
Who conducted US One of the three ultrasonographers specialising in
musculoskeletal US
Comparator CE details DAS28-ESR, TJC, SJC, VAS, CRP, ESR
Who conducted comparator CE One of the five rheumatologists
Follow-up duration (if relevant) 1 year (SRM at 5 months)
Primary outcome of study Responsiveness to disease activity (SRM)
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions Conventional measures are responsive but less reflective of
future bone destruction than image analysis . . . MRI of bone
erosion and quantitative PDUS may be both responsive and
predictive of structural damage progression at 1 year
p. 753
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TABLE 47 Data extraction table: Kane et al.102
First author (study name) Kane102
Year 2003
Abstract or full paper Full paper
Study design Diagnostic
Study objective To compare US with CE:
in the detection of effusion, suprapatellar bursitis and Baker’s
cyst of the knee in RA to determine whether US provides
additional clinical information
p. 966
Population sample size 22
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Active RA
Population baseline characteristics 20 female, 2 male
Mean (SD, range) age 50.2 (15.83, 25–79) years
Mean (SD, range) disease duration 10.5 (7.8, 1.5–33) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
19 taking DMARDs (not specified if bDMARDs or cDMARDs)
Joints assessed Knee
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS
Real-time US was performed using an ATL (Seattle, WA, USA) HDI
3000 machine with L7- to 4-MHz and CL10- to 5-MHz probes
Ultrasonographic assessment of joint effusion was recorded at
each site. A knee effusion was present if hypoechoic fluid
compressible by the transducer was found in either medial or
lateral compartments of the knee
Scoring system not reported
Who conducted US An experienced rheumatologist with > 10 years’ experience in
musculoskeletal ultrasonography
Comparator CE details Tenderness, swelling
Who conducted comparator CE An experienced rheumatologist with > 6 years’ clinical
rheumatology practice
Primary outcome of study Detection of effusion, suprapatellar bursitis and Baker’s cyst of
the knee
Outcome(s) reported in main body of report Diagnosis
Study authors’ conclusions US is more sensitive than CE in the detection of suprapatellar
bursitis, knee effusion and Baker’s cyst in RA. CE underestimates
knee inflammation in RA
p. 966
SD, standard deviation.
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TABLE 48 Data extraction table: Kelly et al.94
First author (study name) Kelly94
Year 2013
Abstract or full paper Abstract
Study design Management
Study objective To describe the impact of US use by rheumatologists on the
diagnosis and management of RA patients in routine UK
clinical practice compared with not using US
p. 101
Population sample size 109 with relevant data (of 258 in the study)
Population diagnosis of RA NR
Population eligibility details (e.g. early RA, remission) Patients aged > 18 years, newly referred to the rheumatology
clinic with suspected inflammatory arthritis
Population baseline characteristics NR for 109 patients with data relevant to this review
All 258 patients: US group 31% male, non-US group 35% male;
US group mean (SD) age 51.28 (15.75) years, non-US group
mean (SD) age 53.12 (SD 17.34) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
NR
Joints assessed NR
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
NR
Who conducted US Consultant
Comparator CE details NR
Who conducted comparator CE Consultant
Follow-up duration (if relevant) NA
Primary outcome of study Impact of US use by rheumatologists on the diagnosis and
management of RA patients in routine UK clinical practice
compared with not using US
Outcome(s) reported in main body of report Treatment
Study authors’ conclusions Routine use of US in newly referred patients is associated with
an earlier diagnosis and earlier DMARD initiation in patients
with RA
p. 101
NA, not applicable; NR, not reported; SD, standard deviation.
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TABLE 49 Data extraction table: Luengroongroj et al.95
First author (study name) Luengroongroj95
Year 2015
Abstract or full paper Abstract
Study design Treatment
Study objective To evaluate the role of subclinical synovitis detected by
musculoskeletal US in predicting disease relapse in
remission RA
p. 107
Population sample size 32
Population diagnosis of RA NR
Population eligibility details (e.g. early RA, remission) Remission CDAI of < 2.8
Population baseline characteristics NR
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
DMARDs, tapered during the study (not specified if bDMARDs
or cDMARDs)
Joints assessed NR
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
PDUS
Total PD score
No further details reported
Who conducted US NR
Comparator CE details DAS28-CRP, number of DMARDs
Who conducted comparator CE NR
Follow-up duration (if relevant) 3 months
Primary outcome of study Disease flare
Outcome(s) reported in main body of report Prognostic
Study authors’ conclusions PDUS assessment may indicate the likelihood of remaining in
a disease remission stage. It seems to be safe to reduce
the dose of [DMARD] dose . . . for a short period of time,
especially when DMARDs tapering is urgent. However, closed
monitoring for disease relapse is needed, especially in patients
with subclinical synovitis
p. 107
NR, not reported.
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TABLE 50 Data extraction table: Luukkainen et al.115
First author (study name) Luukkainen115
Year 2003
Abstract or full paper Full paper
Study design Diagnostic
Study objective To assess the relationship between clinically detected swelling
and effusion diagnosed by US in MTP and talocrural (TC) joints
in patients with RA
p. 632
Population sample size 30
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Active RA
Population baseline characteristics 24 females
Mean (range) age 62 (36–80) years
Mean (range) duration of RA 14 (0.2–27) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
NR
Joints assessed MTP, talocrural (TC)
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS
US measurements were carried out using a Siemens Sonoline
Prima apparatus with a 7.5-MHz transducer. Diagnosis of effusion
was based on the method of Koski278
The normal upper limit for MTP joints, 2.9 mm (mean+ 2 SD)s,
was evaluated according to the control group. If the anechogenic
space was ≤ 2.9 mm it was regarded as normal and if it was
≥ 3.0 mm it was regarded as effusion. Correspondingly, the
normal upper limit for TC joints, 3.0 mm (mean + 2 SDs), was
taken from the control group. If it was ≤ 3.0 mm it was regarded
as normal and if it was ≥ 3.1 mm it was regarded as effusion
Who conducted US A doctor, no further details provided
Comparator CE details Clinical assessment of MTP and TC joints by inspection and
palpation according to the EULAR handbook.279 Swelling was
evaluated on a scale from 0 (normal) to 1 (swelling)
Who conducted comparator CE A doctor (author, from department of rheumatology), no further
details provided
Follow-up duration (if relevant) NA
Primary outcome of study Relationship between CE and US
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions These preliminary results showed poor agreement between
the clinical assessment of swelling and effusion detected by US
in MTP and TC joints. Thus, US may considerably improve the
diagnosis of synovitis in patients with RA
p. 632
NA, not applicable; NR, not reported; SD, standard deviation.
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TABLE 51 Data extraction table: Luukkainen and Sanila103
First author (study name) Luukkainen103
Year 2005
Abstract or full paper Full paper
Study design Diagnostic
Study objective To compare the relationship between clinically detected
swelling and effusion diagnosed by US in elbow joints in
patients with RA
p. 228
Population sample size 50 (also included healthy control subjects, but data were reported
separately for RA patients)
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Active RA
Population baseline characteristics 44 females
Mean (range) age 56 (20–77) years
Mean (range) duration of RA 11.9 (0.2–32) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
NR
Joints assessed Glenohumeral (GH) joints
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS
The diagnosis of effusion of GH joints by US was based on the
method by Koski.278 US measurements were carried out using a
Siemens Sonoline Prima apparatus with a 7.5-MHz transducer
US was scored using a scale of 0 (normal) or 1 (effusion)
Who conducted US One doctor, no further details provided
Comparator CE details Clinical assessment of GH joints was carried out using palpation
according to the EULAR handbook.279 The possible synovial
swelling of the joints was evaluated using a scale of 0 (normal)
or 1 (swelling)
Who conducted comparator CE One doctor, no further details provided
Primary outcome of study Relationship between CE and US
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions The results of this study indicate that:
. . . clinical assessment of swelling and evaluation of effusion
by US in elbow joints in patients with RA show only fair
agreement. Thus, US may improve the accuracy of the
diagnosis of synovitis in many cases in these patients
p. 228
NR, not reported.
DOI: 10.3310/hta22200 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 20
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Simpson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
151
TABLE 52 Data extraction table: Luukkainen and Sanila104
First author (study name) Luukkainen104
Year 2007
Abstract or full paper Full paper
Study design Diagnostic
Study objective To assess the relationship between swelling detected on physical
examination and effusion diagnosed by ultrasonography in
glenohumeral (GH) joints in patients with RA
p. 865
Population sample size 50 (also included healthy control subjects, but data were reported
separately for RA patients)
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Active RA
Population baseline characteristics 40 females
Mean (range) age 56.9 (20–77) years
Mean (range) duration of RA 11.6 (0.2–30) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
NR
Joints assessed GH joints
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS
The diagnosis of effusion of GH joints by US was based on the
method by Koski.278 US measurements were carried out using a
Siemens Sonoline Prima apparatus with a 7.5-MHz transducer
US was scored using a scale of 0 (normal) or 1 (effusion)
Who conducted US One doctor, no further details provided
Comparator CE details Clinical assessment of GH joints was carried out using palpation
according to the EULAR handbook.279 The possible synovial
swelling of the joints was evaluated on a scale of 0 (normal) or
1 (swelling)
Who conducted comparator CE One doctor, no further details provided
Primary outcome of study Relationship between CE and US
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions These results showed poor agreement between the clinical
assessment of swelling and effusion detected by US in GH
joints. Therefore, US may considerably improve the accuracy of
diagnosis of effusion in GH joints
p. 865
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TABLE 53 Data extraction table: Mamoto et al.96
First author (study name) Mamoto96
Year 2013
Abstract or full paper Abstract
Study design Diagnostic
Study objective To determine the reliability of assessments of swollen joints by
patients, physicians and US
p. 710
Population sample size 124
Population diagnosis of RA NR
Population eligibility details (e.g. early RA, remission) Active disease (with RA), no details reported
Population baseline characteristics NR
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
NR
Joints assessed Wrist, MCP, PIP bilaterally (22 joints per patient – 2728 joints
in total)
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
Synovial hypertrophy was scored semiquantitatively using GS
(score 0–3) and PD (score 0–3) signals. Swollen joints were
defined as a GS score of ≥ 2. No further details reported
Who conducted US A US examiner
Comparator CE details DAS28, swollen joint assessment
Who conducted comparator CE Attending physician and US examiner (and patient
self-assessment)
Primary outcome of study Sensitivity
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions US can assess swollen joints in patients with RA more
sensitively than patients or attending physicians
p. 710
NR, not reported.
TABLE 54 Data extraction table: Mandl and Balint116,117
First author (study name) Mandl116,117
Year 2013 and 2012
Abstract or full paper Full paper
Study design Ancillary study to RCT
Study objective To evaluate the intraobserver reliability, face validity and
discriminant capacity of different global US scoring systems for
measuring synovitis in RA
Mandl and Balint,117 p. 1272
To evaluate the metrological properties of composite disease
activity indices in RA, utilising information derived from clinical,
GSUS and PDUS examinations and to assess the classification
of patients according to disease activity using such indices
Mandl and Balint,116 p. 879
Population sample size 62
Population diagnosis of RA ACR 1987 criteria
continued
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TABLE 54 Data extraction table: Mandl and Balint116,117 (continued )
First author (study name) Mandl116,117
Population eligibility details (e.g. early RA, remission) Moderate RA (i.e. a DAS28 of > 3.2 and ≤ 5.1)
Population baseline characteristics 50 (80.6%) female
Mean (SD) age 53.8 (13.2) years
Mean (SD) disease duration 8.8 (7.7) months
Median (IQR) disease duration 6.5 (11) months
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
cDMARDs (MTX)
30 patients receiving various cDMARDs and 32 receiving ETN+MTX
Joints assessed DAS28 joints (bilateral shoulder, elbow, and wrist joints, bilateral
MCP joints 1–5, bilateral PIP joints 1–5, and bilateral knee joints) plus
bilateral MTP joints 1–5 and bilateral ankle and talonavicular joints
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
Systematic multiplanar GSUS and PDUS examinations were carried
out with commercially available real-time scanners (e.g. Esaote
MyLab70 XVG, Esaote Technos MPX, General Electric Logiq 9)
using multifrequency linear transducers (6–18MHz). US scanning
techniques, GS and PD machine settings and definitions of
abnormality were standardised among investigators. Sonographers
were allowed to modify machine settings (e.g. gain, pulse repetition
frequency) on individual machines for the best-quality images, to
appropriately score each image
Synovitis was defined according to OMERACT definitions. Synovitis
on GSUS was evaluated using a 0–3 semiquantitative scale52
(0= absence of synovial thickening, 1=mild synovial thickening,
2=moderate synovial thickening and 3=marked synovial
thickening). PD activity was evaluated using a 0–3 semiquantitative
scale [0= absence of signal, no intra-articular flow; 1=mild, one or
two vessels (including one confluent vessel) for small joints and two
to three signals for large joints (including two confluent vessels);
2=moderate confluent vessels (> grade 1) in < 50% of the
synovium; 3=marked vessel signals in > 50% of the synovium]
Who conducted US Sonographers (no further details)
Comparator CE details DAS28, TJC, SJC, SDAI, global disease activity patient and
physician 100-mm VAS, HAQ-DI, ESR, CRP
Who conducted comparator CE An investigator (no further details provided)
Primary outcome of study Intraobserver reliability of composite synovitis scoring systems
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions GSUS and PDUS have better reliability than generally used
clinical indices for evaluating synovitis in RA
Mandl and Balint,117 p. 1273
Multimodal indices incorporating US and clinical data had
similar metrological properties to their clinical counterparts;
certain indices allowed for a significantly larger number of
patients to be classified as having either high or moderate
disease activity
Mandl and Balint,116 p. 879
IQR, interquartile range; SD, standard deviation.
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TABLE 55 Data extraction table: Naredo et al.55
First author (study name) Naredo55
Year 2007
Abstract or full paper Full paper
Study design Prognostic
Study objective To evaluate the sensitivity to change of PDUS assessment of joint
inflammation and the predictive value of PDUS parameters in
disease activity and radiological outcome in patients with early RA
p. 116
Population sample size 42
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Early RA, starting cDMARDs
Population baseline characteristics 31 female, 11 male
Mean (SD, range) age 53.6 (14.1, 24–77) years
Mean (SD, range) disease duration 6.8 (3.6, 1.5–12) months
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
Starting cDMARDs at baseline: one cDMARD, n = 41; two
cDMARDs, n= 1. Prior to study, 64.3% were taking oral
corticosteroids and 85.7% were taking NSAIDs
Joints assessed 28 joints for CE and US: bilaterally glenohumeral, elbow, wrist,
MCPs, PIPs, knees
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
Real-time scanner (Logiq 500CL; General Electric Medical Systems,
Kyunngi, Korea) using multifrequency linear array transducers
(7–12MHz). Joint synovitis was defined as the presence of
intraarticular effusion and/or synovial hypertrophy. PD parameters
were adjusted at the lowest permissible pulse repetition frequency
(PRF) to maximise sensitivity, resulting in PRF ranging from 500 Hz
to 1000 Hz. PD was graded on a 0–3 semiquantitative scale
(0 = absence, no intra-articular flow; 1 =mild, single-vessel signal
or isolated signals; 2=moderate, confluent vessels; 3=marked
vessel signals in more than half of the intra-articular area)54
Who conducted US Single rheumatologist, experienced, blinded
Comparator CE details DAS28, SJC, TJC, pain VAS, patient global VAS, HAQ
Radiographic assessment by vdHSS measuring erosions and joint
space narrowing
Who conducted comparator CE Single rheumatologist, experienced, blinded (independent of
US conduction)
Follow-up duration (if relevant) 1 year
Primary outcome of study Sensitivity to change of overall PDUS joint assessment and the
predictive value of sequential PDUS parameters in clinical,
functional and radiological outcomes
Outcome(s) reported in main body of report Prognostic
Study authors’ conclusions PDUS is a sensitive and reliable method for longitudinal
assessment of inflammatory activity in early RA. PDUS findings
may have a predictive value in disease activity and radiographic
outcomes
p. 116
SD, standard deviation.
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TABLE 56 Data extraction table: Naredo et al.140
First author (study name) Naredo140
Year 2008
Abstract or full paper Full paper
Study design Prognostic
Study objective To evaluate the validity, responsiveness and predictive value of
PDUS monitoring of response to tumour necrosis factor (TNF)
blocking agents in RA
p. 2248
Population sample size 367 (278 with complete clinical, laboratory and PDUS data)
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) All patients beginning therapy with a TNFi
Population baseline characteristics Mean (SD) age 53.7 (12.3) years
Mean (SD) disease duration 9.1 (8.2) years
Of the 278 patients with complete clinical, laboratory and PDUS
data: 227 female, 51 male; mean (SD) age 53.3 (12.2) years;
mean (SD) disease duration 9.6 (8.2) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
Starting TNFi therapy
Joints assessed 28 joints, including the left and right glenohumeral, elbow and
wrist joints, MCP joints, PIP joints of the hands and knee joints,
were assessed for tenderness and swelling
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
GSUS and PDUS examination was carried out with Logiq 5 Pro
(GE Healthcare, Kyunnggi-do, Korea) scanners in 23 centres and
Logiq 7 (GE Healthcare, Tokyo, Japan) scanners in two centres,
using multifrequency linear array transducers (7–12MHz). US
scanning technique, GS and PD machine settings and definitions
of abnormality were standardised. Synovitis, tenosynovitis and
bursitis were defined according to the OMERACT definitions
Synovial fluid and synovial hypertrophy were graded on a 0–3
semiquantitative scale (0 = absent; 1 =mild; 2=moderate;
3=marked). Synovial, tenosynovial and intrabursal blood flow at
each joint was evaluated by PDUS. Pulse repetition frequencies
were 500–750 Hz and colour gains were 18–30 dB
The intra-articular, tenosynovial and intrabursal PD signal was
graded on a 0–3 semiquantitative scale [0 = absent (no synovial
flow); 1 =mild (three or fewer isolated signals); 2=moderate
(more than three isolated signals or confluent signal in less than
half of the synovial area); 3 =marked (signals in more than half of
the synovial area)]
Modified US DAS was calculated for all patients at each visit, by
replacing the SJC from the DAS28 with the count of joints with a
synovial fluid, synovial hypertrophy or PD signal as determined by
US (USDAS28 SF score, USDAS28 SH score and USDAS28 PD
score, respectively)
Who conducted US The same rheumatologist (one rheumatologist at 23 centres, two
rheumatologists at two centres; all experienced in US), unaware
of the clinical, laboratory and radiographic findings and not
involved in treatment decisions
Comparator CE details DAS28, TJC, SJC, patient-rated pain and disease activity on a
100-mm VAS, HAQ, CRP, ESR (rheumatoid factor)
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TABLE 56 Data extraction table: Naredo et al.140 (continued )
First author (study name) Naredo140
Who conducted comparator CE The same rheumatologist (one rheumatologist in 24 centres, two
rheumatologists in one centre), who was blinded with regard to
the PDUS and radiographic findings
Follow-up duration (if relevant) 12 months
Primary outcome of study Validity and responsiveness of comprehensive PDUS assessment of
synovitis to monitor response to anti-TNF therapy
Outcome(s) reported in main body of report Prognostic
Study authors’ conclusions Study results show:
. . . persistence of a synovial PD signal appears to . . . [predict]
radiological progression in patients with established RA who are
treated with anti-TNF agents
p. 2554
SD, standard deviation.
TABLE 57 Data extraction table: Naredo et al.118
First author (study name) Naredo118
Year 2013
Abstract or full paper Full paper
Study design Diagnostic
Study objective To investigate the sensitivity for detecting subclinical
synovitis of different reduced-joint US assessment models
compared with a comprehensive US assessment in RA
patients in clinical remission
p. 512
Population sample size 67
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) RA clinical remission assessed by their rheumatologist; MTX
treatment for at least 2 years; neither disease flare nor
changes in therapy, including corticosteroid and MTX doses,
in the previous 6 months
Population baseline characteristics 50 female (74.6%), 17 male
Mean (SD) age 60.3 (15.0) years
Mean (SD) disease duration 7.5 (5.8) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
MTX treatment for at least 2 years
Joints assessed Glenohumeral, elbow, wrist, second to fifth MCP, second to
fifth PIP of the hands, hip (i.e. anterior recess), knee, ankle
and second to fifth MTP joints
Type(s) of US and US details (including the machine used,
scoring system used and diagnostic cut-off if applicable)
GSUS and PDUS
Real-time scanner (Mylab 70 XVG, Esaote) equipped with
two multifrequency linear array transducers, a 6- to 18-MHz
transducer for superficial areas and a 4- to 13-MHz transducer
for deep areas
GSUS synovial hypertrophy was scored on a 0–3
semiquantitative scale (0= absent; 1=mild; 2=moderate;
3=marked). The synovial PD signal was scored on a 0–3
continued
DOI: 10.3310/hta22200 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 20
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Simpson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
157
TABLE 57 Data extraction table: Naredo et al.118 (continued )
First author (study name) Naredo118
semiquantitative scale [0= absent (no synovial flow); 1=mild
(three or fewer PD signals); 2=moderate (more than three PD
signals in less than half of the synovial area); 3=marked (more
than three PD signals in more than half of the synovial area)]
Who conducted US A rheumatologist experienced in musculoskeletal US
Comparator CE details DAS28 and SDAI
Who conducted comparator CE One investigator
Primary outcome of study Detection of subclinical synovitis by different reduced-joint
US assessment models compared with a comprehensive US
assessment in RA patients in clinical remission
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions US assessment of the wrist, MCP, ankle and MTP joints
can be highly sensitive for detecting residual B-mode
and Doppler joint inflammation in RA patients
p. 512
67 patients US negative, B-mode= 0 US positive, B-mode > 0 Total
CE positive, a DAS28 of > 2.6 0 26 26
CE negative, a DAS28 of < 2.6 5 36 41
Total 5 62 67
67 patients US negative, PD= 0 US positive, PD > 0 Total
CE positive, a DAS28 of > 2.6 10 16 26
CE negative, a DAS28 of < 2.6 22 19 41
Total 32 35 67
67 patients US negative, B-mode= 0 US positive, B-mode > 0 Total
CE positive, SDAI of > 3.3 1 44 45
CE negative, SDAI of < 3.3 4 18 22
Total 5 62 67
67 patients US negative, PD= 0 US positive, PD > 0 Total
CE positive, SDAI of > 3.3 18 27 45
CE negative, SDAI of < 3.3 14 8 22
Total 32 35 67
Diagnostic accuracy comparison, CE with reference US Sensitivity, % Specificity, % PPV, % NPV, %
DAS28 of > 2.6 with B-mode US reference (> 0 on a
scale of 0 to 3)
42 100 100 12
DAS28 of > 2.6 with PDUS reference (> 0 on a
scale of 0 to 3)
46 69 62 54
SDAI of > 3.3 with B-mode US reference (> 0 on a
scale of 0 to 3)
71 80 98 18
SDAI of > 3.3 with PDUS reference (> 0 on a scale of 0 to 3) 77 44 60 64
Diagnostic accuracy comparison, US with reference CE Sensitivity, % Specificity, % PPV, % NPV, %
B-mode US (> 0 on a scale of 0 to 3), reference DAS28
of > 2.6
100 12 42 100
PDUS (> 0 on a scale of 0 to 3), reference DAS28 of > 2.6 62 54 46 69
B-mode US (> 0 on a scale of 0 to 3), reference SDAI of > 3.3 98 18 71 80
PDUS (> 0 on a scale of 0 to 3), reference SDAI of > 3.3 60 64 77 44
SD, standard deviation.
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TABLE 58 Data extraction table: Naredo et al.156,157
First author (study name) Naredo156,157
Year 2014 and 2015
Abstract or full paper Full paper
Study design Treatment prediction
Study objective To investigate the predictive value of synovitis detected by
Doppler US in relation to failed tapering of biologic therapy in
RA patients in sustained clinical remission
Naredo et al.,157 p. 1408
Population sample size 77 study completers (of 80 recruited)
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) RA, stable bDMARDS in the previous 12 months, clinical remission
by DAS28 or SDAI, no more than 5mg/day of prednisone, no
NSAIDs for more than 1 week and no corticosteroid injections in
the previous 6 months
Population baseline characteristics 52 women, 25 men
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
All stable bDMARDS. Twenty-three (29.9%) patients were treated
with ADA, 21 (27.3%) with ETN, 18 (23.4%) with IFX, 7 (9.1%)
with TCZ, 6 (7.8%) with ABT and 2 (2.6%) with GOL
Joints assessed 42 joints (including hands and feet): glenohumeral, elbow, wrist,
MCP 2–5, PIP 2–5, hip, knee, ankle and MTP 2–5 joints
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
Real-time scanner (Mylab 70 XVG; Esaote, Genoa, Italy) equipped
with two multifrequency linear array transducers, a 6- to 18-MHz
transducer for superficial areas and a 4- to 13-MHz transducer
for deep areas, assessed by presence and grade according to
OMERACT. A global index for GSUS synovitis and a global index
for Doppler synovitis were calculated
Synovial hypertrophy was scored on a 0–3 semiquantitative scale
(0 = absent; 1=mild; 2=moderate; 3=marked). The synovial PD
signal was also scored on a 0–3 semiquantitative scale (0 = no
synovial PD signal; 1=mild (three or fewer PD signals within the
synovial hypertrophy); 2=moderate (more than three PD signals
in less than half of the synovial hypertrophy); 3=marked (PD
signals in more than half of the synovial hypertrophy)
Who conducted US Rheumatologist experienced in US
Comparator CE details DAS28, SDAI, clinical and laboratory assessment every 3 months
Who conducted comparator CE Two study investigators
Follow-up duration (if relevant) 12 months
Primary outcome of study The predictive value of synovitis detected by Doppler US in
relation to failed tapering of biologic therapy at 6 and 12 months
in RA patients in sustained clinical remission
Outcome(s) reported in main body of report Treatment
Study authors’ conclusions The presence of Doppler-detected synovitis may predict
biologic therapy tapering failure in RA patients in sustained
clinical remission
Naredo et al.,157 p. 1408
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TABLE 59 Data extraction table: Osipyants et al.97,150
First author (study name) Osipyants97,150
Year 2013
Abstract or full paper Abstract
Study design Prognostic
Study objective To assess the significance of residual inflammation according
to the presence of SJC and PD signals in relation to
radiographic progression in patients receiving TCZ
Osipyants et al.,150 p. A755
Population sample size 36
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) RA patients receiving TCZ
Population baseline characteristics 26 (72%) female, 10 male
Median (range) age 51 (43–57) years
Median (range) disease duration 54 (24–96) months
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
All patients receiving TCZ
Joints assessed Bilateral, the most affected joints: wrist, MCP 2 and 3 and PIP 2
and 3 joints
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
PDUS
‘Voluson-i’ (GE, USA) with transducer (4–13MHz)
Each joint was scored according to the OMERACT definitions of
pathology. Dichotomised into ‘non- or low-active’ (PD ≤ 1) and
‘middle- or high-active’ (PD > 1)
Who conducted US Single operator
Comparator CE details SJC, dichotomised into ‘non- or low-active’ (SJC ≤ 1) and ‘middle-
or high-active’ (SJC > 1)
Who conducted comparator CE NR
Follow-up duration (if relevant) 1 year
Primary outcome of study Relation of US and clinical baseline parameters with radiographic
progression at 1 year. One-year radiographic progression of the
hands and feet was defined when the change in the vdHSS
(change in TSS) was > 0.5 units per year
Outcome(s) reported in main body of report Prognostic
Study authors’ conclusions In TCZ-treated patients the US imaging activity score appears
to be more predictive of radiographic progression than
SJC status
Osipyants et al.,150 p. A755
NR, not reported.
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TABLE 60 Data extraction table: Pereira et al.119
First author (study name) Pereira119
Year 2015
Abstract or full paper Full paper
Study design Diagnostic
Study objective To determine if there is a correlation between intra-articular
PDUS and pain symptoms in RA
p. 1975
Population sample size 72 considered in two groups: painful MCP, n = 34; painless
MCP, n= 38
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Established RA, chronic swelling of at least one MCP joint for at
least 3 consecutive months and stable use of DMARDs for the
previous 3 months. For painful group, pain of ≥ 4 on VAS 0–10.
No other concomitant inflammatory diseases, no history of
hand surgery or presence of severe hand deformities and no
uncontrolled comorbidities
Population baseline characteristics Female, n (%): painless group 35 (92); painful group 33 (97)
Mean (range) age: painless group 60.3 (32–81) years; painful
group 56.9 (29–88) years
Mean (range) RA duration: painless group 17.3 (2–46) years;
painful group 14.7 (2–38) years
Population treatment (e.g. bDMARDS or cDMARDs) Corticosteroid use, n (%): painless group 15 (39.5), painful group
17 (50); DMARD monotherapy, n (%): painless group 17 (44.7),
painful group 6 (17.6); DMARDs association, n (%): painless
group 9 (23.7), painful group 11 (32.4); dose of MTX, mean
(range): painless group 9.5 (0–25) mg, painful group 12.5
(0–25) mg: biologic therapy use, n (%): painless group 10 (26.3),
painful group 15 (44.1); DMARD + biologic therapy use, n (%):
painless group 7 (18.4), painful group 13 (38.2)
Joints assessed MCP 2–5, bilaterally
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
MyLAb 60 (Esaote SpA, Genoa, Italy) and MyLab Twice (Esaote
SpA, Genoa, Italy) equipped with 6- to 18-MHz broadband
multifrequency linear transducer. MCP joints scanned using a
multiplanar technique adopting the indications provided by
EULAR guidelines. PD settings were standardised at pulse
repetition frequency of 500–750 Hz and Doppler frequency
between 9.1 and 11.1 MHz. OMERACT preliminary definitions
were adopted
Joints were examined by US according to GS, PD, erosion (present or
absent) and 0–3 semiquantitative scores. PD: semiquantitative score:
0= no intra-articular flow, 1= single-vessel signal, 2= confluent
vessels and 3= vessel signal in > 50% of the intra-articular area.54
GS: semiquantitaive score: 0= no synovial thickening, 1=minimal
synovial thickening, 2=moderate synovial thickening with capsule
distension and 3= synovial thickening, extending to bone diaphysis52
Who conducted US Two experienced rheumatology sonographers trained for the
assessment of RA
Comparator CE details CE (on same day as US), SJC
Who conducted comparator CE Expert rheumatologist
continued
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TABLE 60 Data extraction table: Pereira et al.119 (continued )
First author (study name) Pereira119
Follow-up duration (if relevant) NA
Primary outcome of study Correlation between intra-articular PD and pain symptoms
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions Intra-articular PD was not correlated with pain symptom in
this study
p. 1975
NA, not applicable.
TABLE 61 Data extraction table: Ramirez García et al.98
First author (study name) Ramirez García98
Year 2014
Abstract or full paper Abstract
Study design Prognostic, prospective cohort study
Study objective To analyse clinical and sonographic predictors of clinical flares
in patients with RA in clinical remission
p. 888
Population sample size 28
Population diagnosis of RA Criteria NR (‘diagnosed with rheumatoid arthritis’)
Population eligibility details RA, clinical remission (defined as a DAS28 of < 2.6)
Population baseline characteristics 23 female, 5 male
Mean (SD) age 51.9 (11.9) years
Mean (SD) disease duration 108.2 (SD 92.6) months
Population treatment 75% on at least one cDMARD; 39.3% on biological treatment
Joints assessed Knees and hands (wrists, MCP, PIP, flexor and extensor tendons)
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
PDUS
High sensitivity equipment (Acuson AntaresTM; Siemens AG,
Erlangen, Germany) with a 8-to 12-MHz linear probe. Synovial
hypertrophy (grades 0–3) and PD (grades 0–3) quantified
Who conducted US Rheumatologist experienced in musculoskeletal US
Comparator CE details Serum concentrations of several cytokines and angiogenic factors
were analysed by enzyme-linked immunosorbent assay (ELISA) at
baseline [results reported for ESR, concentration of transforming
growth factor-beta1 (TGF-β1)]
Who conducted comparator CE Analysis by RayBiotech Inc.
Follow-up duration 12 months
Primary outcome of study Clinical and sonographic predictors of clinical flares
Outcome(s) reported in main body of report Prognostic
Study authors’ conclusions Although an elevated ESR or a low concentration of TGF-β1 at
baseline seems to be associated with clinical reactivation of
patients with RA in remission, the PD signal is the best
predictor of disease reactivation at 12 months
p. 888
SD, standard deviation.
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TABLE 62 Data extraction table: Reynolds et al.141 and Rees et al.151
First author (study name) Reynolds141 and Rees151
Year 2009 and 2007
Abstract or full paper Full paper
Study design Prognostic
Study objective To determine whether a range of single time point US
measures of synovial disease and serological characteristics are
able to predict progression of US-defined erosive disease in
patients with established RA
Reynolds et al.,141 p. 473
Population sample size 40 (25 with follow-up data)
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Established RA
Population baseline characteristics 29 females
Median (range) age 59 (34–84) years
Median (range) disease duration 6 (1–29) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
Of the 25 patients followed up, 3 were on anti-inflammatory
drugs only, 14 were on DMARDs and 8 were treated with a TNFi
(or started during the study)
Joints assessed One PIP or MCP joint from each patient was chosen as
representative of one of four categories of joint based solely on
the clinical signs. The four categories were (1) not swollen or
tender, (2) swollen only, (3) tender only and (4) swollen
and tender
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
Philips HDI 5000 (Philips Medical Systems, Andover, MA, USA)
with a C7- to 15-MHz ‘hockey-stick’ transducer
Erosions were graded on a 0–3 semiquantitative scoring system
(Lund) (0= absence of erosions; 1= one to two erosions; 2=more
than two erosions; 3= areas of regional bone destruction). GS
images were graded on a 0–3 semiquantitative scoring system
(0= absence of synovial hypertrophy; 1= small degree of synovial
hypertrophy; 2=moderate synovial hypertrophy; 3=marked synovial
hypertrophy). PD images were graded on a 0–3 semiquantitative
scoring system (0= sbsence of PD signal; 1= single-vessel dots;
2= confluent vessel dots over less than half of the area of the
synovium; 3= confluent vessel dots over more than half of the area
of the synovium)
Who conducted US Two radiologists
Comparator CE details Swelling, tenderness, ESR (rheumatoid factor, anti-citrullinated
protein antibody)
Who conducted comparator CE Baseline: experienced rheumatologist; follow-up: NR
Follow-up duration (if relevant) 2 years (mean 26.8 months, range 24–32 months)
Primary outcome of study Joint erosions
Outcome(s) reported in main body of report Prognostic
Study authors’ conclusions The majority of single time point US measures of synovial
disease were not able to identify MCP or interphalangeal joints
destined to develop progressive US-determined bone damage
in patients with established RA
Reynolds et al.,141 p. 473
NR, not reported.
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TABLE 63 Data extraction table: Ribbens et al.120
First author (study name) Ribbens120
Year 2003
Abstract or full paper Full paper
Study design Diagnostic and response to treatment
Study objective To evaluate using GSUS and PDUS and clinical assessment the response of hand
joint synovitis in patients with active RA to treatment with TNFi (IFX)
p. 562
Population sample size 11
Population diagnosis of RA ACR 1987 revised criteria
Population eligibility details
(e.g. early RA, remission)
Active RA despite MTX, six or more swollen joints, 10 or more tender joints and
one of the following: morning stiffness for > 45 minutes, ESR of > 28mm/hour or
CRP of > 20mg/l. Also, presence of erosions
Population baseline characteristics 7 women, 4 men
Mean (range) age 54 (25–74) years
Mean (range) disease duration 9 (2–31) years
Population treatment at baseline
(e.g. bDMARDS or cDMARDs)
Previously treated with a mean of 3.2 (range 1–5) cDMARDs. After baseline
examination, treated with IFX and MTX
Joints assessed Wrist, MCP and PIP joints
Type(s) of US and US details
(including the machine used, scoring
system used and diagnostic cut-off
if applicable)
GSUS and PDUS
US (Aloka Prosound 5500; Aloka, Tokyo, Japan) was performed using a B-mode
13.0-MHz transducer and a PD 5-MHz pulse repetition frequency of 521 Hz. PD
settings were standardised to a pulse repetition frequency of 651 Hz. Synovitis was
defined as a hypoechoic or anechoic area in the joint space. Cut-off for US
positivity was defined as a synovial thickness of ≥ 1 mm
Doppler US measurements were simultaneously carried out and positive signals
were scored according to a 0–3 semiquantitative scale (0 = no perfusion; 1= low
perfusion; 2 =moderate perfusion; 3 = intense intra-articular joint perfusion)
Who conducted US One radiologist and one rheumatologist, experienced in US, both examined
each patient
Comparator CE details DAS28-ESR
Who conducted comparator CE An independent physician experienced in joint assessment
Follow-up duration (if relevant) 6 weeks
Primary outcome of study The response of hand (i.e. wrist, MCP and PIP) joint synovitis in patients with active
RA to treatment with IFX
Outcome(s) reported in main body
of report
Diagnostic
Study authors’ conclusions US is a feasible imaging modality for the measurement of the response of RA
small-joint synovitis to therapy
p. 562
Additional data120
Wrist (20 joints) GSUS negative GSUS positive Total
Clinically swollen 2 13 15
Clinically not swollen 3 2 5
Total 5 15 20
MCP (110 joints) GSUS negative GSUS positive Total
Clinically swollen 17 47 64
Clinically not swollen 19 27 46
Total 36 74 110
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TABLE 63 Data extraction table: Ribbens et al.120 (continued )
PIP (103 joints) GSUS negative GSUS positive Total
Clinically swollen 14 25 39
Clinically not swollen 44 20 64
Total 58 45 103
Population
Diagnostic
accuracy
comparison Sensitivity, % Specificity, % PPV, % NPV, %
Wrist CE with reference US 87 60 87 60
MCP CE with reference US 64 53 73 41
PIP CE with reference US 56 76 64 69
Population
Diagnostic
accuracy
comparison Sensitivity, % Specificity, % PPV, % NPV, %
Wrist US with reference CE 87 60 87 60
MCP US with reference CE 73 41 64 53
PIP US with reference CE 64 69 56 76
TABLE 64 Data extraction table: Riente et al.121
First author (study name) Riente121
Year 2010
Abstract or full paper Full paper
Study design Diagnostic
Study objective To investigate the prevalence of US pathogenic abnormalities
and to compare them with the clinical findings in the knee of
RA patients
p. 300
Population sample size 100
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Patients with RA, no previous knee joint surgery and no
corticosteroid injections within the previous 3 months
Population baseline characteristics 79 female, 21 male
Mean (SD, range) age 58 (5.74, 22–82) years
Mean (SD, range) disease duration 96 (70, 12–288) months
Population treatment (e.g. bDMARDS or cDMARDs) 200 knee joints
Joints assessed Knee
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
Logiq 9 (General Electrics Medical Systems, Milwaukee, WI, USA)
with a linear probe operating at 10MHz when studying joints and
14MHz when studying tendons used in all centres. When synovial
proliferation was detected, PD examination (pulse repetition
frequency 500 Hz, Doppler frequency 7.5 MHz and Doppler gain
to avoid random noise visualisation) was performed
continued
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TABLE 64 Data extraction table: Riente et al.121 (continued )
First author (study name) Riente121
Joint effusion, synovial hypertrophy and enthesopathy and bone
erosions diagnosed according to OMERACT definitions. No details
of scoring system reported
Who conducted US One rheumatologist experienced in musculoskeletal US in each unit
Comparator CE details Pain, tenderness and swelling (presence/absence)
Who conducted comparator CE A rheumatologist (not involved in US examination)
Primary outcome of study Prevalence of US pathogenic abnormalities
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions US examination of the knee is more sensitive than CE in the
detection of joint inflammation and allows for the identification
of different patterns of pathological changes at the knee level
p. 300
SD, standard deviation.
TABLE 65 Data extraction table: Riente et al.122
First author (study name) Riente122
Year 2011
Abstract or full paper Full paper
Study design Diagnostic
Study objective To investigate the prevalence of US abnormalities in the foot
of RA patients and compare these with clinical findings
p. 1
Population sample size 100
Population diagnosis of RA ACR 1987 revised classification criteria
Population eligibility details (e.g. early RA, remission) RA diagnosed, attending outpatient or inpatient clinic, no prior
joint surgery, no corticosteroid injection to foot within 3 months
Population baseline characteristics 72 female, 28 male
Mean (SD) age 56 years (4.8)
Mean (SD) disease duration 65 (75) months
Population treatment (e.g. bDMARDS or cDMARDs) NR (apart from no steroid injection within 3 months prior to study)
Joints assessed Bilateral MTP (2–5), PIP (2–5) and midfoot joints [taloavicular,
calcaneocuboid, medial, intermediate and lateral navicular-
cuneiform and cuneiform-metatarsal joints and cuboid (fourth)
and metatarsal (fifth) joints]
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
US examinations used a Logiq9 (General Electrics Medical
Systems, Milwaukee, WI, USA) system with linear probe at
14MHz, and a MyLab70XVG (Esaote SpA, Genoa, Italy) system
with multifrequency linear probe at 16MHz. Multiplanar scanning
technique was according to EULAR guidelines (dorsal and plantar
aspects). Diagnosis was according to preliminarly definitions from
OMERACT, using a semiquantitative grading method (0–3)
Who conducted US Rheumatologist experienced in US
Comparator CE details CE for swelling, pain and tenderness
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TABLE 65 Data extraction table: Riente et al.122 (continued )
First author (study name) Riente122
Who conducted comparator CE Rheumatologist not involved in the US examination
Primary outcome of study Prevalence of US abnormalities in the foot
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions US examination appears to be a useful technique to study foot
joint and tendon involvement in RA patients . . . [and] is more
sensitive than CE to detect joint inflammation
p. 1
NR, not reported; SD, standard deviation.
TABLE 66 Data extraction table: Salaffi et al.160
First author (study name) Salaffi160
Year 2008
Abstract or full paper Full paper
Study design Diagnostic
Study objective To assess the interobserver agreement of standard joint count
and to compare CE with GSUS findings in patients with early RA
p. 54
Population sample size 44
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Early RA (< 2 years)
Population baseline characteristics 72.7% women
Mean (SD) age 53 (9.8) years
Mean (SD) disease duration 17 (3.8) months
Population treatment (e.g. bDMARDS or cDMARDs) Prior cDMARDs in all, bDMARDs in 17%
Joints assessed Acromioclavicular, glenohumeral, elbow, wrist (radiocarpal),
MCP, PIP of hands, knee and ankle (tibiotalar), MTP and hip
joints, bilaterally
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS
US examinations were performed using an AU5 ‘Harmonic’
(Esaote Biomedica, Genoa, Italy) equipped with two broadband
linear probes (7.5–10 and 10–14MHz). Patients were evaluated
using the Naredo et al.54 scanning protocol. Joint inflammation
was detected using OMERACT definitions. No details of the
scoring system were reported
Who conducted US A rheumatologist experienced in US
Comparator CE details TJC, SJC
Who conducted comparator CE Two rheumatologists
Primary outcome of study Interobserver agreement of standard joint count
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions CE is far from optimal for assessing joint inflammation in
patients with early RA . . . US can considerably improve the
detection of signs of joint inflammation in terms of both
sensitivity and reliability
p. 54
SD, standard deviation.
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TABLE 67 Data extraction table: Saleem and Brown124
First author (study name) Saleem124
Year 2011
Abstract or full paper Full paper
Study design Diagnostic
Study objective To assess:
the accuracy of more stringent remission criteria for indicating
the absence of inflammation, using US imaging assessment of
synovitis as the gold standard
p. 792
Population sample size 128
Population diagnosis of RA ACR criteria
Population eligibility details (e.g. early RA, remission) Clinical remission
Population baseline characteristics Sex NR
Mean (SD) age 54 (14) years
Median (1st to 3rd quartile) disease duration 8 (5–13) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
DMARD or combination of TNFi and MTX
Joints assessed Dominant-hand MCP joints 2–5 and wrist (640 joints)
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
US examination was performed using the Phillips ATL HDI 3000
machine (DMARD group) and the HDI 5000 machine (combination
TNFi group) using 10- to 5-MHz and 15- to 8-MHz/12- to 5-MHz
‘hockey-stick’ transducers, respectively. GSUS and PDUS were used
to assess synovial hypertrophy (SH) and synovial vascularity. The
presence and location of any SH and PD hyperaemia were recorded
according to standardised OMERACT definitions
Individual joints were scored for GS SH and PD using a validated 0–3
semiquantitative method (GS: 0= no SH, 1=mild SH, 2=moderate
SH, 3= severe SH; PD: 0= normal/minimal vascularity, 1=mild
hyperaemia, 2=moderate hyperaemia, 3=marked hyperaemia)
Who conducted US Experienced ultrasonographers
Comparator CE details Morning stiffness (minutes), 0–100 VAS for patient global
assessment of health and disease activity, TJC, SJC, CRP,
HAQ-DI, RAQoL
Who conducted comparator CE Independent trained metrologist
Primary outcome of study Relationship between clinical scores of remission, imaging-
detected synovitis and quality-of-life outcomes
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions Signs and symptoms of inflammation were reduced when more
stringent remission criteria were used, but the percentage of joints
with PD activity was not reduced, even in those without signs or
symptoms. These data suggest that PD is more sensitive than clinical
criteria for accurately detecting low but clinically relevant levels
of inflammation
SD, standard deviation.
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TABLE 68 Data extraction table: Saleem et al.142
First author (study name) Saleem142
Year 2012
Abstract or full paper Full paper
Study design Prognostic
Study objective To determine the clinical, functional and imaging associations
of disease flare in patients with RA in remission and any effect
on long-term outcomes
p. 1316
Population sample size 93
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) In clinical remission as assessed by their consulting
rheumatologist; no flares in the last 6 months
Population baseline characteristics 63 (67.7%) female
Mean (95% CI) age 56.6 (53.9 to 59.4) years
Mean (95% CI) duration of RA 7.0 (4.5 to 9.5) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
cDMARDs, stable treatment for 6 months, no indication for a
change in treatment
Joints assessed Clinical: joints included in the standard 28-joint count
US: dominant-hand MCP joints and wrist (intercarpal, radiocarpal,
ulnar carpal and distal radioulnar compartments)
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
US examination was performed using the Phillips ATL HDI 3000
machine with a 10- to 5-MHz ‘hockey-stick’ transducer (no other
information presented). GSUS and PDUS were used to assess
synovial hypertrophy (SH) and synovial vascularity, respectively.
The presence and location of any synovial pathology were
recorded according to standardised OMERACT definitions
Individual joints were scored for GS SH and PD activity using a
validated 0–3 semiquantitative method (GS: 0= no SH, 1=mild
SH, 2=moderate SH, 3 = severe SH; PD: 0 = normal/minimal
vascularity, 1=mild hyperaemia, 2=moderate hyperaemia,
3=marked hyperaemia)
Who conducted US A single experienced ultrasonographer who was blinded to all
other study findings
Comparator CE details Duration of morning stiffness (minutes), 0–100 VAS for physician
and patient global assessment of health and disease activity, SJC,
TJC, CRP, (anti-cyclic citrullinated protein antibody, rheumatoid
factor), HAQ-DI
Who conducted comparator CE Independent trained metrologist
Follow-up duration (if relevant) 12 months
Primary outcome of study Disease flare (defined as any increase in disease activity requiring
a change in therapy)
Outcome(s) reported in main body of report Prognostic
Study authors’ conclusions Patients without PD activity at baseline have a low likelihood
of flaring
p. 1321
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TABLE 69 Data extraction table: Scheel et al.53
First author (study name) Scheel53
Year 2005
Abstract or full paper Full paper
Study design Diagnostic
Study objective To develop an ultrasonographic synovitis scoring system suitable
for evaluation of finger joint inflammation in patients with
active RA and to compare semiquantitative ultrasonographic
scoring with quantitative ultrasonographic measurements
p. 733
Population sample size 46
Population diagnosis of RA ACR criteria
Population eligibility details (e.g. early RA, remission) Active RA; nine patients had early RA
Population baseline characteristics 37 females, 9 males
Mean (range) age 53 (17–75) years
Mean (SD) disease duration 8.5 (8.2) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
All treated with DMARDs, including 20 treated with bDMARDs
Joints assessed Second to fifth PIP and MCP joints
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS
US was performed with a HDI 3500 high-end US system
(Advanced Technologies Laboratories, Bothell, WA, USA) using a
10- to 5-MHz ‘hockey-stick’ linear array transducer. Two criteria
for active inflammation were evaluated by US: joint effusion
(visualised as a black, anechoic area) and thickening of the
synovial membrane (visualised as hypo- or hyperechoic structures
within the region affected by effusion)
Joint effusion and hypertrophy were scored on a 0–3
semiquantitative scale,52 modified to include both synovitis and
effusion in a combined measure [0 = no anechoic, hypoechoic or
hyperechoic structure visible (no effusion/hypertrophy); the larger
the anechoic structure or extent of synovial hypertrophy seen on
US images, the higher the assigned score (1=minimal effusion/
hypertrophy, 2 =moderate effusion/hypertrophy, 3 = extensive
effusion/hypertrophy)]
Who conducted US Investigator experienced in musculoskeletal US
Comparator CE details DAS28, pain history, CRP, ESR, SJC, TJC
Who conducted comparator CE No details reported
Primary outcome of study Optimal US scoring method from six joint combinations [receiver
operating characteristic (ROC) curve analysis]
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions US evaluation of finger joint synovitis can be considerably
simplified by focusing on the palmar side and by applying
semiquantitative grading instead of quantitative measurements
p. 733
SD, standard deviation.
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TABLE 70 Data extraction table: Spiegel et al.125
First author (study name) Spiegel125
Year 1987
Abstract or full paper Full paper
Study design Diagnostic
Study objective To evaluate:
the correlation of clinically graded joint tenderness and soft
tissue swelling with ultrasonographic findings of the same
joints and evaluate responses to treatment with fenbufen,
a new NSAID
p. 1283
Population sample size 6
Population diagnosis of RA 1958 revision of diagnostic criteria for RA
Population eligibility details (e.g. early RA, remission) Definite or classic RA of ≥ 1 year in duration
Population baseline characteristics HR; duration of at least 1 year
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
NSAIDs; no NSAIDs for 2 weeks prior to SJC, TJC and US
Joints assessed Six joints: both shoulders, wrists and knees (transversely
and longitudinally)
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS
Performed using commercial contact B scanners, with 5.0-MHz and
7.5-MHz transducers and using a high-resolution real-time scanner,
with a 7.5-MHz transducer. Degree of soft tissue proliferation and
amount of effusion were evaluated by a radiologist and graded on
a 0–3 semiquantitative scale (0= none, 1=mild, 2=moderate,
3= severe). Visualisation of an effusion of < 5mm in depth was
diagnosed as a mild soft tissue change. Moderate changes were
those effusions between 5mm and 10mm in depth, plus
visualisation of echogenic soft tissue structures in the joint. Severe
changes were effusions of > 10mm in depth, plus visualisation of
echogenic soft tissue abnormalities in the joint
Who conducted US A radiologist
Comparator CE details Degree of tenderness and swelling in each of the six joints was
graded clinically on the same 4-point scale used for sonograms
Who conducted comparator CE A rheumatologist
Primary outcome of study Correlation of joint swelling, joint tenderness and US effusion
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions The patient’s subjective index of tenderness, the physician’s
assessment of joint swelling on physical examination and the
findings on ultrasonography were correlated in this study.
Findings suggest that ultrasonography is useful in that it allows
an objective and permanent documentation of the amount of
synovial effusion and proliferation present . . .
p. 1288
NR, not reported.
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TABLE 71 Data extraction table: Szkudlarek et al.126
First author (study name) Szkudlarek126
Year 2004
Abstract or full paper Full paper
Study design Diagnostic
Study objective To compare US with MRI, conventional radiography and CE in
the evaluation of bone destruction and signs of inflammation
in the MTP joints of patients with RA
p. 2103
Population sample size 40 patients (200 MTP joints) (also included healthy control subjects
but data reported separately for RA patients)
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Active RA
Population baseline characteristics Female-to-male ratio 3 : 1
Median (range) age 56 (23–78) years
Median (range) disease duration 2 (0–20) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
35 patients being treated with DMARDs
Joints assessed MCP joints
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS
US was performed with a General Electric LOGIQ-500 unit using a
7- to 13-MHz linear array transducer. Joint effusion was defined
as the compressible anechoic intracapsular area, synovitis as a
hypoechoic synovial thickening (non-compressible hypoechoic
intracapsular area) and bone erosions as pathological changes in
the bone surface of the area adjacent to the joint
GSUS findings were scored on a 0–3 semiquantitative scale for
bone destruction and joint effusion,52 including a 0–3 scale for
synovial thickening. Grade 3 synovial thickening was further
divided into grades 3 and 4 to encompass the more advanced
stages of synovial thickening. Grades 0 and 1 were considered to
be physiological and grades 2 and 3 (or 4) were considered to
be pathological
Who conducted US The same rheumatologist, who was trained in the examination of
the small joints of the hands and feet
Comparator CE details Swelling and tenderness
Who conducted comparator CE A consultant rheumatologist
Primary outcome of study Agreement between US, MRI, CE and radiology
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions Compared with MRI, US was found to be markedly more sensitive
and accurate than CE and conventional radiography for the
detection and grading of destructive and inflammatory changes in
the MTP joints of patients with RA. Evaluation of these joints by
US may be of major clinical importance in RA, considering the
early and frequent involvement of the MTP joints
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TABLE 72 Data extraction table: Szkudlarek et al.127
First author (study name) Szkudlarek127
Year 2006
Abstract or full paper Full paper
Study design Diagnostic
Study objective To investigate whether ultrasonography can provide information
on signs of inflammation and destruction in RA finger joints that
are not available with conventional radiography and CE and
which are comparable to the information provided by MRI
p. 1
Population sample size 40 patients (158 second to fifth MCP joints and 140 second to
fifth PAP joints) (also included healthy control subjects but data
reported separately for RA patients)
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Active RA [20 with established disease (> 2 years)]
Population baseline characteristics Female-to-male ratio 4 : 1
Mean (range) age 58 (23–79) years
Mean (range) disease duration 5 (0–20) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
15 being treated with DMARDs
Joints assessed Second to fifth MCP joints and second to fifth PIP joints
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS
Ultrasonography was performed using a General Electric LOGIQ 500
unit (General Electric, Solingen, Germany) using a 7- to 13-MHz
linear array transducer. Each joint was assessed by quadrant for the
presence or absence of bone erosions and the presence or absence
of signs of inflammation (joint effusion and synovitis)
Bone erosion defined as break in bone cortex in the area adjacent
to the joint, visualised in two planes; joint effusion defined as
compressible anechoic intracapsular area; and synovitis defined as
uncompressible hypoechoic intracapsular area. Changes were scored
according to a 0–3 semiquantitative scoring system.52 Scoring of
synovitis was widened to include grade 4 (hypoechoic area bulging
out of the joint and stretching over both bone diaphyses of the joint)
Who conducted US Two radiologists with expertise in musculoskeletal
ultrasonography and a rheumatologist with training in the
examination of the small joints of the extremities
Comparator CE details Swelling and tenderness
Who conducted comparator CE The consultant rheumatologist on duty
Primary outcome of study Agreement between US, MRI, CE and radiology
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions This study shows that ultrasonography has the potential to
improve the assessment of patients with RA
p. 1
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TABLE 73 Data extraction table: Taniguchi et al.128
First author (study name) Taniguchi128
Year 2014
Abstract or full paper Full paper
Study design Diagnostic
Study objective To examine the usefulness of maximum intensity projection MRI
for RA in the hand
Population sample size 30
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) RA, not taking bDMARDs or oral steroids (18 patients in remission
with a DAS28-CRP of < 2.3)
Population baseline characteristics 25 women and 5 men
Mean (range) age 61.5± 9.5 (38–81) years
Mean (range) disease duration 12.5± 11.5 years (4 months to
45 years)
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
No bDMARDs or oral steroids, MTX in 27 patients
Joints assessed US on 60 wrists and 300 MCP joints. (CE of 28 joints of DAS28)
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
Ultrasonography was performed using a HI VISION Avius (Hitachi
Medical Corporation, Tokyo, Japan) with a linear-type (14–6MHz)
probe
GS images with low echo regions within joints were considered to
indicate synovitis. The PD frequency was set at 7.5 MHz and the
pulse repetition frequency was set between 800 Hz and 1000 Hz.
For PD images, each joint was scored on a semiquantitative scale
(0–3) with a score of grade 1 or higher taken as positive (grade
0= no flow in the synovium, grade 1 = single-vessel signals, grade
2= confluent-vessel signals in less than half of the area of the
synovium, grade 3 = vessel signals in more than half of the area
of the synovium52)
Who conducted US Orthopaedic surgeon trained in US examination of the small joints
of rheumatoid hands. Two orthopaedic surgeons specialising in
RA scored the joints independently
Comparator CE details DAS28-CRP
Who conducted comparator CE NR
Primary outcome of study Sensitivity of CE with reference MRI or PDUS
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions CE:
showed low sensitivity and high specificity compared with both
MRI and PDUS images. A statistically significant correlation
between the scores of MRI and PDUS images was found
p. 911
NR, not reported.
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TABLE 74 Data extraction table: Vlad et al.129
First author (study name) Vlad129
Year 2015
Abstract or full paper Full paper
Study design Diagnostic
Study objective To investigate the responsiveness of tenosynovitis of the wrist and
hands compared with the responsiveness of synovitis in a 6-month
follow-up period, by ultrasonography (US) in a cohort of active RA
patients starting biologic therapy; to compare the responsiveness of
finger flexor tenosynovitis with the responsiveness of wrist extensor
tenosynovitis by US; and to describe the subclinical synovitis and
tenosynovitis by US in RA patients in clinical remission
Population sample size 57 (55 at follow-up)
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Active disease; history of treatment with two different cDMARDs
at a maximal dosage for at least 3 months each (initiating
bDMARDs)
Population baseline characteristics 50 female patients
Mean (SD, range) age 55.28 (10.13, 26–75) years
Mean (SD, range) disease duration 113.9 (105.2, 6–414) months
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
Initiation of biological DMARDs
Joints assessed Bilateral wrists at the level of the radius, lunate and capitate bones
from the dorsal side, MCP joints 2–5 and PIP joints 2–5 from both
the dorsal and the volar sides
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
Ultrasonography was performed using Esaote MyLab 25, 50 and
70 equipped with a linear transducer with 12- to 18-MHz
frequency, adjusted for small joint evaluation. For PD, machines
were set for maximal sensitivity to detect blood flow (Doppler
frequency 6.5–7.5MHz, pulse repetition frequency 500–750 Hz,
low wall filters). All settings were maintained constant throughout
the study
Joint synovitis was graded on separate 0–3 semiquantitative scales
for GS and PD.52 Synovitis on GS was defined as the presence of
abnormal hypoechoic material within joint recesses. PD synovitis
was defined as the presence of Doppler signals inside the intra-
articular hypoechoic area. In addition to the semiquantitative scale,
a binary grading was performed for joint synovitis [0= no synovitis,
1 = present synovitis (including grades 1, 2 and 3 on the
semiquantitative scale)], for both GS and PD
US remission was defined as the absence of GS and PD synovitis in
all examined joints. Low level of imaging activity was defined less
strictly, allowing gradually one to a maximum of two joints or
tendons with positive synovitis or tenosynovitis, binary graded
(GS and PD global scores for binary evaluation of synovitis and
tenosynovitis ≤ 1 or ≤ 2)
Who conducted US Rheumatologist with ≥ 5 years’ experience in musculoskeletal US
(at each site)
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TABLE 74 Data extraction table: Vlad et al.129 (continued )
First author (study name) Vlad129
Comparator CE details TJC, SJC, patient VAS for pain and general disease evaluation,
physician VAS evaluation, ESR, CRP, CDAI and SDAI
Who conducted comparator CE Rheumatologist. One joint assessor at each of five sites (same one
for the duration of the study)
Follow-up duration (if relevant) 6 months
Primary outcome of study Responsiveness of synovitis (vs. responsiveness of tenosynovitis)
Outcome(s) reported in main body of report Diagnostic (SRM)
Study authors’ conclusions Tenosynovitis US scoring in RA may be as good as synovitis
scoring for characterisation of disease activity and responsiveness
p. 352
SD, standard deviation.
TABLE 75 Data extraction table: Wakefield et al.130
First author (study name) Wakefield130
Year 2008
Abstract or full paper Full paper
Study design Diagnostic
Study objective To compare CE and US with high-field MRI for the detection
of rearfoot and midtarsal joint synovitis and tenosynovitis of
the ankle tendons in patients with established RA
p. 1678
Population sample size 22
Population diagnosis of RA Modified ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) RA with symptoms of midfoot and rearfoot disease
Population baseline characteristics 14 female, 8 male
Mean (range) age 52 (33–70) years
Mean (range) disease duration 6.8 (1–20) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
All patients were on stable doses of NSAIDs. Ten were taking
MTX monotherapy, one was taking SSZ, one was taking HCQ,
one was taking gold and six were on a combination of MTX and
a TNFi
Joints assessed Right tibiotalar, subtalar, talonavicular and calcaneocuboid joints
(tendons also examined)
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS
ATL HDI (Advanced Technologies Laboratories, High Definition
Imaging, Bothell, WA, USA) 3000 machine employing a 10- to
5-MHz linear array ‘hockey-stick’ transducer
Synovitis was defined as an abnormal hypoechoic area within the
joint, compatible with the OMERACT US group definition
Who conducted US An experienced sonographer; a second experienced sonographer
examined five patients
Comparator CE details CE for synovitis (and tenosynovitis)
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TABLE 75 Data extraction table: Wakefield et al.130 (continued )
First author (study name) Wakefield130
Who conducted comparator CE A podiatrist; a second podiatrist examined five patients
Primary outcome of study Sensitivity of US and CE for detecting synovitis and tenosynovitis,
with a reference standard of MRI
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions CE was sensitive but US was more specific in identifying
hindfoot pathology in RA compared with the reference
standard of MRI
p. 1678
The authors suggest:
a need for standardisation of acquisition and interpretation of
US images of the hindfoot
p. 1678
Outcome data additional to main report Interobserver variability between ultrasonographers was low,
although this was based on five patients only
TABLE 76 Data extraction table: Wakefield et al.143
First author (study name) Wakefield143
Year 2007
Abstract or full paper Full paper
Study design Prognostic
Study objective To examine the longitudinal relationship between clinical
remission and imaging remission with the hypothesis that it
may be more appropriate to aim for persistent absence of
imaging synovitis rather than clinical remission
p. 1564
Population sample size 10
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) Patients with early RA (< 12 months of symptoms). None of the
patients had ever received DMARDs or biological treatments and
none had received corticosteroids during the preceding month
Population baseline characteristics 5 male, 5 female
Median (range) age 52.5 (21–78) years
Median (range) disease duration 6 (3–11) months
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
None of the patients had ever received DMARDs or biological
treatments and none had received corticosteroids during the
preceding month. At the start of the study, patients were started
on a bDMARD (IFX) and rapidly escalating MTX
Joints assessed CE: 28 joints of DAS. US: 42 joints (bilateral glenohumeral, elbow,
wrist, MCP, PIP, knee, tibiotalar, midtarsal and MTP joints)
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TABLE 76 Data extraction table: Wakefield et al.143 (continued )
First author (study name) Wakefield143
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
GSUS and PDUS
Philips HDI 5000 (Phillips Medical Systems, Best, the Netherlands)
employing either 12- to 5- or 13- to 7-MHz linear transducers
Individual joints were scored for synovitis using a semiquantitative
scoring method on a 0–3 scale for both GS and PD (not referenced).
Scores were expressed per joint and as a total score. Absence of
imaging synovitis was arbitrarily defined as both a total GS and a
total PD score of 0
Who conducted US An experienced sonographer
Comparator CE details DAS28 assessment (also HAQ and the RAQoL) questionnaire and
CRP). Clinical remission was defined as a DAS28 of < 2.6 and
clinical response was defined as a decrease in DAS28 of > 1.2
Who conducted comparator CE Treating clinician
Follow-up duration (if relevant) 46 weeks
Primary outcome of study Spearman’s rho correlation coefficients between baseline GS, PD
scores and DAS28, time to clinical remission and time spent in
clinical remission
Outcome(s) reported in main body of report Prognostic
Study authors’ conclusions Even when clinical remission is achieved with TNFis, the
absence of imaging synovitis may not be achieved
p. 1566
TABLE 77 Data extraction table: Xiao et al.131
First author (study name) Xiao131
Year 2014
Abstract or full paper Full paper
Study design Diagnostic
Study objective To investigate the value of US for diagnosing synovitis associated
with RA
p. 767
Population sample size 46 (also healthy control subjects, but data reported separately for
RA patients)
Population diagnosis of RA ACR 1987 criteria
Population eligibility details (e.g. early RA, remission) RA patients
Population baseline characteristics 31 females, 15 males
Age [average, no further details (range)] 51 (21–67) years
Mean (SD, range) disease duration 8.7 (8.7, 0.08–30.0) years
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TABLE 77 Data extraction table: Xiao et al.131 (continued )
First author (study name) Xiao131
Population treatment (e.g. bDMARDS or cDMARDs) NR
Joints assessed 828 joints – CP 2–5, PIP 2–5 and wrist joints bilaterally
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
PDUS
Ultrasonography was performed using the GE Logiqbook XP
colour ultrasonic apparatus (General Electric Company, Fairfield,
CT, USA) with high-frequency linear matrix probes, the centre
frequency of which was 11MHz
OMERACT diagnostic criteria were used for reference. A 0–3
semiquantitative score59 was used for PDUS (0 = no blood image;
1 = single-vessel image; 2 = several vessels that are partially
confluent; 3 = confluent vessels covering more than half of the
area of the synovium)
Who conducted US Two skilled doctors who had undergone specialist training in US
Comparator CE details Tenderness and/or swelling
Who conducted comparator CE Experienced doctors from rheumatology departments
Primary outcome of study US synovitis detection
Outcome(s) reported in main body of report Diagnostic
Study authors’ conclusions US is a valid method for diagnosing early-stage synovitis, with
high-accuracy cut-off points for MCP, PIP and wrist joints set at
2.5, 2.6 and 5.2 mm
p. 767
NR, not reported; SD, standard deviation.
TABLE 78 Data extraction table: Yoshimi et al.144,145
First author
(study name) Yoshimi144,145
Year 2013 and 2014
Abstract or full paper Full paper
Study design Prognostic
Study objective To assess whether US can predict progressive joint destruction during clinical remission of RA
Yoshimi et al.,144 p. 456
Population sample size 31
Population diagnosis
of RA
ACR 1987 criteria
Population eligibility
details (e.g. early RA,
remission)
RA in clinical remission (clinical remission criteria using DAS28-ESR of < 2.6 or DAS28-CRP of
< 2.3) for at least 2 months
Population baseline
characteristics
Male 4, female 27
Mean (SD) age 55.2 (13.4) years
Median (range) disease duration 5 years 0 months (2 months to 6 years 5 months)
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TABLE 78 Data extraction table: Yoshimi et al.144,145 (continued )
First author
(study name) Yoshimi144,145
Population treatment at
baseline (e.g. bDMARDS
or cDMARDs)
Biological therapy: n= 13 (IFX, n= 4; ETN, n= 9); DMARDs: n= 28 (MTX, n= 23; SSZ, n= 6;
tacrolimus, n= 1); steroids: n= 9 (up to 5 mg/day); drug free: n= 1
Joints assessed 28 joints (as for DAS28) for clinical assessment; 22 of these joints (excluding bilateral
glenohumeral, elbow and knee joints) for US
Type(s) of US and US
details (including the
machine used, scoring
system used and
diagnostic cut-off
if applicable)
PDUS and GSUS
Aplio SSA-700 A apparatus (Toshiba, Tokyo, Japan) with 12-MHz linear array transducers
PD signals were graded on a 0–3 semiquantitative scale [0 = absent (no synovial flow); 1=mild
(single-vessel signal or isolated signals); 2=moderate (confluent signals in less than half of the
synovial area); 3=marked (signals in more than half of the synovial area)].54 For the PIP and MCP
joints, GS images were scored on a 0–3 semiquantitative scale [0 = none (no synovial thickening);
1 =mild (filling the angle between the periarticular bones without bulging over the line linking the
tops of the bones); 2=moderate (synovial thickening bulging over the line linking the tops of the
periarticular bones but without extension along the bone diaphysis); 3= severe (synovial thickening
bulging over the line linking the tops of the periarticular bones and with extension to at least one
of the bone diaphyses)].52 For wrists, GS images were scored on a 0–3 semiquantitative scale
(0 = none, 1=mild, 2=moderate, 3= severe) on subjective appraisal
Who conducted US Experienced rheumatologists
Comparator CE details TJC, SJC, CRP, ESR, matrix metalloproteinase, DAS28-ESR and DAS28-CRP
Who conducted
comparator CE
Rheumatologists
Follow-up duration
(if relevant)
2 years
Primary outcome of
study
Relationship between US at baseline and radiographic progression at 2 years
Outcome(s) reported in
main body of report
Prognostic
Study authors’
conclusions
PDUS detects synovitis causing joint destruction even when the patient is in clinical remission
Yoshimi et al.,144 p. 456
Prognostic sensitivity (no clinical comparator sensitivity data reported)
Study Population
Measure being
assessed
for prediction
US
measure Sensitivity, % Specificity, % PPV, % NPV, %
Yoshimi 2013144 22 in RA
clinical
remission
Radiographic
progression at
2 years
Total PD
scores
of > 1
100 (95% CI
59.0 to 100)
73.3 (95% CI
44.9 to 92.2)
63.6 100
SD, standard deviation.
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TABLE 79 Data extraction table: Zuffery99,132
First author (study name) Zuffery99,132
Year 2014
Abstract or full paper Full paper
Study design Diagnostic
Study objective To evaluate whether RA patients considered to be in remission
according to clinical criteria sets still have persisting US
synovitis. Also, to evaluate the capacity of the US score to
discriminate between the patients with clinically active disease
and those in remission
Zuffery,132 p. 220
To evaluate the correlation between clinical measures of
disease activity and a US scoring system for synovitis applied
by many different ultrasonographers in a daily routine care
setting within the Swiss registry for RA (SCQM) and further to
determine the sensitivity to change of this US score
Zuffery,99 p. 35
Population sample size 30799
536 in a cross-sectional cohort and 183 in a longitudinal cohort132
Population diagnosis of RA NR
Population eligibility details (e.g. early RA, remission) Clinical remission
Population baseline characteristics Active disease (n = 167): 82% female; mean (SD) age 57 (13)
years; median (IQR) disease duration 6.8 (2.4–16.5) years
DAS remission (n = 129): 70% female; mean (SD) age 55 (15)
years; median (IQR) disease duration 6.1 (3.0–12.2) years
ACR/EULAR remission (n= 69): 67% female; mean (SD) age 53
(15) years; median (IQR) disease duration 4.4 (2.6–10.2) years
DAS remission only (n = 71): 78% female; mean (SD) age 56 (15)
years; median (IQR) disease duration 7.2 (3.0–16.5) years
Population treatment at baseline (e.g. bDMARDS
or cDMARDs)
48–59% on biological therapy99
57% on biological therapy132
Joints assessed 22 joints (knee, elbow, wrist and fingers bilaterally)
Type(s) of US and US details (including the machine
used, scoring system used and diagnostic cut-off
if applicable)
Multiplanar GSUS and Doppler mode (PDUS)
The SONAR score is a semiquantitative score employing both
multiplanar GSUS and Doppler mode (PDUS). Synovitis was
graded from 0 to 3 according to the OMERACT consensus. PD
scoring was graded on a 0–3 scale according to OMERACT
recommendations. Some operators did not look for PD on the
dorsal aspect of the joints when only grade 1 synovitis on GSUS
was present on the volar side. Those missing values were
assumed to be equivalent to grade 0 on PD
Who conducted US 30 ultrasonographers trained on the SONAR score
Comparator CE details ACR/EULAR, DAS28, ESR and CRP
Who conducted comparator CE Could be performed by the ultrasonographer or by
another physician
Follow-up duration (if relevant) Mean (SD) follow-up duration 11.7 (5.6) months
Primary outcome of study Correlation between clinical and US data
Outcome(s) reported in main body of report Diagnostic (SRM)
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TABLE 79 Data extraction table: Zuffery99,132 (continued )
First author (study name) Zuffery99,132
Study authors’ conclusions This observational study confirms that many patients
considered to be in clinical remission according the DAS and
the ACR/EULAR definitions still have residual synovitis on US
Zuffery,99 p. 35
The SONAR score is practicable and . . . demonstrates significant
correlations with the degree of as well as change in disease
activity as measured by DAS. On the level of the individual, the
US score shows many discrepancies and overlapping results exist
Zuffery,132 p. 220
IQR, interquartile range; NR, not reported; SD, standard deviation.
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Appendix 6 Quality assessment
Relevant items to assess study bias were taken from Karsh et al.,
84 the QUADAS tool,82 GATE83 and the
QUIPS tool.81
These are validated, widely used tools. Other tools are available. The QUADAS-2 tool280 is a more recent
version of the QUADAS tool, which could have been used if the QUADAS tool was not sufficient, namely if
there had been concerns about applicability of studies to the review. Applicability had been addressed in
the review inclusion/exclusion criteria.
As there were several types of study included in the review, not all items were applicable to all study designs.
Note that when studies included healthy control subjects in addition to RA patients, in line with the exclusion
criteria, studies were included only if outcome data were reported separately for the RA subgroup. As stated
previously, there is currently no gold standard/reference standard for detecting synovitis objectively.
Diagnostic study quality assessment items taken from the QUADAS tool
Many items from the QUADAS tool82 did not apply as the inclusion/exclusion criteria for the review meant
that all studies would meet the following criteria:
l Was the spectrum of patients representative of the patients who will receive the test in practice?
l Is the reference standard likely to correctly classify the target condition?
l Did patients receive the same reference standard regardless of the index test result?
l Was the reference standard independent of the index test?
l Were the same clinical data available when test results were interpreted as would be available when
the test is used in practice?
Items considered relevant to this review were:
l Were selection criteria clearly described?
l Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
l Was the execution of US described in sufficient detail to permit replication of the test?
l Was the execution of the CE described in sufficient detail to permit replication of the test?
l Were the US results interpreted without knowledge of the results of the CE?
l Were the CE results interpreted without knowledge of the results of US?
l Were uninterpretable test results reported?
l Were withdrawals from the study explained?
Prognostic study quality assessment items taken from GATE
l Was the outcome measure assessment blinded?
l Was the follow-up time sufficiently long (to detect important prognostic factors)?
Prognostic study quality assessment items taken from GATE and the
QUIPS tool
l Were the prognostic factors clearly defined?
l Was the outcome measure clearly defined?
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Prognostic study quality assessment items taken from the QUIPS tool
l Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders).
l The method and setting of outcome measurement is the same for all study participants.
l Important potential confounders are accounted for in the study design (e.g. matching for key variables,
stratification or initial assembly of comparable groups) or in statistical analyses (i.e. appropriate adjustment).
Quality assessment items taken from Karsh et al.84
Most quality assessment items from Karsh et al.84 did not apply as they referred to trials of therapy.
RA-specific quality assessment items taken from Karsh et al.84 were:
l Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA?
l Were joint assessments performed by a trained, independent blinded joint assessor? (Broken down into
questions about independence of testing and training for clinical and US examinations, for which we
included experienced staff as trained).
Quality assessment forms
When studies were diagnostic studies or prognostic studies, the level of study in the hierarchy according to
Merlin et al.159 was recorded. This is as follows:
l diagnostic study hierarchy of evidence –
¢ level II – diagnostic test accuracy studies with an independent, blinded comparator of a valid
reference standard, tested on consecutive patients
¢ level III-1 – comparative studies with an independent, blinded comparator of a valid reference
standard tested on non-consecutive patients
¢ level III-2 – comparative studies not meeting criteria for higher-level evidence
¢ level III-3 – diagnostic case–control studies
l prognostic study hierarchy of evidence
¢ level II – prospective cohort study
¢ level III-1 – all-or-none study
¢ level III-2 – single arm of a RCT
¢ level III-3 – retrospective cohort study.
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TABLE 80 Quality assessment: Backhaus et al.69
First author (study name) Backhaus69
Year 2013
Study design Prognostic prospective cohort
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? U
Were US joint assessments conducted by a trained assessor? U
Were clinical and US joint assessments conducted independently? U
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y (OMERACT52,53,281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? U
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for influence
on prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
U
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders)
Y
Important potential confounders are accounted for in the study design (e.g. matching for
key variables, stratification or initial assembly of comparable groups) or in statistical
analyses (i.e. appropriate adjustment)
P
N, no; P, partially; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 81 Quality assessment: Balsa et al.105
First author (study name) Balsa105
Year 2010
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 III-2
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification
criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? U
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y (OMERACT281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 82 Quality assessment: Beckers106
First author (study name) Beckers106
Year 2004
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 III-1
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR
classification criteria for RA?
N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the
ACR or EULAR classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting
the eligibility criteria?
U
Is the time period between US and CE short enough to be reasonably
sure that the synovitis did not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring
system (e.g. OMERACT)?
N (semiquantitative system for PD, not referenced)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of
the CE (i.e. blinded)?
Y
Were the CE results interpreted without knowledge of the results of
US (i.e. blinded)?
Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 83 Quality assessment: Bhamra et al.89
First author (study name) Bhamra89
Year 2014
Study design Treatment decision
If diagnostic study, what level according to hierarchy?159 NA
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? U
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
U
Were clinical joint assessments conducted by a trained assessor? U
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? U
Is the time period between US and CE short enough to be reasonably sure that the synovitis did
not change between the two tests?
Y
Was the conduct of the US examination clearly described? P
Were US results interpreted according to an established scoring system (e.g. OMERACT)? U (no details,
not referenced)
Was the conduct of the CE clearly described? N
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? NA
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? NA
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; NA, not applicable; P, partially; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 84 Quality assessment: Boyesen and Haavardsholm134
First author (study name) Boyesen134
Year 2011
Study design Prognostic,
prospective
cohort
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification
criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? U
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y (Naredo et al.54)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? U
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? N
Were the prognostic factors clearly defined (i.e. the variables being assessed for influence on
prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy response measure)? Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
U
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders)
U
Important potential confounders are accounted for in the study design (e.g. matching for key
variables, stratification or initial assembly of comparable groups) or in statistical analyses
(i.e. appropriate adjustment)
Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 85 Quality assessment: Brown et al.135 and Ikeda et al.136
First author (study name) Brown,135 Ikeda136
Year 2008, 2007
Study design Prognostic (cohort)
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria
for RA?
N
Was diagnosis of RA confirmed by an earlier version (pre-2010) ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Is the time period between US and CE short enough to be reasonably sure that the
synovitis did not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
Y (OMERACT; 0–3
semiquantitative scale57,282,283)
Was the conduct of the CE clearly described? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for
influence on prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders)
Y
Important potential confounders are accounted for in the study design (e.g. matching
for key variables, stratification or initial assembly of comparable groups) or in statistical
analyses (i.e. appropriate adjustment)
Y
N, no; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 86 Quality assessment: Bugatti et al.147 and Scirè et al.137
First author (study name) Bugatti,147 Scirè137
Year 2012
Study design Prognostic (prospective cohort)
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria
for RA?
N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or
EULAR classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
Y (Meenagh et al.,277 Schmidt et al.,284
Naredo et al.56)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE
(i.e. blinded)?
Y
Were the CE results interpreted without knowledge of the results of US
(i.e. blinded)?
U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for
influence on prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
Y for US, U for low disease activity
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders)
Y
Important potential confounders are accounted for in the study design (e.g.
matching for key variables, stratification or initial assembly of comparable groups)
or in statistical analyses (i.e. appropriate adjustment)
Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
DOI: 10.3310/hta22200 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 20
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Simpson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
191
TABLE 87 Quality assessment: Cavet et al.138 and Taylor et al.100
First author (study name) Cavet,138 Taylor100
Year 2009, 2004
Study design Prognostic (part of RCT comparing MTX + IFX
with MTX alone in aggressive early RA)
If prognostic study, what level according to hierarchy?159 III-2 (prognostic), II (treatment)
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR
classification criteria for RA?
N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the
ACR or EULAR classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? U
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
N
Was the conduct of the CE clearly described? N
Were the US results interpreted without knowledge of the results of
the CE (i.e. blinded)?
U
Were the CE results interpreted without knowledge of the results of US
(i.e. blinded)?
U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being
assessed for influence on prognosis or therapy response)?
P
Was the outcome measure clearly defined (i.e. the clinical prognosis or
therapy response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical
prognosis or therapy response measure)?
Y
Was the follow-up time sufficiently long (to detect important
prognostic factors)?
Y
Loss to follow-up is not associated with key characteristics (prognostic
factor and potential confounders)
Y
Important potential confounders are accounted for in the study design
(e.g. matching for key variables, stratification or initial assembly of
comparable groups) or in statistical analyses (i.e. appropriate
adjustment)
Y
N, no; P, partially; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 88 Quality assessment: Ceponis et al.152
First author (study name) Ceponis152
Year 2014
Study design Treatment decision and
diagnostic comparison
If diagnostic study, what level according to hierarchy?159 III-1
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria
for RA?
N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the
eligibility criteria?
U
Is the time period between US and CE short enough to be reasonably sure that the
synovitis did not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
Y (OMERACT52,53)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE
(i.e. blinded)?
Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 89 Quality assessment: Ciurtin et al.90,158
First author (study name) Ciurtin90,158
Year 2013, 2012
Study design Treatment decision
If diagnostic study, what level according to hierarchy?159 NA
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? U
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification
criteria for RA?
U
Were clinical joint assessments conducted by a trained assessor? U
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? U
Did population recruitment consist of consecutive patients meeting the eligibility criteria? NA
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? P
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y (OMERACT86)
Was the conduct of the CE clearly described? N
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? U
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? NA
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; NA, not applicable; P, partially; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 90 Quality assessment: Dale et al.153,154
First author (study name) Dale153,154 (TaSER)
Year 2013, 2014
Study design Treatment (treat-to-target strategy RCT: DAS28
target vs. DAS28 +musculoskeletal US target)
If intervention study, what level according to hierarchy?159 II
Were eligibility criteria clearly described? P
Was diagnosis of RA confirmed by the 2010 ACR and EULAR
classification criteria for RA?
Y
Was diagnosis of RA confirmed by an earlier version (pre 2010) of
the ACR or EULAR classification criteria for RA?
NA
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? N
Is the time period between US and CE short enough to be
reasonably sure that the synovitis did not change between the
two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring
system (e.g. OMERACT)?
Y (OMERACT52)
Was the conduct of the CE clearly described? P
Were the US results interpreted without knowledge of the results of
the CE (i.e. blinded)?
N
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being
assessed for influence on prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis
or therapy response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical
prognosis or therapy response measure)?
N
Was the follow-up time sufficiently long (to detect important
prognostic factors)?
Y
Loss to follow-up is not associated with key characteristics
(prognostic factor and potential confounders)
Y
Important potential confounders are accounted for in the study
design (e.g. matching for key variables, stratification or initial
assembly of comparable groups) or in statistical analyses
(i.e. appropriate adjustment)
Y
N, no; NA, not applicable; P, partially; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 91 Quality assessment: Dougados et al.139,149 and Cheung et al.148
First author (study name) Dougados139,148,149
Year 2013, 2014
Study design Prognostic, prospective cohort; 4 months of biologic
therapy, then further follow-up up to 2 years
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR
classification criteria for RA?
N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of
the ACR or EULAR classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring
system (e.g. OMERACT)?
Y (OMERACT54,55,281,284)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results
of the CE (i.e. blinded)?
Y
Were the CE results interpreted without knowledge of the results
of US (i.e. blinded)?
Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being
assessed for influence on prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical
prognosis or therapy response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical
prognosis or therapy response measure)?
Y
Was the follow-up time sufficiently long (to detect important
prognostic factors)?
Y
Loss to follow-up is not associated with key characteristics
(prognostic factor and potential confounders)
Y
Important potential confounders are accounted for in the study
design (e.g. matching for key variables, stratification or initial
assembly of comparable groups) or in statistical analyses
(i.e. appropriate adjustment)
Y
N, no; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 92 Quality assessment: Ellegaard et al.101
First author (study name) Ellegaard101
Year 2011
Study design Treatment
(cohort study)
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification
criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? N
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for influence on
prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy response measure)? Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy response measure)? NA
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
N, no; NA, not applicable; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 93 Quality assessment: Filippucci et al.107
First author (study name) Filippucci107
Year 2006
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria
for RA?
N
Was diagnosis of RA confirmed by an earlier version (pre-2010) ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the
eligibility criteria?
Y
Is the time period between US and CE short enough to be reasonably sure that the
synovitis did not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
Y (0–3 semiquantitative scale;
not referenced)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE? Y
Were the CE results interpreted without knowledge of the results of US? U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 94 Quality assessment: Gandjbakhch et al.91
First author (study name) Gandjbakhch91
Year 2008
Study design Treatment decision
If diagnostic study, what level according to hierarchy?159 NA
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? U
Is the time period between US and CE short enough to be reasonably sure that the synovitis did
not change between the two tests?
Y
Was the conduct of the US examination clearly described? N
Were US results interpreted according to an established scoring system (e.g. OMERACT)? U (no details reported;
not referenced)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; NA, not applicable; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 95 Quality assessment: Garrigues et al.108
First author (study name) Garrigues108
Year 2013
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 III-2
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification
criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? N
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT52,281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? U
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 96 Quality assessment: Gartner et al.109
First author (study name) Gartner109
Year 2013
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? Y
Was diagnosis of RA confirmed by an earlier version (pre-2010) ACR or EULAR classification criteria
for RA?
NA
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT52,281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE? Y
Were the CE results interpreted without knowledge of the results of US? U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
NA, not applicable; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 97 Quality assessment: Haavardsholm and Ostergaard110
First author (study name) Haavardsholm110
Year 2009
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria
for RA?
N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the
eligibility criteria?
Y
Is the time period between US and CE short enough to be reasonably sure that the
synovitis did not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
Y (0–4 semiquantitative score;
not referenced)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE
(i.e. blinded)?
Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 98 Quality assessment: Haavardsholm et al.79
First author (study name) Haarvardsholm79 (ARCTIC)
Year 2015
Study design Treatment (treat-to-target strategy RCT: DAS44
strategy vs. DAS44 +MSUS strategy)
If intervention study, what level according to hierarchy?159 II
Were eligibility criteria clearly described? P
Was diagnosis of RA confirmed by the 2010 ACR and EULAR
classification criteria for RA?
Y
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the
ACR or EULAR classification criteria for RA?
NA
Were clinical joint assessments conducted by a trained assessor? U
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? U
Is the time period between US and CE short enough to be reasonably
sure that the synovitis did not change between the two tests?
Y
Was the conduct of the US examination clearly described? P
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
Y (Hammer et al.111)
Was the conduct of the CE clearly described? P
Were the US results interpreted without knowledge of the results of the
CE (i.e. blinded)?
U
Were uninterpretable test results reported? U
Were withdrawals from the study explained? N
Were the prognostic factors clearly defined (i.e. the variables being
assessed for influence on prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or
therapy response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical
prognosis or therapy response measure)?
U
Was the follow-up time sufficiently long (to detect important
prognostic factors)?
Y
Loss to follow-up is not associated with key characteristics (prognostic
factor and potential confounders)
U
Important potential confounders are accounted for in the study design
(e.g. matching for key variables, stratification or initial assembly of
comparable groups) or in statistical analyses (i.e. appropriate
adjustment)
U
N, no; NA, not applicable; P, partially; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 99 Quality assessment: Hammer and Kvien68 and Hammer et al.111
First author (study name) Hammer68,111
Year 2010, 2011
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification criteria
for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 100 Quality assessment: Hayashi et al.92
First author (study name) Hayashi92
Year 2014
Study design Diagnostic study
If diagnostic study, what level according to hierarchy?159 III-2
Were selection criteria clearly described? N
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria
for RA?
U
Was diagnosis of RA confirmed by an earlier version (pre-2010) ACR or EULAR
classification criteria for RA?
U
Were clinical joint assessments conducted by a trained assessor? U
Were US joint assessments conducted by a trained assessor? U
Were clinical and US joint assessments conducted independently? U
Did population recruitment consist of consecutive patients meeting the
eligibility criteria?
U
Is the time period between US and CE short enough to be reasonably sure that the
synovitis did not change between the two tests?
Y
Was the conduct of the US examination clearly described? P
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
Y (semiquantitative scoring
system; not referenced)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE? U
Were the CE results interpreted without knowledge of the results of US? U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; P, partially; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 101 Quality assessment: Horikoshi et al.112
First author (study name) Horikoshi112
Year 2010
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 III-2
Were selection criteria clearly described? P
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification criteria
for RA?
Y
Were clinical joint assessments conducted by a trained assessor? U
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? U
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT52)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? N
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; P, partially; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 102 Quality assessment: Ikeda et al.113,146
First author (study name) Ikeda113,146
Year 2013, 2012
Study design Prognostic,
prospective cohort
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? U
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did
not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y (Naredo et al.56,140)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for influence on
prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy response measure)? Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy response
measure)?
Y
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and potential
confounders)
U
Important potential confounders are accounted for in the study design (e.g. matching for key
variables, stratification or initial assembly of comparable groups) or in statistical analyses
(i.e. appropriate adjustment)
Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 103 Quality assessment: Inanc et al.93
First author (study name) Inanc93
Year 2014
Study design Prospective cohort study (prediction of response to
bDMARDs by baseline US and clinical features)
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? P
Was diagnosis of RA confirmed by the 2010 ACR and EULAR
classification criteria for RA?
U
Was diagnosis of RA confirmed by an earlier version (pre 2010) of
the ACR or EULAR classification criteria for RA?
U
Were clinical joint assessments conducted by a trained assessor? U
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? U
Is the time period between US and CE short enough to be
reasonably sure that the synovitis did not change between the
two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring
system (e.g. OMERACT)?
Y (OMERACT281)
Was the conduct of the CE clearly described? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being
assessed for influence on prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis
or therapy response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical
prognosis or therapy response measure)?
U
Was the follow-up time sufficiently long (to detect important
prognostic factors)?
Y
Loss to follow-up is not associated with key characteristics
(prognostic factor and potential confounders)
Y
Important potential confounders are accounted for in the study
design (e.g. matching for key variables, stratification or initial
assembly of comparable groups) or in statistical analyses
(i.e. appropriate adjustment)
Y
P, partially; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 104 Quality assessment: Iwamoto et al.155
First author (study name) Iwamoto155
Year 2014
Study design Prospective
cohort
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? Y
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification
criteria for RA?
NA
Were clinical joint assessments conducted by a trained assessor? U
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT140,285)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE? Y
Were the CE results interpreted without knowledge of the results of US? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for influence on prognosis
or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy response measure)? Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and potential confounders) Y
Important potential confounders are accounted for in the study design (e.g. matching for key variables,
stratification or initial assembly of comparable groups) or in statistical analyses (i.e. appropriate adjustment)
Y
NA, not applicable; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 105 Quality assessment: Kamishima et al.114
First author (study name) Kamishima114
Year 2011
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification
criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did
not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y (Meenagh et al.277)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 106 Quality assessment: Kane et al.102
First author (study name) Kane102
Year 2003
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification criteria
for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not change
between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? N
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 107 Quality assessment: Kelly et al.94
First author (study name) Kelly94
Year 2013
Study design Treatment
decision
If prognostic study, what level according to hierarchy?159 NA
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? U
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification
criteria for RA?
U
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Was the conduct of the US examination clearly described? N
Were US results interpreted according to an established scoring system (e.g. OMERACT)? U
Was the conduct of the CE clearly described? N
Were uninterpretable test results reported? U
Were withdrawals from the study explained? Y
N, no; NA, not applicable; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 108 Quality assessment: Luengroongroj et al.95
First author (study name) Luengroongroj95
Year 2015
Study design Treatment – cohort
(treatment tapering)
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? N
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? U
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
U
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? U
Was the conduct of the US examination clearly described? N
Were US results interpreted according to an established scoring system (e.g. OMERACT)? U
Was the conduct of the CE clearly described? N
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? U
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for influence
on prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
U
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders)
Y
Important potential confounders are accounted for in the study design (e.g. matching for
key variables, stratification or initial assembly of comparable groups) or in statistical
analyses (i.e. appropriate adjustment)
Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 109 Quality assessment: Luukkainen and Saltyshev115
First author (study name) Luukkainen115
Year 2003
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? P
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification criteria
for RA?
Y
Were clinical joint assessments conducted by a trained assessor? U
Were US joint assessments conducted by a trained assessor? U
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? P
Were US results interpreted according to an established scoring system (e.g. OMERACT)? N
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for influence on prognosis or
therapy response)?
NA
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy response measure)? NA
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy response measure)? NA
Was the follow-up time sufficiently long (to detect important prognostic factors)? NA
Loss to follow-up is not associated with key characteristics (prognostic factor and potential confounders) NA
Important potential confounders are accounted for in the study design (e.g. matching for key variables,
stratification or initial assembly of comparable groups) or in statistical analyses (i.e. appropriate adjustment)
NA
N, no; NA, not applicable; P, partially; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 110 Quality assessment: Luukkainen and Sanila103
First author (study name) Luukkainen103
Year 2005
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification criteria
for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? N
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 111 Quality assessment: Luukkainen and Sanila104
First author (study name) Luukkainen104
Year 2007
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification criteria
for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? N
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 112 Quality assessment: Mamoto et al.96
First author (study name) Mamoto96
Year 2013
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 III-2
Were selection criteria clearly described? N
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria
for RA?
U
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
U
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? P
Did population recruitment consist of consecutive patients meeting the
eligibility criteria?
U
Is the time period between US and CE short enough to be reasonably sure that the
synovitis did not change between the two tests?
Y
Was the conduct of the US examination clearly described? N
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
Y (0–3 semiquantitative scale;
not referenced)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE
(i.e. blinded)?
U
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; P, partially; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 113 Quality assessment: Mandl et al.116,117
First author (study name) Mandl116,117
Year 2012, 2013
Study design Ancillary study to RCT
If diagnostic study, what level according to hierarchy?159 III-1 (diagnostic), II
(intervention study)
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? N (from a trial sample)
Is the time period between US and CE short enough to be reasonably sure that the synovitis
did not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y (OMERACT52,281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 114 Quality assessment: Naredo et al.55
First author (study name) Naredo55
Year 2007
Study design Prognostic,
prospective cohort
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y (OMERACT54)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for influence on
prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders)
Y
Important potential confounders are accounted for in the study design (e.g. matching for key
variables, stratification or initial assembly of comparable groups) or in statistical analyses
(i.e. appropriate adjustment)
U
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 115 Quality assessment: Naredo et al.140
First author (study name) Naredo140
Year 2008
Study design Prognostic
(prospective cohort)
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did
not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y (OMERACT53,281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for influence on
prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders)
U
Important potential confounders are accounted for in the study design (e.g. matching for key
variables, stratification or initial assembly of comparable groups) or in statistical analyses
(i.e. appropriate adjustment)
Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 116 Quality assessment: Naredo et al.118
First author (study name) Naredo118
Year 2013
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification
criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT140,281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 117 Quality assessment: Naredo et al.156,157
First author (study name) Naredo156,157
Year 2015, 2014
Study design Prospective cohort study of
treatment prediction,
12 month follow-up, bDMARD
tapering at baseline
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria
for RA?
N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
Y (OMERACT281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE
(i.e. blinded)?
Y
Were the CE results interpreted without knowledge of the results of US
(i.e. blinded)?
Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for
influence on prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders)
Y
Important potential confounders are accounted for in the study design (e.g.
matching for key variables, stratification or initial assembly of comparable groups) or
in statistical analyses (i.e. appropriate adjustment)
Y
N, no; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 118 Quality assessment: Osipyants et al.97,150
First author (study name) Osipyants97,150
Year 2013
Study design Prognostic,
prospective cohort
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? U
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y (OMERACT281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for influence on
prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
U
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders)
Y
Important potential confounders are accounted for in the study design (e.g. matching for key
variables, stratification or initial assembly of comparable groups) or in statistical analyses
(i.e. appropriate adjustment)
U
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 119 Quality assessment: Pereira et al.119
First author (study name) Pereira119
Year 2015
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification
criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT52,54,281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE? Y
Were the CE results interpreted without knowledge of the results of US? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 120 Quality assessment: Ramirez García et al.98
First author (study name) Ramirez García98
Year 2014
Study design Prognostic, prospective
cohort study
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria
for RA?
U
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
U
Were clinical joint assessments conducted by a trained assessor? U
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
Y (0–3 semiquantitative scoring;
not referenced)
Was the conduct of the CE clearly described? P
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for
influence on prognosis or therapy response)?
P
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
U
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders)
Y
Important potential confounders are accounted for in the study design (e.g. matching
for key variables, stratification or initial assembly of comparable groups) or in statistical
analyses (i.e. appropriate adjustment)
U
P, partially; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
DOI: 10.3310/hta22200 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 20
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Simpson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
225
TABLE 121 Quality assessment: Reynolds et al.141 and Rees and Pilcher151
First author (study name) Reynolds,141 Rees151
Year 2009, 2007
Study design Prognostic
(prospective cohort)
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y (0–3 semiquantitative
scoring scales286)
Was the conduct of the CE clearly described? P
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for influence
on prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders)
U
Important potential confounders are accounted for in the study design (e.g. matching for
key variables, stratification or initial assembly of comparable groups) or in statistical
analyses (i.e. appropriate adjustment)
U
N, no; P, partially; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 122 Quality assessment: Ribbens et al.120
First author (study name) Ribbens120
Year 2003
Study design Diagnostic and response to treatment
(before-and-after study)
What level of study according to hierarchy?159 III-1
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification
criteria for RA?
N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or
EULAR classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the
eligibility criteria?
U
Is the time period between US and CE short enough to be reasonably sure that
the synovitis did not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
N (0–3 semiquantitative scale58,283)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE
(i.e. blinded)?
Y
Were the CE results interpreted without knowledge of the results of US
(i.e. blinded)?
Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 123 Quality assessment: Riente et al.121
First author (study name) Riente121
Year 2010
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 III-1
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification criteria
for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? U
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE? Y
Were the CE results interpreted without knowledge of the results of US? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 124 Quality assessment: Riente et al.122
First author (study name) Riente122
Year 2011
Study design Diagnostic, blinded comparison among
non-consecutive RA patients
If diagnostic study, what level according to hierarchy?159 III-1
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification
criteria for RA?
N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or
EULAR classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the
eligibility criteria?
U
Is the time period between US and CE short enough to be reasonably sure
that the synovitis did not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
Y (OMERACT281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE? Y
Were the CE results interpreted without knowledge of the results of US? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 125 Quality assessment: Salaffi et al.160
First author (study name) Salaffi160
Year 2008
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 III-1
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification criteria
for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? U
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE? Y
Were the CE results interpreted without knowledge of the results of US? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 126 Quality assessment: Saleem and Brown124
First author (study name) Saleem124
Year 2011
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? Y
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification
criteria for RA?
NA
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT57,75,281,282)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
NA, not applicable; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 127 Quality assessment: Saleem et al.142
First author (study name) Saleem142
Year 2012
Study design Prognostic
(prospective cohort)
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y (OMERACT281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for influence on
prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
U
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders)
Y
Important potential confounders are accounted for in the study design (e.g. matching for key
variables, stratification or initial assembly of comparable groups) or in statistical analyses
(i.e. appropriate adjustment)
Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 128 Quality assessment: Scheel et al.53
First author (study name) Scheel53
Year 2005
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification criteria
for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? U
Did population recruitment consist of consecutive patients meeting the eligibility criteria? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT52)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 129 Quality assessment: Spiegel et al.125
First author (study name) Spiegel125
Year 1987
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 III-1
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria
for RA?
N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
N (1958 criteria – no mention of
ACR or EULAR)
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the
eligibility criteria?
U
Is the time period between US and CE short enough to be reasonably sure that the
synovitis did not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
Y (0–3 semiquantitative scale;
not referenced)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE
(i.e. blinded)?
Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 130 Quality assessment: Szkudlarek et al.126
First author (study name) Szkudlarek126
Year 2004
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 III-2
Were selection criteria clearly described? U
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification criteria
for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? U
Did population recruitment consist of consecutive patients meeting the eligibility criteria? U
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT52)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 131 Quality assessment: Szkudlarek et al.127
First author (study name) Szkudlarek127
Year 2006
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 III-2
Were selection criteria clearly described? U
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification criteria
for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? U
Did population recruitment consist of consecutive patients meeting the eligibility criteria? U
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT52)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 132 Quality assessment: Taniguchi et al.128
First author (study name) Taniguchi128
Year 2014
Study design Diagnostic comparison, blinded, not
consecutive patients
If diagnostic study, what level according to hierarchy?159 III-1
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria
for RA?
N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or
EULAR classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the
eligibility criteria?
U
Is the time period between US and CE short enough to be reasonably sure that
the synovitis did not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
Y (0–3 semiquantitative scale52)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE
(i.e. blinded)?
Y
Were the CE results interpreted without knowledge of the results of US
(i.e. blinded)?
Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 133 Quality assessment: Vlad et al.129
First author (study name) Vlad129
Year 2015
Study design Diagnostic
(responsiveness)
If diagnostic study, what level according to hierarchy?159 III-1
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? U
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification
criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? U
Is the time period between US and CE short enough to be reasonably sure that the synovitis did
not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y (OMERACT52)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 134 Quality assessment: Wakefield et al.130
First author (study name) Wakefield130
Year 2008
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification criteria
for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? Y
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 135 Quality assessment: Wakefield et al.143
First author (study name) Wakefield143
Year 2007
Study design Prognostic, prospective cohort
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria
for RA?
N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the
eligibility criteria?
Y
Is the time period between US and CE short enough to be reasonably sure that the
synovitis did not change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system
(e.g. OMERACT)?
Y (0–3 semiquantitative scoring;
not referenced)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE
(i.e. blinded)?
Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for
influence on prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
NA
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders)
Y
Important potential confounders are accounted for in the study design (e.g. matching
for key variables, stratification or initial assembly of comparable groups) or in statistical
analyses (i.e. appropriate adjustment)
Y
N, no; NA, not applicable; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 136 Quality assessment: Xiao et al.131
First author (study name) Xiao131
Year 2014
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 III-2
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification
criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Did population recruitment consist of consecutive patients meeting the eligibility criteria? U
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT59,281)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE? U
Were the CE results interpreted without knowledge of the results of US? U
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 137 Quality assessment: Yoshimi et al.144,145
First author (study name) Yoshimi144,145
Year 2014, 2013
Study design Prognostic,
prospective cohort
If prognostic study, what level according to hierarchy?159 II
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? N
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR
classification criteria for RA?
Y
Were clinical joint assessments conducted by a trained assessor? Y
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? Y
Was the conduct of the US examination clearly described? Y
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y (0–3
semiquantitative
scoring52,54)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? Y
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? Y
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
Were the prognostic factors clearly defined (i.e. the variables being assessed for influence on
prognosis or therapy response)?
Y
Was the outcome measure clearly defined (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the outcome measure assessment blinded (i.e. the clinical prognosis or therapy
response measure)?
Y
Was the follow-up time sufficiently long (to detect important prognostic factors)? Y
Loss to follow-up is not associated with key characteristics (prognostic factor and
potential confounders)
Y
Important potential confounders are accounted for in the study design (e.g. matching for key
variables, stratification or initial assembly of comparable groups) or in statistical analyses
(i.e. appropriate adjustment)
P
N, no; P, partially; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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TABLE 138 Quality assessment: Zuffery99,132
First author (study name) Zuffery99,132
Year 2014
Study design Diagnostic
If diagnostic study, what level according to hierarchy?159 III-2
Were selection criteria clearly described? Y
Was diagnosis of RA confirmed by the 2010 ACR and EULAR classification criteria for RA? U
Was diagnosis of RA confirmed by an earlier version (pre 2010) of the ACR or EULAR classification
criteria for RA?
U
Were clinical joint assessments conducted by a trained assessor? U
Were US joint assessments conducted by a trained assessor? Y
Were clinical and US joint assessments conducted independently? N
Did population recruitment consist of consecutive patients meeting the eligibility criteria? U
Is the time period between US and CE short enough to be reasonably sure that the synovitis did not
change between the two tests?
Y
Was the conduct of the US examination clearly described? U
Were US results interpreted according to an established scoring system (e.g. OMERACT)? Y
(OMERACT64,85)
Was the conduct of the CE clearly described? Y
Were the US results interpreted without knowledge of the results of the CE (i.e. blinded)? N
Were the CE results interpreted without knowledge of the results of US (i.e. blinded)? N
Were uninterpretable test results reported? Y
Were withdrawals from the study explained? Y
N, no; U, unclear; Y, yes.
Note
‘Y’ indicates higher quality (lower risk of bias).
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Appendix 7 Detection of synovitis
This review concentrated on US as the intervention. There is no conclusive gold standard/referencestandard for assessing synovitis. This makes interpretation of detection rates difficult. Other imaging
techniques are available for detecting synovitis in RA patients. Imaging techniques used in RA include US,
conventional radiography, MRI and CT scans. Other imaging techniques may be useful for detecting
disease indications other than synovitis, such as bone oedema or erosion.9,28 It is noted that MRI has a role
in diagnosing RA and for detecting other indications such as bone erosion within RA.
Ultrasound is more likely to be practical in assessing synovitis than other imaging techniques. US is more
comfortable for the patient than MRI, is less expensive and has an advantage over other imaging
techniques, as it can be used immediately after CE to assess symptomatic areas.30
As for any imaging technique, the value of detecting subclinical synovitis is determined by the influence of
non-clinically detected synovitis on the course of the disease. This review investigated the association of
US-detected synovitis with later outcomes, in prognostic studies (see Chapter 3). This can be considered as
validating the test results.287 As this review concentrated on US as the intervention, the decision was taken
not to compare US-detected synovitis with synovitis detected by other imaging techniques.
In terms of synovitis, a review published in 201328 found that scintigraphy and PET detected similar rates of
inflammation to CE and that US and MRI found higher rates of inflammation than CE but with similar
rates to each other (compared with CE US detected 2.18-fold synovitis and MRI 2.20-fold synovitis).
Studies included in the 2013 review overlapped with studies included in this review; however, two
studies128,131 included in this review that were published since the 2013 review reported synovitis detection
rates in both US and MRI. Taniguchi et al.128 reported that synovitis was detected by PDUS in 31 out of 60
(51.7%) wrist joints and 23 out of 300 (7.7%) MCP joints; more joints were reported as positive for
synovitis when considering maximum intensity projection MRI grades 1 and 2 [47/60 (78.3%) wrist joints
and 84/300 (28.0%) MCP joints]. Xiao et al.131 examined 180 joints with MRI and PDUS; the results were
positive for synovitis in 86 joints assessed by MRI (47.7%) and 81 joints assessed by PDUS (45.0%).
Imaging techniques other than US are not considered further here.
When diagnostic accuracy data were reported, these were usually presented as the diagnostic accuracy of
CE, with US as the reference standard. Because of this, Table 139 shows the sensitivity and specificity of
CE with reference US. When TPs, FPs, TNs and FNs were reported or calculable, these are presented in the
data extraction tables in Appendix 5, as are diagnostic accuracy data for US with reference CE.
Twenty studies92,96,102–105,107,109,115,118–122,124–128,160 reported sensitivity data. Two of these studies105,118 used
DAS as the clinical comparator, whereas the others used CE for synovitis.
There was seemingly a very wide range of sensitivity (13–95%) and specificity (30–100%) of CE with US as
the reference standard across the 20 studies. However, for most studies, CE had a high specificity and low
sensitivity when using US as the reference standard. This indicates some agreement between CE and US,
with US detecting synovitis in some joints in which CE did not and only a few cases in which CE detected
synovitis and US did not. This agrees with the higher detected rates of synovitis for US over CE reported in
the majority of studies (Table 140).
Sensitivity of CE of swollen and/or tender joints with a reference standard of GSUS or PDUS in 14
studies92,96,102–104,107,109,115,119,120,124,126–128,133 ranged from 13% to 69% (MCP and PIP joints for Ribbens
et al.120). Most of these studies assessed synovitis in hand and wrist joints, but they also included ankle,
elbow and shoulder joints (see Table 139). Sensitivity would range from 37% to 69% if three studies with
sensitivities at the lower end of the range84,103,124 were excluded. Studies with sensitivities at the lower end
of the range were those in which all patients were in remission (25%;84 13% or 20% depending on PDUS
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TABLE 139 Clinical examination diagnostic accuracy with US as reference standard
Study Populationa
CE
assessment
of joints
Diagnostic accuracy
comparison (CE
with reference US)
Sensitivity of
CE (95% CI), %
Specificity of
CE (95% CI), %
Balsa
2010105
97 patients
42 joints (PIP, MCP, wrist,
elbow, glenohumeral,
knee, ankle and midtarsal
and MTP joints)
(4074 joints in total)
SDAI of > 5 PDUS 66 (52 to 77) 55 (40 to 69)
SDAI of > 3.3 PDUS 57 (44 to 70) 74 (59 to 85)
Filippucci
2006107
24 patients
48 wrists
192 examinations
Swollen PDUSb 41 (NR) 71 (NR)
Tender PDUSb 39 (NR) 78 (NR)
Gartner
2013109,133
90 patients (60 in clinical
remission, CDAI of ≤ 2.8),
1320 joints (MCP, PIP and
wrist joints)
Swollen PDUS grade 3c and
GSUS grade 3c
25 (NR) 100 (NR)
Hayashi
201492
208 patients
416 wrist joints, 2080
MCP joints, 2080
interphalangeal/PIP joints
Swollen
and/or
tender
GSUS score of ≥ 1c or
PDUS score of ≥ 2c
Wrist 53 (NR),
MCP 50 (NR),
interphalangeal/
PIP 51 (NR)
Wrist 89 (NR),
MCP 95 (NR),
interphalangeal/
PIP 94 (NR)
Kane
2003102
22 patients
44 knees
Effusion GSUS effusiond 59 (NR) 65 (NR)
Luukkainen
2003115
30 patients
288 MTP joints
Swollen GSUSd 40 (NR) 77 (NR)
30 patients
60 talocrural joints
Swollen GSUSd 46 (NR) 60 (NR)
Luukkainen
2005103
50 patients
100 humeroradial joints
Swollen GSUSe 41 (NR) 92 (NR)
50 patients
100 olecranon fossa joints
Swollen GSUSe 21 (NR) 99 (NR)
Luukkainen
2007104
50 patients
100 glenohumeral joints
Swollen GSUSe 37 (NR) 82 (NR)
Mamoto
201396
124 patients
2728 joints (wrist, MCP
and PIP joints bilaterally)
Swollen
(assessed by
patient or
physician)
GSUS of ≥ 2c Physician 47
(NR), patient
34 (NR)
NR (NR)
GSUS of ≥ 2 and
PDUS of ≥ 1c
Physician 52
(NR), patient
37 (NR)
Naredo
2013118
67 patients in clinical
remissionf
28 joints (of DAS28)
DAS28 of
> 2.6
GSUSb 42 (NR) 100 (NR)
SDAI of > 3.3 GSUSb 71 (NR) 80 (NR)
DAS28 of
> 2.6
PDUSb 46 (NR) 69 (NR)
SDAI of > 3.3 PDUSb 77 (NR) 43 (NR)
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
246
TABLE 139 Clinical examination diagnostic accuracy with US as reference standard (continued )
Study Populationa
CE
assessment
of joints
Diagnostic accuracy
comparison (CE
with reference US)
Sensitivity of
CE (95% CI), %
Specificity of
CE (95% CI), %
Pereira
2015119
Painless group:
38 patients
304 MCP joints
Swollen GSUSb 64 (NR) 55 (NR)
PDUSb 75 (NR) 50 (NR)
Painful group:
34 patients
272 MCP joints
Swollen GSUSb 66 (NR) 51 (NR)
PDUSb 79 (NR) 47 (NR)
Ribbens
2003120
11 patients
20 wrist joints, 110 MCP
joints, 103 PIP joints
Swollen PDUSb Wrist 87 (NR),
MCP 64 (NR),
PIP 56 (NR)
Wrist 60 (NR),
MCP 53 (NR),
PIP 76 (NR)
Riente
2010121
100 patients
200 knee joints
Swollen and/
or painful
GSUS and PDUSc 80 (NR) 87 (NR)
Riente
2011122
100 patients
200 foot joints
Swollen
or painful
US effusion, GSUS
and PDUSc
79 (NR) 54 (NR)
Salaffi
2008160
44 patients
440 PIP joints, 440 MCP
joints, 440 MTP joints
Swollen GSUS PIP 95 (NR),
MCP 95 (NR),
MTP 74 (NR)
PIP 80 (NR),
MCP 66 (NR),
MTP 69 (NR)
Saleem
2011124
128 patients in remission
(i.e. a DAS28 of < 2.6)
640 MCP and wrist joints
Swollen PDUS > 0c 13 (8 to 22) 93 (90 to 95)
PDUS > 1c 20 (1 to 70) 92 (90 to 94)
Spiegel
1987125
6 patients
36 joints (shoulders, wrists
and knees)
Swollen (0
vs. 1–3 on a
0–3 scale)
GSUSb 90 (NR) 30 (NR)
Szkudlarek
2004126
40 patients
200 MTP joints
Swollen
or tender
GSUS
g
48 (NR) 89 (NR)
Szkudlarek
2006127
40 patients
158 MCP and
140 PIP joints
Swollen
or tender
GSUS
g
53 (NR) 94 (NR)
Taniguchi
2014128
30 patients (18 in
remission; i.e. a DAS28
of < 2.3)
60 wrists and
300 MCP joints
Swollen
or tender
PDUS referenceb Wrist 69 (NR),
MCP 57 (NR)
Wrist 89 (NR),
MCP 95 (NR)
NR, not reported.
a Active RA unless otherwise stated.
b > 0 on a 0–3 scale.
c Graded on a 0–3 scale.
d Graded on a 0–1 scale.
e > 0 on a 0–1 scale.
f Neither disease flare nor changes in therapy (including corticosteroid and MTX) in the past 6 months.
g > 0 on a 0–4 scale.
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TABLE 140 Detection rates of synovitis by US and CE
Author Populationa Joints Type of US
Detection of
synovitis on US
Type
of CE
Detection of
synovitis on CE
Balsa
2010105
97 patients 4074 joints
(PIP, MCP, wrist,
elbow, bilateral
glenohumeral,
knee, ankle and
midtarsal and
MTP joints)
GSUS 92/97 patients
(95%)
SDAI of
> 5
43/97 patients
(44%)
PDUS 41/97 patients
(42%)
SDAI of
> 3.3
54/97 patients
(56%)
Beckers
2004106
21 patients 356 joints
(knee, wrist,
MCP, PIP, ankle
and MTP joints)
PDUSb 199/356 joints
(42%)
Swollen 266/356 joints
(75%)
Tender 282/356 joints
(79%)
Filippucci
2006107
24 patients 48 wrists (four
time points ×
48 wrists totalling
192 examinations)
PDUSb 147/192
examinations
(77%)
Swollen 74/192
examinations
(39%)
Tender 68/192
examinations
(36%)
Garrigues
2013108
40 patients 1600 joints
(shoulder, elbow,
wrist, MCP, PIP,
tibiotalar and
MTP joints)
GSUS of ≥ 1c 477/1600 joints
(30%)
Swollen 200/1600 joints
(12%)
PDUS of ≥ 1c 279/1600 joints
(17%)
Tender 317/1600 joints
(20%)
GSUS of or
PDUS of ≥ 1c
479/1600 joints
(30%)
Gartner
2013109,133
90 patients
(60 in
clinical
remission,
CDAI of
≤ 2.8)
1980 finger and
wrist joints
(1320 remission,
660 active RA)
GSUS of 1–3c 89/90 patients
(99%)
CDAI of
> 2.8
30/90 patients
(33%)
GSUS of 2–3c 77/90 patients
(86%)
PDUS of 1–3c 80/90 patients
(89%)
PDUS of 2–3c 37/90 patients
(41%)
60 in clinical
remission
(CDAI of
≤ 2.8)
1320 finger and
wrist joints
GSUS of 1–3c 887/1320 joints
(67%)
Swollen 15/1320 joints
(1%)
PDUS of 1–3c 269/1320 joints
(20%)
30 with
active RA
660 finger and
wrist joints
GSUS of 1–3c 436/660 joints
(66%)
Swollen 97/660 joints
(15%)
Hayashi
201492
208 patients 416 wrist joints GSUS 1–3c or
PDUS of 2–3c
197/416 joints
(47%)
Swollen 52/416 joints
(13%)
Tender 20/416 joints
(5%)
Swollen
and tender
58/416 joints
(14%)
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TABLE 140 Detection rates of synovitis by US and CE (continued )
Author Populationa Joints Type of US
Detection of
synovitis on US
Type
of CE
Detection of
synovitis on CE
2080 MCP joints GSUS of 1–3c
or PDUS of
2–3c
331/2080
joints (16%)
Swollen 106/2080 joints
(5%)
Tender 65/2080 joints
(3%)
Swollen
and tender
74/2080 joints
(4%)
2080
interphalangeal/
PIP joints
GSUS 1–3c or
PDUS 2–3c
107/2080
joints (5%)
Swollen 43/2080 joints
(2%)
Tender 93/2080 joints
(4%)
Swollen
and tender
46/2080 joints
(2%)
Horikoshi
2010112
6 patients 156 joints
[interphalangeal,
radiocarpal,
intercarpal,
radioulnar, PIP
(2–5) and
MCP joints]
GSUSb 74/156 (47%) Swollen 7/132 joints (5%)
PDUSb 10/156 (6%)
Kane
2003102
22 patients 44 knees GSUS
effusion
(effusion vs.
no effusion)d
27/44 (61%) CE for
swelling
(fluctuant
fluid
observed)
22/44 joints
(50%)
Luukkainen
2003115
30 patients 288 MTP joints GSUSd 73/288 joints
(25%)
Swollen 79/288 joints
(27%)
30 patients 60 talocrural
joints
GSUSd 13/60 joints
(22%)
Swollen 25/60 joints
(42%)
Luukkainen
2005103
50 patients 100
humeroradial
joints
GSUSe 29/100 joints
(29%)
Swollen 18/100 joints
(18%)
50 patients 100 olecranon
fossa joints
GSUSe 29/100 joints
(29%)
Swollen 7/100 joints (7%)
Luukkainen
2007104
50 patients 100
glenohumeral
joints
GSUSe 27/100 joints
(27%)
Swollen 23/100 joints
(23%)
Naredo
2013118
67 patients
clinical
remission
28 joints per
patient
(1876 in total)
GSUSb 62/67 patients
(93%)
DAS28 of
> 2.6
41/67 patients
(61%)
PDUSb 35/67 patients
(52%)
SDAI of
> 3.3
22/67 patients
(33%)
Pereira
2015119
Painless
group:
38 patients
304 MCP joints GSUSb 193/304 joints
(63%)
Swollen 174/304 (57%)
PDUSb 88/304 joints
(29%)
Painful
group:
34 patients
272 MCP joints GSUSb 165/272 joints
(61%)
Swollen 161/272 (59%)
PDUSb 67/272 joints
(25%)
continued
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TABLE 140 Detection rates of synovitis by US and CE (continued )
Author Populationa Joints Type of US
Detection of
synovitis on US
Type
of CE
Detection of
synovitis on CE
Ribbens
2003120
11 patients 20 wrist joints PDUSb 15/20 joints
(75%)
Swollen 15/20 joints
110 MCP joints PDUSb 74/110 joints
(67%)
Swollen 64/110 joints
103 PIP joints PDUSb 45/103 joints
(44%)
Swollen 39/103 joints
Riente
2010121
100 patients 200 knees GSUS 140/200 joints
(70%)
Swollen
and/or
tender
116/200 joints
PDUSc 115/140 joints
(82%)f
Riente
2011122
100 patients 200 foot joints GSUS
and PDUSc
135/200 joints
(68%)
Swollen
or painful
137/200 joints
Salaffi
2006123
44 patients 440 PIP joints GSUSb 104/440 joints
(23.6%)
Swollen 165/440 joints
(37.5%)
440 MCP joints GSUSb 152/440 joints
(34.5%)
Swollen 241/440 joints
(54.8%)
440 MTP joints GSUSb 120/440 joints
(27.3%)
Swollen 189/440 joints
(43%)
Saleem
2011124
128 patients
in remission
(i.e. a
DAS28 of
< 2.6)
640 MCP and
wrist joints
GSUS = 0
and
PDUS= 0c
22/128 patients
(17%)
Swollen 40/128 patients
(31%)
GSUS > 1
and
PDUS > 1c
72/128 patients
(56%)
Tender 23/128 patients
(18%)
PDUS= 0c 63/128 patients
(49%)
CRP
(≥ 5 mg/dl)
46/128 patients
(36%)
PDUS > 1c 101/128 patients
(79%)
Scheel
200553
46 patients 184 MCP and
184 PIP joints
GSUS 1–3c 86% across MCP
and PIP
Swollen 138/368 (37.5%)
MCP and PIP
joints
73/184 MCP
joints (39.7%)
65/184 PIP joints
(35.3%)
Tender 137/368 (37.2%)
MCP and PIP
joints
64/184 MCP
joints (34.8%)
73/184 PIP joints
(39.7%)
Spiegel
1987125
6 patients 36 joints
(shoulders, wrists
and knees)
GSUSb 71/101 (70%) Swollen 85/101 (84%)
Szkudlarek
2004126
40 patients 200 MTP joints GSUS
g
129/200 joints
(65%)
Swollen
or tender
70/200 joints
(35%)
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definition of synovitis124) and those investigating elbow joints (21% or 41% depending on joint studied103) or
shoulder joints (37%104) in which US synovitis was scored as a binary variable rather than semiquantitatively
(see Table 3 for scoring systems).
Higher sensitivities (75–95%) were found in six studies119–122,125,160 (wrist joints for Ribbens et al.120). Of
these, one study, with a sensitivity of 90%, included only six patients and differed from other studies as CE
was graded from 0 to 3125 and one study was primarily investigating the difference between painful and
painless joints.119 In one study, CE had higher sensitivity for wrists (n = 20) than for other joints 120 and, in
another study, CE had lower sensitivity for MTP joints than for other joints.160 One study investigated foot
joints (sensitivity 79%122) and one study investigated knee joints (sensitivity 80%21). Detection rates for
synovitis were higher for CE than for US (see Table 140) in one study of foot joints.130 This suggests that
US is less useful for detecting synovitis in foot joints (not including MTP) than in other joints. However, this
was not a within-study comparison and so this cannot be concluded with certainty.
Four of these studies119,120,122,125 [Ribbens (MCP joints),120] also reported lower specificities (30–55%) than
the other studies (see Table 139), whereas two121,160 did not (specificities of 66–87%).
TABLE 140 Detection rates of synovitis by US and CE (continued )
Author Populationa Joints Type of US
Detection of
synovitis on US
Type
of CE
Detection of
synovitis on CE
Szkudlarek
2006127
40 patients 158 MCP and
140 PIP joints
GSUS
g
194/480 joints
(40%)
Swollen
or tender
121/480 joints
(25%)
Taniguchi
2014128
30 patients
(18 in
remission;
i.e. a DAS28
of < 2.3)
60 wrists PDUSb 31/60 joints
(52%)
Swollen
or tender
25/60 joints
(42%)
300 MCP joints PDUSb 23/300 joints
(8%)
Swollen
or tender
26/300 joints
(9%)
Wakefield
2008130
22 patients 22 TTJ GSUSd 10/22 (45%) Swollen 17/22 (77%)
22 STJ Medial aspect
2/22 (9%),
lateral aspect
14/22 (64%)
17/22 (77%)
22 TNJ 12/22 (55%) 17/22 (77%)
22 CCJ 11/22 (50%) 12/22 (55%)
Xiao
2014131
46 patients 368 bilateral
MCP joints
PDUSb 147/368 joints
(40%)
Swollen
and/or
tender
180/368 joints
(49%)
368 bilateral
PIP joints
PDUSb 173/368 joints
(47%)
Swollen
and/or
tender
154/368 joints
(42%)
92 wrist joints PDUSb 61/92 joints
(66%)
Swollen
and/or
tender
56/92 joints
(61%)
CCJ, calcaneocuboid joint; STJ, subtalar joint; TNJ, talonavicular joint; TTJ, tibiotalar joint.
a Active RA unless otherwise stated.
b > 0 on a 0–3 scale.
c Graded on a 0–3 scale.
d Graded on a 0–1 scale.
e > 0 on a 0–1 scale.
f Only joints in which synovial proliferation was detected were examined using PDUS.
g > 0 on a 0–4 scale.
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The specificity of CE of swollen/tender joints, with US as a reference standard, ranged from 60% to 100%
in 14 of the studies, in which joints included were mostly wrists and hand joints but also ankle, knee,
elbow and shoulder joints92,102–104,107,109,115,120,121,124,126–128,133,160 (wrist and PIP joints for Ribbens et al.120).
Study quality hierarchy did not explain the differences between the studies. Of four studies in which CE
had both higher sensitivity and lower specificity than in other trials, only one119 was of level II hierarchy
(blinded comparison among consecutive patients). The other three studies120,122,125 did not include (or it was
unclear if they included) consecutive patients, but were blinded comparisons. However, other studies lower
on the hierarchy92,96,126–128 had results consistent with level II studies.102–104,107,109,115,118,124,133
For studies in which US synovitis was scored on a scale from 0 to 1,103,104,115 sensitivities and specificities of
CE were within the range of those reported by studies using a 0–3 or 0–4 scoring system (see Table 139).
This was also the case for the study using a US score of ≥ 2 as the reference standard96 (see Table 139).
Studies using DAS as the clinical comparator assessed sensitivity and specificity for diagnosis by patient,
rather than for each joint (see Tables 5 and 6). Like CE for swollen/tender joints, DAS28 had low sensitivity
and high specificity when US was the reference standard.118 SDAI also had high specificity when US was
the reference standard; however, SDAI had fairly high sensitivity.105,118
When studies reported data separately by joint, sensitivities and specificities for CE were similar for wrist,
MCP and PIP joints in the study by Hayashi et al.92 and for MTP and talocrural joints in the study by
Luukkainen and Saltyshev115 Mamoto et al.96 reported that physicians and patients assessed swelling less
effectively in MCP than in PIP or wrist joints. CE of olecranon fossa joints had lower sensitivity than CE of
humeroradial joints103 and CE of MTP joints had lower sensitivity than that of PIP and MCP joints,160 but
with a similar specificity. In the study by Ribbens et al.,120 CE had higher sensitivity for wrists (n = 20) than
MCP (n = 110) or PIP (n = 103) joints and lower specificity for MCP joints than wrists and PIP joints.
Table 140 shows the types of US and CEs and detection rates in 25 studies.53,92,102–109,112,115,118–128,130,131 Three
studies105,109,118 (see Table 6) investigated DAS. GSUS detected synovitis in more patients than had active
disease indicated by SDAI,105,118 CDAI109 or DAS28118 and this was also the case for PDUS, with the
exception of PDUS in one study not detecting as many patients as met a SDAI of > 3.3.105
Twenty-three studies53,92,102–104,106–109,112,119–128,130,131 assessed swollen and/or tender joints by CE (see Table 6).
Nearly all of these studies53,92,102–104,107–109,112,115,119–122,124,126–128,131 reported a higher rate of detection of
synovitis by US than the rate of detection of swelling or tenderness by CE (see Table 140). There were
mixed results in two studies,108,119 with higher detection rates with GSUS than CE, but lower detection
rates with PDUS than CE; in addition, one study131 found a lower detection rate for PDUS than CE for MCP
joints but a higher detection rate for PDUS than CE for PIP and wrist joints.
Five studies found lower rates of detection by US than by CE, of which two studies investigated ankle and
MTP joints,106,115 one looked at foot joints,130 one included MTP but also PIP and MCP joints123 and one was
a study in six patients of GSUS of shoulders, wrists and knees.125 Higher rates of detection by CE than US
were suggested to be the result of inflammation from other pathology, such as osteophytes or oedema,123,130
or external factors such as obesity.130
Table 141 shows responsiveness to change of US and CE reported as the SRM. When interpreting their data,
Ikeda et al.113 cited the study by Husted et al.,80 in which a SRM of < 0.2 is considered nil (meaning between
–0.2 and + 0.2) and a SRM of > 0.6 is considered relevant, whereas Haavardsholm and Ostergaard110 cited
thresholds introduced by Cohen288 for effect sizes: < 0.2, trivial; > 0.2 to ≤ 0.5, small; > 0.5 to ≤ 0.8,
moderate; > 0.8, large. Using broad definitions (small/moderate/large), most studies reporting the SRM
found similar responsiveness for US and CE. GSUS had similar responsiveness to DAS28,110,111,113,116,132
SDAI,111,116,117 CDAI,111,113 SJC,111 TJC111 and CRP.129 PDUS had similar responsiveness to DAS28,111,113,116,117,132
CDAI,111,113 SDAI,111,116117 SJC111 and CRP.129 Looking at the types of US within studies, GSUS had similar
responsiveness to PDUS.111,113,114,129,132
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TABLE 141 Ultrasound and CE responsiveness to change
Author Populationa Follow-up US SRM (95% CI) (p= value) CE SRM (95% CI)
Haavardsholm
2009110
36 patients starting
TNFis
Wrists
12 months GSUS –0.37 (–0.89 to 0.16) (NR) DAS28 –0.36 (–1.26 to 0.35);
SDAI –0.59 (–1.31 to –0.02);
CDAI –0.55 (–1.17 to –0.04)
Hammer
2010111
20 patients starting
biologic therapy
(ADA)
MCP, PIP, elbow,
shoulder, hip, knee,
ankle and feet
joints
12 months GSUS (78 joints) –1.27 (NR);
PDUS (78 joints) –0.89 (NR)
DAS28 –1.32 (NR); CDAI –1.25
(NR); SDAI –1.20 (NR);
assessor’s global –0.78 (NR);
swollen joints (of 40) –1.29
(NR); tender joints (of 40)
–1.07 (NR); ESR –0.13 (NR);
CRP –0.12 (NR)
Ikeda 2013113 66 patients who
were taking MTX
(n= 22), TNFi
(n= 27) and TCZ
(n= 17)
28 joints of DAS28
12 weeks Total GSUS score –1.17 (NR)
(MTX –1.19, TNFi –1.48, TCZ
–1.05) (NR); total PDUS score
–1.37 (NR) (MTX –1.48, TNFi
–1.53, TCZ –1.40) (NR)
DAS28-CRP –1.37 (NR) (MTX
–1.36, TNFi –1.52, TCZ –1.49)
(NR); CDAI –1.20 (NR) (MTX
–1.43, TNFi –1.24, TCZ
–1.18) (NR)
Kamishima
2011114
29 patients, starting
TCZ
MCP joints
5 months PDUS (score 0–3)
Sum of PDUS grades at 10 MCP
joints –0.2595 (NR); PDUS joint
index for vascular flow at
10 MCP joints –0.3063 (NR)
CRP –0.6024 (NR); ESR –1.100
(NR); TJC –0.9288 (NR); SJC
–0.6506 (NR); DAS28-ESR
–1.9692 (NR)
Mandl
2013116,117
62 patients (n = 32
randomised to
ETN +MTX; n= 30
randomised to
cDMARDs)
28 joints of DAS28
12 weeks GSUS and PDUS combined
measure based on a DAS28 of
0.79 (0.70 to 0.88); GSUS and
PDUS combined measure
based on SDAI 0.9 (0.52
to 1.17)
Clinical only DAS28 0.87 (NR);
clinical only SDAI 1.11 (NR)
Vlad 2015129 55 patients starting
bDMARDs
Wrist, MCP and
PIP joints
6 months Global GSUS synovitis score
(score 0–3, global score based
on dorsal and volar scores)
–1.80 (NR); global PDUS
synovitis score –1.30 (NR)
CRP –0.90 (NR)
Zufferey
2014132
183 patients
(most already on
bDMARDs)
22 joints: knees,
elbows, wrists
and fingers
11.7 months
(mean)
GSUS –0.31 (–0.45 to –0.16);
log(PDUS + 1) score –0.23
(–0.39 to –0.08)
DAS-CRP –0.50
(–0.65 to –0.35)
NR, not reported.
a Active RA unless otherwise stated.
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One study found that US had higher responsiveness than ESR or CRP.111 ESR and CRP in this study were
the only measures in any study with a SRM of < 0.2 (i.e. counted as a nil effect). Two studies found US to
be less responsive than the clinical comparator, with US having lower responsiveness than SDAI or CDAI110
or than CRP, ESR, TJC, SJC or DAS28-ESR.114
Studies suggested that US detects more synovitis than CE alone. Thirty-three studies provided diagnostic
data.53,92,96,102,104,105,107–116,118–122,124–132,160 The majority of these studies reported that US detected more
synovitis than CE alone. US could also distinguish synovitis from other pathologies. Most of these studies
assessed synovitis in hand and wrist joints, reporting that US detected more synovitis in these joints than
CE, and this was also the case for elbow and shoulder joints. Foot and ankle joints were less likely to show
an advantage of US over CE. The detection of subclinical synovitis would be useful only if clinically relevant
and prognostic studies suggested that US-detected synovitis was associated with radiographic progression.
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Appendix 8 Characteristics of included studies
TABLE 142 Characteristics of included studies
Author (study) Year; abstract or full paper Data provided to review
Sample size (RA
patients recruited)
Haarvardsholm
(ARCTIC)
2015; abstract79 Treatment 238
Luengroongroj 2015; abstract95 Treatment 32
Naredo 2015; full paper157
2014; abstract156
Treatment 77
Bhamra 2014; abstract89 Treatment 17
Ceponis 2014; full paper152 Treatment 51
Dale (TaSER) 2014; full paper (one study arm)153
2013; abstract (both study arms)154
Treatment 110
Inanc 2014; abstract93
2014; abstract93
Treatment 43
Iwamoto 2014; full paper155 Treatment 42
Kelly 2013; abstract94 Treatment 109
Ciurtin 2013; abstract90
2012; abstract158
Treatment 39
Ellegaard 2011; full paper101 Treatment 109
Gandjbakhch 2008; abstract91 Treatment 52
Dougados/Cheung 2014; abstract148
2013; full paper139
2013; abstract149
Prognostic and treatment 77
Cavet/Taylor 2009; abstract138
2004; full paper100
Prognostic and treatment 24
Ramirez García 2014; abstract98 Prognostic 28
Yoshimi 2014; full paper145
2013; full paper144
Prognostic 31
Backhaus 2013; full paper69 Prognostic 432
Osipyants 2013; abstract97
2013; abstract150
Prognostic 36
Bugatti/Scirè 2012; full paper147
2009; full paper137
Prognostic 161
Saleem 2012; full paper142 Prognostic 93
continued
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TABLE 142 Characteristics of included studies (continued )
Author (study) Year; abstract or full paper Data provided to review
Sample size (RA
patients recruited)
Boyesen 2011; full paper134 Prognostic 84
Reynolds 2009; full paper141
2007; full paper151
Prognostic 40
Brown/Ikeda 2008; full paper135
2007; abstract136
Prognostic 107
Naredo 2008; full paper140 Prognostic 367
Wakefield 2008; full paper130 Diagnostic 22
Naredo 2007; full paper55 Prognostic 42
Wakefield 2007; full paper143 Prognostic 10
Ikeda 2012; abstract146
2013; full paper113
Diagnostic and prognostic 57
Pereira 2015; full paper119 Diagnostic 72
Vlad 2015; full paper129 Diagnostic 55
Hayashi 2014; abstract92 Diagnostic 208
Taniguchi 2014; full paper128 Diagnostic 30
Xiao 2014; full paper131 Diagnostic 46
Zufferey 2014; full paper132
2014; full paper99
Diagnostic 108
Garrigues 2013; full paper108 Diagnostic 40
Gartner 2013; full paper109
2012; abstract133
Diagnostic 90
Mamoto 2013; abstract96 Diagnostic 124
Mandl 2013; full paper116
2012; full paper117
Diagnostic 62
Naredo 2013; full paper118 Diagnostic 67
Hammer 2011; full paper68
2010; full paper111
Diagnostic 20
Kamishima 2011; full paper114 Diagnostic 29
Riente 2011; full paper122 Diagnostic 100
Saleem 2011; full paper124 Diagnostic 128
Balsa 2010; full paper105 Diagnostic 97
Horikoshi 2010; full paper112 Diagnostic 6
Riente 2010; full paper121 Diagnostic 100
Haavardsholm 2009; full paper110 Diagnostic 36
Luukkainen 2007; full paper104 Diagnostic 50
Filippucci 2006; full paper107 Diagnostic 24
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TABLE 142 Characteristics of included studies (continued )
Author (study) Year; abstract or full paper Data provided to review
Sample size (RA
patients recruited)
Salaffi 2006; full paper123 Diagnostic 44
Szkudlarek 2006; full paper127 Diagnostic 40
Luukkainen 2005; full paper103 Diagnostic 50
Scheel 2005; full paper53 Diagnostic 46
Beckers 2004; full paper106 Diagnostic 21
Szkudlarek 2004; full paper126 Diagnostic 40
Kane 2003; full paper102 Diagnostic 22
Luukkainen 2003; full paper115 Diagnostic 30
Ribbens 2003; full paper120 Diagnostic 11
Spiegel 1987; full paper125 Diagnostic 6
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